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Abstract  
In recent years, the cancer stem cell hypothesis has emerged as a compelling but 
controversial model of cancer progression.  Contrary to the clonal evolution model, the 
cancer stem cell hypothesis postulates that, akin to normal tissues, tumours are hierarchical 
and only a rare subpopulation of cells, so-called “cancer stem cells” (CSCs), possess the 
unique biological properties required for tumourigenesis.  In addition to tumour initiation, 
cancer stem cells are held solely accountable for tumour differentiation, tumour 
maintenance, tumour spread and tumour relapse following therapy.  Of late, there has been 
much evidence to suggest that cancer cells reactivate the latent embryonic programme, 
epithelial to mesenchymal transition (EMT), in order to acquire the invasive and migratory 
properties necessary for the successful completion of the invasion-metastasis cascade.  
Intriguingly, the EMT programme was recently implicated in the generation of cells with 
the properties of stem cells in a breast cancer model, therefore, it is evident that multiple 
populations of CSCs may exist within a given tumour.  Since metastasis is accountable for 
the vast majority of cancer-associated mortalities and CSCs are implicated in therapy 
failure and subsequent cancer relapse, it is apparent that epithelial to mesenchymal 
transition and cancer stem cells are of utmost clinical relevance.  Consequently, this study 
sought to investigate the properties of CSCs and EMT in human prostate cancer.  Using the 
method previously reported in the literature, this work failed to identify and isolate putative 
prostate CSCs.  However, this study successfully identified the OPCT-1 cell line as a 
suitable model for the investigation of EMT and subsequently derived and selected five 
phenotypically distinct clones that provided a model to determine a possible correlation 
between EMT and the generation of CSCs in human prostate cancer. 
The present work revealed that EMT of prostate cancer cells does not always generate cells 
with the properties of stem cells.  Furthermore, this study demonstrated evidence for the 
existence of multiple cancer stem cell-like populations in human prostate cancer.  In 
addition, evidence of EMT in primary cultures and clinical specimens from prostate cancer 
patients was shown and evidence to suggest that tumours contribute to their own stromal 
microenvironment via EMT was also provided.  The foundations laid by the completion of 
this project provide considerable scope for future studies which may reveal valuable 
insights into the fundamental mechanisms involved in prostate cancer progression.  
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Chapter 1:   
Introduction 
 
1.1 Cancer: A Brief Overview 
The word cancer is broadly used to describe a collection of over 200 diverse diseases 
which share a number of fundamental traits.  It is essentially a disease process that is 
characterised by uncontrolled cellular proliferation and invasion of surrounding tissues 
which arise as a result of dysregulated cellular growth and cause a disruption of tissue 
homeostasis.  Cancer can arise in almost any tissue of the body and some tissues may even 
yield multiple types. Several years of cancer research have contributed to an improved 
understanding of this complex group of diseases which, in turn, has led to rapid advances 
in cancer treatment.  However, further efforts are undoubtedly required in order to discover 
uncharacterised mechanisms behind cancer initiation and its prevention.   
1.1.1 Cancer: Facts and Figures 
Cancer is accountable for a significant number of morbidities and mortalities worldwide; 
hence it represents a major health concern across the globe.  In 2008, there were an 
estimated 12.7 million new cases of cancer worldwide and in 2010, there were 157,275 
reported cancer deaths in the UK, which is an increase from the 156,723 deaths recorded in 
2008 (Cancer Research UK, 2012).  In 2010 cancer was by far the leading cause of death 
with 28% of all UK deaths resulting from cancer (Figure 1.1).   
In 2010, almost half (47%) of all cancer deaths in the UK arose from cancers of the lung, 
bowel, breast and prostate (Figure 1.2).  Although cancer continues to represent a 
considerable cause of death worldwide, due to advances in cancer detection and treatment 
over the years, mortality rates from cancer fell by a fifth (20%) between 1979 and 2008 
(Cancer Research UK, 2010).  
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Figure 1.1: The 10 leading causes of death in the UK in 2010 (Cancer Research UK, 2012) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: The 20 most common causes of death from cancer in the UK in 2010 (Cancer 
Research UK, 2012) 
All malignant neoplasms    157, 275    (100%)        
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Figure 1.3: Age related incidence and deaths from cancer in men and women the UK in 2010 
(Cancer Research UK, 2012) 
Cancer can affect people of all ages although more than three quarters of cancer deaths 
(77%) in 2010 occurred in people aged 65 and over.  Therefore, the death rates from cancer 
rise with increasing age, with cancer being the leading cause of death in all age groups 
with the exception of 15 to 25 year olds. (Figure 1.3).  
Some tissues are more susceptible to developing cancer than others and there is a notable 
difference in the pattern of the incidence and mortality of cancers between men and women 
(Figures 1.4 and 1.5 ) (King, 2000, Cancer Research UK, 2012).   
Almost any site in the body can be subject to malignant transformation.  The vast majority 
of cancers arise in epithelial cells and are known as carcinomas, cancers arising from 
glandular tissue (such as the prostate) are known as adenocarcinomas. Cancers which 
develop in cells of mesodermal origin, such as muscle, bone and fat cells, are known as 
sarcomas and cancers of the nervous system include neuroblastomas, retinoblastomas and 
astrocytomas.  Not all cancers form solid tumours (abnormal growths) for example 
haematological cancers, known as leukaemias, are characterised by an abnormal increase 
of blood cells which circulate in the bloodstream (King, 2000).   
The etiology of any given malignancy is complex, involving the interaction of a mixture of 
genetic, lifestyle and environmental factors.  Therefore, cancer can be caused by both 
external and internal factors (discussed in detail in section 1.1.2) which may work 
synergistically to initiate or promote carcinogenesis up to several years after exposure 
(American Cancer Society, 2010).   
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Figure 1.4: Cancer mortalities of UK men in 2010 (Cancer Research UK, 2012). 
 
Figure 1.5: Cancer mortalities of UK women in 2010 (Cancer Research UK, 2012). 
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1.1.2 Carcinogenesis: A Multifactoral, Multistep Process 
Carcinogenesis is the multistep process by which normal cells are transformed into cancer 
cells and occurs as a result of an accumulation of genetic abnormalities which affect vital 
regulatory pathways (King, 2000).  The cells of the body are normally maintained under 
stringent developmental control hence, in order to sustain homeostasis, cells are required to 
differentiate, proliferate, migrate and apoptose under strict instruction from other cells in 
their vicinity.  These tight controls ensure that each tissue size and architecture is 
appropriate to the requirements of the body (Weinberg, 1997).  Cancer arises when cells 
become non-responsive to their developmental controls and proliferate excessively, which, 
in the case of solid malignancies, consequently results in the formation of tumours.  Benign 
tumours, such as warts and adenomas are non-invasive and often remain encapsulated in 
connective tissue.  These rarely pose a threat to life unless they form in enclosed spaces 
and compress vital structures or secrete high levels of hormones for example (Cancer 
Research UK, 2012).  However, adenomas may progress to malignancy and give rise to 
adenocarcinomas (Talmadge and Fidler, 2010).   Unlike benign tumours, malignant 
tumours are often fatal as they lack contact inhibition and grow in an invasive manner into 
surrounding tissues which may be vital for the survival of the organism as a whole.  
Moreover, they can also shed cells which are capable of spreading, via the bloodstream or 
lymphatic system, to other sites of the body where they can colonise and invade in a 
process known as metastasis. 
Tumours are believed to derive from a single cell in a multi-step process which usually 
develops over many years and consists of different phases following a trend rather like that 
of Darwinian evolution; a process which depends on random  mutations acquired over time 
to give rise to selective advantages to individuals (Vogelstein and Kinzler, 1993).  Random  
mutations in genes controlling proliferation or apoptosis are strongly implicated in 
carcinogenesis and the mutations in individual genes which confer evasion of normal 
homeostatic controls are those which are detected in successful cancer cells (Bertram, 
2001). 
The majority of mutations that result in cancer are non-hereditary and arise spontaneously 
as a consequence of DNA damage which alters the function of vital genes (Bertram, 2001). 
Studies on colon carcinoma demonstrated that a successful human cancer cell requires 
mutations in at least five genes (Cho and Vogelstein, 1992; Cahill et al., 1999).  Genomic 
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instabilities including point mutations (leading to amino acid substitutions), mutations 
resulting in truncated proteins or proteins with a scrambled sequence, chromosomal 
imbalance or instability (resulting in amplification), loss of a gene or fusion with another 
gene (as a consequence of chromosomal breakage and rearrangement), over-expression or 
inappropriate expression of a particular gene and epigenetic modifications to DNA (which 
may result in gene silencing) contribute towards the induction of malignant transformation 
of cells (Shar, 2001).  The advent of modern sequencing technologies has enhanced our 
understanding of mutagenesis and revealed that malignant transformation is an extremely 
complex process requiring extensive genetic damage in the form of 1,000 to 100,000 
mutations, depending on the individual and tumour type (Stratton et al., 2009). These 
mutations collectively confer malignancy by contributing to the autonomous growth of 
cancer cells in the host organism (Bertram, 2001).   
1.1.2.1 Induction of DNA Damage 
DNA damage resulting in malignant transformation most frequently arises as a result of 
exposure to physical, or chemical carcinogens which are encountered throughout life both 
internally and externally (Lodish et al., 2000).  However, spontaneous DNA damage is 
also thought to give rise to cancers with no obvious cause (Bertram, 2001).   
1.1.2.1.1 Spontaneous DNA damage 
Studies using Saccharomyces cerevisiae as a model organism to investigate spontaneous 
DNA damage have revealed that deficiencies with nucleotide excision repair and base 
excision repair lead to elevated levels of unrepaired, spontaneous oxidative DNA damage 
producing genetically unstable cells reminiscent of cancer cells (Evert et al., 2004).  In 
addition to deficiencies in DNA repair mechanisms, spontaneous DNA damage may arise 
as a result of the inherent instability of the DNA molecule, or oxidative damage from by-
products of metabolism (Lodish et al., 2000; Bertram, 2001). 
1.1.2.1.2 Environmental carcinogens 
There is an abundance of frequently occurring factors with the ability to modify the 
physical structure of genes.  As such, arguably the most common group of carcinogens are 
those readily encountered in the environment. 
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1.1.2.1.2.1 Chemical carcinogens 
Carcinogenic chemicals include simple compounds, such as arsenic, and more complex 
compounds, such as the fungal chemical aflatoxin, which can be encountered as a result of 
ingestion, inhalation and direct skin exposure (King, 2000).  As several compounds are 
capable of inflicting DNA damage, the list of chemical carcinogens is ever increasing.  
Perhaps the most renowned example of a chemical carcinogen is cigarette smoke, 
containing chemicals such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 
benzo[a]pyrene (BaP), which have been proven to induce lung cancer (Hecht, 1994). 
1.1.2.1.2.2 Physical carcinogens 
As with chemical carcinogens, physical carcinogens, in the form of radiation, are 
ubiquitous in the environment.  Ionising radiation is prevalent from natural sources, such 
as the sun, industrial sources, such as nuclear fall-out, medical sources, such as x-rays and 
therapeutic radiotherapy, domestic sources, such as cathode ray tubes, and even in human 
bodies as a result of potassium-40 ingestion (Little, 2003).  The carcinogenesis of 
electromagnetic fields remains a controversial topic, with some studies implicating a 
carcinogenic role (Alhbom et al., 2001) while others report on their therapeutic 
applications (Barbault et al., 2009).  Skin cancer is an example of a malignancy which can 
be induced by artificial or solar ultra-violet radiation  (Ananthaswamy, 2001). 
1.1.2.2 Epigenetic Aberrations 
While genetic abnormalities may account for some of the changes which lead to the 
progressive conversion of normal cells, many of the alterations in gene expression 
observed in cancer arise as a result of epigenetic modifications (Esteller, 2011).  Epigenetic 
mechanisms include chromatin remodelling, DNA methylation, histone modification 
nucleosome remodelling, and RNA interference (Ducasse and Brown, 2006).  Such 
mechanisms may be induced by hormones such as oestradiol, which plays an instrumental 
role in the initiation and progression of breast cancer (Mann et al., 2011).  
Aberrant global levels of histone modification and incorrect methylation of gene promoter 
regions may lead to the activation of genes which promote malignant behaviour and/or 
repression of genes involved in protective mechanisms such as DNA damage repair and 
activation of apoptosis in response to irreparable insult (Santos-Reboucas et al., 2007) (See 
1.1.2.4 Oncogenes and Tumour Suppressor Genes).  Therefore, missregulation of 
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epigenetic mechanisms works synergistically with genetic mutations to drive the 
progression of neoplastic disease (Ducasse and Brown, 2006).   
Unlike genetic mutations, epigenetic modifications are reversible.  As such, small molecule 
inhibitors of the epigenetic enzymes are currently in development with DNA 
methyltransferase (DNMT) inhibitors and histone deacetylase inhibitors already approved  
modalities for the treatment of haematological cancers (Copeland et al., 2010). 
1.1.2.3 Infection-induced Carcinogenesis 
Induction of DNA damage in proliferating epithelial cells, as a result of repeated exposure 
to reactive oxygen species generated by inflammatory cells, is known to contribute to 
oncogenesis (Coussens and Werb, 2001).  As such, cancer frequently arises in different 
tissues and organs as a consequence of chronic inflammatory disease.  (Schaeffer and 
Werner, 2008).  Accordingly, approximately 18% of all cancers worldwide are attributed 
to chronic infections with microorganisms including bacteria, viruses and parasitic worms 
(Thun et al., 2009).  The most common malignancies induced by microorganisms include 
cervical, stomach and liver cancers, which are caused by, human papiloma virus (HPV), 
the bacterium Helicobacter pylori  (H.pylori), and Hepatitis C virus (HCV), respectively 
(Thun et al., 2009). 
Aside from causing chronic inflammation, RNA and DNA tumour viruses have been 
shown to contribute significantly to carcinogenesis by directly interfering with a variety of 
different host functions and are estimated to be the etiological agents of approximately 
17% of human cancers (Parkin, 2006).  Retroviruses transform cells via provision of 
cancer-causing “oncogenes” which play a role in mitogenic signalling and growth control 
whereas DNA viruses have been shown to transform cells via suppression of cellular 
repressor proteins known as “tumour supressors” (Butel, 2000; King, 2000).    
1.1.2.4 Oncogenes and Tumour Suppressor Genes 
Normal cell growth and division is tightly controlled and regulated by stimulatory and 
inhibitory cell signalling pathways which convey growth-controlling messages from the 
outer surface to the nucleus of the cell.  Within the nucleus “the cell cycle clock”, the 
molecular machinery which collects the messages, determines whether the cell should 
divide.  Any mutations which hinder the genes involved in inhibitory pathways (known as 
tumour suppressor genes) may lead to excessive cellular proliferation (cancer).  
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Conversely, cancer may arise as a result of mutations which over-activate the genes 
involved in the stimulatory pathways (proto-oncogenes) (Weinberg, 1997).  
The two gene classes, oncogenes and tumour suppressor genes play major roles in 
tumourigenesis.  In a healthy cell, these genes are responsible for the maintenance of the 
cell cycle.  However, when mutated they drive uncontrolled, excessive multiplication.    
1.1.2.4.1 Proto-oncogenes and Oncogenes 
Proto-oncogenes are genes expressed by normal, healthy cells which contribute primarily 
to cell signalling pathways involved in cell cycle progression, proliferation, angiogenesis 
and response to growth factors (King, 2000).  As result of mutation, structural 
rearrangement or gene copy number gain, proto-oncogenes become altered or activated to 
form oncogenes, thereby resulting in disruption of their normal function which is exploited 
to promote tumourigenesis (Soh et al., 2009).  Oncogenes have a dominant gain of 
function.  Hence, cell growth becomes dysregulated when a mutation in a proto-oncogene 
renders a critical growth stimulatory pathway constitutively active when it should be silent.  
The growth-promoting properties of oncogenes are due to either a larger production or 
increased activity or sensitivity to protein products which endorse uncontrolled cellular 
proliferation in cancer (Weinberg, 1997).  In the case of viral-induced oncogenesis, 
oncogenic retroviruses insert their oncogenes into the host cell’s DNA, thereby triggering 
uncontrollable cell division (Thorat et al., 2012).    
Oncogenes are one of the most influential groups of genes in cancer and contribute 
significantly towards tumourigenesis. The first oncogene to be discovered in human cancer 
cells was the Ras oncogene, it is the most widely activated oncogene in all human cancers 
and was originally discovered in rat sarcomas (Bertram, 2001). 
1.1.2.4.2 Tumour Suppressor Genes 
Overstimulation of growth-promoting machinery alone is not sufficient do drive 
malignancy as cells must also be capable of escaping and ignoring growth inhibitory 
signals (King, 2000).  Tumour suppressor genes are of significant importance in human 
carcinogenesis and play an “anti-oncogenic” role by controlling cell growth, cell survival 
and DNA repair.  Contrary to oncogenes, a recessive loss of tumour suppressor genes is 
associated with cancer development.   Inactivation of tumour suppressors enables 
transformed cells to survive and continue to multiply thus favouring the progression of 
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malignancy.  Therefore, inactivation of tumour suppressor genes is a common feature of 
cancer cells.  p53 is a tumour suppressor gene which plays a critical role in conserving 
genetic stability and preventing genomic mutations via various mechanisms.  Also referred 
to as “the guardian of the genome”, p53 can activate DNA repair, initiate growth arrest and 
induce apoptosis in response to stress (Weinberg, 1997).  The key role of p53 in cancer 
prevention is emphasised by the fact that this gene is defective in over 70% of human 
cancers and almost 100% of individuals with hereditary mutations in p53, a condition 
known as Li Fraumani syndrome, suffer with cancer (Bertram, 2001).     
1.1.2.5 Summarising the Pathway to Malignancy 
Figure 1.6 demonstrates the steps involved in carcinogenesis.  The process begins with a 
rare initiating event which causes genetic damage in a cell.  Such an event may be induced 
by exogenous factors such as tobacco smoke, viruses and ionising radiation, or endogenous 
factors such as metabolic free radical generation or hormonal changes.  A single (initial) 
event is not sufficient for tumourigenesis and progression to cancer requires promotional 
agents, such as hormones which stimulate mitosis and thereby promote further mutation 
(King, 2000).  Mutations in DNA repair mechanisms and inhibition of apoptosis and 
replicative senescence enable malignant progression. Tumour formation results from 
uncontrolled cellular proliferation of immortal, self-renewing cancer cells which 
demonstrate the “hallmarks of cancer”.        
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Figure 1.6:  Overview of pathways to malignancy.  Demonstrating the stepwise acquisition of malignant traits 
via mutation and the inhibitory processes a tumour must overcome to survive and thrive, demonstrating the 
hallmarks of cancer.  (Adapted from Bertram, 2001). 
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1.1.3 Defining the Features of Cancer  
In January 2000, Douglas Hanahan and Robert Weinberg published a review “The 
Hallmarks of Cancer” which surmised six defining features common to all cancer types 
and in 2011 they revisited their concepts and introduced two additional, emerging 
hallmarks of   cancer (Figure 1.7). 
 
   
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7:  The Hallmarks of cancer.  (Adapted from Hanahan and Weinberg, 2000;2011). 
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1.1.3.1 Self-Sufficiency in Growth Signals 
As previously explained, normal (healthy) cells are tightly regulated and maintained via 
signalling and adhesion molecules from adjacent cells.  In the absence of such molecules, 
normal cells are unable to move from an inactive, quiescent state into a proliferate state.  
However, as a result of oncogenic transformation, tumour cells are able to proliferate 
independently by producing and responding to their own growth signals in an autocrine 
manner.  Acquired growth signal autonomy can be achieved at three levels; extracellular, 
via excessive production of growth signalling molecules, transcellular, via over-expression 
or structural changes of/to growth factor receptors, or intracellular, via alterations in 
downstream cytoplasmic signalling molecules (Hanahan and Weinberg, 2000).        
1.1.3.2 Insensitivity to Growth-Inhibitory Signals 
Unless normal cells are required to proliferate, they are maintained in a quiescent state by 
tumour suppressor genes which issue anti-proliferative signals to maintain tissue 
homeostasis. Cells with sustained DNA damage apoptose under the control of tumour 
suppressor genes.  However, inactivating mutations in both alleles of tumour suppressor 
genes render them unable to regulate the cell cycle and promote apoptosis in response to 
irreparable DNA damage.  As a result, transformed cells continue to proliferate in the 
absence of DNA repair mechanisms and become increasingly genomically unstable.  An 
accumulation of mutations in proto-oncogenes and tumour suppressor genes consequently 
allows cells to progress towards a malignant cell phenotype. 
Tumour suppressor proteins can be inactivated directly by protein binding or 
phosphorylation.  Alternatively, mutation of tumour suppressor genes can result in an 
altered protein product or complete loss of product.  The p53 gene is the most frequently 
altered tumour suppressor gene in human cancers and there have been over 2000 p53-
inactivating mutations identified (King, 2000).       
1.1.3.3 Inexhaustible Self-Renewal (replicative) Capacity 
Normal cells have a finite lifespan hence, once they have progressed through their 
maximum number of population doublings, they lose their ability to divide in a process 
known as senescence.  It is a natural phenomenon otherwise known as “aging” and is 
attributed to the progressive erosion of telomeres, the ends of chromosomes, during 
successive cycles of replication.  Unlike normal cells, tumour cells appear to exhibit 
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limitless replicative potential, hence are immortal.  The immortality of tumour cells has 
been attributed to their ability to maintain their telomeres by either upregulating the 
expression of the telomerase enzyme, or by activating a mechanism which maintains 
telomere length through recombination.  Both mechanisms maintain telomeres at a length 
which enables unlimited replication of successive cells thus defying the natural aging 
process (Hanahan and Weinberg, 2000).  Interestingly, the role of telomerase in conferring 
inexhaustible replicative capacity can be demonstrated in vitro through transformation of 
normal cells with a plasmid construct expressing telomerase. 
In recent years, an increasing body of evidence has developed to support “the cancer stem 
cell theory”, a theory that implicates stem cells or stem-like cells in tumourigenesis.  In 
addition to multilineage differentiation potential, stem cells are known to possess a robust 
capacity for clonal self-renewal.  Recent studies have provided evidence to suggest that 
cancer arises as a result of malignant transformation of tissue stem cells (Reya et al.,  2001; 
Richardson et al.,  2004; Collins et al.,  2005; Bjerkvig et al.,  2005; Ailles and Weissman, 
2007; Bapat, 2007; Huang et al.,  2006; Lawson and Witte, 2007; Neuzil et al.,  2007; Gao, 
2008).  The pathways involved in the regulation of normal stem cell self-renewal have 
been found to be deregulated in cancer stem cells thus rendering them capable of 
uncontrolled, infinite expansion which results in tumour formation (Al-Hajj and Clarke, 
2004).  Furthermore, stem cells have been shown to inherently express higher levels of 
telomerase than somatic cells.  Therefore, the self-renewal property of cancer cells could 
be attributed to the fact that they derive from transformed tissue stem cells.  Cancer stem 
cells will be discussed further in Section 1.5.  
1.1.3.4  Reprogramming of Energy Metabolism 
In order to fuel the rapid cell growth and proliferation exhibited by cancer, cancer cells 
must adjust their energy metabolism accordingly.  For this purpose, cancer cells have long 
been known to reprogram their glucose metabolism, hence, energy production, by limiting 
their energy metabolism to glycolysis, even in the presence of oxygen.  This phenomenon 
was first observed by Otto Warburg, thus, is referred to as “the Warburg effect” in addition 
to “aerobic glycolysis”.  This metabolic switch is accompanied by an upregulation of 
glucose transporters, which substantially increase the import of glucose into the cytoplasm 
thereby partially compensating for the ˜18-fold lower efficiency of ATP production 
afforded by glycolysis in comparison to mitochondrial oxidative phosphorylation 
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(Hanahan and Weinberg, 2011).  The hypoxic cancer cell is dependent on glycolysis for 
energy metabolism.  Therefore, glycolysis is upregulated by the transcription factors HIF-
1α and HIF-2α which increase in response to hypoxia.  Interestingly, by increasing the 
levels of HIF-1α and HIF-2α, the Ras oncoprotein can also upregulate glycolysis (Hanahan 
and Weinberg, 2011).   
Warburg-like metabolism also appears to be present in several rapidly proliferating 
embryonic tissues and stem cells.  This will be discussed further in Section 1.5.5.5.3. 
1.1.3.5  Evasion of Immune Destruction 
The immune system is comprised of multiple cells, proteins and other factors which 
collectively work to seek and destroy/neutralise invading pathogens, infected cells, toxins 
and cancer cells.  However, cancer cells are armed with several mechanisms for evading 
immune destruction therefore, are able to thrive in spite of the immune system. 
The key cells of the immune system for tumour surveillance are T-cells, which form part of 
the adaptive immune response (Igney and Krammer, 2002).  Tumours can escape from the 
main line of defence (T-cells) by downregulating the expression of classical HLA class I 
antigens, effectively rendering them invisible to these immune cells but susceptible to 
attack by NK cells (Rees et al., 1988; Ahmad et al., 2004). 
The expression of surrogate HLA molecules can be employed by cancer cells to resist-NK-
mediated lysis.  HLA-G is a non-classical HLA class I molecule involved in 
immunomodulation.  Its expression is generally restricted to cytotrophoblasts, embryonic 
tissues, erythroid precursors, corneal and thymic epithelial cells and stem cells (Lozano et 
al., 2003).  However, aberrant HLA-G expression by tumour cells has also been observed 
in several human malignancies and has been proposed to play multiple roles in immune 
evasion, in either its soluble or membrane-bound forms (Rouas-Freiss et al.,2005).  Soluble 
HLA-G has been detected in body fluids of cancer patients such as serum and effusion 
samples and is believed to be secreted by the capable tumour cells in order to inactivate the 
local immune response, even for tumour cells without cell-surface HLA-G expression 
(Sheu and Smith, 2010).  This molecule is known to play multiple immunosuppressive 
functions exerted by inhibition of several immune effector cells.  Direct inactivation of 
immune effectors such as T-cells, B cells, monocytes (macrophages), myeloid dendritic 
cells  and NK cells is achieved via direct interaction between HLA-G and leukocyte 
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immunoglobulin-like receptors LILRB1 and LILRB2 (Cosman et al., 1997).  In addition, 
HLA-G directly interacts with the NK inhibitory receptor KIR2DL4 resulting in inhibition 
of NK-cell-mediated cytolytic activity (Clements et al., 2007).  Other studies have revealed 
that immune tolerance, mediated by HLA-G can be achieved via induction of regulatory T-
cells (Le Rond et al., 2006).   
Therefore, it is evident that the aberrant expression of this immunosuppressive molecule 
can greatly assist the immune evasion of both the tumour cells which express membrane-
bound HLA-G and those in the vicinity of the cells which secrete this molecule.  These 
examples represent only a few of the vast mechanisms of HLA-G mediated 
immunosuppression.  For a more detailed insight into the role of HLA-G in cancer, the 
reader is referred to reviews by Sheu and Shih, 2010 and Rouas-Freiss et al., 2005.   
Cytokines are also known to play an important role in immune evasion and tumours have 
been shown to secrete high levels of specific cytokines, which reduce the activity of the 
local immune cells.  Transforming growth factor beta (TGF-β) is an example of an 
immunosuppressive cytokine which affects proliferation, activation and differentiation of 
cells of innate and adaptive immunity, hence, inhibits the anti-tumour immune response.  
This cytokine may be secreted directly from tumour cells or by activated tumour-
associated stromal cells.  In addition, several other immunosuppressive factors have been 
shown to be expressed by tumour cells, these include VEGF, which inhibits the 
differentiation of progenitors to dendritic cells, prostaglandins, interleukin 10 (IL-10) 
macrophage-colony stimulating factor and soluble tumour gangliosides (Igney and 
Krammer, 2002).  
These examples demonstrate that cancer cells are equipped with an array of defensive 
mechanisms which render them resistant to immune attack.  It is important to acknowledge 
that the examples provided here outline only a few of the multiple strategies employed by 
cancer cells to evade immune destruction.  For a more detailed overview, the reader is 
referred to the review articles by Ahmad et al., 2004 and Igney and Krammer, 2002.  
1.1.3.6 Resistance to Apoptosis (Cell Death) 
Normal tissue growth is maintained by a balance between cellular proliferation, 
differentiation and death. There are two types of cell death, necrosis and apoptosis.  
Necrosis is the passive process by which a cell breaks down in response to a poor nutrient 
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supply or acute cellular injury which leads to a loss of membrane integrity.  Apoptosis, 
also known as “cell suicide”, is the active process of programmed cell death and requires 
the synthesis of macro molecules.  Apoptosis is a normal process involved in tissue 
remodelling and tissue growth or atrophy is determined by the rate of proliferation versus 
the rate of cell death.  The apoptotic pathway can be induced in response to a number of 
different external events which trigger regulatory proteins to initiate the pathway in 
response to stress.  Such events include; DNA damage, accumulation of toxins, withdrawal 
of growth cytokines, viral infection, nutrient depravation and hypoxia.  The induction of 
apoptosis results in the activation of a family of cysteine proteases (caspases) which 
promote the release of cytochrome C from mitochondria into the cytoplasm thus activating 
additional caspases which cleave cellular proteins and bring about cellular degradation 
without inducing an inflammatory response (King, 2000; Bertram, 2001).  
Mounting evidence indicates that an acquired ability to resist apoptosis is a characteristic 
that is common to most, if not all, forms of cancer.  Cancer cells can acquire the ability to 
resist apoptosis through various different strategies.  One example of which is the 
inactivation of p53 as a result of mutation to both alleles, or production of proteins which 
inhibit its transcriptional activity (e.g. HPV E7) (Massimi and Banks, 1997).  p53 plays a 
critical role in the induction of apoptosis in response to DNA damage by upregulating the 
expression of pro-apoptotic Bax, a potent stimulator of cytochrome C release.  In the 
absence of p53, cells with sustained DNA damage are able to escape apoptosis and 
continue to proliferate in the absence of DNA repair mechanisms which subsequently 
results in increasing genomic instability (Hanahan and Weinberg, 2000). 
1.1.3.7 Sustained Angiogenesis  
Angiogenesis (neovascularisation) is the vital physiological process by which new blood 
vessels form from pre-existing vessels.  In a normal tissue environment the formation of 
new blood vessels is a natural process which is tightly maintained.   
In the absence of new capillaries, tumours cannot grow beyond 1-2 mm in diameter as 
further growth must be supported with a fresh blood supply (Talmadage and Fidler, 2010).  
Therefore, in order to expand, tumour cells promote angiogenesis by producing angiogenic 
growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth 
factors (FGF-1 and FGF-2).  Furthermore, tumours are capable of suppressing anti-
angiogenic factors such as thrombospondin (Hanahan and Weinberg, 2000).  Interestingly, 
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these angiogenic factors appear to be closely associated with tumour suppressor genes and 
oncogenes.  For example, where the tumour suppressor gene p53 positively regulates the 
angiogenic inhibitor thrombospondin, the ras oncogene is associated with an increased 
secretion of VEGF (Bertram, 2001).  In addition to these mechanisms, the cancer stem cell 
component has been shown to be directly capable of vessel wall formation via 
differentiation into endothelial cells (Ricci-Vitiani, et al., 2010; Wang et al., 2010).  The 
contribution of cancer stem cells to angiogenesis will be discussed in more detail in 
Section 1.5.5.5.6. 
1.1.3.8 Tissue Invasion and Metastasis 
Providing that transformed cells possess all of the characteristics previously discussed, 
they can multiply excessively to form a clinically detectable mass of cells referred to as a 
primary tumour.  Unlike normal cells, which exhibit contact inhibition, the cells of a 
primary tumour are able to invade and disrupt surrounding tissues (Voet and Voet, 1995).  
However, the disruption to homeostasis caused by the invading cells of a primary tumour 
is rarely fatal and the vast majority of deaths due to cancer are as a result of metastasis.  
Being responsible for over 90% of cancer-associated mortality, metastasis is of paramount 
clinical significance (Brabletz, 2012).  Metastasis is an extremely complicated and 
arguably inefficient process, involving several distinct steps which must be executed by 
successful carcinoma cells.  The so-called “invasion-metastasis cascade” describes the 
series of events required for this enormous undertaking (Fidler, 2003).  In order to 
complete the invasion-metastasis cascade, malignant cells must escape from the primary 
tumour site, penetrate the local stroma, enter the local vascular or lymphatic vessels, in a 
process termed intravasation, aggregate with platelets, interact and adhere to distant 
endothelia, escape from the circulation via extravasation, recolonise in a foreign 
environment and expand to form secondary tumours, all the while avoiding immune 
destruction and surviving in multiple microenvironments (Thompson and Newgreen, 
2005).  Given the complexity of the process and the incredible challenge with which the 
carcinoma cells are faced throughout their dissemination from the primary site to their 
arrival and colonisation at the secondary sites, metastasis remains a controversial and 
poorly understood phenomenon, with more than one mechanism proposed. 
It is highly probable that carcinoma cells are not equally endowed with the properties 
required for metastasis, as evidenced by the fact that the presence of tumour cells in the 
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circulation does not predict metastasis.  In fact, in vivo studies using radiolabelled cancer 
cells injected intravenously revealed that most are efficiently eliminated (Talmadge and 
Fiddler, 2010).  The notion of heterogeneity among cancer cells is further supported by the 
inefficiency of metastasis, which rarely exceeds 0.01% despite the abundance of tumour 
cells shed daily into the blood stream of cancer patients (up to a million per gram of 
tumour) (Talmadge and Fidler, 2010).   
Emerging concepts in cancer biology are offering new insights into the previously 
unexplainable phenomena observed in cancer metastasis.  The cancer stem cell hypothesis 
and epithelial to mesenchymal transition have both been largely implicated in metastasis 
and will be discussed in more detail in sections 1.5 and 1.6. 
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1.2 Prostate Cancer 
Prostate cancer is a major cause of morbidity and mortality in men, particularly in the 
developed world (Drewa and Styczynski, 2008).  It is the third most common cancer in 
men worldwide and is most prevalent in European and North American men (Gronberg, 
2003).  Prostate cancer accounts for a quarter of all new cancer cases diagnosed in men in 
the UK, hence it is the most common male malignancy in the UK (Cancer Research UK, 
2012).  In 2010, 10,721 men died of prostate cancer in the UK (Cancer Research UK, 
2012).   Prostate cancer occurs when tumours present in the prostate gland.  The prostate, 
which is located between the bladder and the rectum, composes part of the male 
reproductive system and is involved in the production and storage of seminal fluid.  
Prostate cancer can  present with an absence of symptoms however, common symptoms 
include changes in urinary or sexual functions.  Urinary symptoms may present as a result 
of prostatic swelling which can affect the flow of urine and, since the prostate is involved 
in production of seminal fluid, damage to this gland can affect sexual function (Caroll et 
al., 2005).   
In 2008 around 913,000 men were diagnosed with prostate cancer worldwide.  With more 
than 40,000 cases of prostate cancer being diagnosed annually in the UK, the incidence of 
prostate cancer has almost tripled over the last 30 years.  However, much of the increase 
has been attributed to better detection through widespread use of the prostate specific 
antigen (PSA) test (Cancer Research UK, 2012). 
Prostate cancer is predominantly a disease of the aged male with less than 0.1% of cases 
occurring in males under the age of fifty and more than three quarters of cases occurring in 
men over the age of sixty five (Cancer Research UK, 2012).  Therefore, with increasing 
age there is an increased risk of prostate cancer (Figure 1.8).  Although the strongest risk 
factor for prostate cancer is age, other factors are known to play a role.  For example, there 
is an increased risk of prostate cancer in first-degree relatives of those diagnosed with 
prostate cancer, particularly if they were diagnosed under the age of sixty.  West African 
and black Caribbean men are known to have two to three times more risk of developing 
prostate cancer than white men whereas Asian men are at a lower risk of developing 
prostate cancer than any other group.   
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Figure 1.8: Number of deaths and age-specific mortality rates, prostate cancer, UK 2008-2010. 
(Cancer Research UK, 2012) 
 
 
 
 
 
 
 
 
 
 
Although genetic factors undoubtedly account for some of the associated risk, lifestyle 
factors are known to play a large role since Asian men living in the UK have an increased 
risk of developing prostate cancer compared with Asian men living in Asia (Cancer 
Research UK, 2010; Cancer Research UK, 2012).      
Due largely to earlier detection, as a result of increased PSA testing in the UK, more than 
three quarters (>81%) of men diagnosed with prostate cancer now survive beyond five 
years.  This is compared with less than a third (<33%) of men in the 1970s) (Cancer 
Research UK, 2012).  Prostate cancer death rates have decreased by approximately 20% 
since the early 1990s when they peaked.  That said however, after lung cancer, prostate 
cancer is still the second most common cause of cancer death  in UK men and each year an 
estimated 10,150 men in the UK die from this disease (Cancer Research UK, 2010).   
Localised prostate cancer is curable by surgery and radiation therapy and the most widely 
used therapy against advanced prostate cancer is androgen ablation which almost always 
produces objective and clinical responses (Miki et al., 2007; Miki and Rhim, 2008).  
However, the majority of patients relapse with ablation-resistant prostate cancer which 
develops into metastatic disease (Miki and Rhim, 2008).  Therefore, the management of 
disease spread is a difficult task (Drewa and Styczynski, 2008).  There is currently no 
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treatment to cure progressive hormone-refractory metastatic prostate cancer (Miki and 
Rhim, 2008).   
Resistance to hormone ablation therapy and progression to hormone-refractory prostate 
cancer may be governed by a population of cancer cells which exhibit stem-like properties.  
Indeed, there has been much evidence implicating epithelial prostate stem cells as targets 
for malignant transformation in prostate cancer and this has been the topic of several well-
written reviews and research articles (Collins et al., 2005; Maitalnd et al., 2006; Lawson 
and Witte, 2007; Miki et al.,  2007; Signoretti and Loda, 2007; Kasper, 2008; Maitland and 
Collins, 2008; Miki and Rhim, 2008).  The role of cancer stem cells in prostate cancer 
initiation and progression has sparked enormous interest and, as such, prostate cancer stem 
cells are currently the subject of intense investigation. 
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1.3 Stem Cells 
1.3.1 Stem Cells: A Brief History 
In recent years, the topic of stem cells has roused much excitement, controversy and 
promise.  Through various isolation and transplantation techniques, stem cells are hoped to 
hold the key to the treatment of several incurable diseases.  During the 1950’s, a series of 
experiments by radiation biologists elucidated that the reintroduction of whole bone 
marrow cells to lethally irradiated mice could save them from an inevitable death 
(Houghton et al., 2007).  Further work, conducted by Till and McCulloch in the 1960’s, 
found that the restoration of a functional haematopoietic system was accompanied by 
colony formation in the spleen.  Furthermore, they found that the cells of these colonies 
were capable of forming more colonies when injected into a second mouse (Till and 
McCulloch, 1961).  These influential studies led to the first strict definition of so called 
“colony forming cells”, which we now refer to as “stem cells”. 
1.3.2 Stem Cell Characteristics 
Stem cells are the founders and sustainers of most, if not all, tissues and organs in the body 
(Szilvassy et al., 2003).  The ultimate, totipotent, stem cell is the fertilised oocyte which 
gives rise to a complex organism composed of approximately 200 types of specialised 
somatic cells (Wobus, 2001).  During embryonic development, the fertilised egg initially 
generates progeny that retain totipotency. As the cells continue to divide and determination 
occurs the cells begin to lose their ability to differentiate into multiple cell types and 
instead begin to gain the specialised functions necessary to generate mature organs (Sell, 
2004a).  The primary germinal layers, the ectoderm, endoderm and mesoderm are 
pluripotent and give rise to all tissues in the body.  
The role of stem cells is not restricted to tissue formation during embryogenesis as they are 
also known to reside in adult tissues and play an essential role in tissue repair, 
reconstitution and maintenance (Suzuki and Nakauchi, 2002).  Adult stem cells are 
believed to generate cells committed to specific tissues and organs and are thought to play 
a particular role in the maintenance and repair of such tissues throughout life (Sanders Jr et 
al., 2006).  Depending on the complexity of the tissues they form and maintain, stem cells 
vary in differentiation potential (potency).  Haematopoietic stem cells, for example, are 
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pluripotent, whereas prostate stem cells are an example of unipotent stem cells (Sell, 
2004b).   
One of the main hallmarks of stem cells is their ability to “self-renew” almost indefinitely 
without senescence.  Depending on which signals they receive, stem cells are capable of 
proliferating by symmetrical division, giving rise to two identical daughter (stem) cells, 
and asymmetrically, giving rise to an identical, quiescent daughter (stem) cell and an active 
differentiating (progenitor/transit amplifying) daughter cell (Verfaillie, 2002).  Such 
properties are unique to stem cells and therefore, distinguish them from progenitor or 
precursor cells, which are unable to self-renew indefinitely (Friel et al., 2005).  The 
generation of mortal progenitor/transit amplifying cells to take on the role of differentiation 
enables the stem cells to remain in a relatively dormant state thereby protecting the genome 
of the stem cell while delegating the genetically dangerous task of repeat-replication to a 
dispensable cell (Houghton et al., 2007). 
Stem cells are generally considered to constitute a minute population amongst a majority 
of differentiated, specialised cells.  As such, one of the challenges of stem cell research is 
the identification of specific markers which distinguish stem cells from their more 
differentiated  progeny.  Furthermore, stem cells have been shown to reside in the so-called 
“stem cell niche”, the specific microenvironment which plays a critical role in stem cell 
homeostasis and differentiation of its progeny (Miller et al., 2005).  Therefore, in order to 
maintain the potency of stem cells in culture, or to induce differentiation to generate stem-
cell progeny, it is necessary to recreate the correct microenvironment, as far as possible, 
using specific growth factors which either promote symmetrical division or induce 
differentiation, respectively.   
The functional identification of a tissue stem cell involves demonstrating that a single stem 
cell is capable of reconstituting a given tissue in vivo.  Although, to date, this remains to be 
demonstrated for the majority of candidate stem cells (Houghton et al., 2007).  
Nonetheless, this property has generated much interest in the scientific world due to hopes 
that stem cells may be exploited for a number of different clinical applications such as 
organ transplantation and repair of damaged tissues as a result of serious injury.   
Since totipotent stem cells derive naturally from embryonic tissue, despite the great 
potential and the expectation that it will revolutionise biomedical research, human 
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embryonic stem cell research has been the topic of much ethical controversy which has 
hindered the applications of human embryonic stem cells (Takahashi et al., 2007). 
1.4 Induced Pluripotent Stem Cells 
The induction of pluripotency in somatic cells is a new field which holds great promise for 
stem cell research.  Since human embryonic stem cells may have a multitude of 
applications, ranging from disease treatment to drug screening, in 2006, Yamanaka and 
colleagues developed a method to circumvent ethical issues by inducing pluripotency in 
somatic mouse cells by direct reprogramming.  This feat was achieved by exploiting a 
retrovirus to transfect the four transcription factors, Oct3/4, Sox2, c-Myc and Klf4 into 
murine fibroblasts to induce reprogramming into pluripotent stem cells which exhibited the 
morphology, growth properties and genetic signature of embryonic stem cells (Takahashi 
and Yamanaka, 2006).   
Following the success of induced pluripotency in mouse fibroblasts, this group went on to 
generate induced pluripotent stem (iPS) cells from human somatic cells, which they found 
to be comparable to human embryonic stem cells in terms of morphology, gene expression, 
proliferation, surface antigen expression, epigenetic status of pluripotent cell-specific 
genes, telomerase activity and teratoma formation (Takahashi et al., 2007). 
The concept of induced pluripotency has sparked intense interest and excitement in recent 
years, particularly because it may provide the means to generate patient-specific stem cells 
(Takahashi et al., 2007).   
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1.5  Cancer Stem Cells 
1.5.1  Cancer Stem Cells: An Overview 
Cancer is a class of diseases known to affect all vertebrate species and has been studied 
extensively for decades.  Although many of the mechanisms involved in carcinogenesis 
have been elucidated, several questions, including the cell of origin of cancer, remain 
unanswered (Houghton et al., 2007). The stochastic and clonal evolution models are 
among several models used to describe cancer development.  The general consensus is that 
cancer may arise in any cell as a result of many genetic mutations in oncogenes and tumour 
suppressor genes which consequently result in uncontrolled cell growth.  Most models 
claim that every cell within a tumour is capable of reconstituting new tumours (Gao, 2007).  
However, the cancer stem cell hypothesis challenges previous opinion and states that: 
“Tumours are hierarchical like normal tissues and only the rare subpopulation of 
cells at the pinnacle of that hierarchy have the unique biological properties 
necessary for tumour initiation.” (Lawson and Witte, 2007). 
Where the stochastic theory implies that cancer cells have equal malignancy, the cancer 
stem cell hypothesis opposes this by suggesting that only a rare subpopulation of cells have 
the biological properties required to initiate and sustain tumour growth.      
Cancer stem cells and their potential role in tumourigenesis have been the topic of much 
debate in recent years as they may help to elucidate some of the unknown phenomena in 
cancer research including cancer relapse and metastasis.   
1.5.2 The History of the Cancer Stem Cell Hypothesis 
Although cancer stem cells have only recently become the subjects of intense 
investigation, the stem cell theory of cancer dates back over 100 years, when parallels were 
drawn between the histology of certain tumours (such as teratocarcinomas) and the 
developing foetus (Houghton et al., 2007).  However, the discovery of oncogenes and 
tumour suppressor genes in the 1970s shifted the focus away from the stem cell theory as 
Nowell formulated the clonal evolution concept (Nowell, 1976; Clevers, 2011).   
Recent, advances in stem cell biology have led to the identification of adult tissue stem 
cells in various organs which, in turn, has enabled research into such populations as 
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potential candidates for malignant transformation.  In 1997, Bonnet and Dick prompted 
huge interest in the stem cell theory of cancer when they implicated adult (haematopoietic) 
stem cells in tumourigenesis.  In their study Bonnet and Dick demonstrated that a single 
rare leukaemia cell (present at 1 in 250,000 cells), with the cell surface marker expression 
pattern of haematopoietic stem cells (CD34+/CD38-), was capable of inducing leukaemia 
that was phenotypically identical to the parent tumour when transplanted into non-obese 
diabetic/severe combined immunodeficient (NOD/SICD) mice (Bonnet and Dick, 1997).  
In demonstrating tumourigenesis by these rare cells, Bonnet and Dick provided compelling 
evidence for the role of stem cells in the initiation of cancer.  Consequently, others sought 
to identify tumour-initiating cells (aka cancer stem cells) from heterogeneous populations 
of cells in solid malignancies.  In 2003, Al-Hajj et al., were the first to successfully identify 
and prospectively isolate cells with in vivo tumour-forming ability from a solid human 
tumour (breast).  Since then, putative cancer stem cells have been identified and isolated 
from several other solid malignancies including prostate, pancreatic, brain, colon, head and 
neck, lung, liver, ovarian and skin cancers (Singh et al., 2003; Collins et al., 2005; Szotek 
et al., 2006; Li et al., 2007; Ricci-Vitiani et al., 2007; Zhao et al., 2008; Visvader and 
Lindeman, 2008).        
1.5.3 What is a Cancer Stem Cell? 
The cancer stem cell is hypothesised to be the original cell of a tumour which is held solely 
responsible for tumourigenesis, tumour differentiation, tumour maintenance, tumour 
spread (metastasis) and tumour relapse following therapy (Moltzahn et al., 2008).  
Analogous to normal stem cells, cancer stem cells have been shown to demonstrate a 
marked capacity for proliferation, self-renewal and differentiation and are believed to 
constitute a very rare population of cells amongst a majority of non-tumourigenic tumour 
cells.  Furthermore, like normal stem cells, CSC’s are known to divide both symmetrically, 
giving rise to more CSC’s, and asymmetrically to give rise to progenitor-like cells which 
then go on to differentiate (Table 1.1).  Unlike the bulk of the tumour, which consists of 
rapidly proliferating cells in addition to post-mitotic, differentiated cells, CSCs have the 
capacity to self-renew therefore, contribute to the long-term sustenance of the tumour 
(Clevers, 2011).    
Aside from their self-renewal and differentiation capabilities, cancer stem cells have been 
shown to share many other properties with adult stem cells. For example, in accordance 
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with the numbers of normal stem cells reported in healthy tissue, cancer stem cells are 
frequently reported to comprise only 0.1-2% of the mass of a tumour (Ailles and 
Weissman, 2007).  Furthermore, cancer stem cells can spawn phenotypically diverse 
progeny with variable proliferative potential (Zhao et al., 2008).  Akin to normal stem 
cells, CSCs are reported to be highly resistant to drugs and toxins, through the expression 
of drug efflux pumps and high aldehyde dehydrogenase activity, and are resistant to 
radiotherapy and apoptosis, through a variety of mechanisms including active DNA-repair 
(Testa et al., 2007, Baumann et al., 2008; Iannolo et al., 2008; Johanness et al., 2008; 
Baumann et al., 2009; Fulda and Pervaiz, 2010; Koch et al., 2010; Wang et al., 2010; 
Zhang et al., 2010) (See Section 1.6.3.8). Considering these facts, the proposed properties 
of cancer stem cells may explain why disease relapses occur in many cancers, since it is 
believed that current cancer therapies only eliminate the bulk of the tumour, leaving the 
(resistant) cancer stem cells behind to reinitiate tumour growth (Neuzil et al., 2007). 
Figure 1.9 summarises the cancer stem cell hypothesis and reveals that CSC’s could 
potentially arise from mutated adult tissue stem cells (SC),  mutated progenitor cell/transit 
amplifying cells or differentiated cells which acquire mutations conferring de novo self-
renewal and differentiation capabilities.  Although the origin of the cancer stem cell has 
not yet been elucidated for every tumour type, there is evidence to support all three 
mechanisms and perhaps CSC’s can arise by any one of the three mechanisms proposed. 
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Figure 1.9: The cancer stem cell hypothesis.  Cancer stem cells may arise from the malignant 
transformation of adult tissue stem cells, progenitor/transit amplifying cells or differentiated cells which 
acquire stem-like properties.  Conventional therapies are unable to target, resistant, cancer stem cells 
which reside and subsequently repopulate the tumour.  Combination therapy targeting the rapidly diving 
bulk of the tumour and the quiescent cancer stem cells is required in order to achieve complete tumour 
eradication (Dunning et al., 2011). 
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Table 1.1  Demonstrating the properties of normal stem cells and cancer stem cells and the 
surface markers of each from different tissues (adapted from Zhao et al., 2008; Dunning et 
al., 2011). 
Properties 
 
Long-lived 
Constitute a minority among a majority of differentiated cells 
Capable of symmetrical & asymmetrical division 
Demonstrate a marked capacity for differentiation 
Capable of indefinite self-renewal 
Capable of anchorage independent growth 
Highly proliferative or quiescent (depending on signals from the microenvironment) 
Highly resistant to drugs and toxins 
Resistant to apoptosis 
Organ Cancer CSC Markers 
Normal SC 
Markers 
 
References 
 
 
Hematopoietic 
 
Leukaemia 
CD34
+
CD38
-
Thy1
-
Lin
-
 
CD34
+
CD38
-
Thy1
-
Lin
-
 
Baum et al., 1992; 
Lapidot et al., 1994 
 
Hemangioblastic 
 
Chronic Myeloid 
leukaemia 
Flk1
+
CD31
-
CD34
-
 Flk1
+
CD31
-
CD34
-
 Fang et al., 2005 
 
Breast 
 
Mammary cancer 
CD44
+
CD24
-
/
low 
ESA
+
Lin
-
 
CD24
med
 
Al-Hajj et al., 2003; 
Al-Hajj & Clarke, 
2004 
 
 
Brain 
 
Brain tumour CD133
+
Nestin
+
 CD133
+
Lin
-
 
Uchida et al., 2000; 
Singh et al., 2003 
 
Prostate 
 
Prostate cancer 
CD44
+
integrin α2β1hi 
CD133
+
 
Integrin α2β1
hi 
CD133
+
 
Richardson et al., 
2004; Collins et al., 
2005 
 
 
Skin 
 
Melanoma 
CD133
+
/CD166
+ 
Nestin
+
CD20
+
 
CD133
+
CD166
+
 
Nestin
+
 K19
+
 β1
+
 
Rappa et al.,  2008; 
Cotsarelis et al., 
1999; Fang D et al., 
2005 
Tongue, larynx, 
throat, sinus 
Head and neck 
squamous cell 
carcinoma 
CD44
+
Lin
-
 CD44
+
Lin
-
 Prince et al., 2007 
 
Pancreas 
 
Pancreatic cancer CD44
+
CD24
+
ESA
+
 CXCR4
+
Nestin
+
 
Li et al., 2007; Koblas 
et al., 2007 
 
Colon 
 
Colorectal cancer 
ESA
hi
/CD44
+
/ 
CD166
+
 CD133
+
 
CD133
+
 
Ricci-Vitiani et al.,  
2007; Dalerba et al.,  
2007 
 
Liver 
 
Liver cancer CD133
+
 CD133
+
ESA
+
 
Ma et al.,  2007; 
Schmelzer et al., 2007 
 
Lung 
 
Lung cancer CD133
+
 CD133
+
 Eramo et al., 2007 
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1.5.4 What is the Origin of Cancer Stem Cells? 
Although the cancer stem cell theory draws parallels between normal tissue stem cells and 
tumour-initiating cells, thus far, several studies have failed to address whether or not 
cancer arises due to the transformation of normal stem cells and rather suggests that, 
irrespective of the cell of origin, cancers are comprised of a heterogeneous population of 
cells which may be organised in a hierarchical manner much like normal tissues 
(Shackleton et al., 2009).  Hence, like normal tissues, which are maintained by a small 
population of self-renewing stem cells, tumours are thought to contain a stem-like 
component which drives proliferation and the origin of such a component is controversial, 
with more than one theory for the origin of cancer stem cells having been proposed.   
1.5.4.1  Evidence to Suggest CSCs Derive from Adult Stem Cells  
There is much evidence to support the notion that tumours frequently originate from the 
malignant transformation of adult tissue stem cells.  Not only are adult tissue stem cells the 
only cells believed to live long enough to accumulate sufficient genetic mutations and 
epigenetic modifications for malignant transformation, CSCs from several neoplasms have 
been shown to share many common markers with the normal tissue stem cells (Table 1.1).  
For example, when one considers the average epidermal cell turnover, which is 6 weeks for 
humans, it is evident that only a long-lived stem cell could be subjected to the extensive 
neoplastic changes required to induce malignancy (Bergtresser and Taylor, 1977; Miller et 
al., 2005).  The stem cell origin of corneal epithelial carcinomas is compellingly evidenced 
by the fact that the only carcinomas associated with this tissue occur in the peripheral 
corneal region, the site of corneal epithelial stem cells (Waring et al., 1984; Schermer et 
al., 1986; Miller et al., 2005).  Haematopoietic stem cells are believed to be the source of 
malignant transformation for chronic myeloid leukaemia and acute lymphoblastic 
leukaemias which demonstrate the Philadelphia chromosome.  The Philadelphia 
chromosome occurs as a result of a translocation between chromosome 9 and 22 and gives 
rise to the Oncogenic fusion gene BCR-ABL.  As this cytogenetic abnormality can be 
found in 95% of CML patients in myeloid, erythroid, megakaryocytic and B lymphoid 
cells, the original translocation is believed to occur in a haematopoietic stem cell (Sawyers, 
1999; Cobaleda et al., 2000; Miller et al., 2005).  Perhaps the most compelling evidence, 
implicating stem cells in tumour initiation, comes from studies of childhood leukaemia in 
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identical twins, revealing a common clonal origin in some instances, thus indicating that 
the initiation occurred prenatally (Greaves, 2003).  
These examples collectively provide evidence to suggest that, in some cancers, adult tissue 
stem cells are the site of malignant transformation hence, are the source of the tumour-
initiating cancer stem cells. 
1.5.4.2  Evidence to Suggest CSCs Derive from Progenitor/Transit Amplifying cells 
Although there is a strong case implicating stem cells as the original tumour-initiating 
cells, studies have also provided evidence to suggest that, in some cancers, cancer stem 
cells arise from the transformation of more committed, progenitor cells.  Given the 
relatively shorter life-span of progenitor cells, it is most likely that, for these cases, the 
initial genetic insults arise in stem cells but the final transforming events take place 
downstream, in early progenitor/transit-amplifying cells (Miller, 2005; Argyle and 
Blacking 2008).  Through studies on human and murine tumours carrying the BRCA1 
mutation, several groups have implicated luminal progenitor cells as the likely cell of 
origin for both luminal and basal-like breast carcinomas (Castano et al., 2012).  Studies on 
brain tumour development revealed that neural progenitor cells, which reverted to a stem-
like form following the acquisition of mutations conferring self-renewal abilities, were the 
likely candidates of malignant transformation (Zhao et al., 2008).  
1.5.4.3  Evidence to Suggest CSCs Derive from Differentiated cells 
There is also evidence to suggest that in certain contexts, paracrine interactions and 
epigenetic mechanisms may bestow stem-like properties on differentiated cells, a 
phenomenon referred to as dedifferentiation (Castano et al., 2012).  In addition to paracrine 
and epigenetic causes, it is plausible that activating mutations in otherwise silenced stem-
cell genes such as OCT3/4, SOX2, and C-MYC may confer stem-like properties in 
differentiated cells.  This is supported by the fact that it is possible to reprogram 
differentiated cells to induce pluripotency via transfection with the aforementioned genes 
(Takahashi et al., 2007; Yamanaka, 2007). 
In 2011, Chaffer et al., demonstrated that both normal and cancer stem-like cells could be 
generated de novo from more differentiated cells spontaneously in culture, thereby 
demonstrating plasticity in differentiated cells (Chaffer et al.,  2011).   
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In recent years, great interest has developed in the latent embryonic programme, shown to 
be reactivated in some cancer cells, known as epithelial to mesenchymal transition (EMT) 
(See section 1.6).  Although a link between this phenomenon and metastasis had been 
demonstrated previously, in 2008 Mani et al., released a groundbreaking paper which 
connected two fields of cancer research by establishing a link between EMT and the 
generation of cells with the properties of stem cells, thereby demonstrating that cancer-
stem-like cells could be generated via transdifferentiation of cancer cells (See section 1.6) 
(Mani et al., 2008). 
1.5.4.4  Other Sources of Cancer Stem Cells 
It is important to note that the three origins proposed are based on the most reported 
hypotheses of cancer stem cell development and are likely to be over-simplified.  In future, 
new insights into phenomena such as cell fusion and transdifferentiation will undoubtedly 
introduce new hypotheses addressing other plausible mechanisms of cancer stem cell 
development (Moltzahn et al., 2008).   
1.5.5  Evidence and Rationale for the Fxistence of CSCs 
Despite the fact that the cancer stem cell theory provides an explanation for many of the 
unexplained phenomena observed in cancer, such as tumour initiation, tumour 
heterogeneity and relapse following therapy, it is not accepted by all (Hill, 2006).    
However, despite criticism there is a large body of evidence to support the existence of a 
stem-like component in several malignancies.   
1.5.5.1  Cancer Stem Cells Share Several Properties With Normal Adult Stem Cells  
As previously described, putative cancer stem cells isolated from both cell lines and 
primary cultures have been shown to exhibit several properties common to normal adult 
stem cells (Table 1.1).  
1.5.5.2  Tumours are Heterogeneous 
Several studies have demonstrated heterogeneity among the cells present in cell lines, 
primary cultures, patient tumours and xenograft tumours.   
Heterogeneity in the behaviour of tumour cells is evidenced by the fact that only 1 in 1,000 
to 1 in 5,000 neuroblastoma, lung cancer and ovarian cancer cells have been demonstrated 
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to form colonies in soft agar, thereby revealing that only a small proportion of cells from 
these malignancies possess colony forming abilities (Argyle and Blacking, 2008).  In 
addition, sphere forming assays on cancer cell populations revealed that only a small 
population of cells, seeded at clonal density, were capable of anchorage independent 
growth, a property considered unique to stem cells (Dontu et al., 2003; Mani et al., 2008; 
Kong et al., 2010).  Furthermore, depletion of putative cancer stem cells from the bulk of 
the tumour cells often leads to a decrease in in vivo tumourigenicity (Al-Hajj et al., 2003; 
Wei et al., 2007), whereas, as few as 100 putative cancer stem cells have been shown to be 
capable of tumour initiation in mice (compared to tens of thousands of cells depleted of 
cancer stem cells which failed to form tumours) (Al-Hajj et al., 2003).   
These studies demonstrated the existence of small populations of cells with enhanced 
clonogenicity, sphere-forming capability and tumourigenicity among a majority of non-
clonogenic, non-sphere-forming and non-tumourigenic cells, findings which are consistent 
with the cancer stem cell hypothesis. 
1.5.5.3  Pathways That Regulate Normal Stem Cells are Implicated in Oncogenesis 
The balance between self-renewal and differentiation of stem cells is tightly maintained by 
regulatory signalling pathways.  Critical proteins involved in the regulation of 
proliferation, differentiation and self-renewal of healthy stem cells include Sonic 
Hedgehog, Wnt, Notch and Bmi-1 (Moltzahn et al., 2008).  Disruptions in these pathways, 
leading to up or down-regulation, have been shown to contribute to tumourigenesis in 
several cancers (Miller et al., 2005).  In fact, many of the genes involved in Hedgehog 
signalling are known oncogenes which can also function as tumour suppressors, high 
levels of β-catenin, an integral component of the canonical Wnt pathway, have been 
observed in most common human malignancies, and, depending on the cell type, Notch 
can function as an oncogene or a tumour suppressor gene (Zhao et al., 2008).  
These findings provide evidence for the stem cell origin of cancer, as mutations in inherent 
stem cell pathways, leading to the activation of oncogenes or inhibition of tumour 
suppressors, have been shown to contribute to tumourigenesis. 
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1.5.5.4  Cancers Demonstrate Expression of Embryonic Stem Cell Markers 
Tumour development has long been acknowledged to resemble abnormal embryogenesis 
(Pierce and Speers, 1988).  In recent years, several groups have identified the expression of 
embryonic stem (ES) cell markers in several human cancers (Jeter et al., 2009; Schoenhals 
et al., 2009; Guo et al., 2011).  Such markers included Oct4, Sox2, Nanog, Klf4 and c-
Myc, which have all been shown to induce pluripotency in somatic cells (Takahasi et al., 
2007; Theunissen et al., 2011).  Therefore, these genes are known to play key roles in the 
maintenance of pluripotency and self-renewal in stem cells.   
In rectal tumours, the expression of Oct4 and Sox2 were shown to correlate with poor 
disease free survival, thereby revealing a deleterious role of these transcription factors in 
cancer (Saigusa et al., 2009).  In addition, Nanog has been shown to contribute to tumour 
development in prostate cancer patients via promotion of CSC characteristics and 
resistance to androgens (Jeter et al., 2011).   
Therefore, not only have embryonic stem cell markers been identified in human tumours, 
their expression has also been demonstrated to correspond with tumour development and 
poor patient prognoses.  Cancer stem cells are believed to be the real driving force behind 
tumour development and progression therefore, the correlative expression of ES cell 
markers in aggressive tumours is consistent with the cancer stem cell hypothesis. 
1.5.5.5  Cancer Stem Cells Denote the Hallmarks of Cancer 
Perhaps the most important aspect of cancer stem cells is that they confer the so-called 
“hallmarks of cancer”, first outlined by Hanahan and Weinberg in 2001 and revised in 
2011 (See section 1.1.3) 
1.5.5.5.1 Sustainability of Proliferative Signalling and Evasion of Growth Suppressors 
As previously outlined, activation of oncogenes and inhibition of tumour suppressor genes 
is a long, multistep process which contributes greatly to the malignant transformation of 
cells and it has been argued that only stem cells live long enough to acquire enough 
mutations and epigenetic modifications to confer malignancy (Miller et al., 2005).  Several 
studies have demonstrated the significance of stem cell signalling pathways in oncogenesis 
and revealed the oncogenic and/or tumour suppressor functions of key genes in these 
pathways (Moltzahn et al., 2008; Zhao et al., 2008).  As such, it is feasible that an 
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accumulation of mutations and epigenetic modifications in adult tissue stem cells could 
lead to the malignant transformation of these cells and subsequent processes involved in 
tumourigenesis.   
1.5.5.5.2  Demonstration of Replicative Immortality 
The telomeres of most somatic cells shorten with each cell division and once the telomere 
shortens beyond the critical length, DNA damage pathways are activated, leading to cell 
death or replicative senescence (Hiyama and Hiyama, 2007).  Telomerase is a complex of a 
reverse transcriptase protein which adds telomeric repeats onto chromosome ends to 
prevent the replication-dependent loss of telomere and subsequent cellular senescence in 
highly proliferative cells such as germline cells and embryonic stem cells (Hiyama and 
Hiyama, 2007).  Therefore, telomerase activity enables prolonged cellular proliferation.  
To maintain tissue homeostasis and the balance between proliferation and cell death, with 
the exception of adult stem cells, telomerase expression is silenced in most adult somatic 
tissues.  Telomerase activity in adult stem cells grants these cells the longest telomeres 
within a given tissue, thereby enabling them to undergo multiple cell divisions before they 
finally senesce (Rajaraman et al., 2006; Marion and Blasco, 2010).  Although telomerase is 
usually expressed at low levels in stem cells, during periods of heightened proliferation it 
is known to be upregulated (Haik et al., 2000).  Furthermore, telomerase activity is readily 
detected in most cancers (Aranois and Greider, 2005).  It was previously believed that 
cancer cells reactivate telomerase in late stages of cancer progression, however, the 
malignant transformation of adult tissue stem cells which already demonstrate telomerase 
activity is, perhaps, a more feasible explanation.   
Therefore, the expression of telomerase by cancer cells conceivably reflects one of the 
inherent properties of the cells from which they derive (stem cells). 
1.5.5.5.3  Reprogramming of energy metabolism 
Akin to cancer cells, stem cells have been shown to exhibit the “Warburg effect” whereby 
they maintain anaerobic metabolism, even in the presence of oxygen (aka aerobic 
glycolysis) (Varum et al., 2011).  This process enables these cells to survive in hypoxic 
environments.  In fact, it is believed that self-renewal and differentiation of stem cells are 
well maintained in hypoxia whereas proliferation dominates with increasing oxygen levels 
(Bjerkvig et al., 2009).  The reprogramming of energy metabolism is yet another feature 
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shared by stem cells and cancer cells, and the PTEN/PI3K/Akt pathway, involved in 
glycolysis and often activated in cancer, has been shown to be particularly up-regulated in 
cancer stem-like cells (Kendall et al., 2008).  This pathway is also critical for the self-
renewal of haematopoietic stem cells (Miyamoto et al., 2007). However, when activated in 
cancer, the PI3K pathway confers a competitive growth advantage, metastatic competence 
and, often, therapeutic resistance (Hennessy et al., 2005). 
Cancer cells and stem cells, therefore, both demonstrate reprogramming of energy 
metabolism thus, revealing another connection between cancer and stem cells. 
1.5.5.5.4  Avoidance of Immune Destruction 
Among tumour cells, cancer stem cells are particularly enhanced in their ability to evade 
immune destruction.  Immune recognition and consequent destruction of cancer stem cells 
are actively disturbed by a number of processes including altered immunogenicity of 
CSCs, production of CSC-derived regulatory molecules and direct interaction between 
CSCs and immune cells (Qi et al., 2012).  In addition, transdifferentiation of cancer cells to 
mesenchymal stem-like cells via epithelial to mesenchymal transition (See Section 1.6) 
may provide an additional mechanism of immune evasion. 
Cancer stem cells have been shown to exhibit loss of MHC class I molecules and 
selectively silence tumour associated antigen expression thereby resulting in resistance to 
immune rejection.  This has been demonstrated in ABCB5-positive malignant melanoma 
initiating cells (MMICs) with absent/downregulated MHC class I molecules and in MMICs 
which lacked expression of the tumour-associated antigen MART-1 (melanoma antigen 
recognised by T-cells) (Qi et al., 2012).  One study, investigating the immunogenicity of 
putative astrocytoma and glioblastoma cancer stem cells (CD133+ cells), revealed that the 
majority of CD133 expressing cells did not express detectable MHC class I or NK cell-
activating ligands. Therefore, not only would such cells prove resistant to adaptive and 
innate immune surveillance, they would appear to be unsuitable targets for 
immunotherapy. However, upregulation of MHC class I and NK cell ligands was 
successfully achieved following treatment with interferon gamma hence the 
immunogenicity of the cells was restored (Wu et al., 2007).   
Expression of the immunosuppressive HLA-G molecule is generally restricted to a few cell 
types including stem cells.  However, HLA-G has also been detected in several human 
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malignancies and, via several molecular mechanisms, this molecule induces 
immunosuppression thereby granting a selective advantage to cancer cells (Sheu and Shih, 
2010).  Very recently, studies have begun to reveal the expression of HLA-G by putative 
cancer stem cells and metastatic bone marrow-infiltrating cells (Brown et al., 2012; 
Morandi et al., 2012).  The expression of HLA-G in putative cancer stem cells may 
provide evidence to suggest that these cells arise from the malignant transformation of 
adult tissue stem cells, which inherently express HLA-G.  Alternatively, HLA-G 
expression on metastatic stem-like cells may occur as a result of EMT which has been 
shown to generate cells with the properties of mesenchymal stem cells (Battula et al., 
2010).  This is feasible as mesenchymal stem cells have been shown to constitutively 
express HLA-G in addition to secreting other immunomodulatory molecules such as 
transforming growth factor beta (TGF-β) (Nasef et al., 2007; Qi et al., 2012). 
The expression of HLA-G by cancer stem cells may explain why these cells are not 
successfully eradicated by the immune system and hence, why tumour growth is permitted. 
In addition to alterations in HLA status, cancer stem cells have been shown to suppress T-
cell immunity via secretion of immunosuppressive cytokines including interleukin 4 (IL-
4), interleukin 10 (IL-10) and TGF-β (Qi et al., 2012).  High levels of IL-4 and its receptor 
have been directly detected in CD133-positive putative colon cancer stem cells whereas 
glioblastoma stem cells were shown to inhibit interferon gamma (IFN-γ) secretion whilst 
upregulating IL-10 secretion by peripheral blood mononuclear cells (PBMCs) in co-culture 
(Sabbagh et al.,  2009; Qi et al.,  2012).  Transforming growth factor beta has been shown 
to directly target the function of cytotoxic T lymphocytes (CTL), having a negative effect 
on their anti-tumour capabilities (Thomas and Massague, 2005).  Shipitsin and colleagues 
(2007) demonstrated that the TGF-β pathway was specifically activated in the cancer stem 
cell component of malignant breast tissue.  In line with this finding, secreted morphogens 
of the TGF-β superfamily and their receptors were shown to be preferentially expressed by 
CD133-positive brain cancer stem cells and ABCB5-positive MMICs (Piccirillo et al., 
2006; Schatton et al., 2008; Qi et al., 2012). 
Collectively, these studies demonstrate the immunosuppressive role of putative cancer 
stem cells via a wide range of mechanisms, some of which are innate to normal stem cells. 
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1.5.5.5.5  Resistance to Apoptosis 
As previously explained, akin to normal stem cells, cancer stem cells are capable of 
resisting apoptosis using a number of different mechanisms.  Examples of these include the 
secretion of IL-4, which has been reported to inhibit apoptosis by enhancing the expression 
of anti-apoptotic proteins; PED, cFLIP and Bcl-XL in many cancer cell lines  and 
increased expression of apoptosis-inhibiting genes such as Bcl-2, c-I, AP2, XIAP and 
NAIP by CD133-expressing putative glioblastoma stem cells (Qi et al., 2012; Conticello et 
al.,  2004).  Furthermore, putative glioblastoma stem cells were shown to down-regulate 
pro-apoptotic genes at the mRNA level (Liu et al., 2006). 
In addition to inherent mechanisms, the induction of epithelial to mesenchymal transition 
by cancer cells has been shown to contribute to apoptotic resistance (Hollier et al., 2009) 
which may be due to the generation of mesenchymal stem-like cells.  This is arguable 
because mesenchymal stem cells have been shown to be highly resistant to chemotherapy-
induced apoptosis (Mueller et al., 2006). 
Therefore, cancer stem cells demonstrate heightened resistance to apoptosis and, as such, 
are thought to contribute significantly to the failure of therapy and disease relapse (See 
Section 1.6.3.8) 
1.5.5.5.6  Induction of Angiogenesis 
Several studies have revealed cancer stem cells to be the most strongly angiogenic cells 
within a tumour (Ribatti, 2012).  Indeed, blood vessel-forming cancer stem cells 
expressing markers of vascular endothelium have even been described (Ricci-Vitiani, et 
al., 2010; Wang et al., 2010).  In addition, brain tumour stem cells have been shown to 
interact with brain tumour endothelial cells, which were shown to promote the expansion 
of brain CSCs and accelerate tumour growth (Calabrese et al., 2007).  The differentiation 
of cancer stem cells to endothelial cells was achieved when Ricci-Vitiani et al., cultured 
glioblastoma stem-like cells in conditions favourable for the differentiation of stem cells 
into endothelial cells.  This was subsequently validated in an in vivo murine model when 
injected glioblastoma stem cells generated large anaplastic tumour xenografts 
demonstrating vessel wall formation by human endothelial cells.  This was also confirmed 
in studies by Wang et al., 2010. 
41 
 
In addition to being capable of transdifferentiating into endothelial cells, cancer stem cells 
have been shown to produce elevated levels of the pro-angiogenic vascular endothelial 
growth factor (VEGF), compared with the bulk of the tumour (Bao et al.,  2006).  
Therefore, cancer stem cells have been shown to contribute significantly to angiogenesis, 
even more so than their more differentiated counterparts.  
1.5.5.5.7  Activation of Invasion and Metastasis 
Epithelial to mesenchymal transition (EMT) is largely implicated in metastasis and will be 
discussed in more detail in Section 1.6. 
In addition to the cancer stem-like cells generated by EMT, there is evidence to suggest the 
role of other stem-like populations in invasion and metastasis.  In recent years, researchers 
have demonstrated cellular heterogeneity within the cancer stem cell compartment, with 
some CSCs demonstrating enhanced metastatic capabilities (Sampieri and Foddle, 2012).  
For example, Hermann et al., 2007 revealed that CXCR4-positive pancreatic cancer cells 
within the CD133-positive CSC compartment demonstrated enhanced migratory capacity 
thus, were shown to possess high malignant and metastatic potential (Herman et a, 2007).  
Furthermore, in an in vivo model, only the CXCR4-positive/CD133-positive cells gave rise 
to liver metastases.  Similarly, Pang et al., 2010 identified a subpopulation of CD26-
expressing colon cancer stem cells.  These cells were detected in both primary and 
metastatic tumours isolated from high-grade colorectal cancer patients however, only one 
third of the primary tumours contained a population of CD26-positive cells  compared to 
100% of the metastases examined (n=16).  Furthermore, in vivo studies revealed that, 
although CD26-negative cells were tumourigenic, only CD26-positive cells gave rise to 
distant metastases (Pang et al., 2010).  Perhaps the most compelling evidence 
demonstrating the role of CD26-positive cancer stem cells in metastasis was the fact that 
none of the patients without CD26-positive cells in their primary tumours developed 
metastases, whereas the majority of patients with CD26-positive cells did (Pang et al., 
2010). 
Further evidence implicating CSCs in metastasis was demonstrated by Charafe-Jauffret et 
al., (2009), who revealed that breast cancer cells expressing high levels of aldehyde 
dehydrogenase 1 (ALDH1), an enzyme involved in stem cell survival and early 
differentiation, were significantly more metastatic in an in vivo model.  This finding was 
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confirmed in a similar study by Croker et al (2009).  In another study, ALDH1 was shown 
to be a predictor of poor clinical outcome for breast cancer patients (Ginestier et al., 2007). 
Collectively, these data provide compelling evidence for the critical role of cancer stem 
cells in metastasis and, through a variety of mechanisms, it is evident that cancer stem cells 
exhibit the hallmarks of cancer, stipulated by Hanahan and Weinberg (2000; 2011).  It is 
however, apparent that tumours present with more than one stem-like cell population; the 
cells which may represent transformed stem/progenitor/dedifferentiated cells, and the 
mesenchymal stem-like cells generated by EMT, both of which appear to contribute 
significantly to tumourigenesis.  The existence of more than one so called “cancer stem 
cell” population will be discussed in more detail in Section 1.6.3.7. 
1.5.6  Identification, Isolation and Enrichment of CSCs 
As cancer stem cells are reported to constitute a rare population of cells within a given 
tumour, it is essential to accurately identify these cells prior to isolation.  Direct 
identification of CSC’s can be achieved by flow cytometry-based assays using 
characteristic surface or internal markers, DNA labelling and assessing the ability of CSCs 
to actively expel dyes, such as Hoechst 33342 using drug transporter proteins.  In addition, 
fluorescence microscopy is frequently used to identify cells expressing putative cancer 
stem cell markers.  However, these methods are not entirely robust since CSC markers may 
be common to other cell types and some progenitor cells are also known to possess active 
drug efflux mechanisms conferred by the ABC transporter ABCG2, which has been 
implicated in multiple drug resistance (Argyle and Blacking, 2008).   In addition, DNA 
labelling is reliant on the quiescent nature of CSC’s which is common to normal tissue 
stem cells (Moltzahn et al., 2008).  Therefore, due to the inability to distinguish between 
normal and cancer stem cells in many cases, none of the CSC identification methods are 
completely reliable.  
Table 1.1 shows some of the most common cell surface markers used to identify and 
isolate cancer stem cells and normal stem cells.  Perhaps the two most common cell-
surface CSC markers, which have been used to identify putative cancer stem cells from 
several tissues, are CD44 and CD133, as such, antibodies to identify these markers and kits 
to isolate them from a mixed population of tumour cells are readily, commercially 
available.  Putative cancer stem cells can be isolated based on the expression of cell 
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surface-proteins by cell sorting or alternatively, by magnetic-activated cell sorting 
(MACS), a technique which is argued to be gentler on the cells than cell sorting. However, 
since CSCs constitute a rare population of the tumour, an enrichment step may be required 
in order to generate enough CSCs to interrogate thoroughly.  Enrichment steps may include 
those which exploit the unique properties of cancer stem cells to grow under certain 
conditions, such as sphere-forming assays, in which tumour cells are grown in non-
adherent conditions to enrich for cells capable of anchorage independent growth, or the use 
of harsh treatments which only the resistant cells, including the CSC population, can 
survive.  Such treatments include the use of chemotherapeutic agents and radiation since 
the ABC transporters and active DNA repair mechanisms permit the resistant CSCs to 
reside (Huang et al., 2007). 
In order to satisfy the conditions of a cancer stem cell, several criteria must be tested, 
exploiting the specific growth characteristics unique to cancer stem cells.  Numerous 
assays have been used to assess cancer “stemness”, the most common of which are colony 
forming assays (a), assessing cancer stem cell proliferation and differentiation capabilities, 
sphere-forming-based self-renewal assays (b), whereby spheres are grown and repeatedly 
dissociated and re-seeded  in order to assess the ability of CSCs to self-renew indefinitely, 
and in vivo transplantation of enriched CSCs in immunocompromised mice (c), confirming 
their tumour-initiating capability and self-renewal capacity (Figure 1.10).  
 
 
 
 
 
 
 
 
 
 
Figure 1.10:  Common cancer stem cell assays a) colony forming assay, b) self-renewal assay, C) in vivo 
tumourigenesis assay (Adapted from Visvader and Lindeman, 2008) 
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Once putative cancer stem cells are isolated from the bulk of the tumour population, it is 
important to maintain them in defined serum-free conditions, with specific growth factors 
which promote self-renewal while inhibiting differentiation.  There are several 
commercially available media and supplements for the maintenance of normal and cancer 
stem cells. 
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1.6  Epithelial to Mesenchymal Transition 
1.6.1  Epithelial to mesenchymal Transition: An overview 
Epithelial to mesenchymal transition (EMT) is a complex biological process which is 
activated from the beginning of life, during implantation and embryogenesis, throughout 
life, during organ remodelling and tissue repair in response to injury, and in pathological 
states such as organ fibrosis and cancer.  The EMT programme enables polarised epithelial 
cells to undergo multiple biochemical changes, permitting them to assume a mesenchymal 
phenotype - which is entirely different from that of an epithelial cell (Kalluri, 2009).  
1.6.2  Epithelial and Mesenchymal Tissues 
The differences between epithelial and mesenchymal tissues are illustrated using a prostate 
gland as an example (Figure 1.11).  Although epithelia may originate from any of the three 
germ layers, ectoderm, mesoderm or endoderm, all epithelial tissues share several cellular 
and molecular characteristics (Blanpain et al., 2007).  Epithelial tissues line the cavities of 
the human body and comprise the main functional unit (parenchyma) of many glands, such 
as the prostate.  These tissues perform several critical functions including protection, 
filtration, absorption, diffusion and secretion (Hollier et al., 2009).  For example, the 
secretory luminal epithelial cells (Figure 1.11, blue cells) of the prostate secrete prostatic 
fluids containing prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) into 
the lumen.  Differentiated epithelial cells possess a rich network of cytokeratin 
intermediate filaments, which can distinguish them from mesenchymal cells.  Epithelial 
cells are well organised in continuous sheets of cuboidal or columnar cells connected 
laterally by intercellular adhesion complexes (Foroni et al., 2012).  Such adhesion 
complexes, including tight junctions, adherens junctions, gap junctions and desmosomes, 
ensure tight connections between adjacent cells.  The epithelial layer is polarised, with 
distinction between the two sides, one being defined as apical and the other as basal.  
Apical-basal polarity, localised distribution of adhesion molecules and polarised 
organisation of the actin cytoskeleton are maintained by the anchorage of the epithelial 
cells to the basement membrane in addition to the lateral cell-cell adhesive junctions.  Such 
adhesive structures maintain the shape and position of the epithelial cells, thereby 
preventing their migration away from the epithelial layer and entry into the underlying 
stromal compartment (Hollier et al., 2009).   
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Figure 1.11:  A functional prostate gland, illustrating the differences between the epithelial and 
mesenchymal (stromal) cells. (Adapted from Czyż et al., 2012). 
As is evident, in contrast to the epithelial compartment, the stromal compartment is 
comprised of loosely organised mesenchymal cells and fibroblasts which are not closely 
associated with the basement membrane (Figure 1.11).  Unlike epithelial cells, these cells 
form only weak contacts with adjacent cells, display spindle-like morphology and exhibit 
front to back polarity (Hollier et al., 2009).  In addition to morphological features, 
mesenchymal cells are commonly identified by their expression of the intermediate 
filament vimentin.  Mesenchymal cells function to support the growth of the parenchyma 
via production and secretion of extracellular matrix proteins and growth factors.  These 
cells are highly mobile and produce and secrete extracellular matrix degrading enzymes 
which facilitate their invasion and migration through surrounding tissues. 
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1.6.3 The EMT Programme  
The EMT programme involves a complex sequence of events which enable polarised 
epithelial cells, which are typically tightly bound to one another and associated with the 
basement membrane, to shed their epithelial traits and assume a mesenchymal cell 
phenotype (Figure 1.12).  Thereby conferring increased motility, via disassembly of cell-
cell contacts and acquired vimentin expression, enhanced invasiveness, via production of 
extracellular matrix degrading enzymes, increased production of extracellular matrix 
proteins, immunosuppressive function and increased resistance to apoptosis. (Kalluri and 
Weinberg, 2009; Kudo-Saito et al., 2009).  This process is marked by a decrease in the 
expression of epithelial markers, such as cytokeratins, E-Cadherin and pakoglobin and a 
concomitant increase in the expression of mesenchymal-associated markers including 
vimentin, N-Cadherin, smooth muscle actin (SMA), fibronectin and matrix 
metalloproteinases (MMPS) (Hollier et al., 2009).  A shift from cobblestone morphology, 
characteristic of epithelial cells, to spindle-like, fibroblastic morphology is also evident in 
monolayer culture (Figure 1.13), along with increased motility which can be observed 
using time-lapse imaging. 
Several reversible molecular processes are engaged for the initiation and progression of 
EMT, a programme involving activation of numerous transcription factors, suppression 
and upregulation of specific microRNAs (miRNAs), drastic reorganisation of the 
cytoskeletal network, suppression and upregulation of specific cell-surface proteins and 
synthesis of extracellular matrix proteins and MMPs.  The epigenetic nature of the 
activators of this programme in several contexts often renders it a transient and reversible 
process.  Indeed, the reverse transition from a mesenchymal to an epithelial phenotype 
(MET) is also known to occur and, among other functions, is known to play a critical role 
in the generation of mesoderm-derived epithelial organs such as the kidneys (Thiery et al., 
2009).  Therefore, this cyclic process is characterised by high phenotypic plasticity and is 
predominantly activated and regulated by environmental factors and contextual signals 
(Figure1.12) (Brabletz, 2012). 
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Figure 1.12:  Epithelial to mesenchymal transition (EMT) and the reverse process mesenchymal to 
epithelial transition (MET).  This figure demonstrates that epithelial cells are highly plastic and that 
the transitions between epithelial and mesenchymal states are often transient therefore, cyclic.  Key 
proteins characteristic of either epithelial or mesenchymal cells are listed, along with some of the 
significant events and the effectors which regulate EMT and MET.  ECM – extracellular matrix, 
FGFR2 – fibroblast-growth-factor receptor 2, FSP1 – fibroblast-specific protein-1, MFs – 
microfilaments.  (Adapted from Thiery and Sleeman, 2006).   
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Figure 1.13:  Examples of epithelial and mesenchymal morphologies observed in clonally derived 
populations from the prostate cancer cell line OPCT-1 in 2D culture.  A) Pure population of 
epithelial cells exhibiting typical cobblestone morphology B) Pure population of EMT-derived 
mesenchymal cells with characteristic spindle-like morphology C) Mixed population of epithelial and 
mesenchymal cells with mesenchymal cells surrounding the colonies of epithelial cells.  Image 
magnification at x10.  
A 
B 
C 
50 
 
Epithelial to mesenchymal transitions contribute to distinct biological processes where they 
vary in functional consequences.  In some settings, EMT contributes to essential 
developmental and homeostatic processes however, in other contexts it contributes towards 
disease states and may have fatal consequences.  Based on the biological and biomarker 
context in which they occur, epithelial to mesenchymal transitions are classified into three 
subtypes, Types 1-3 (Kalluri, 2009). 
1.6.3.1 Type 1 EMT:Involved in Implantation, Embryogenesis & Organ Development 
Several Type 1 epithelial to mesenchymal transitions are known to accompany and 
underlie embryonic morphogenesis.  For example, following the earliest stages of 
embryogenesis, Type 1 EMTs play a role in embryonic implantation and initiation of 
placental formation.  Subsequent formation of the three germ layers during gastrulation is 
also an EMT-dependent process, as the primitive ectodermal cells of the primitive streak 
initiate the EMT programme prior to ingression and migrate to eventually form the 
endoderm and mesoderm, thereby transforming the embryo from a single layer to three 
germ layers (Kalluri and Weinberg, 2009; Foroni et al., 2012).  Indeed, the significant role 
of EMT in this process is emphasised by the fact that without EMT, gastrulation cannot 
occur, hence, embryonic development is halted at the blastula stage (Hollier et al., 2009).  
The EMT process is also key in the development of the neural crest, whereby cells of the 
neural plate gain a mesenchymal phenotype via EMT to enable their migration through the 
periphery where they differentiate into different cell types (Kalluri and Weinberg, 2009).  
In addition to these examples, Type 1 EMT has also been implicated in several other 
developmental processes which will not be discussed here. 
1.6.3.2 Type 2 EMT:Involved in Tissue Regeneration and Organ Fibrosis 
Type 2 EMTs are activated in the context of inflammation, in response to growth factors 
such as TGF-β, EGF and FGF2 secreted by inflammatory cells, and are associated with 
wound healing, tissue regeneration and organ fibrosis.  In contrast to Type 1 and Type 3 
EMTs, which generate mesenchymal cells, Type 2 EMTs generate fibroblasts from mature 
epithelial cells (Hollier et  al., 2009; Zeisberg and Neilson, 2009). 
1.6.3.2.1  Wound Healing and Tissue Regeneration 
The activation of Type 2 EMT in response to epithelial tissue injury has been shown to 
facilitate wound healing and restore the original tissue architecture.  This can be 
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demonstrated using in vitro models, whereby an artificial scratch is introduced to a 
confluent monolayer of epithelial cells which are then monitored during re-growth or by 
in/ex vivo wound healing assays conducted on mice.  These assays reveal that epithelia 
assume a mesenchymal phenotype in order to migrate and close the artificial wound, in 
vitro, or in order to invade the surrounding tissue and migrate to the wound site to 
participate in re-epithelialisation, in/ex vivo (Hollier et al., 2009; Vuoriluoto et al., 2010).   
The upregulated expression of the transcription factor Slug/Snail2, a direct repressor of E-
Cadherin known to play an influential role in EMT, in cells bordering in vitro and in/ex 
vivo wounds provides further evidence for the role of EMT in tissue regeneration.  
Furthermore, ectopic expression of Slug has been shown to accelerate wound healing 
(Bolos et al., 2002; Savagner et al., 2005). 
1.6.3.2.2  Organ Fibrosis 
In addition to assisting essential physiological processes, epithelial to mesenchymal 
transitions may also contribute to pathological processes.  Organ fibrosis, which occurs as 
a result of Type 2 EMT in response to inflammation and/or tissue damage, may interfere 
with organ function and may prove fatal.  The significant contribution of Type 2 EMT in 
renal fibrosis is highlighted by the fact that over a third of the fibroblasts which accumulate 
in the interstitials of diseased kidneys originate from tubular epithelia at the site of injury 
(Kalluri and Neilson, 2003).  In addition, there is evidence to suggest that endothelial cells 
undergo an analogous transition EndMT and contribute to diseases such as cardiac fibrosis 
(Kalluri and Weinberg, 2009).   
Malignant transformation may occur as a severe complication of non-healing ulcers and 
the development of cancer in fibrotic tissue is also a common event (Schaefer and Werner, 
2008).  Many of the mechanisms which govern wound healing are known to regulate 
tumour progression (Hollier et al., 2009).  Analogous observations made between the 
composition of healing wounds and tumour stroma led Dvorak, 1986, to propose that 
“tumors are wounds that do not heal”.  This analogy is supported by the fact that, akin to 
healing wounds, cancer cells have been shown to activate epithelial to mesenchymal 
transitions.  
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1.6.3.3  Type 3 EMT: Involved in Tumour Progression and Metastasis 
In recent years, Type 3 EMT has been proposed as the critical mechanism commandeered 
by epithelial cancer cells, resulting in the acquisition of malignant characteristics enabling 
invasion, migration, apoptotic resistance and immunosuppression, all of which are required 
for progression through the invasion-metastasis cascade.  Furthermore, in 2008, Mani et 
al., linked EMT with the acquisition of stem-like properties thereby accounting for the 
characteristics required for the successful establishment of macrometastases (Mani et al., 
2008).   
Interestingly, evidence of Type 2 EMTs generating fibroblasts can be observed in the 
context of cancer.  For example, fibroblasts adjacent to primary epithelial tumours have 
been shown to share some genetic mutations with the cancer cells, suggesting that they 
may have arisen as a result of Type 2 EMT prior to the full onset of tumourigenesis 
(Kurose et al., 2002).  However, studies comparing mutations in cancer cells and cancer-
associated fibroblasts (myofibroblasts) isolated from distant metastases failed to denote a 
cancer cell of origin for these fibroblasts, thereby suggesting that epithelial tumour cells 
are no longer a source of fibroblasts (Zeisberg and Neilson, 2009).  It is worth noting that 
unlike Type 2 EMT, Type 3 EMT is not a mechanism for generating fibroblasts and is 
rather a means to acquire an invasive and migratory phenotype to enable successful 
completion of the invasion-metastasis cascade (Zeisberg and Neilson, 2009). 
It is now widely accepted that as cancer progresses, some cells at the periphery of the 
primary tumour are capable of transitioning (via EMT) into a mesenchymal state in order 
to facilitate the metastatic process.  Activation of the EMT programme suppresses proteins, 
such as E-Cadherin, involved in cell adhesion whilst upregulating proteins involved in 
invasion, such as MMPs, and migration, such as vimentin.  Indeed, contrary to epithelial 
cells, which reside in tight colonies with strong cell-cell and cell-substratum adhesion, 
mesenchymal cells possess several of the key attributes which facilitate tissue invasion and 
migration, in addition to apoptotic resistance and immunosuppressive functions, which 
ensure their survival during the invasion-metastasis cascade.   
The observation that a high proportion of metastases are differentiated, often reflecting the 
heterogeneity of the corresponding primary tumour without an apparent mesenchymal 
phenotype, seems to contradict the notion that secondary tumours arise from disseminated 
mesenchymal-like cells (Fornoi et al., 2012).  However, this apparent paradox has been 
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explained by the fact that the epigenetic mechanisms which govern EMT, in many cases, 
are reversible.  Hence, tumour cells may undergo transient transitions, initially activating 
EMT to escape from the primary tumour, invade, disseminate and seed at distant sites 
where they are then believed to re-differentiate via the reverse transition, MET, in order to 
colonise and form macrometastases (Brabletz, 2012).  However, this process does not 
account for the existence of undifferentiated metastases.  In order to address this, Thomas 
Brabletz (2012) recently proposed a simplified classification of two principle types of 
metastasis formation, termed plasticity type I metastasis and genetic type II metastasis.  
Plasticity type I metastasis corresponds to those with a differentiated phenotype, generated 
by highly plastic cells capable of activating both EMT and MET as a result of epigenetic 
modifications triggered by environmental and contextual signals.  Conversely, genetic type 
II metastases present with an undifferentiated phenotype whereby the cells remain in a 
permanent mesenchymal-like state and only weak differentiation is possible/necessary for 
the formation of macrometastases.  These are believed to arise as a result of an irreversible 
EMT governed by cell intrinsic properties and permanent genetic alterations.  Hence, the 
key differences between the two proposed metastases are the cause of the EMT, which 
therefore dictates whether or not it is reversible (Brabletz, 2012).  As the events governing 
plasticity type I metastasis are more common and consequently, better understood, this 
introduction will mainly focus on the triggers, mechanisms and evidence of the EMT and 
MET events involved in plasticity type I.  For more information on genetic type II 
metastasis, please refer to the article by Thomas Brabletz (2012).  
1.6.3.4  Induction of EMT in Carcinoma Cells 
Irrespective of the physiological or pathological outcome, epithelial to mesenchymal 
transitions are very similar at the cellular level, as they are triggered by like stimuli and are 
governed by analogous effecter molecules, signalling pathways and regulators.  The EMT 
programme involves a complex series of events, requiring significant cross-talk among 
EMT-inducing signals, several interacting transcription factors and a complex regulatory 
network consisting of multiple positive and negative feedback loops (Garcia de Herreros 
and Baulida, 2012; Foroni et al., 2012).  Indeed, the transition from an epithelial cell type 
to a phenotypically distinct, mesenchymal-like cell, capable of synthesising and secreting 
new growth factors, ECM proteins and MMPs, is not a simple task. 
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Several stimuli have been shown to induce EMT in cancer cells.  These include paracrine 
growth factor signalling, tumour-stromal cell interactions, hypoxic conditions and even 
chemotherapy (Cannito et al., 2008; Polyak and Weinberg, 2009; Foroni et al., 2012; Sun 
et al., 2012).  Tumour-associated stroma is believed to contribute significantly to EMT 
induction.  In fact, in some circumstances, tumours are believed to recruit different cell 
types (fibroblasts, macrophages etc.) into the surrounding stroma which activate the stroma 
to induce EMT via heterotypical signalling to the cancer cells (Polyak and Weinberg, 
2009; Foroni et al., 2012).  Several secreted molecules including extracellular matrix 
components and growth factors such as epidermal growth factors (EGF), hepatocyte 
growth factors (HGF), fibroblast growth factors (FGF), platelet derived growth factors 
(PDGF), Insulin-like growth factors 1 and 2 (IGF-1 and -2) and members of the TGF-β 
family have been shown to induce EMT in different cell types (Hollier et al., 2009; Kalluri 
and Weinberg, 2009; Foroni et al., 2012).  These molecules trigger EMT via the functional 
activation of a series of EMT-associated transcription factors including Snail1, Snail2 (aka 
Slug), zinc-finger E-box-binding homobox 1 and 2 (ZEB1 and ZEB2), Twist, Goosecoid 
and FOXC2 which act pleiotropically to choreograph the EMT programme (Haraguchi, 
2009; Das et al., 2009; Yang et al., 2004; Li and Zhou, 2011; Bolos et al., 2002; Casas et 
al., 2011; Savagner et al., 1997; Kalluri and Weinberg, 2009). 
Several signal transduction pathways including Notch, Hedgehog, Integrin and Wnt 
signalling have been shown to coordinate EMT programmes, some of which are 
developmental pathways.  The involvement of these pathways in EMT provides another 
link between EMT and stemness (Bailey et al., 2007; Foroni et al., 2012). 
Loss of E-Cadherin is considered a hallmark of EMT.  Indeed, several of the EMT-
inducing transcription factors activate EMT via repression of E-Cadherin either directly, 
such as Snail1 and Slug, or indirectly, such as Twist.  Snail1 is rapidly expressed during 
the EMT process and has been shown to be directly induced by Notch signalling in 
response to TGF-β.  Furthermore, upregulation of Snail1 was shown to be required for 
induction of additional E-Cadherin-repressing transcription factors (Matsuno et al., 2012).  
As inhibition of Snail1 was not sufficient to promote upregulation of E-Cadherin, it has 
been suggested that while Snail1 initiates the process of CDH1 (the E-Cadherin gene) 
repression, ZEB1 is required for the full inhibition (Garcia de Herreros and Baulida, 2012).  
In a similar manner, Twist-induced EMT has been shown to be mediated by Slug (Casas et 
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al., 2011).  Therefore, it is evident that distinct transcription factors are required to interact 
in order to induce and execute EMT in different contexts.   
Recently, micro RNAs have been shown to play a vital role in the maintenance of an 
epithelial phenotype and reciprocal interactions between EMT-inducing transcription 
factors and micro RNAs have been shown to be critical in cellular plasticity.  For example, 
a reciprocal feedback loop between the ZEB family of EMT-inducers and the micro RNA 
200 family (miR-200) is critical in the induction of EMT and MET.  Within the ZEB-miR-
200 feedback loop, ZEB inhibits the transcription of miR-200 thereby repressing epithelial 
differentiation and promoting EMT and a stem-like state, whereas, miR-200 family 
members inhibit the translation of ZEB, thereby inhibiting the induction of EMT and 
promoting epithelial differentiation via MET.  Therefore, the dynamics of this feedback 
loop are critical for the invasion-metastasis cascade, inducing EMT for the invasion and 
dissemination of the cancer cells and inducing MET for metastatic colonisation and 
macrometastasis formation.  The same principle is followed in a second reciprocal 
feedback loop between miR-34 and Snail1.  In this mechanism, Snail1 induces 
mesenchymal and stem-like characteristics via EMT whereas, miR-34 induces MET and 
consequently promotes drug sensitivity (Brabletz, 2012).  In these examples, both factors 
control the expression of one another hence, target their own repressors.  
Recently, Chang et al., 2011, revealed a link between p53 and the control of EMT when 
they demonstrated that the transcription of the miR-200 and miR-34 families were induced 
by p53 (Chang et al., 2011).  This finding has enormous implications as it demonstrated 
that one of the most critical tumour suppressors plays a crucial role in the regulation of 
phenotypic plasticity (Brabletz, 2012).  Furthermore, it linked the most important gene 
alteration in cancer (mutations in p53) to the emerging fields of cancer stem cells and EMT 
and their significance for metastasis (Schubert and Brabletz, 2011). 
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1.6.3.5  Evidence for the Occurrence of EMT in  Cancer 
There is a wealth of evidence to support the involvement of EMT in cancer progression 
and metastasis.  Several of the biomarkers used to demonstrate EMT have been observed 
in cancers and have also been shown to correlate with disease progression and a poor 
prognosis. 
In 2004, Yang et al., revealed that the EMT-associated transcription factor Twist, an 
indirect repressor of E-Cadherin, plays an essential role in tumour metastasis as 
suppression of Twist in highly metastatic mammary carcinoma cells specifically inhibited 
metastasis and high levels of Twist expression correlated with human invasive lobular 
breast carcinoma, a highly infiltrating tumour type associated with loss of E-Cadherin 
expression (Yang et al., 2004).  In addition to this, expression levels of Twist have been 
shown to positively correlate with Gleason grading and metastasis in human prostate 
cancer (Kwok et al., 2005).  Furthermore, Twist has been shown to inhibit apoptosis in 
cancer cells and it is thought to play a central role in the resistance to microtubule 
disrupting agents (Wang et al., 2004).  Additional studies have also correlated the presence 
of critical EMT drivers, such as Snail1 and the ZEB family, with tumour progression, 
relapse and poor survival (Fuchs et al., 2002; Peinado et al., 2007). 
Loss of E-Cadherin is a hallmark of EMT.  Several studies have correlated a loss of this 
molecule with a decrease in patient survival (Hirohashi, 1998).  In addition, cell lines with 
low/no E-Cadherin expression have been shown to demonstrate increased tumourigenicity 
and metastasis when transferred into immunodeficient mice (Birchmeier and Behrens, 
1994).  Furthermore, mutations in the E-Cadherin gene have been identified in cancer cells 
which have been shown to be more susceptible to EMT and metastasis (Kalluri and 
Weinberg, 2009).  
Evidence of EMT can be observed in cancer tissues based on the expression levels of 
different Cadherins.  The so-called “Cadherin switch” from E-Cadherin to N-Cadherin, 
which is expressed by mesenchymal cells, neural tissue, fibroblasts and cancer cells, has 
often been used to monitor the progression of EMT during embryonic development and 
cancer progression  (Zeisberg and Neilson, 2009).  Gravdal et al., (2007) revealed that 
Cadherin switching (from E-Cadherin to N-Cadherin) observed in prostate cancer tissue 
microarrays showed strong and significant associations with multiple end points of 
progression and cancer-specific death (Gravdal et al., 2007).  Hence, provided evidence for 
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the contributory role of EMT in cancer progression and its association with a poor clinical 
outcome.  In support of these findings, a recent study, conducted by Tanaka and 
colleagues, demonstrated a clear link between the expression of N-Cadherin and invasive, 
metastatic, castration resistant prostate cancer (CRPC).  In this study, N-Cadherin-specific 
antibodies were shown to delay the progression to castration resistance, inhibit invasion of 
surrounding tissues, suppress tumour growth and reduce metastasis in castrated mice. 
Hence, this work provided further support for the critical role of EMT in prostate cancer 
progression and the potential of immunotherapy as a strategy to combat this disease 
(Tanaka et al., 2010).  However, it is important to note that the Type 3 EMTs, which occur 
in the context of cancer, may not represent a complete transition from an epithelial to a 
mesenchymal phenotype, therefore, dual expression of epithelial and mesenchymal 
Cadherins has also been reported (Lou et al., 1999). 
In the context of breast cancer, basal-like tumours, which show high expression of the 
mesenchymal markers N-Cadherin and vimentin and low expression of E-Cadherin, 
demonstrate a poor prognosis with a higher risk of metastasis, compared to other invasive 
breast carcinomas (Foroni et al., 2012).  Furthermore, several cell line studies have 
revealed that the more invasive and metastatic breast cancer cell lines display hallmarks of 
EMT-derived cells (Hollier et al., 2009).     
Circulating tumour cells (CTCs) of primary breast cancer patients have been found to 
express EMT-associated markers such as vimentin (Kasimir-Bauer et al., 2012).  However, 
CTCs with an EMT signature are likely to have been overlooked in the majority of studies 
which exploit epithelial markers to purify CTCs from patient blood (Nieto and Cano, 
2012). 
Several in vitro and in vivo studies have revealed a correlation between EMT and an 
invasive and metastatic phenotype.  Moreover, evidence of EMT in patient material has 
been provided based on the expression of EMT-associated transcription factors, 
mesenchymal-associated markers expressed by CTCs and evidence of Cadherin switching, 
which correlated with disease progression, metastasis and a poor prognosis.  However, 
despite the wealth of data implicating EMT in cancer progression, there is no direct 
evidence of this phenomenon occurring in human tumours.    
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1.6.3.6  Doubts Surrounding the Role of EMT in Cancer Progression 
Although several studies have provided evidence to support the role of EMT in cancer 
progression, a lack of direct evidence in clinical specimens has rendered it an incredibly 
controversial subject, which, consequently is not accepted by all (Garber, 2008).  In his 
contentious article, Tarin (2005) argued that there was insufficient evidence to support a 
role of EMT in neoplasia as “In >40 years of experience of reporting the pathology of 
many thousands of tumor samples, the author has not seen convincing evidence of EMT...”  
In addition, Tarin argued that EMT cannot be a significant event in carcinogenesis and 
tumour progression due to a lack of extensive documentation by other surgical pathologists 
and because it (EMT) isn’t used to score cancers (Tarin, 2005).  The occurrence of 
epithelial to mesenchymal transition in cancer can account for several of the previously 
unexplained phenomena associated with disease progression.  Therefore, to disregard the 
possibility that a known biological process (EMT) may be reactivated in cancer cells, a 
concept supported by more than 15 years of research and a large body of in vitro and in 
vivo data, requires the proposal of an alternative hypothesis which may better address the 
phenomena observed and account for the successful completion of the invasion-metastasis 
cascade.  However, to date, a more convincing hypothesis, suggesting the mechanisms 
employed for the successful completion of the invasion-metastasis cascade, has yet to be 
presented.  Furthermore, the inability to observe EMT in clinical specimens can be 
explained by the fact that 1) EMT is a transient process which may be overlooked 2) there 
are currently no markers which distinguish cancer cells which have transitioned through 
EMT from the mesenchymal cells of the tumour stroma 3) EMT may be an extremely rare 
event, supported by the inefficiency of metastasis and 4) metastasising EMT cells are 
believed to revert to an epithelial form via mesenchymal to epithelial transition (MET) in 
order to colonise at secondary sites thereby eliminating any evidence of a previous passage 
through EMT (Foroni et al., 2012).  
Nonetheless, despite controversy it is widely accepted that epithelial to mesenchymal 
transition, and the stem-like properties which accompany this change in phenotype, of 
differentiated cancer cells can strongly enhance tumour cell dissemination (Brabletz, 
2012). 
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1.6.3.7  Cancer Stem Cells and EMT 
In 2008, Mani et al.,  combined two of the emerging fields in cancer biology by revealing a 
link between EMT and cancer stem cells when they demonstrated the acquisition of stem-
like properties (enhanced sphere formation, self-renewal and a change in antigenic profile) 
by transformed human mammary epithelia artificially induced to undergo EMT.  
Furthermore, this group demonstrated that both normal and putative breast cancer stem 
cells, with the antigenic profile CD44
hi
CD24
lo
, expressed several of the EMT-associated 
markers at the mRNA level (Mani et al., 2008).   
Since the release of this paper, several groups have implicated EMT in the generation of 
cancer stem-like cells (Fazul et al., 2009; Santisteban et al., 2009; Kong et al., 2010). It is 
however, important to note that these studies demonstrated the generation of stem-like 
cells via EMT of differentiated cancer cells.  Therefore, the cells generated via EMT must 
be distinct from the original tumour initiating cell.  This notion is supported by the fact that 
the EMT marker profile sometimes contradicts the profile of the CSCs from the same 
tissue.  For example, prostate cancer stem cells are postulated to express high levels of the 
transmembrane receptor integrin α2β1, (Collins et al., 2005)  however, EMT-derived cells 
from the prostate cancer cell line OPCT-1 did not demonstrate expression of this protein 
(Unpublished data – See Chapter 5).   
The cancer stem cell hypothesis states that the cancer stem cell is solely responsible for 
tumour initiation, tumour differentiation, tumour maintenance, tumour spread (metastasis) 
and tumour relapse following therapy.  As is evident, EMT-derived cells cannot fulfil the 
cancer stem cell criteria as they are not implicated in initiation of the primary tumour.  
However, there is much evidence to support the role of EMT-derived cells in metastasis 
and chemotherapeutic resistance (Zhau et al., 2008; Kyprianou et al., 2010; Tanaka et al., 
2010).  Thus, it is plausible that, contrary to the CSC hypothesis, the progeny of 
transformed stem cells are also tumourigenic and that such progeny may undergo EMT 
which then confers stem-like properties and the ability to invade and metastasise. 
Therefore, whereas the adult tissue stem cell may be the initial site of malignant 
transformation, their transitioning progeny (differentiated cancer cells undergoing EMT), 
rather than the cancer(ous) stem cells themselves may be accountable for invasion and 
metastasis. Therefore, the term “cancer stem cell” may be considered to refer to a number 
of different cell populations including transformed stem/progenitor cells and EMTs, rather 
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than one “super-malignant” cell population, all of which have a role to play in 
tumourigenesis.   
The acquisition of stem-like properties by metastatic cancer cells which have activated the 
EMT programme addresses several of the conceptual dilemmas in cancer biology.  Firstly, 
both cancer stem-like cells and EMTs are known to resist apoptosis and evade immune 
destruction (See Section 1.6.3.8), properties which may account for the survival of 
metastatic cells during the invasion-metastasis cascade.  Secondly, the stem-like 
characteristics of enhanced proliferative potential, differentiation and self-renewal ability 
may explain the formation of differentiated macroscopic metastases in the case of plasticity 
type I metastasis.   
Figure 1.14 illustrates the possible events involved in the invasion-metastasis cascade in 
plasticity type I metastasis taking cancer stem cells, EMT-derived cancer stem-like cells 
and circulating tumour cells (also EMT derived) into consideration.   
In 2010, Battula et al., revealed that cells which had transitioned via EMT exhibited 
characteristics of mesenchymal stem cells (MSCs) as the EMT-derived cells demonstrated 
a MSC gene signature, the ability to migrate towards cells in vitro and wounds in vivo and 
multilineage differentiation potential (Battula et al., 2010).  Generation of MSCs via EMT 
would account for the existence of more than one “cancer stem cell” population in tumours 
and may also explain several of the phenomena observed in cancer.  For example, MSCs 
are known to possess multiple immunosuppressive functions, chemotherapeutic resistance 
mechanisms and resistance to apoptosis which would certainly assist with the completion 
of the invasion-metastasis cascade (Selmani et al., 2008; Szegezdi et al., 209; Roodhart et 
al., 2011; Ertas et al., 2012; Houthuijzen et al., 2012). 
While the original cancer stem cell hypothesis may address tumour initiation and other 
aspects of tumourigenesis, it is evident that it should be revised, taking EMT into 
consideration for the generation of a distinct population of cancer stem-like cells which 
contribute significantly to tumour progression.  It is evident that both the tumour-initiating 
cancer stem cells and those generated via EMT have serious therapeutic implications and 
must be targeted in order to prevent tumour progression and reoccurrence.   
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Figure 1.14:   Illustrating the steps of the invasion-metastasis cascade for plasticity type I metastasis. 
The process begins when the tumour associated stroma or tumour cells release signals, activating  
the generation of invasive and metastatic stem-like cells via EMT which escape from the primary 
tumour, invade the surrounding stroma, penetrate local vessels (intravasation) and disseminate as 
circulating tumour cells (CTCs) prior to penetrating the vessel wall at distant sites (extravasation), 
reverting to an epithelial form via MET and colonising to form macrometastases. (EMT – epithelial 
to mesenchymal transition, MET – mesenchymal to epithelial transition, CSC – cancer stem cell, CTC 
– circulating tumour cell). (Adapted from Foroni et al., 2012). 
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EXTRAVASATION 
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1.6.3.8  Therapeutic Implications of EMT and CSCs. 
The tumour-initiating cancer stem cells and the cancer stem-like cells generated through 
EMT represent an important clinical challenge.  Through a variety of inherent and acquired 
traits, both cell types have been shown to resist chemotherapy, radiotherapy and 
immunotherapy.  In fact, by targeting only the bulk of the tumour, conventional therapies 
often enrich for the cancer stem/stem-like cells, as shown in clinical studies of breast 
cancer, where the proportions of CD44
+
/CD24
-/low
 CSC/EMT-derived cells increased 
significantly after chemotherapy (Li et al., 2008).  
A number of traits account for the increased resistance of cancer stem/stem-like cells to 
therapy, the majority of which are also common to their normal stem cell counterparts.    
Conventional chemo/radiotherapies mainly target rapidly dividing cells, as such, the 
inherent quiescent and slow cycling nature of CSCs renders them resistant to radiotherapy 
and several of the first-line chemotherapeutic agents.  In addition, increased expression of 
multi-drug resistant proteins and related members of the ATP-binding cassette (ABC) 
transporter family, provide further protection by facilitating the efflux of drugs (Alison et 
al., 2012).  Furthermore, high ALDH activity, observed in CSCs, has been shown to assist 
with drug metabolism, thereby providing cancer stem/stem-like cells with an additional 
defensive mechanism (Hollier et al., 2009).  Failing these defences, cancer stem/stem-like 
cells also demonstrate efficient DNA repair mechanisms, increased expression of anti-
apoptotic proteins and downregulation of pro-apoptotic genes hence, are highly resistant to 
apoptosis (Qi et al., 2012; Liu et al., 2006; Conticello et al., 2004) (See Section 1.5.5.5.5).   
The cancer stem-like cells generated via EMT have been shown share several properties 
with mesenchymal stem cells (Battula et al., 2010).  As such, it is possible that these cells 
may provide further therapeutic resistance via secretion of antiapoptotic factors, secretion 
of fatty acids which protect against chemotherapy, and resistance to tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL) receptor mediated apoptosis (Szegezdi et 
al., 2009; Roodhart et al., 2011; Houthuijzen et al., 2012) 
As previously discussed, both cancer stem cells and EMT-derived stem-like cells possess a 
variety of mechanisms which enable immune-avoidance.  Such mechanisms include 
downreguation of MHC class I molecules, expression and secretion of HLA-G and 
secretion of immunosuppressive cytokines (Brown et al., 2012; Morandi et al., 2012; Qi et 
al., 2012).   (See section 1.5.5.5.4).   
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These populations present a serious dilemma to cancer biologists and oncologists as 
conventional therapies are thought to only target the bulk of the tumour, leaving the 
resistant CSCs and EMT-derived cancer stem-like cells behind to repopulate the tumour, 
hence the disease will inevitably progress.  To achieve full and permanent eradication of 
tumours, it is necessary to further our understanding of the resistant populations in order to 
design CSC/EMT-specific therapies which should be used in combination with therapies 
targeting the rapidly-dividing bulk of the tumour.  Indeed, the development of cancer stem 
cell-specific therapies is currently underway (Foroni et al., 2012; OncoMed 
Pharmaceuticals, 2012).  Furthermore, treatments targeting the molecular activators of 
EMT are hoped to prevent metastasis and reduce the generation of resistant, stem-like cells 
(Hollier et al., 2009).   In addition, therapies targeting the epigenetic changes governing 
EMT aim to revert EMT-derived cells to a more differentiated, more sensitive epithelial 
form (Brabletz, 2012).   Together, these therapies hope to overcome the challenges faced 
by therapeutic resistance and offer a permanent cure.  
 
1.7 Rationale and Outline of the Study 
Cancer stem cells (CSCs) and epithelial to mesenchymal transition (EMT) have recently 
emerged as important concepts in cancer biology.  Once considered separate phenomena, 
these two areas were recently combined when Mani et al., (2008) demonstrated that EMT 
generates cells with the properties of stem cells.  However, as these areas of research 
remain in their infancy, the current literature presents several conflicting hypotheses.  
Furthermore, many of the studies investigating the relationship between EMT and CSCs 
have used breast cancer as a model hence, further studies investigating this relationship are 
required in the prostate cancer field.   
In 2005, Collins and colleagues isolated putative prostate cancer stem cells by exploiting 
the markers they had previously identified for normal prostate stem cells.  The present 
study initially aimed to follow the method established by Collins et al., (2005), in an 
attempt to isolate and characterise putative prostate cancer stem cells from primary cultures 
and prostate cancer cell lines, with a view to investigating their immunological status and 
determining whether or not these cells could provide viable targets for immunotherapy.  
However, using the methods established by Collins et al., (2005), this study failed to 
identify and isolate putative prostate cancer stem cells.  Consequently, the focus of the 
64 
 
study shifted to investigating the properties of epithelial to mesenchymal transition and 
exploring a possible link between EMT and the generation of CSCs in human prostate 
cancer. 
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Chapter 2: 
Materials and Methods 
 
2.1  Laboratory Consumables and Equipment 
2.1.1 Reagents  
All reagents were stored according to the manufacturer’s instructions and used within the 
expiry date. 
 
Culture Media      Supplier 
DMEM       BioWhittaker Europe 
HAM’S F12       BioWhittaker Europe  
KSFM        Invitrogen, Gibco 
RPMI 1640       BioWhittaker Europe 
 
Culture Media Supplements    Supplier 
Aprotinin       Sigma Aldrich 
Bovine Pituitary Extract (BPE)     Invitrogen, Gibco 
Bovine Serum Albumin     Sigma Aldrich 
Cholera Toxin (CT)      Sigma Aldrich 
Collagenase       Sigma Aldrich 
Epidermal Growth Factor (EGF)    Invitrogen, Gibco 
Foetal Calf Serum (FCS)     Bio Whittaker Europe 
Granulocyte-Macrophage Colony Stimulating Factor  Sigma Aldrich                                            
(GMCSF) 
Hydrocortisone      Sigma Aldrich 
L-Glutamine        BioWhittaker Europe 
Leukaemia Inhibitory Factor (LIF)    Sigma Aldrich 
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Pen/strep antibiotic solution     BioWhittaker Europe 
Non-Essential Amino Acids (NEAA)   BioWhittaker Europe 
Sodium Pyruvate      BioWhittaker Europe 
Stem Cell Factor (SCF)     Sigma Aldrich 
Testosterone       Sigma Aldrich 
 
Other Cell Culture Materials     Supplier 
BD Matrigel
TM
      BD Biosciences  
Dimethyl sulfoxide (DMSO)     Sigma Aldrich 
Dulbecco’s phosphate buffered saline (DPBS)  Lonza 
Poly-L-lysine        Sigma Aldrich  
Trypan Blue solution 0.4% (v/v)    Sigma Aldrich 
Trypsin/Versene      Lonza 
 
Chemical Reagents      Supplier 
[3H]-Thymidine       Perkin-Elmer 
Acrylamide        Geneflow 
Ammonium Persulphate (APS)    Geneflow 
Bovine Serum Albumin (BSA)    Sigma Aldrich 
Chloroform       Sigma Aldrich 
Copper phthalocyanine-3,4′,4″,4″′-tetrasulfonic   Sigma Aldrich                      
acid tetrasodium salt 
Crystal violet       Fisher Scientific 
DAPI VECTASHIELD® Mounting media   Vector Labs 
Deoxyribonucleotide Triphospahte (dNTP)   Bioline 
Dithiothreitol (DTT)      Sigma Aldrich 
Docetaxel       Sigma Aldrich 
Ethanol       BDH 
Ethyldiamine Tetraacetic Acid (EDTA)   Sigma Aldrich 
Glycerol       Sigma Aldrich 
Hydrochloric acid (HCl)     Fisher Scientific 
Isopropanol       Sigma Aldrich 
Isoton        Beckman Coulter 
Liquid nitrogen      BOC 
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Marvel milk powder      Premier Brands 
Methanol Fisher Scientific 
Microscint-O scintillation fluid    Perkin-Elmer 
MTT        Sigma Aldrich 
NANOpure Diamond distilled water    Barnstead 
Paraformaldehyde 96%     Sigma Aldrich 
PBS tablets       Sigma Aldrich 
Phenol/Chloroform/Isomyl alcohol    Sigma Aldrich 
Phosphate Buffered Saline (PBS) tablets   Oxoid 
Presept       Johnson and Johnson 
Propidium Iodide (PI)      Sigma Aldrich 
RapidStep ECL Reagent      Calbiochem 
Ribonuclease (RNase)     Quiagen 
RNA-STAT-60      AMS Biotechnology 
Sodium chloride (NaCl)     Fisher Scientific/ Sigma 
Sodium dodecyl sulphate (SDS)    Sigma Aldrich 
Stacking gel buffer for SDS gels     Geneflow 
SYBR® Green Supermix     BioRad  
Teepol        Fisher Scientific  
TEMED       Geneflow  
Tris-base       Melford 
Tween-20       Sigma Aldrich 
Ultrapure 10X Tris/Glycine/SDS    Geneflow 
Ultrapure 10X Tris/Glycine      Geneflow 
Western-C Precision Plus molecular weight marker  BioRad 
 
Immunochemical Reagents     Supplier 
Primary antibodies 
Mouse anti-human HLA-G (5A6G7)    Abcam 
Mouse anti-human P63     Abcam 
Mouse anti-human Fibronectin (IST-9)   Abcam 
Mouse anti-human AR     Abcam 
Rabbit anti-human S100A4 (FSP1)    Abcam 
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Rabit anti-human vimentin (RV202)    Abcam 
Rabbit anti-human CD133     Abcam 
Mouse IgG isotype negative control antibody  AbD Serotec 
Mouse anti-human β-Catenin     BD Biosciences 
Mouse anti-human E-Cadherin    BD Biosciences 
Mouse anti-human N-Cadherin BD Biosciences 
Mouse anti-human CD44 (156-3C11) Cell Signalling Technology 
Rabbit anti-human Sox2 (D6D9) XP(R) Cell Signalling Technology 
Rabbit  anti-human Oct4 Cell Signalling Technology 
Rabbit anti-human -actin antibody Cell Signalling Technology 
Rabbit anti-human Nanog (D73G4) XP(R) Cell Signalling Technology 
Rabbit anti-human Survivin (71G4B7) Cell Signalling Technology 
Rabbit anti-human HER1     Epitomics 
Mouse anti-human E-Cadherin Invitrogen 
Mouse anti-human VLA-2 (α2β1 integrin) Millipore 
Rabbit IgG isotype negative control antibody Pierce Biotechnology 
Goat anti-human SNAI1 (E-18) Santa Cruz Biotechnology 
Goat anti-human SLUG (D-19) Santa Cruz Biotechnology 
Goat anti human CD24     Santa Cruz Biotechnology 
Goat anti human PSCA     Santa Cruz Biotechnology 
Rabbit anti-human twist (H-81) Santa Cruz Biotechnology 
Rabbit anti-human CD24 (FL-80) Santa Cruz Biotechnology 
Mouse anti-human cytokeratin pan    Sigma Aldrich 
Secondary antibodies 
Steptavidin-HRP secondary antibody  Biorad 
Goat anti-mouse-HRP secondary antibody   Dako 
Rabbit anti-goat-HRP secondary antibody   Dako 
Swine anti-rabbit-HRP secondary antibody   Dako 
Chicken anti-rabbit Alexafluor®488    Invitrogen 
Donkey anti-goat Alexafluor®488    Invitrogen 
Donkey anti-goat Alexafluor®568    Invitrogen 
Goat anti-rabbit Alexafluor®488    Invitrogen 
Goat anti-mouse Alexafluor®488    Invitrogen 
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Goat anti-rabbit Alexafluor®568    Invitrogen 
Goat anti-mouse Alexafluor®568    Invitrogen 
Conjugated antibodies 
Mouse anti-human CD44-FITC    AbD Serotec 
Mouse IgG-FITC isotype negative control antibody AbD Serotec 
Mouse anti-human CD157-FITC    AbD Serotec 
Mouse anti-human Vimentin (clone RV202)-PE BD Bioscience 
Mouse IgG1k-PE isotype control BD Bioscience 
Mouse anti-human CD45-APC Alexafluor®750 Beckaman Coulter 
Mouse anti-human CD105-PE (SN6) eBioscience 
Mouse anti-human CD90 (Thy-1)-APC (SE10) eBioscience 
Mouse anti-human CD73-EFluor®450 (AD2) eBioscience  
Mouse anti-human CD133/1-APC    MACS 
Mouse anti-human CD133/2-PE    MACS 
Iso mouse IgG1a-APC     MACS 
Iso mouse IgG2b-PE      MACS 
 
Kits        Supplier 
Stem Cell Assay: 
ALDEFLUOR
TM
      Stem Cell Technologies 
 
Protein Assay:                                                                                                                
Bicinchoninic Acid Kit     Sigma Aldrich 
 
Cell Invasion: 
Biocoat Matrigel
TM
 Invasion Chamber (8m pore)  BD 
 
Proliferation Assay: 
ViaLight® Plus proliferation assay kit   Lonza 
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2.1.2  Equipment  
All glass items were washed in dilute presept/teepol and rinsed twice in distilled water 
prior to use.  Please refer to Appendix II for the complete list of equipment used.  
Laboratory plastics, glassware and sharps 
Item        Supplier 
0.1 μm pore size filters     Starstedt 
0.2 μm pore size filters     Sartorius 
3 ml syringes       Stem Cell Technologies  
6,24,96-well tissue culture plates    Sarstedt 
96 well black/clear, tissue culture treated imaging plate BD Bioscience   
96 well microtiter plate     Nunc, Denmark 
96-well round-bottom culture plates    Sarstedt 
96-well white microplate     Porvair advanced mats 
Bijou Tubes (7 ml)      Sterilin 
Blunt end needles      Stem Cell Technologies 
Cell culture flasks (T25,T75,T175 cm
3
)   Sarstedt, UK 
Cell strainers       BD Falcon 
Collagen dishes (35 mm, 10 mm)    BD Biocoat
TM
 
Collagen cell culture flasks (T25,T75 cm
3
)   BD Biocoat
TM
 
Companion plates      BD Biosciences 
Coverslips       SLS 
Conical flasks (50 ml,100 ml)    Pyrex 
Cryovials (1.5 ml)      TPP 
Duplex dish       Zeiss, Germany 
Eppendorf tubes (0.5 ml,1.5 ml,2 ml)    Sarstedt 
Flow cytometry tubes      Tyco healthcare group 
Falcon tubes (50 ml, 15 ml)     Sarstedt 
Filter tips (0.5-10 µl, 2-20 µl, 20-200 µl, 200-1000 µl) Greiner bio-one/Sarstedt 
Flat-bottom culture dishes (6 well/ 24 well)   Sarstedt 
Glass coverslips      SLS 
Nitrocellulose Western blot membrane GE Water and Process 
Technologies 
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LS columns       Miltenyi 
Micro tips (0.5-10 µl, 20-200 µl, 200-1000 µl)  Sarstedt 
MS Columns       Miltenyi  
Measuring cylinders (0-10 ml, 0-100 ml, 0-500 ml,   Pyrex               
0-1000 ml, 0-2000 ml) 
Pasteur pipettes      Sarstedt 
Petri dishes       Sterillin 
Pipettes (5 ml, 10 ml, 25 ml)     Sarstedt 
Plastic Pasteur pipettes     Sarstedt 
Pre separation filters      Miltenyi 
Real-time qPCR tubes Qiagen/ Axygen Scientific 
Scalpels       Swann Morton/TPP 
Screw-top tubes (15 ml)     Sarstedt 
Sealing tape (Nescofilm)     Bando Chemicals 
Serological pipettes      Sarstedt 
Syringes (10 ml,20 ml)     Becton Dickenson 
T25/T75/T175cm
3
 culture flasks    Sarstedt 
Tissue culture dishes (35 mm)    Stem Cell Technologies 
Ultra low adherent 24 well/ 96 well plates   Corning 
Universal tubes (20 ml)     Sterillin 
Unifilter 96-well filter plates     Perkin-Elmer 
Western blot filter paper     Schleicher-Schwell 
Amersham X-ray film      G.E. Healthcare 
0.2 m filters       Sartorious  
 
Equipment   
Item        Supplier 
2100 Bioanalyzer      Agilent Technologies 
CCD Camera       Fuji Systems 
Coulter Counter      Beckman Coulter 
Cryostat       Leica 
Electrophoresis Gel Tanks     Geneflow 
Filtermate Harvester      Perkin Elmer 
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Gallios Flow Cytometer     Beckman Coulter 
iCycler I Q Multicolour RT PCR Machine   Qiagen 
Leica TCS SP5 Confocal Microscope   Leica 
PALM Laser-capture microdissector (LCM)   Carl Zeiss 
Micropipettes (2 µl,10 µl, 20 µl, 100 µl, 200 µl, 1000 µl) Genex/ Beta/ Gilson/ Sealpette 
Microplate Luminometer Berthold Detection Systems 
Midi MACS magnet      Miltenyi 
Mini MACS magnet      Miltenyi  
MoFlo
TM
 XDP High-Speed Cell Sorter   Beckman Coulter 
Nanodrop ND-800 spectrophotometer   Thermo Scientific 
Nanopure Diamond water reservoir    Barnstead 
Nikon Eclipse Ts100 Light Microscope   Olympus  
NXT Top-Count Microplate Scintillation Counter  Perkin Elmer 
Octo MACS magnet      Miltenyi 
Olympus BX51 Fluorescence Microscope   Olympus 
Orbital Incubator      Stuart 
Plate reader       Biorad and Tecan 
96-well plate harvester     Packard 
Real-time qPCR thermal cycler    Qiagen 
Sonicator       VWR 
Tecan Ultra Microtiter Plate Reader    Tecan 
Transfer apparatus      Geneflow 
Top count scintillation counter    Packard 
UNO-thermoblock      Biometra 
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2.1.3   Buffers and Stains 
 
Buffers/Stains used for cell culture 
Trypan Blue for enumeration of cells: 
0.1% (v/v) solution Trypan Blue in DPBS. 
 
MACS Buffer: 
DPBS 
2 mM EDTA  
0.5 % (w/v) BSA 
pH adjusted to 7.2 
Sterile-filtered and de-gassed by sonication for 15 minutes prior to use. 
 
Crystal Violet Stain: 
0.5% (w/v) Crystal Violet 
70% (v/v) Ethanol  
 
Buffers/Stains used for western blot analysis 
Total Cell Lysis Buffer: 
50 mM Tris 
5 mM EDTA 
1% (w/v) SDS 
 
1x 8% Resolving SDS gel:    1x10% Resolving SDS gel: 
2300 l ddH2O     1900 l ddH2O 
1300 l Acrylamide     1700 l Acrylamide 
1300 l 1.5M Tris-HCl (pH 8.8)   1300 l 1.5M Tris-HCl (pH 8.8) 
50 l 10% (w/v) SDS     50 l 10% (w/v) SDS 
50 l 10% (w/v) APS     50 l 10% (w/v) APS 
3 l TEMED      3 l TEMED 
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1x 5% Stacking SDS gel:     
1400 l ddH2O       
330 l Acrylamide      
250 l 1M Tris-HCL (pH 6.8)     
20 l 10% (w/v) SDS      
20 l 10% (w/v) APS   
2 l TEMED 
 
Reducing sample buffer: 
0.5 M Tris-HCl (pH 6.8) 
2% (w/v) SDS 
10% (v/v) Glycerol 
1% DTT 
ddH2O to final volume 
 
Deionised phosphate buffered saline+ TWEEN-20 (DPBS-0.1% (v/v) TWEEN):  
1x DPBS 
0.05% TWEEN-20 
 
DPBS-0.1% (v/v) TWEEN+ Marvel blocking buffer: 
3% (w/v) Marvel Milk powder 
100 ml DPBS-0.1% (v/v) TWEEN 
   
Tris/Glycine/SDS Gel Running Buffer:  
10x Tris/Glycine/SDS (0.25 M Tris, 1.92 M Glycine, 1% (w/v) SDS) 
Made to 1x with ddH2O 
 
Tris/Glycine Gel Transfer Buffer: 
100 ml 10x Tris/Glycine 
200 ml Methanol 
700 ml ddH2O 
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Buffers used for flow cytometry analysis 
Fixation solution:      
1% (w/v) paraformaldehyde in DPBS    
 
Permeabilisation solvent: 
100% Methanol 
 
Flow cytometry buffer: 
0.5% (w/v) BSA 
1x DPBS 
 
Buffers for Immunofluorescence 
 
Fixation solution 
4% (w/v) paraformaldehyde 
1x DPBS 
 
Deionised phosphate buffered saline+ TWEEN-20 (DPBS-0.1% (v/v) TWEEN):   
As previously   
 
Blocking solution 
1x DPBS-0.1% (v/v) TWEEN 
10% (w/v) BSA 
 
2.1.4 Primary Cell Culture Media/Solutions/Feeder Cells 
 
Transport Media for Transport of Primary Tissue 
RPMI1640 
5% (v/v) FCS 
 
Prepared, aliquotted and stored at the hospital prior to surgery.  If the tissue was to be 
retained overnight, 10,000 IU of the protease inhibitor aprotinin was added per 500 ml 
media.  
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Primary Epithelial Growth (PEG) Media for Culture of Prostate Epithelia 
500 ml Keratinocyte serum-free media (KSFM) 
2.5 μg epidermal growth factor human recombinant protein (EGF) 
25 mg bovine pituitary extract (BPE) 
1 μg leukaemia inhibitory factor (LIF) 
1 μg stem cell factor (SCF) 
50 μg cholera toxin (CT) 
0.5μg granulocyte-macrophage colony stimulating factor GM-CSF 
5 ml L-glutamine 
5 ml pen/strep antibiotic solution 
The supplements were added to 5 ml KSFM which was sterile-filtered prior to combining 
with the remaining 495 ml of KSFM.  The media was refrigerated at 4˚C between use. 
 
RPMI 1640 plus 10% (v/v) FCS (R10)  
500 ml of RPMI1640  
50 ml FCS 
5 ml L-glutamine  
5 ml pen/strep antibiotic solution 
The media was refrigerated at 4˚C between use.  
 
0.3%  (w/v) BSA in 1x DPBS  
Prepared in advance in 50 ml aliquots, heat inactivated for 1 hour at 56˚C and sterile 
filtered prior to use.  In between use, it was refrigerated at 4˚C. 
 
Collagenase solution 
Freshly prepared in primary epithelial growth (PEG) medium and R10 (1:1) to a final 
concentration of 200 IU/ml and sterile-filtered prior to use.   
 
Mouse fibroblast feeder cells (STOs)  
Cultured in T175 tissue culture flasks in DMEM plus 10% (v/v) FCS until 70-80% 
confluent.  Then harvested, re-suspended in 35 ml media and irradiated for 10 minutes 
using a 60 Gγ gamma source.  These were refrigerated and could be used up to 5 days 
following irradiation. 
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2.1.5    Cell Lines and Growth Conditions 
All cells were cultured in incubators supplying a 37
o
C, 5% (v/v) CO2 atmosphere 
Table 2.1: List of tumour cell lines used in this study, describing their characteristics, 
source and culture media.  
Cell Line Description Source Media 
PC3 
Androgen independent 
metastatic prostate 
cancer 
American Type 
Culture Collection  
HAM’S F12 + 10% (v/v) 
FCS, 2 mM L-Glutamine + 
1% (v/v) NEAA 
DU145 
Androgen independent 
metastatic prostate 
cancer 
American Type 
Culture Collection 
DMEM + 10% (v/v) FCS,        
2 mM L-Glutamine, 1% (v/v) 
NEAA +1% (v/v) Sodium 
Pyruvate 
P4E6 
Androgen independent 
primary prostate cell 
line 
Professor Norman 
Maitland (University 
of York, England) 
KSFM + 2% (v/v) FCS +       
2 mM L-Glutamine 
OPCT-1 
Androgen independent 
primary prostate  cancer 
cell line 
ONYVAX 
KSFM + 2% (v/v) FCS +       
2 mM L-Glutamine 
OPCT-2 
Androgen independent 
primary prostate cancer 
cell line 
ONYVAX 
KSFM + 2% (v/v) FCS +       
2 mM L-Glutamine 
SK-BR-3 
Human Breast 
adenocarcinoma 
American Type 
Culture Collection  
McCoy’s 5A + 10% (v/v) FCS 
NTERA2/D1 
Human pluripotent 
testicular embryonal 
carcinoma 
Dr Neil Cross 
(Sheffield Hallam 
University) 
DMEM + 10% (v/v) FCS 
NIH 3T3 
Murine embryonic 
fibroblasts 
American Type 
Culture Collection  
DMEM+ 10% (v/v) FCS 
STO 
Murine embryonic 
fibroblasts 
American Type 
Culture Collection  
DMEM + 10% (v/v) FCS 
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2.1.6    Additional Cells/ Tissue/ Mice  
Cord Blood  
Ethically approved, fresh or frozen cord blood was kindly donated from the Anthony 
Nolan Cell Therapy Centre and was processed immediately at the Anthony Nolan Cell 
Therapy Centre with the help of the staff.  Therefore, no media was used to maintain the 
cells.  Isolated cord blood stem cells were also provided by the Anthony Nolan Cell 
Therapy Centre in frozen aliquots.  These were processed without media. 
Fresh prostate tissue  
Ethically approved, fresh prostate tissues were collected from Nottingham City Hospital 
following radical prostatectomies and trans-urethral resectioning of the prostate (TURP) 
procedures and were processed immediately on return to the John van Geest Cancer 
Research Centre.  Isolated cell populations were maintained in media as described in 
Section 2.1.4. 
Athymic Mice 
Thirty male athymic nude mice, six weeks of age, were kindly provided by Harlan 
Laboratories, UK.  These were maintained in accordance with UK Home Office 
regulations and allowed to acclimatise for two weeks in the animal facility prior to 
conducting in vivo studies. Mice were kept in IVC cages supplied with laminar air flow 
and autoclaved food and water taken ad libitum. 
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2.2   Methods 
2.2.1   Cell Culture 
2.2.1.1   Routine Cell Culture and Cell Counting 
The cell lines used for the duration of this project are listed with the required culture 
conditions in Table 2.1.  Cryovials of approximately 1x10
6
 cells were stored long-term in 
liquid nitrogen and initiating a cell line required removal, thawing and washing of cells by 
centrifugation at 400 g for 3 minutes in 10 ml of appropriate media.  The wash step was 
required for the removal of excess DMSO, an agent used to protect the cells by preventing 
ice crystal formation during the freezing process. Following centrifugation, cell pellets 
were re-suspended in 6 ml of the appropriate media, transferred into a T25 culture flask 
and incubated at 37
o
C in air atmosphere with 5% (v/v) CO2. Once cells reached 70-80% 
confluency the media was poured off, the cells were washed twice with DPBS and they 
were then harvested from the flask by incubation at 37
o
C with 1 ml 0.05% trypsin mixed 
with 0.02% versene (T&V).  Following trypsinisation, 10 ml of media was added to the 
cells in the flask and the cells were transferred into a 20 ml universal tube which was then 
centrifuged at 400 g for 3 minutes.  The pellet was then re-suspended in 10 ml of 
appropriate media and the cells were split between the original T25 and a new T75 flask in 
a process known as “passaging”.  Each passage was recorded and the use of cell lines in 
assays with as low a passage as possible was desirable.   
Cell counting was performed by re-suspending a harvested cell pellet in 10 ml of 
appropriate media (or less volume if smaller number of cells was expected) and performing 
a 1:10 dilution with trypan blue.  A haemocytometer was used to enumerate the cells and 
dead cells, which stained blue, were identified and excluded from the cell count. 
2.2.1.2    Fresh Prostate Tissue Processing 
2.2.1.2.1   Separation of stroma from epithelia and selection of  integrin α2β1-high cells 
Using a “Nottingham needle”, 6 cores of prostate tissue were taken at different points from 
a surgically removed prostate.  Three cores were snap-frozen in optimum cutting 
temperature compound (OCT) and the remaining 3 cores were placed separately in 15 ml 
of transport media and were stored at 4˚C prior to collection.  Alternatively, pieces of 
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tissue from trans-urethral resectioning of the prostate (TURP) procedures were either snap 
frozen in OCT, preserved in formalin, or placed in transport media for processing. 
Providing the surgery was completed and the cores were extracted prior to 3pm, the tissue 
was collected the same day and was transported on dry ice to our facilities.  The cores were 
then stored at 4˚C awaiting processing until 3pm.  At 3pm sterile DPBS, Petri dishes, 
tweezers and scalpels were placed in a laminar flow hood.  Each core was processed 
separately; hence this procedure was executed in triplicate.  Sterile tweezers were used to 
remove the cores from the transport media and place them in sterile Petri dishes where they 
were washed with 7 ml sterile DPBS and then cut into many small pieces using a scalpel.  
Subsequently 7.5 ml of freshly prepared collagenase solution was pipetted onto the 
chopped tissue and the tissue was pipetted up and down before being transferred into a 
sterile glass conical flask which was sealed with parafilm.  The flasks were then incubated 
overnight at 37˚C in a shaking incubator set at 80 rpm. 
Following overnight incubation the flasks were removed, wiped with ethanol and placed in 
the hood for further processing. The mixture was then disaggregated by repeated pipetting 
using a 5 ml pipette and the suspension was transferred into a sterile 25 ml universal.  A 20 
ml syringe and blunt needle were used to further triturate the suspension which was then 
centrifuged at 770 g for 10 minutes at 20˚C.   
Meanwhile, type I collagen plates were blocked by incubation with 5 ml of 0.3% (w/v) 
heat-inactivated BSA in DPBS for 1 hour at 37˚C, 5% (v/v) CO2.   
Following the centrifugation step, a plastic Pasteur pipette was used to very carefully 
pipette off the supernatant.  The pellet was then washed twice by re-suspending in 10 ml of 
sterile DPBS and centrifuging at 770 g for 10 minutes at 20˚C.  The pellet was then re-
suspended in 10 ml R10 and was centrifuged at 308 g for a further 1 minute at 20˚C.  
During this step, the epithelial cells settled to the bottom of the universal whereas the 
fibroblasts and other stromal cells remained suspended in the supernatant.  A plastic 
Pasteur pipette was rinsed with sterile DPBS and used to collect the settled epithelial cells 
and transfer them to a sterile 25 ml universal whilst avoiding the collection of too much 
supernatant.  The supernatant was re-centrifuged at 308 g for 1 minute at 20˚C and the 
epithelial cells were again collected and transferred.  This step was repeated until all 
epithelial cells had been collected and they were subsequently washed in 5 ml sterile DPBS 
by centrifugation at 770 g for 10 minutes at 20˚C.   
81 
 
Meanwhile, the remaining fibroblasts and stromal cells were transferred directly along with 
the R10 media into a T25 tissue culture flask and were cultured at 37˚C, 5% (v/v) CO2.   
Following the centrifugation step, a plastic Pasteur pipette was used to carefully remove 
the supernatant, the cells were re-suspended in 5 ml of pre-warmed trypsin+EDTA and the 
suspension was incubated for 30 minutes at 37˚C in a shaking incubator set at 80 rpm.  
After the elapsed time, the trypsin was inhibited with 5 ml of R10 and the cells were 
centrifuged at 577 g for 3 minutes at 20˚C.  The pellet was then re-suspended in 5 ml R10 
and was centrifuged for a further 3 minutes at 577 g at 20˚C.  Next, the pellet was re-
suspended in 3 ml of PEG media and was pipetted repeatedly in order to achieve a single-
cell suspension.  The suspension was then pipetted over a BD falcon cell strainer above a 
50 ml flacon tube and was incubated at 37˚C, 5% (v/v) CO2. 
Meanwhile, the cell strainer was inverted over a sterile Petri dish and 3 ml of PEG media 
was pipetted onto it in order to transfer any remaining tissue onto the dish.  A further 5 ml 
of PEG media was pipetted over the cell strainer and the dish was incubated at 37˚C, 5% 
(v/v) CO2. 
The blocked type I collagen plate was rinsed with 5ml sterile DBS prior to plating out the 
warmed epithelial cell suspension, which was then incubated for 20 minutes at 37˚C, 5% 
(v/v) CO2.  During this time, the cells expressing high levels of the collagen binding 
receptor integrin α2β1 bound tightly to the collagen plate whereas those expressing low 
levels of the receptor remained suspended in the PEG media.  The PEG media containing 
the integrin α2β1 low expressing cells was then collected from the plate and transferred 
into a sterile 25 ml universal.  The plate was subsequently rinsed with 5 ml sterile DPBS 
which was collected and combined with the media plus integrin α2β1 low-expressing cells.  
The rinse step was repeated until cells were no longer observed in suspension.   
The collected washes plus media with the integrin α2β1 low population was centrifuged at 
577g for 3 minutes, the pellet was re-suspended in 3 ml PEG media and the cells were 
plated onto a small non-blocked collagen plate with 1 ml of the irradiated STO suspension.  
The plate was incubated at 37˚C, 5% (v/v) CO2. 
The integrin α2β1 high-expressing cells were cultured on the collagen plate which was 
supplemented with 5 ml PEG media plus 2 ml of the irradiated STO suspension and then 
incubated at 37˚C, 5% (v/v) CO2. 
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The cells were monitored daily during the week and, with the exception of the weekend, 
the media was replaced every other day (Monday mornings, Wednesday afternoons and 
Friday evenings). 
2.2.1.2.2.1   Modifications to the method 
The method described was utilised when the ultimate goal was to isolate CD133+ putative 
prostate cancer stem cells.  However, due to the limitations of the method, namely the use 
of irradiated fibroblasts and the size of the collagen dishes, the method was optimised 
when cells were cultured/bulked for other areas of interest. 
Modifications to the method included the omission of the integrin α2β1-high selection step, 
the use of collagen coated T25 and T75 tissue culture flasks, the culturing of remaining 
tissue bits in collagen dishes in  PEG media+2% (v/v) FCS,   and the omission of irradiated 
murine fibroblasts for the culture of epithelial cells. 
2.2.2    Flow Cytometry and Immunofluorescence 
2.2.2.1   Flow Cytometry  
During this project, flow cytometry was exploited to identify and quantify different 
populations of cells expressing a given marker/markers.  Antibodies were either used in 
accordance with manufacturer’s recommendations or were titrated to determine the 
optimum working concentrations prior to use.  Where possible, appropriate positive and 
negative controls were utilised.  
2.2.2.1.1   Extracellular staining protocol 
Cells were harvested by trypsinisation, counted using a haemocytometer and 1x 10
6
 cells 
were distributed per flow cytometry tube.  The cells were then washed twice in 2 ml flow 
cytometry buffer (0.5% (w/v) BSA in DPBS) by centrifugation at 400 g for 3 minutes at 
4
o
C.  Afterwards, the cells were labelled with primary/conjugated antibody and were 
incubated in accordance with the manufacturers’ instructions.  Following incubation, the 
cells were washed twice with 2 ml flow cytometry buffer, as previously described, and 
unconjugated antibodies were incubated with their respective secondary antibodies.  Cells 
were then washed twice more in 2 ml flow cytometry buffer and were re-suspended in 300-
400 µl of Isoton and kept on ice prior to flow cytometric analysis using a Beckman Coulter 
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Gallios flow cytometer. Histograms and dot plots were derived and analysed using the 
Beckman Coulter Kaluza version 1 software program.  
2.2.2.1.2   Intracellular staining protocol  
Cells were harvested by trypsinisation, counted using a haemocytometer and 1.5x 10
6
 cells 
were distributed per flow cytometry tube.  To remove cell culture media, 2 ml DPBS was 
added and the cells were centrifuged for 10 minutes at 300 g.  For fixation, cells were 
resuspended in 1 ml DPBS then 1 ml of 4% (w/v) paraformaldehyde was added to make a 
final concentration of 2% (w/v) paraformaldehyde and cells were incubated for 10 minutes 
at 37˚C.  Following incubation, cells were chilled on ice for 1 minute.  The 
paraformaldehyde was washed off using 2 ml DPBS followed by a centrifugation step of 
400 g for 3 minutes.  The supernatant was discarded and the cell pellets were resuspended 
in the tubes and chilled on ice prior to adding 1 ml 90% (v/v) ice-cold methanol and 
incubating on ice for 30 minutes.  The methanol was washed off using 2 ml of cold flow 
cytometry buffer (0.5% (w/v) BSA in 1x DPBS) followed by a centrifugation step of 400 g 
for 3 minutes, this step was repeated twice.  Cells were resuspended in 100 μl of flow 
cytometry buffer prior to addition of primary/conjugated antibodies.  Cells were incubated 
with the desired antibody/antibodies for 30 minutes in the dark at 4˚C after which time 
they were washed, as previously, by two centrifugation steps with 2 ml cold flow 
cytometry buffer.  Where applicable, secondary antibodies were applied and incubated as 
for the primary antibodies.  The secondary antibodies were removed using flow cytometry 
buffer (as previously described) prior to resuspending the cells in 400 μl of Isoton.  Flow 
cytometric analysis was performed using a Beckman Coulter Gallios flow cytometer. 
Histograms and dot plots were derived using the Beckman Coulter Kaluza version 1 
software program.  
2.2.2.2   Immunofluorescence 
This technique was employed several times throughout the duration of this project to 
observe the expression of various markers, to identify different cell populations, to 
determine the purity of isolated cell populations and to observe cell behaviour in response 
to different treatments.  Prior to use, all antibodies were titrated to determine the optimum 
working concentrations and, where applicable, appropriate positive and negative controls 
were utilised.  
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2.2.2.2.1   24 well plate format 
In a laminar flow hood, glass coverslips were dipped in 100% methanol, placed into wells 
of a 24 well plate and allowed to air-dry.  Once dry, 0.5 x 10
5
 adherent cells were seeded 
onto the glass coverslips and the plates were incubated for a minimum of 36 hours at 37˚C, 
5% (v/v) CO2.  Following incubation, the media was removed and cells were washed once 
with x1 DPBS.  Cells were then fixed with 500 μl 4% (w/v) paraformaldehyde at room 
temperature for 15 minutes.  Next, the paraformaldehyde was removed and the cells were 
washed twice with 1 ml x1 DPBS.  Cells were then blocked and permeabilised using 10% 
(w/v) BSA in 1x DPBS-0.1% (v/v) TWEEN (blocking solution) for 1 hour at room 
temperature.  Meanwhile, antibodies were prepared by diluting with blocking solution.  
Following the blocking step, cells were incubated with 200 μl of prepared antibody for 1 
hour at room temperature on a rocking platform.  To remove unbound primary antibody, 
the cells were washed 3 times for 10 minutes with 1 ml x1 DPBS-0.1% (v/v) TWEEN 
prior to incubation with 200 μl of secondary antibody for 1 hour at room temperature on a 
rocking platform.  The plates were wrapped in silver foil to minimise light exposure.  The 
secondary antibody was then removed and the cells were washed 3 times for 10 minutes 
with 1 ml x1 DPBS-0.1% (v/v) TWEEN.  The coverslips were subsequently removed from 
the wells, inverted and placed on microscope slides with DAPI mounting media. Hence, 
the cells were face-down on the slides and the nuclei were stained.  In order to secure the 
coverslips, colourless nail varnish was applied around the edge.  The slides were then 
wrapped in foil and transported to an Olympus BX51 fluorescence microscope for imaging.   
2.2.2.2.2   96 well fluorescence-compatible plate format 
Cells were plated at the desired density (subject to variation depending on the assay).  
Following completion of the assay, culture media was removed from the wells and cells 
were washed once with DPBS prior to fixation with 50 μl 4% (w/v) paraformaldehyde for 
15 minutes at room temperature.  Next, the paraformaldehyde was removed and cells were 
washed twice with 200 μl x1 DPBS prior to incubation with 50 μl blocking solution for 1 
hour at room temperature.  Cells were labelled with primary and secondary antibodies and 
washed as per 24 well plate protocol (volumes were scaled down to 50 μl of antibody 
solution and 200 μl 1x PBS-0.1% (v/v) TWEEN per well).  Following the final wash step, 
all liquid was removed from the wells and the nuclei were stained with 10 μl of mounting 
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fluid with DAPI per well. The plate was then wrapped in foil and transported to an 
Olympus BX51 fluorescence microscope for imaging.  
2.2.2.2.3   Immunofluorescent staining of spheres 
Cells were cultured at a density of 10,000 cells/well, 4 wells per clone, in ultra low 
adherent 24 well plates (See section 2.2.6.4.2).  The antibody staining protocol was 
executed as per the 24 well plate format.  In order to avoid loss of spheres, washes and 
blocking solutions were collected in addition, centrifuged in 20 ml universal tubes at 250 g 
for 10 minutes and collected spheres were stained in parallel.  Nuclear staining was 
achieved by transferring the spheres, resuspended in 50 μl DPBS, onto a glass slide with 
DAPI mounting media and covering with a large, rectangular coverslip.  Prior to imaging, 
on an Olympus BX51 fluorescence microscope, slides were sealed with colourless nail 
varnish.  
2.2.2.2.4   Immunofluorescent staining of tissue sections 
Patient prostate cancer and benign prostatic hyperplasia tissues and tumours from in vivo 
studies were sectioned onto sialinised slides using a Cryostat and frozen at -80˚C.  Prior to 
immunofluorescent staining, the slides were removed, dried and the sections were circled 
using an ImmEdge hydrophobic barrier pen.  Fixing, blocking and staining procedures 
were executed as per the 24 well plate format, however, volumes were scaled down 
accordingly and a rocking platform was not utilised.  Nuclear staining was achieved by 
pipetting DAPI mounting media directly onto the sections which were then covered with a 
large, rectangular coverslip.  Prior to imaging, on an Olympus BX51 fluorescence 
microscope, slides were sealed with colourless nail varnish.    
2.2.3   Magnetic Activated Cell Sorting (MACS) 
MACS technology has been used throughout the project on a number of different cell 
populations in attempt to isolate stem cells or cancer stem cells which were present as a 
very small percentage in a large number of cells.  The technique was optimised at the 
Anthony Nolan Cell Therapy Centre using cord blood to isolate cord blood stem cells 
according to their expression of the cell surface marker CD133 and the method was then 
applied when attempting to isolate CD133 expressing cells from prostate cancer cell lines 
and primary prostate cancer cells. 
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2.2.3.1   MACS of Prostate Cancer Cells from Cell Lines and Primary Cultures 
This method was used in an attempt to isolate CD133-positive putative prostate cancer 
stem cells. 
To isolate CD133-positive populations from cell lines, the cells from 10 T175 flasks 
(approximately 1x10
8
 cells; 80% confluency) were harvested by trypsinisation whereas, to 
isolate CD133-expressing cells from primary cultures, the cells from a maximum of four 
T75 flasks were harvested by trypsiniastion.  The cells were then washed in appropriate 
media by centrifugation at 400 g for 3 minutes, the pellets were re-suspended in 
appropriate media and the cells were pooled and washed once more.  The pooled pellet was 
re-suspended in 10 ml of MACS buffer and the cells were counted using the trypan blue 
exclusion method.  One million cells were removed from the cell suspension and retained 
for future analysis as the “mixed fraction”.  The remaining cells were spun down and the 
pellet was labelled with 300 µl MACS buffer, 100 µl FcR block and 100 µl CD133 
microbeads.  The tube was gently agitated to ensure mixing and the cells were incubated 
with intermittent agitation for 30 minutes at 4°C in a cold room.  After the elapsed time, 
the cells were re-suspended in 10 ml MACS buffer and were centrifuged at 300 g for 10 
minutes.  Meanwhile, an LS column was prepared by washing 3 times with 1 ml MACS 
buffer, ensuring that the column was not dry prior to addition of the cell suspension.  After 
centrifugation, the supernatant was discarded, the cells were re-suspended in 5 ml MACS 
buffer and the cell suspension was pipetted 1 ml at a time onto a pre-separation filter 
(placed above the LS column).  Once the cell suspension had passed through the column 
(CD133 negative cells passed through and were captured in a 50 ml falcon tube) the 
column was washed, 1 ml at a time, with 12 ml MACS buffer.  The column was then 
removed from the magnet, the filter was discarded, 5 ml of MACS buffer was applied 
directly to the column and the CD133 positive cells were rapidly purged from the column 
into a 50 ml falcon tube.  This step was repeated 3 more times. Hence, the positive fraction 
was suspended in 20 ml MACS buffer.  The positive fraction was centrifuged for 3 minutes 
at 400 g, the supernatant was discarded and the cells were re-suspended in 500 µl MACS 
buffer.   
In order to increase the purity, the CD133 positive fraction was applied to a second, 
smaller column.  An MS column was prepared by washing 4 times with 500 µl MACS 
buffer and the positive fraction was applied directly to the column.  Once the cell 
suspension had passed through, the column was washed 8 times with 500 µl MACS buffer.  
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The MS column was then removed from the magnet and the cells were purged out with 1 
ml MACS buffer.  This step was repeated 3 more times.  Hence, the positive fraction was 
suspended in 4 ml MACS buffer. 
Following isolation the mixed, positive, and negative fractions were analysed immediately 
by flow cytometry, plated out for immunofluorescence, or plated into 6 well plates and 
analysed at a later date.  
2.2.4    Molecular Biology Techniques 
2.2.4.1   RNA Extraction from Cell Lines and Cord Blood Stem Cells 
To conduct gene expression analyses, high quality, non-degraded nucleic acid was 
extracted from several cell types.  In order to avoid RNA degradation by RNAses, all RNA 
extraction procedures and consequent assays were conducted with RNAse free materials in 
a laminar flow hood. 
To extract RNA from cord blood stem cells, 0.5 ml RNA STAT 60 was added directly to 
the cryovial in which the isolated stem cells had been frozen and the mix was incubated at 
room temperature for 5 minutes.  All reagents were scaled down by half when extracting 
RNA from cord blood stem cells.   
To extract RNA from prostate cell lines cultured in T75 flasks, 1 ml of RNA STAT 60 was 
pipetted onto the cells and the flask was rotated to ensure complete coverage.  A cell 
scraper was then used to scrape all lysed cells and RNA stat 60 into one corner of the T75 
flask.  The mix was subsequently pipetted into a 1.5 ml eppendorf tube and was incubated 
at room temperature for 5 minutes.   
Subsequently, 0.2 ml of chloroform was added and the eppendorf was shaken vigorously 
for 60 seconds.  After incubation at room temperature for 3 minutes the eppendorf was 
centrifuged at 4˚C for 10 minutes at 12,000 g.  Following centrifugation three layers 
formed and the clear upper layer was transferred into a sterile 1.5 ml eppendorf.  Next, 0.5 
ml of isopropanol was added and the eppendorf was repeatedly inverted for 30 seconds to 
precipitate the RNA.  This step was followed by an incubation of 8 minutes at room 
temperature followed by centrifugation at 4˚C for 5 minutes at 12,000 g.  The supernatant 
was then discarded and the white RNA pellet was washed in 1 ml 75% (v/v) ethanol by 
vortexing.  In order to remove the ethanol, the eppendorf was centrifuged at 7,500 g for 5 
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minutes and the supernatant was discarded.  The eppendorf was left open for 10-15 
minutes to enable the RNA pellet to dry.  Once the ethanol had evaporated, the pellet was 
re-suspended in 20 μl molecular grade water.  Finally, RNA concentration, quantity and 
quality were evaluated using a NanoDrop UV spectrophotometer at wavelengths of 260 nm 
and 280 nm.  
2.2.4.2   Reverse Transcription  
Prior to quantitative RT-PCR, RNA must be converted into cDNA in an enzymatic 
reaction known as reverse transcription.  Firstly, 2 μg of RNA was incubated with 1 μl 
Oligo DT and 13 μl molecular grade water for 5 minutes at 70˚C.  Following this step, 
samples were placed immediately on ice to prevent the formation of secondary structures.  
To this mixture, the following components were added: 5 μl 5x Buffer, 1 μl dNTPs, 0.7 μl 
RNAsin RNAse inhibitor, 2.3 μl molecular grade water and 1 μl MLV-Reverse 
transcriptase.  Samples were then incubated in a water bath for 80 minutes at 42˚C, after 
which time the reaction was terminated by a 5 minute heat-step at 95˚C.  The samples were 
then pulse-centrifuged prior to storage at 4˚C.     
2.2.4.3  Quantitative Real-Time PCR 
Real-time quantitative RT-PCR was utilised to evaluate the mRNA expression levels of the 
markers of interest (CD44 and CD133) in prostate cancer cell lines and cord blood stem 
cells. 
Each reaction was prepared on ice in duplicate in 0.2 ml PCR strip tubes.  Each tube 
contained 4.75 µl molecular grade water, 6.25 µl SYBR-green master mix, 0.5 µl forward 
and 0.5 µl reverse oligonucleotide primers and 0.5 µl of cDNA template.  A Rotor-Gene Q 
real-time PCR detection system was used and GAPDH, HPRT-1 and TBP were used as 
reference genes to standardise the results. 
Primers: 
CD44 Forward: 5’-GCCAGAGGCCCAGACAGGCT-3’ 
CD44 Reverse: 5’-TGGGGCGACAGGTAGAGGCT-3’ 
  
CD133 Forward: 5’-TGGCTGGGTGGCCTGGTCAT-3’ 
CD133 Reverse: 5’-ACGCCTCCGGTGTTGGAGACA-3’ 
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2.2.5    Acquisition of OPCT-1 clones 
2.2.5.1   Isolation of Single Cells by Live Cell Laser-Capture Microdissection 
During this project laser-capture microdissection was attempted as a means of isolating 
single E-Cadherin-positive cells for expansion and subsequent investigation of EMT. 
1x 10
5
 parental OPCT-1 cells were plated onto a Duplex dish in 2 ml of culture media and 
incubated overnight at 37°C with 5% (v/v) CO2.  Following incubation, the medium was 
removed, the cells were washed twice with 1 ml of culture media, the primary antibody, 
diluted in 1 ml of culture media, was applied and the cells were incubated for  1 hour at 
37°C, 5% (v/v) CO2.  Next, the primary antibody was removed, the cells were washed 
three times with 1 ml of culture media, the fluorescent conjugated secondary antibody, 
diluted in 1 ml culture media, was applied and the cells were incubated for 1 hour at 37°C, 
5% (v/v) CO2.  Following incubation, the secondary antibody was removed and the cells 
were washed three times with 1 ml of culture media, prior to a 30 minute incubation step 
with 1 ml culture media at 37°C, 5% (v/v) CO2.   
Prior to conducting live cell microdissection, the media was removed and 100 μl of media 
was applied.  The plate was subsequently examined using the Palm laser-capture 
microdissector, E-Cadherin positive and negative cells were identified, microdissected 
from the plate and transferred into a 96 well plate with conditioned media.  The 96 well 
plate was incubated at 37°C, 5% (v/v) CO2 and examined daily for cell growth. 
2.2.5.2   Cloning of the OPCT-1 Cell Line by Limiting Dilution 
This technique was utilised to derive clones with distinct E-Cadherin/vimentin and 
CD44/CD24 expression profiles from the OPCT-1 cell line. 
OPCT-1 cells were harvested by trypsinisation, counted and diluted in culture media to a 
concentration of 1 cell per 600 μl.  This suspension was then plated out in 96 well plates, 
200 μl per well, in order to obtain a count of 0.33 cells per well.  The plates were examined 
immediately to ensure that multiple cells were not present in the wells.  Plates were then 
incubated at 37°C, 5% (v/v) CO2 and examined twice a week until single colonies of cells 
were observed. 
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2.2.5.3   Bulking, Screening and Selection of the OPCT-1 Clones 
This procedure yielded 74 clones.  Following ~21 days of culture, the clones were 
transferred from the 96 well plates to 6 well plates by trypsinisation.  Once confluent, they 
were harvested from the 6 well plates, frozen down for cell culture and re-plated in the 6 
well plates.  Once confluent, the clones were frozen down a second time, re-plated and 
screened in duplicate for the expression of E-Cadherin/vimentin and CD44/CD24 by 
immunofluorescence.  The clones were then frozen down a third time prior to selecting 
suitable clones for further examination.  A total of 51 clones were bulked, frozen down and 
screened by immunofluorescence.  Twelve clones were selected for further investigation, 
these were cultured and screened 3 times by IF (as above) at different passages to ascertain 
the stability of their phenotypes.  From these, 5 clones with distinct E-Cadherin/vimentin 
expression profiles were selected and interrogated for the purpose of this study. 
2.2.5.4   Cell Sorting – Re-cloning of OPCT-1 Clones 
In order to re-confirm that a single OPCT-1 cell was capable of generating both epithelial 
and mesenchymal cell types, it was necessary to re-clone the OPCT-1 clones using a 
MoFlo
TM
 XDP High-Speed Cell Sorter. 
Single cell suspensions of the 5 OPCT-1 clones of interest were sorted at a density of one 
cell per well (32 wells per clone) into fluorescence compatible 96 well plates using a 
MoFlo
TM
 XDP High-speed cell sorter.  The plates were incubated at 37°C, 5% (v/v) CO2  
for 14 days after which time the cells were fixed with 4% (w/v) paraformaldehyde for 15 
minutes at 4°C, stained with anti-E-Cadherin and anti-vimentin (See Section 2.2.2.2.2) and 
imaged using an Olympus BX51 fluorescence microscope.  This assay was conducted in 
three separate experiments.  The mean colony forming efficiency of each of the clones was 
calculated by dividing the average number of colonies which grew per clone by the number 
of wells seeded (32) and multiplying by 100.  
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2.2.6    Characterisation of OPCT-1 clones 
The following assays were executed in order to characterise the OPCT-1 clones and 
investigate a possible link between the cancer stem cell phenotype and epithelial to 
mesenchymal transition.  In parallel to each assay, the phenotype of the clones was 
monitored by immunofluorescence.   
2.2.6.1   Investigating the Protein Expression of Stem and EMT-Associated Markers 
in OPCT-1 Clones  
In order to compare the protein expression profiles of the OPCT-1 clones, both Western 
blotting and immunofluorescence were conducted using a panel of several EMT and stem 
cell-associated markers. 
2.2.6.1.1   Preparation of cell lysates 
Following culture in standard conditions, 70-80% confluent cells growing in T175 tissue 
culture flasks were washed twice with sterile DPBS and scraped in the residual DPBS 
using a cell scraper.  The cells+DPBS were transferred into an eppendorf tube and 
centrifuged at 10,000 g for 10 minutes.  Immediately after centrifugation, the supernatant 
was discarded, the pellets were lysed in total cell lysis buffer (volumes depended on the 
size of the pellet) and the lysate was heated in a thermoblock at 99°C for 10 minutes.  
Lysates were either stored at -20°C for future use or the protein concentration was 
immediately quantified using the BCA assay. 
2.2.6.1.2   BCA Protein Assay 
This assay was conducted in order to calculate the concentration of total protein in the cell 
lysates and was executed in accordance with the manufacturers’ instructions.  In brief, 
triplicate standards were prepared in a flat bottom 96 well plate from a stock BSA solution 
(1 mg/ml) of the range 0, 5, 10, 15, 20, 25 μg and the volumes were adjusted to 25 μl with 
total cell lysis buffer.  Cell lysates were pipetted in triplicate wells, 2.5 μl/well and the total 
volume was adjusted to 25 μl with total cell lysis buffer.  Next, solution A and solution B 
were prepared in a 1:50 dilution, in accordance with the manufacturer’s instructions, and 
200 μl was distributed per well.  The plate was then covered with a plastic seal and 
incubated at 37°C, 5% (v/v) CO2 for 30 minutes.  After the elapsed time, the plate was read 
using a Tecan Ultra microtiter plate reader at a wavelength of 560 nm.  Using Excel, a 
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standard curve was plotted from the BSA standard absorbance data and this was used to 
quantify the concentration of protein in the lysates.   
2.2.6.1.3   Western Blot Analysis of Protein 
2.2.6.1.3.1   SDS PAGE 
Prior to immunoblotting, SDS PAGE was conducted in order to separate the proteins in a 
sample. 
SDS gels were prepared and immersed in a tank containing 1x tris-glycine-SDS running 
buffer.  Lysates were prepared with sample reducing buffer at a ratio of 3:1 (lysate: 
reducing buffer) by heating on a thermoblock at 95°C for five minutes.  Next, sample 
containing 20 or 30 μg or protein (depending on the experiment) was loaded into the wells 
of the SDS gels alongside a molecular weight marker.  Once loaded, 80V were applied to 
the gels for 10 minutes to allow the proteins to pass through the stacking gel, this was 
increased to 150V to allow the proteins to separate in the resolving gel.   
2.2.6.1.3.2   Wet Transfer 
Once the proteins had run through the gel (~75 minutes), they were transferred onto a 
nitrocellulose membrane via “wet transfer”.  Briefly, a “sandwich” was prepared using a 
gel frame, a sponge soaked in transfer buffer, two pieces of filter paper soaked in transfer 
buffer, the SDS gel, a nitrocellulose membrane, two additional pieces of transfer buffer-
soaked filter paper and one more transfer buffer-soaked sponge.  This was sealed with 
another gel frame and inserted into a transfer tank filled with ice cold transfer buffer.  
Proteins were transferred overnight for 16 hours at 30V or alternatively, for one hour at 
100V. 
2.2.6.1.3.3   Copper staining 
In order to image the protein bands, hence confirm a successful transfer process and equal 
protein loading, nitrocellulose membranes were stained for 10 minutes in Copper 
phthalocyanine-3,4′,4″,4″′-tetrasulfonic acid tetrasodium salt and imaged using a darkbox.  
The membranes were then cut to allow for probing with different antibodies.  Prior to 
immunoprobing, the membranes were de-stained in DPBS with two drops of 10 M sodium 
hydroxide and then blocked with 3% (w/v) Marvel milk solution for one hour at room 
temperature on a rocking platform.   
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2.2.6.1.3.4   Immunoprobing 
Prior to obtaining the final results, all antibodies were titrated using a mixed cell lysate in 
order to determine optimum working dilutions. 
Cut nitrocellulose membranes were incubated with the corresponding primary antibody 
diluted in 3% (w/v) Marvel milk solution on a rocking platform over night at 4°C.  The 
following day, the membranes were washed three times for 10 minutes in DPBS-0.1% (v/v) 
TWEEN prior to adding the corresponding HRP-linked secondary antibody diluted in 3% 
(w/v) Marvel milk solution.  A streptavidin-HRP secondary antibody was used to stain the 
molecular weight marker present on each membrane.  Following one hour incubation at 
room temperature on a rocking platform, the membranes were washed as previously 
described.  The membranes were developed using ECL reagent which was applied for one 
minute prior to exposure (exposure times varied depending on the abundance of the protein) 
and development using a CCD camera.  
2.2.6.2   Proliferation Assays 
The proliferation of the OPCT-1 clones was investigated using the [3H]-Thymidine 
incorporation assay, the ViaLight® Plus kit and the MTT assay.   
2.2.6.2.1   [3H]-Thymidine Incorporation Assay 
This assay assesses proliferation based on the incorporation of [3H]-Thymidine into the 
cells’ DNA during replication.  Prior to obtaining the final results, this method was 
optimised in terms of plate format, cell density, incubation periods and harvesting method. 
Briefly, 10,000 cells were plated in quadruplicate wells of a 96 well plate and incubated for 
24 hours at 37°C, 5% (v/v) CO2.  [3H]-Thymidine was added to the cells with a final 
concentration of 0.037 MBq/ml and incubated at 37°C with 5% (v/v) CO2 for 19.5 hours.  
A Filtermate Harvester was utilised to transfer the media from the cells grown in the 96 
well plate to a 96 well Unifilter plate.  The cells were then incubated for 15 minutes with 
30 μl of trypsin prior to harvesting onto the Unifliter plate using the Filtermate Harvester 
and the plate was then left for 2 hours at room temperature to dry.  Once dry, the Unifilter 
plate was overlaid with 40 μl of Microscint-O scintillation fluid and analysed using an 
NXT Top-Count microplate scintillation counter to detect radioactivity in the form of 
“counts per minute” (cpm) for each well.  This assay was conducted in three separate 
experiments.  Data obtained were analysed using GraphPad Prism 5 software.      
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2.2.6.2.2   ViaLight® Plus Proliferation Assay 
The ViaLight® Plus proliferation assay detects cellular proliferation by determination of 
ATP levels using bioluminescence based on the luciferin-luciferase reaction.  Prior to 
obtaining the final results, this method was optimised in terms of cell density and 
incubation periods. 
This assay was conducted as per the manufacturer’s recommendations.  In brief, 10,000 
cells in 100 μl of culture media were plated in quadruplicate wells of a 96 well plate and 
incubated for 24 hours at 37°C, 5% (v/v) CO2.  Following incubation, cells and reagents 
were brought to room temperature for 15 minutes prior to a 10 minute cell lysis step with 
50 μl Cell Lysis Reagent.  As a control, 100 μl of media/lysis buffer (1:1) was transferred 
to 4 wells of a white walled luminometer plate.  After cell lysis, 100 μl of cell lysate was 
transferred to the luminometer plate, 100 μl of the reconstituted ViaLight®  Plus reagent 
(AMR PLUS) was added to each appropriate well and the plate was incubated for 2 
minutes at room temperature.  The plate was read in a microplate luminometer which took 
one second integrated readings expressed as relative light units (RLUs).  This assay was 
conducted in three separate experiments.  Data obtained were analysed using GraphPad 
Prism 5 software.     
2.2.6.2.3   MTT Proliferation Assay 
This assay measures cell proliferation based on the reduction of the yellow tetrazolium salt, 
3,[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), to an insoluble 
purple formazan dye by mitochondrial enzymes associated with metabolic activity.  This 
assay was optimised previously and was conducted as per recommendation. 
Cells were plated at a density of 25,000 per well in 1 ml media in triplicate wells of a 24 
well plate and incubated for 24 hours at 37°C, 5% (v/v) CO2.  The reconstituted MTT 
reagent (5mg/ml) was brought to room temperature and 50 μl was added per well, prior to 
incubation for 30 minutes at 37°C, 5% (v/v) CO2.  Following incubation, the media was 
removed from the wells and 500 μl DMSO was added per well and pipetted up and down 
to solubilise the formazan dye.  As a control, 200 μl of DMSO was transferred to 6 wells of 
a 96 well microtiter plate.  Next, 200 μl of DMSO/formazan dye was transferred in 
duplicate, to the 96 well microtiter plate hence, 6 wells per cell line.  The absorbance in 
each well was read using a Tecan microtiter plate reader at a wavelength of 570 nm. This 
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assay was conducted in three separate experiments.  Data obtained were analysed using 
GraphPad Prism 5 software.      
2.2.6.3     Drug Assays 
2.2.6.3.1  Determination of the Docetaxel IC50 for Parental OPCT-1 using the      
[3H]-Thymidine Incorporation Assay 
This assay was executed in order to determine the IC50 dose of docetaxel on parental 
OPCT-1 for use in drug sensitivity studies on the OPCT-1 clones.  Prior to obtaining the 
final result, this method was optimised in terms of cell density, volume of drug media, 
addition of [3H]-Thymidine, incubation periods and drug concentration range. 
Briefly, 10,000 OPCT-1 cells were plated in 32 wells of a 96 well plate and incubated for 
approximately 20 hours at 37°C, 5% (v/v) CO2.  Following incubation, the media was 
removed and replaced with 200 μl control media (media only) and docetaxel-laced media 
of the range 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1000 nM.  The plate was then 
incubated for 48 hours at 37°C, 5% (v/v) CO2.  Following incubation, [3H]-Thymidine was 
added to the cells with a final concentration of 0.037 MBq/ml and incubated at 37°C with 
5% (v/v) CO2 for 19.5 hours.  As previously, a Filtermate Harvester was utilised to transfer 
the media from the cells grown in the 96 well plate to a 96 well Unifilter plate.  The cells 
were then incubated for 15 minutes with 30 μl of trypsin prior to harvesting onto the 
Unifliter plate using the Filtermate Harvester and the plate was left for 2 hours at room 
temperature to dry.  Once dry, the Unifilter plate was overlaid with 40 μl of Microscint-O 
scintillation fluid and analysed using an NXT Top-Count microplate scintillation counter 
to detect radioactivity in the form of “counts per minute” (cpm) for each well.  This assay 
was conducted in five separate experiments, in quadruplicate.  The data obtained were used 
to plot a dose response curve and ascertain the IC50 dose using GraphPad Prism 5 software.  
Using this assay, the docetaxel IC50 for parental OPCT-1 was determined as 5.617 nM.  
2.2.6.3.2  Determination of the Docetaxel IC50 on Parental OPCT-1 using the 
ViaLight®  Plus Proliferation Assay 
In addition to the [3H]-Thymidine Incorporation Assay, this assay was performed in order 
to determine the IC50 dose of docetaxel on parental OPCT-1 for use in drug sensitivity 
studies on the OPCT-1 clones.  Prior to obtaining the final results, this method was 
optimised in terms of cell density, incubation periods and drug concentration range. 
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In Brief, 10,000 OPCT-1 cells were plated in 32 wells of a 96 well plate and incubated for 
approximately 20 hours at 37°C, 5% (v/v) CO2.  Following incubation, the media was 
removed and replaced with 100 μl control media (media only) and docetaxel-laced media 
of the range 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1000 nM.  The plate was then 
incubated for 48 hours at 37°C, 5% (v/v) CO2.  Following incubation, cells and reagents 
were brought to room temperature for 15 minutes prior to a 10 minute cell lysis step with 
50 μl Cell Lysis Reagent.  As a control, 100 μl of media/lysis buffer (1:1) was transferred 
to 4 wells of a white walled luminometer plate.  After cell lysis, 100 μl of cell lysate was 
transferred to the luminometer plate, 100 μl of the reconstituted ViaLight® Plus reagent 
(AMR PLUS) was added to each appropriate well and the plate was incubated for 2 
minutes at room temperature.  The plate was read in a luminometer which took 1 second 
integrated readings expressed as relative light units (RLUs).  This assay was conducted in 
three separate experiments, in quadruplicate.  The data obtained were used to plot a dose 
response curve and ascertain the IC50 dose using GraphPad Prism 5 software.  Using this 
assay, the docetaxel IC50 for parental OPCT-1 was determined as 11.15 nM.       
2.2.6.3.3   Thymidine Clone IC50 Assay 
After ascertaining the IC50 concentration of docetaxel on parental OPCT-1, this assay was 
performed in order to compare the sensitivity of the clones to docetaxel.   
Briefly, 10,000 cells were plated in 12 wells of a 96 well plate per clone and incubated for 
approximately 20 hours at 37°C, 5% (v/v) CO2.  Following incubation, the media from 4 
wells per clone was removed and replaced with 200 μl control media (media only), the 
media from 4 wells per clone was removed and replaced with 200 μl docetaxel-laced 
media at 5.5 nM (the IC50) and the media from 4 wells per clone was removed and 
replaced with 200 μl docetaxel-laced media at 11 nM (double the IC50).  The plate was 
then incubated for 48 hours at 37°C, 5% (v/v) CO2.  Following incubation, [3H]-
Thymidine was added to the cells with a final concentration of 0.037 MBq/ml and 
incubated at 37°C with 5% (v/v) CO2 for 19.5 hours.  As previously, a Filtermate Harvester 
was utilised to transfer the media from the cells grown in the 96 well plate to a 96 well 
Unifilter plate.  The cells were then incubated for 15 minutes with 30 μl of trypsin prior to 
harvesting onto the Unifliter plate using the Filtermate Harvester.  Once dry, the Unifilter 
plate was overlaid with 40 μl of Microscint-O scintillation fluid and analysed using an 
NXT Top-Count microplate scintillation counter to detect radioactivity in the form of 
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“counts per minute” (cpm) for each well.  This assay was conducted in five separate 
experiments, in quadruplicate.  STATISTICA software was used to analyse the data 
obtained by means of a Factorial ANOVA.  The percentage inhibition of proliferation was 
calculated by dividing the difference between the values for control and test by the test 
values and multiplying by 100. 
2.2.6.4     Clonogenic, Sphere-forming and Self-renewal Assays 
2.2.6.4.1    Clonogenic Assay 
This assay was conducted in order to assess and compare the clonogenicity of the OPCT-1 
clones and ascertain whether the clones with an EMT phenotype were more clonogenic. 
Single cell suspensions were plated at the clonal density of 125 cells per well of a 6 well 
plate, 2 wells per clone.  Following 10 days in culture, the colonies were fixed with 4% 
(w/v) paraformaldehyde for 15 minutes at 4°C and stained with crystal violet solution 
(0.5% (w/v) crystal violet in 70% (v/v) ethanol) for 15 minutes at room temperature, after 
which, the colonies were washed with DPBS and allowed to dry prior to counting under a 
light microscope.  Colonies with fewer than 32 cells were excluded from the counts.  The 
plates were then photographed.  This assay was conducted in duplicate wells in three 
separate experiments.  Data collected were analysed using GraphPad Prism 5 software.       
2.2.6.4.2    Sphere-Forming Assay 
This assay was conducted in order to assess and compare the sphere-forming ability of the 
OPCT-1 clones and ascertain whether the clones with an EMT phenotype possessed 
enhanced sphere-forming capabilities.  Prior to obtaining final results, this assay was 
optimised in terms of media composition, plate format, cell density and duration of culture. 
Single cell suspensions were plated in triplicate wells of an ultra-low adherent 24 well 
plate at a density of 10,000 cells per well and were cultured in normal media (KSFM 2% 
(v/v) FCS) for 12 days at 37°C, 5% (v/v) CO2.  Spheres were observed microscopically 
and counted by two individuals; an average of the counts was taken.  This assay was 
conducted in triplicate wells in three separate experiments.  Data collected were analysed 
using GraphPad Prism 5 software.       
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2.2.6.4.3    Self-Renewal Assay 
This assay was conducted in order to assess and compare the self-renewal capabilities of 
the OPCT-1 clones and ascertain whether the clones with an EMT phenotype possessed 
enhanced self-renewal abilities. 
As with the sphere-forming assay, single cell suspensions were plated in triplicate wells of 
an ultra-low adherent 24 well plate at a density of 10,000 cells per well and were cultured 
in 1 ml of normal media (KSFM 2% (v/v) FCS) for 12 days at 37°C, 5% (v/v) CO2, after 
which time the spheres were observed microscopically and counted by two individuals.  
Next, the spheres and culture media were collected from 2 wells per clone (handled 
separately) and centrifuged for 3 minutes at 300 g.  The supernatant was discarded and the 
spheres were re-suspended in 300 μl trypsin and versene (T&V) prior to incubation at 37°C 
for 30 minutes.  Following incubation, the spheres were further dissociated by persistent 
pipetting and were subsequently sorted at a density of  750 cells per well of an ultra low 
adherent 24 well plate with 750 μl  KSFM 2% (v/v) FCS+pen/strep using a MoFloTM XDP 
High-speed cell sorter.  Cells were cultured for 12 days at 37°C, 5% (v/v) CO2 after which 
time, the wells were examined microscopically for the presence of secondary sphere 
formation.  Spheres were counted by two individuals and an average of the counts was 
taken.  This assay was conducted in triplicate wells in three separate experiments.  Data 
collected were analysed using GraphPad Prism 5 software.       
2.2.6.5   Aldefluor
TM 
 Assay  
Aldehyde dehydrogenase 1 (ALDH1) has been shown to be essential for stem cell survival 
and early differentiation and has been utilised to identify haematopoietic, mammary and 
neural stem cells.  ALDH1 activity has also been exploited as a potential marker for CSCs 
and ALDH1
hi
 populations have been shown to be highly tumourigenic.  Therefore, the 
Adefluor
TM
 assay was conducted in this study in order to ascertain whether the clones with 
an EMT phenotype possessed a larger subpopulation of cells with enhanced ALDH1 
activity. 
Prior to obtaining final results, this assay was optimised in terms of incubation periods, cell 
numbers and volume of reagents used. 
Briefly, cells were harvested and counted and a suspension of 1x10
6
 cells per clone was 
made up to 1 ml with Aldefluor
TM
 Assay Buffer and split equally between two flow 
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cytometry tubes.  To inhibit ALDH1 activity in the control tubes, 2.5 μl of AldefluorTM 
DEAB Reagent was added and incubated at room temperature for 10 minutes.  Next, 2.5 μl 
of activated Aldefluor
TM
 Reagent was added to each tube prior to incubation 37°C, 5% (v/v) 
CO2 for 45 minutes.  After the elapsed time, cells were centrifuged at 400 g for 3 minutes, 
to remove excess substrate.  Cells were subsequently resuspended, on ice, in 500 μl of cold 
Aldefluor
TM
 Assay Buffer.  In order to avoid loss of staining, as a result of efflux from the 
cells, cells were analysed immediately using a Beckman Coulter Gallios flow cytometer 
and  cells awaiting analysis were kept covered, on ice at all times.  Furthermore, the order 
in which the cells were analysed was changed in each repeat of the experiment.  This assay 
was conducted in four separate experiments.  Histograms and dot plots were derived using 
the Beckman Coulter Kaluza version 1 software program.  The percentage of ALDH1
hi
 
cells was determined by gating around a density plot of control cells (treated with DEAB 
reagent), applying the same gate to the test cells and subtracting the number of cells within 
the control gate from the number of cells within the test gate.  Data obtained were analysed 
using GraphPad Prism 5 software and the mean percentage of ALDH1
hi
 cells present in 
each clone, compared with parental OPCT-1, was calculated. 
2.2.6.6     Invasion and Migration Assays 
2.2.6.6.1   Scratch Assay 
This assay was performed in order to observe the possible migration of mesenchymal 
(vimentin-positive) cells into an artificial wound.  Prior to obtaining final results, this assay 
was optimised in terms of media composition, cell density, scratching technique and 
duration. 
Fluorescence-compatible 96 well plates were coated during a 1 hour incubation with 30 μl 
poly-L-lysine per well.  The unbound poly-L-lysine was subsequently removed from each 
well prior to seeding cells in quadruplicate wells at the high density of 50,000 cells per 
well.  Twenty four hours later, 200 μl pipette tips coated with poly-L-lysine were 
employed to create a scratch in the confluent monolayer, in the centre of each well.  The 
cells were washed twice with sterile DPBS prior to being cultured in serum free KSFM 
media for 12 hours at 37°C, 5% (v/v) CO2.  After the elapsed time, cells were fixed with 
4% (w/v) paraformaldehyde for 15 minutes at 4°C, stained with anti-E-Cadherin and anti-
vimentin (See Section 2.2.2.2.2) and observed using an Olympus BX51 fluorescence 
microscope.  This assay was conducted in four separate experiments. 
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2.2.6.6.2    In Vitro Matrigel
TM
 Invasion Assay 
This assay was conducted in order to compare the invasiveness of the OPCT-1 clones and 
observe a possible connection between EMT and invasion.  For this purpose, 24 well 
Biocoat Matrigel
TM
 Invasion Chambers containing BD Falcon Cell Culture Inserts with 8 
μm pore-size PET membranes that had been treated with MatrigelTM Matrix were used.  
Prior to obtaining final results, this assay was optimised in terms of cell density, media 
composition and method of enumeration.  
Cells were serum-starved for 24 hours prior to conducting the assay.  Two hours prior to 
plating the cells, Matrigel
TM
-containing inserts were hydrated using 500 μl serum-free 
culture medium and incubated 37°C, 5% (v/v) CO2.  Meanwhile, cells were counted and 
re-suspended in 2.5 ml serum free KSFM.  After hydration, the media was removed from 
the Matrigel
TM
 inserts and the Matrigel
TM
 and control inserts were transferred into a sterile 
24 well companion plate.  Next, 750 μl of chemoattractant, KSFM 10% (v/v) FCS, was 
pipetted into each well, avoiding the inserts.  The cells were then plated carefully into the 
Matrigel
TM
 and control inserts at a density of 1.5x10
6
 cells per insert (500 μl cell 
suspension) and were incubated at 37°C, 5% (v/v) CO2 for 22 hours.  After the elapsed 
time, tweezers were utilised to remove the inserts and pour off the media.  In order to 
remove Matrigel
TM
 matrix and non-invading cells, the inside of each insert was scrubbed 
with a DPBS-soaked cotton bud.  After scrubbing, the cells were fixed by placing each 
insert into a companion plate with 750 μl ethanol and incubating on ice for 15 minutes.  
Meanwhile, two 24 well wash plates were prepared with 750 μl DPBS per well.  After the 
elapsed time, excess ethanol was poured from the inserts prior to placing them into the first 
wash plate and incubating for two minutes.  Next, the wash step was repeated by 
transferring the inserts into the second wash plate and incubating for a further two minutes.    
Meanwhile, a 0.1 mg/ml solution of propidium iodide (PI) was prepared, by diluting the 
stock solution (1 mg/ml) with DPBS and 750 μl of PI solution was pipetted into each well 
of a new companion plate.  The inserts were then transferred from the second wash plate 
into the companion plate with PI, wrapped in aluminium foil and incubated at 37°C, 5% 
(v/v) CO2 for 20 minutes.  Following incubation, the inserts were washed, as previously, 
air dried and transferred into a new companion plate prior to scanning and imaging using a 
C.T.L ELISPOT plate reader.  The images were analysed using ImmunoSpot® software.  
Percentage invasion was calculated by dividing the cell counts for the Matrigel
TM
 inserts 
by the counts for the control inserts and multiplying by 100.  This assay was conducted in 
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three separate experiments.  Data were analysed using Microsoft Excel and GraphPad 
Prism 5 software.    
2.2.6.7    Response to Matrigel
TM
 Assay 
Prior to conducting in vivo studies with Matrigel
TM
, it was necessary to ascertain whether 
the OPCT-1 clones would maintain a stable phenotype during incubation with Matrigel
TM
, 
which contains known inducers of EMT, including TGF-β. 
Glass coverslips were plated into 24 well plates (See Section 2.2.2.2.1) and were covered 
with 100 μl MatrigelTM: serum free KSFM media (1:6).  Cells were plated onto the 
Matrigel
TM
 at a density of 10,000 cells per well, in quadruplicate wells and were cultured 
at 37°C, 5% (v/v) CO2  for either 72 hours or 7 days.  After the elapsed time, cells were 
fixed with 4% (w/v) paraformaldehyde for 15 minutes at 4°C, stained with anti-E-Cadherin 
and anti-vimentin and observed using an Olympus BX51 fluorescence microscope.   
2.2.6.8    In vivo Tumourigenesis  
Male nude athymic mice were used as a model to investigate an association between EMT 
and tumourigenesis.  Four OPCT-1 clones of interest, exhibiting distinct E-Cadherin and 
vimentin expression profiles; P5B3, P6D4, P2B9 and P4B6, plus parental OPCT-1 were 
injected and monitored over a period of 52 days.  
In brief, cells were injected at a density of 2.5x10
6
 with 100 μl 1:6 serum free media: 
Matrigel
TM
, sub-cutaneously into the right flank of male athymic nude mice, 6 mice per 
cell line.  Tumour development was observed twice weekly using calliper measurements 
until one of the tumours had reached a diameter of 1 cm, after which time the experiment 
was terminated and the mice were euthanised.  Tumours were then extracted, mounted on 
cork boards with OCT, snap frozen in liquid nitrogen-cooled 2-butanol and stored at -80°C, 
prior to cryostat sectioning. 
2.2.6.9   Statistical Analysis 
Unless stated, all data are presented as mean ± standard error of the mean (SEM).  Due to 
the fact that fewer than 12 replicates were performed in most of the assays conducted 
throughout this study, most of the data generated did not follow a normal (Gaussian) 
distribution.  Therefore, unless stated, non-parametric tests were utilised to analyse the data.   
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Data are presented as overall significance between the clones and parental OPCT-1 in a 
given test represented, in some figures, by asterisks with the significance levels p ≤ 0.05 
(*), p ≤ 0.01 (**), and p ≤ 0.001 (***).  When investigating overall significance between 
the clones and parental OPCT-1, unless otherwise stated, non-parametric testing was 
performed by means of a Friedman test, where the same number of replicates was used, or 
a Kruskal-Wallis test, when the number of replicates varied.  Significant differences 
between the clones and parental OPCT-1 were investigated using the Dunn's Multiple 
Comparison (Post-Hoc) test. 
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Chapter 3: 
Attempted Identification and Isolation of 
Putative Prostate Cancer Stem Cells 
 
3.1 Introduction 
3.1.1 Stem Cells in Prostate Cancer  
The stem cell model for prostate epithelia was established by Isaacs and Coffey (1989) 
following a series of androgen cycling experiments in a rodent model.  In demonstrating 
that the prostate, an androgen-dependent organ, could completely regenerate following 
castration once androgen levels were restored, they proposed that androgen independent 
stem cells yield a population of androgen-responsive cells which, in turn, give rise to the 
more differentiated androgen-dependent secretory luminal cells (Isaacs and Coffey, 1989).  
This model for the hierarchy of the prostate gland is now widely accepted and prostate 
stem cells have since been isolated and investigated (Richardson et al., 2004). 
In 2005 Collins et al., isolated “tumourigenic prostate cancer stem cells” using the same 
markers they had previously established for normal prostate tissue stem cells (Richardson 
et al., 2004; Collins et al., 2005).  The marker profile identified for prostate cancer stem 
cells was integrin α2β1
high
/CD44
+
/CD133
+
.   
Integrin α2β1 (also referred to as VLA-2) is an extracellular matrix protein receptor for 
laminin, collagen, fibronectin and E-Cadherin.  Among other functions, it is known to play 
a role in the generation and organisation of extracellular matrix proteins.  
CD44, a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion, 
migration and lymphocyte activation, has been implicated as a cancer stem cell marker for 
several other cancers including breast (Sheridan et al., 2006), head and neck (Chen et al., 
2010) and colorectal (Du et al., 2008).  Since CD44 is known to play a role in supporting 
cell survival it is thought to be pro-oncogenic by nature (Naor et al., 2008).  According to 
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the cancer stem cell theory, secondary tumour formation (metastasis) is attributed to the 
migration and seeding of cancer stem cells at the secondary site.  Since CD44 has been 
shown to play a role in both migration and adhesion, it may be a critical molecule for the 
cancer cells which express it.  Furthermore, the expression of several CD44 proteins has 
been shown to correlate with aggressive stages of a variety of human cancers (Orian-
Rousseau, 2010).       
CD133 has also been implicated as a marker for putative cancer stem cells in several other 
cancers including brain (Uchida et al., 2000; Singh et al., 2003), liver (Ma et al., 2007; 
Schmelzer et al., 2007), melanoma (Rappa et al., 2008), colorectal  (Ricci-Vitiani et al., 
2007) and lung (Eramo et al., 2007).  To date, the function of this molecule remains to be 
elucidated.  Although very little is known about the role of CD133, since this molecule is 
often also expressed by the normal tissue stem cells corresponding to the tissue from which 
the cancer stem cells are identified (See Table 1.1), it provides compelling evidence for the 
theory that cancer stem cells are derived from transformed adult tissue stem cells.  
In 2005, Collins and colleagues demonstrated that cells with the marker profile integrin 
α2β1
high
/CD44
+
/CD133
+ 
possessed significant capacity for self-renewal, differentiation and 
invasiveness in vitro, all of which have been attributed to cancer stem cells.  Such cells 
may be responsible for both the initiation and progression of prostate cancer i.e. relapse 
and metastatic spread despite androgen ablation or other treatments.  Therefore, these 
markers can be exploited to isolate putative prostate cancer stem cells. 
As the markers for prostate cancer stem cells had already been reported and had been 
previously exploited to isolate these cells from a mixed population, this work endeavoured 
to reproduce the method in order to isolate and further characterise prostate cancer stem 
cells from both established prostate cancer cell lines and cultured primary prostate cancer 
cells. 
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3.2 Results 
The prostate cancer cell lines PC3 and DU145 were selected for the preliminary studies 
because these, well characterised, cell lines were derived from metastatic lesions, as such; 
are androgen dependent and have been shown to be highly tumourigenic (Coso and 
Williams, 2009, Malhi et al., unpublished data).  Prostate cancer stem cells are believed to 
contribute significantly to tumourigenesis, therefore, it was hypothesised that these cell 
lines may provide a suitable model from which to identify, isolate and characterise putative 
prostate cancer stem cells.  Furthermore, in 2007, Wei and colleagues identified a 
population of “cancer stem-like cells” in the DU145 cell line by exploiting the markers 
identified by Collins et al., 2005 (Collins et al., 2005; Wei et al., 2007).   
Training undertaken with Professor Norman Maitland and his group at The University of 
York enabled the culture of primary prostate cancer cells from patient samples which were 
subsequently exploited for the attempted isolation of putative prostate cancer stem cells. 
Therefore, this work attempted to reproduce and advance the method reported in order to 
resolve some of the additional questions regarding the prostate cancer stem cell phenotype. 
3.2.1 Analysis of CD44 and CD133 Expression in Prostate Cancer Cell 
Lines by Quantitative Real-Time PCR  
Prior to conducting studies on the expression of PCSC-associated markers at the protein 
level, quantitative real-time PCR was performed in attempt to detect CD44 and CD133 in 
DU145 and PC3 cells at the mRNA level. 
To that end, RNA from two metastatic prostate cancer cell lines; PC3 and DU145 and cord 
blood stem cells (CBSCs), which were used as a positive control, was extracted and 
reverse transcribed.  Forward and reverse primers were designed for CD44 and CD133 and 
exploited for qRT-PCR.  Figures 3.1 and 3.2 demonstrate that CD133 and CD44 were both 
detected in PC3 and DU145 cells at the mRNA level.  
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Figure 3.1:  Relative expression of CD44 in PC3 and DU145 cells determined by real-time qPCR using 
forward and reverse primers designed for CD44. (n=3).  Results were analysed using the comparative 
CT method.  The housekeeping genes; GAPDH, TBP and HPRT-1 were used for CT value normalisation 
and cord blood stem cells were used to compare the expression of CD44 in the prostate cancer cell lines.  
Figure 3.2:  Relative expression of CD133 in PC3 and DU145 cells determined by real-time qPCR using 
forward and reverse primers designed for CD133. (n=3).  Results were analysed using the comparative 
CT method.  The housekeeping genes; GAPDH, TBP and HPRT-1 were used for CT value normalisation 
and cord blood stem cells were used to compare the expression of CD133 in the prostate cancer cell 
lines.  
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Both PC3 and DU145 cells expressed CD44 at the mRNA level, with DU145 expressing 
higher levels than PC3.  However, these cell lines expressed lower levels of CD44 mRNA 
than cord blood stem cells (Figure 3.1). 
Quantitative real-time PCR determined that both PC3 and DU145 cells expressed very low 
levels of CD133 at the mRNA level, with DU145 expressing higher levels than PC3 
(Figure 3.2).  As anticipated, both cell lines expressed much lower levels of CD133 mRNA 
than cord blood stem cells.  This was as expected because CD133-positive putative PCSCs 
have been reported to represent a very small population among a mixed population of 
predominantly differentiated cells (Collins et al., 2005; Wei et al., 2007).  As such, both 
DU145 and PC3 cells, which had not been enriched for CD133-positive cells, were 
expected to express lower levels of CD133 mRNA than the purified population of CD133-
positive cord blood stem cells.   
The detection of the PCSC-associated antigens; CD44 and CD133 in PC3 and DU145 cells 
at the mRNA level provided justification for further investigation of these markers at the 
protein level.   
3.2.2. Analysis of CD44 and CD133 Expression in Prostate Cancer Cell 
Lines by Flow Cytometry 
To investigate the expression of CD44 and CD133 on the surface of PC3 and DU145 cells 
and quantify the number of cells expressing these proteins, single-colour flow cytometry 
was performed, using conjugated antibodies directed against CD44 and CD133.  
Appropriate isotype controls were used to define the gated regions and the cells which fell 
into these regions during the test run were considered positive for the expression of the 
given marker with which the isotype corresponded. 
Flow cytometric analysis was initially performed using one antibody per tube.  However, it 
is important to note that putative prostate cancer stem cells have been shown to express 
both CD44 and CD133 hence, in order to identify PCSCs it would be necessary to conduct 
analysis on cells labelled with both antibodies.  Nonetheless, prior to conducting dual-
staining it was necessary to identify if these proteins were expressed by PC3 and DU145 
cells. 
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Figure 3.3:  Demonstrating sample flow cytometric data from which the percentage of CD44-positive 
cells present in the PC3 cell line was determined.  Flow cytometry was performed using a FITC-
conjugated isotype control to gate the cells and FITC-conjugated anti-CD44 antibody to identify the 
population of cells expressing CD44. A histogram overlay of isotype versus test is also shown.  The 
positive population was defined as cells present in gate D (CD44-FITC) and was calculated by 
subtracting the percentage of cells in gate C (iso-FITC) from the percentage in gate D (CD44-FITC).  A 
total of 10,000 events were collected and analysed per sample.  (n=3). Representative data. 
 
Figure 3.4:  Demonstrating sample flow cytometric data from which the percentage of CD133-positive 
cells present in the PC3 cell line was determined.  Flow cytometry was performed using an APC-
conjugated isotype control to gate the cells and an APC-conjugated anti-CD133 antibody to identify the 
population of cells expressing CD133. A histogram overlay of isotype versus test is also shown. The 
positive population was defined as cells present in gate B (CD133-APC) and was calculated by 
subtracting the percentage of cells present in gate A (iso-APC) from the percentage in gate B (CD133-
APC).  A total of 10,000 events were collected and analysed per sample. (n=2). Representative data.  
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The mean percentages of CD44 and CD133 positive cells present in the PC3 cell line were 
calculated from the flow cytometric analyses and are presented in Table 3.1.  
 
Table 3.1 Demonstrating the mean percentage of CD44 and CD133 positive cells in the PC3 cell 
line as determined by flow cytometry 
 
 
 
 
 
Flow cytometric analysis determined that almost all PC3 cells analysed (99.52%) 
expressed CD44.  However, none of the cells were found to express CD133.  Therefore, 
despite the fact that the majority of PC3 cells expressed one of the reported markers of 
prostate cancer stem cells, a putative cancer stem cell population (as defined by Collins et 
al., 2005) was not identified in these cells, using this technique. 
Table 3.2 reveals that similar results were observed with DU145 cells, the majority of 
which (94.08%) expressed CD44 however no cells expressing CD133 were detected by 
flow cytometry (Figures 3.5 and 3.6).   
 
Table 3.2 Demonstrating the mean percentage of CD44 and CD133 positive cells in the DU145 
cell line as determined by flow cytometry 
 
 
 
 
 
Marker  
 
Mean % Positive cells 
 
 
CD44 
 
99.52 
CD133 0 
Marker  
 
Mean % Positive cells 
 
 
CD44 
 
94.08 
CD133 0 
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Figure 3.5:  Demonstrating sample flow cytometric data from which the percentage of CD44-positive 
cells present in the DU145 cell line was determined.  Flow cytometry was performed using a FITC-
conjugated isotype control to gate the cells and a FITC-conjugated anti-CD44 antibody to identify the 
population of cells expressing CD44. A histogram overlay of isotype versus test is also shown.  The 
positive population was defined as cells present in gate B (CD44-FITC) and was calculated by 
subtracting the percentage of cells in gate A (iso-FITC) from the percentage in gate B (CD44-FITC).     
A total of 10,000 events were collected and analysed per sample. (n=3).  Representative data.  
 
Figure 3.6:  Demonstrating sample flow cytometric data from which the percentage of CD133-positive 
cells present in the DU145 cell line was determined.  Flow cytometry was performed using an APC-
conjugated isotype control to gate the cells and an APC-conjugated anti-CD133 antibody to identify the 
population of cells expressing CD133. A histogram overlay of isotype versus test is also shown.  The 
positive population was defined as cells present in gate C (CD133-APC) and was calculated by 
subtracting the percentage of cells in gate D (iso-APC) from the percentage in gate C (CD133-APC).     
A total of 10,000 events were collected and analysed per sample. (n=2).  Representative data.  
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Therefore, using this technique, neither PC3 nor DU145 cells were found to contain a 
population of CD133-expressing cells.   As such, other techniques were explored in 
attempt to identify putative CSCs expressing the CD133 antigen. 
 
3.2.3. Profiling of Prostate Cancer Cell Lines by Immunofluorescence  
The origin of prostate cancer stem cells, with regards to basal or luminal precursors, is 
somewhat controversial with several studies providing conflicting data (Maitland et al., 
2011).  Overall, most evidence suggests that human prostate cancer stem cells reside in the 
basal compartment and are of basal origin (Oldridge et al., 2012).   
During this study the prostate cancer cell lines; PC3, DU145 and P4E6 were examined by 
immunofluorescence for the expression of markers associated with prostate stem cells, 
intermediate prostate cells, basal prostate cells and secretory luminal prostate cells. 
Table 3.3 identifies the profiles of some of the cell types found in the human prostate 
according to Richardson et al., 2003; Collins et al., 2005 and Kasper, 2008. 
Table 3.3 Demonstrating the prostate cell marker profiles and corresponding cell types 
they identify 
 
 
 
 
 
 
 
 
 
* PSCA – prostate stem cell antigen, AR – androgen receptor 
Marker Profile 
 
Corresponding Cell 
Type 
 
 
P63- CD133+ 
 
Prostate stem cell 
CD44+ CD133+ Prostate stem cell 
AR+ PSCA+
*
 Intermediate cell 
CD44+CD24+ Intermediate cell 
CD44+ CD24- Basal cell 
CD44- CD24+ Luminal cell 
AR+ CD24+ Luminal cell 
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Figures 3.7 to 3.9 demonstrate that the only marker to be consistently expressed across the 
three prostate cancer cell lines was CD44.  In keeping with the flow cytometric data, the 
majority of PC3 and DU145 cells observed by immunofluorescence expressed high levels 
of this protein.  This was also apparent with P4E6 cells.  In addition to CD44, DU145 cells 
expressed high levels of CD24 (Figure 3.8).  Therefore, the dual CD44/CD24 positivity of 
this cell line indicated that it demonstrated an intermediate phenotype. Using this antibody 
panel PC3 and P4E6 cells only expressed CD44, therefore, the majority of cells in these 
cell lines fitted the profile of a basal cell.  As most evidence suggests that CD133-positive 
prostate cancer stem cells reside in the basal compartment, these cell lines may have 
contained a population of cancer stem cells.  However, a lack of CD133 staining across all 
cells examined gave evidence to the contrary.   
It is important to acknowledge that, despite efforts to identify an in-house cell line with a 
distinct population of CD133-expressing cells (data not shown), a suitable positive control 
was not available to test the validity of the antibody used in this study.  The P4E6 cell line, 
kindly donated by Professor Norman Maitland from The University of York, had been 
previously shown to contain a very small population of CD133-positive cells, however, 
this cell line did not prove to be a suitable positive control as it did not contain a large 
enough population of CD133-expressing cells.   
Isotype control staining revealed that a minimal level of background staining was observed 
for all three cell lines (See Appendix I).  Hence, the staining patterns observed for the 
CD44 and CD24 antibodies were considered genuine. 
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Figure 3.7:  Dual immunofluorescent staining of PC3 cells with several markers to identify cell types.  
Secondary antibody labelling was performed using AlexaFluor® antibodies. Nuclear staining was 
achieved using mounting media with DAPI.  (n=3).  Representative images.  Image magnification at x20. 
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Figure 3.8:  Dual immunofluorescent staining of DU145 cells with several markers to identify cell types.  
Secondary antibody and nuclear staining were achieved as described in Figure 3.7. (n=3).  
Representative images.  Image magnification at x20. 
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Figure 3.9:  Dual immunofluorescent staining of P4E6 cells with several markers to identify cell types.  
Secondary antibody and nuclear staining were achieved as described in Figure 3.7. (n=3).  
Representative images.  Image magnification at x20. 
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According to the panel of markers defined in Table 3.3, this technique failed to identify a 
population of putative cancer stem cells in any of the cell lines examined.  Table 3.4 
summarises the results from the screening of these cell lines. 
 
Table 3.4 Summarising the expression of the various antigens by PC3, DU145 and P4E6  cells and   
the proposed cell types based on their marker profiles by immunofluorescence. 
 
Antigen  DU145 PC3 P4E6 
P63 - 
- 
+ 
- 
- 
+ 
- 
 Intermediate 
 
No  
- 
- 
+ 
- 
- 
- 
- 
Basal 
 
No 
- 
- 
+ 
- 
- 
- 
- 
Basal 
 
No 
CD133 
CD44 
AR 
PSCA 
CD24 
HLA-G 
Proposed cell 
type 
Putative   CSC’s 
observed? 
 
 
These results were consistent with those obtained by flow cytometric analysis of PC3 and 
DU145 in that most of the cells examined expressed CD44 however CD133 expression 
was not detected on any of the cells. 
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3.2.4. Attempted Isolation of CD133-positive P4E6 cells by MACS 
Despite an inability to identify CD133-positive cells by flow cytometry and IF, magnetic 
activated cell sorting (MACS) was attempted as a means to isolate putative prostate cancer 
stem cells.  It was believed that having enriched for this population, it would be easier to 
identify putative PCSCs by flow cytometry and IF.  This approach was adopted because 
CD133-expressing cells have been reported to represent as few as 0.01% of cells in a cell 
line hence, could have been below the threshold for detection without prior enrichment 
(Pfeiffer and Schalken, 2010).  
To that end, approximately 1x10
8
 P4E6 cells were subjected to MACS of CD133-positive 
cells.  This cell line was chosen as our collaborators had previously identified and isolated 
CD133-positive putative CSCs using the same techniques.  This technique involved 
labelling P4E6 cells with CD133 antibodies, conjugated with paramagnetic beads, prior to 
subjecting them to a magnetic field by running them through a magnetically-charged 
column.  Antibody-bound cells expressing CD133 should have remained in the column 
while negative cells were able to pass through.  The positive fraction was then purged from 
the column and subsequently analysed along with the negative and mixed fractions. 
Unfortunately, despite several attempts (data not shown), the success of this technique 
could not be validated by flow cytometry due to the very low yield of putative CD133-
positive cells.  Furthermore, despite the use of different antibodies, immunofluorescence 
repeatedly failed to identify CD133-positive cells in any of the fractions (Figure 3.10 C).  
In addition, culturing the “positive fraction” of cells prior to examination (in order to allow 
them to recover from the isolation procedure) did not assist with the identification of 
CD133-positive cells in this cell line. 
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A) Unseparated 
 
 
 
 
 
 
 
B) Negative Fraction 
 
 
 
 
C) Positive Fraction 
 
 
 
 
 
             
 
 
 
Figure 3.10:  Dual immunofluorescent staining of non-selected P4E6 cells (A), CD133-negative P4E6 
cells (B), and putative CD133-positive cells (C).  Cells were subjected to MACS of CD133-positive cells 
and stained immediately by immunofluorescence.  Secondary antibody and nuclear staining were 
achieved as described in Figure 3.7. (n=3).  All stained cells were visualised.  Representative images.  
Image magnification at x20. 
 
119 
 
3.2.5. Attempted Isolation of CD133-Positive Primary Prostate Cancer 
Cells by MACS 
The CD133 molecule has been shown to be extremely sensitive to cell culture conditions 
(Maitland et al., 2011).  As such, the failure to isolate CD133-positive cells from the P4E6 
cell line may have been due to variation in the expression of CD133, as a result of 
differences in the media composition (such as foetal calf serum) between our lab and the 
lab at The University of York.   
To establish whether this method of isolating putative prostate cancer stem cells was more 
appropriate for cultured primary cells, primary cultures of epithelial cells derived from 
patients with prostate cancer were established for the first time in our labs (Figure 3.11) 
(please refer to Chapter 7 for further studies with the primary cells).  For the purpose of 
isolating putative prostate CSCs, these cells were primarily selected based on their rapid 
adhesion to collagen, to select for integrin α2β1hi cells, and were maintained with 
specialised media and irradiated murine fibroblast feeder cells (See Section 2.2.1.2).  These 
conditions were optimised by the York group to promote self-renewal and inhibit 
differentiation of prostate cancer stem cells.  Furthermore, the components of the defined 
media had been shown by this group not to interfere with the expression of CD133. 
As with the P4E6 cells, the cultured prostate cancer-derived epithelial cells were subjected 
to MACS of CD133-positive cells and were subsequently examined by 
immunofluorescence.  However, due to the slow growth of primary prostate epithelial 
cultures, only approximately 2x10
7
 cells were subjected to MACS hence, the yield was 
extremely low (fewer than 1000 cells were obtained for each repeat of the experiment).  
Unfortunately, despite multiple attempts and concurrent with what was observed with 
P4E6 cells, these methods failed to isolate and identify a population of cells expressing the 
CD133 molecule (Figure 3.12).  
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Figure 3.11:  Illustrating the work flow for the attempted isolation of CD133-positive, putative prostate 
cancer stem cells (CSCs).  Patient tissue was mechanically dissociated and digested overnight in 
collagenase solution prior to separating the stromal fraction from the epithelial fraction in a series of 
centrifugation steps.  Epithelial cells were subjected to further selection based on rapid adhesion to 
collagen I-coated dishes.  Those which bound to the collagen-coated dishes within 20 minutes belonged 
to the integrin α2β1 high fraction and were cultured with irradiated murine fibroblast feeder cells until 
they reached confluency, after which time they were subjected to magnetic-activated cell sorting (MACS) 
of CD133-positive cells.  The red cross symbolises the failure to confirm the isolation of CD133-positive, 
putative prostate CSCs by immunofluorescence. 
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Figure 3.12:  Dual immunofluorescent staining of non-selected primary prostate cancer epithelial cells 
(A), CD133-negative primary prostate cancer epithelial cells (B), and putative CD133-positive prostate 
cancer epithelial cells (C).  Cells were subjected to MACS of CD133-positive cells and stained 
immediately by immunofluorescence.  Secondary antibody and nuclear staining were achieved as 
described in Figure 3.7. (n=3). All stained cells were visualised. Representative images.  Image 
magnification at x20. 
 
A) Unseparated  
 
B) Negative Fraction 
 
C) Positive Fraction 
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3.2.6 Summary 
Using the methods presented, this study failed to identify and isolate putative prostate 
cancer stem cells, with the marker profile reported by Collins et al., 2005, from three cell 
lines (PC3, DU145 and P4E6) and primary cultures of prostate cancer epithelia. 
 
3.3 Discussion 
Recent evidence supports the hypothesis that prostate cancer stem cells are responsible for 
prostate cancer initiation and progression (Collins et al., 2005; Collins and Maitland, 2006; 
Lawson and Witte, 2007; Signoretti and Loda, 2007; Kasper, 2008a; Kasper, 2008b, 
Goldstein et al., 2010; Tu and Lin, 2012).  This study attempted to exploit the prostate 
cancer stem cell markers, previously established by Collins et al., 2005, to identify and 
isolate prostate cancer stem cells from androgen independent prostate cancer cell lines and 
primary epithelial cultures, derived from prostate cancer tissue.  This was in an effort to 
further characterise these cells with a view to investigating their immunological status and 
expression of cancer-associated antigens to ascertain if prostate cancer stem cells (PCSCs) 
represent viable targets for immunotherapy.  However, using the methods described, this 
study failed to identify and isolate putative cancer stem cells from cell lines and primary 
cultures. 
Quantitative real-time PCR revealed that PC3 and DU145 cells expressed very low levels 
of CD133 at the mRNA level.  This finding was as could be anticipated for a mixed 
population of prostate cancer cells which had not been enriched for putative cancer stem 
cells, since CD133 has been reported to be expressed by only a minute population of 
prostate cancer cells in cells lines and primary cultures (Collins et al., 2005; Wei et al., 
2007).  This technique also revealed that PC3 and DU145 cells expressed CD44 at the 
mRNA level, a molecule largely implicated in cancer progression and metastasis (Naor et 
al., 2008).  Hence, quantitative real-time PCR demonstrated that PC3 and DU145 cells 
expressed two of the reported prostate cancer stem cell-associated markers at the mRNA 
level.  However, since expression at the mRNA level does not confirm that the protein is 
functionally expressed, further investigation into the expression of these antigens was 
conducted at the protein level.   
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Flow cytometry is widely used in the field of cancer stem cell research as it enables 
identification of minute populations from large, mixed populations, using defined markers.  
During this study, the cell-surface expression of CD44 and CD133 by PC3 and DU145 
cells was investigated by flow cytometry.  This technique revealed that the majority of PC3 
and DU145 cells expressed the CD44 antigen.  As CD44 has been largely implicated in 
metastasis, this finding was in keeping with the fact that these cell lines were both derived 
from metastatic lesions (Naor et al., 2008; Orian-Rousseau, 2010).  In addition, CD44 has 
been reported to identify transit-amplifying prostate cells and prostate cells of basal origin, 
therefore, this finding revealed that these cell lines possessed a basal/transit-amplifying 
signature as opposed to a luminal phenotype.  The expression of basal markers in primary 
cultures and cell lines derived from prostate cancer is a common yet paradoxical finding 
since prostate cancers are known to lack cells with a basal phenotype (the absence of the 
basal-specific marker P63 is used by histologists to score prostate cancers) and mostly 
express luminal markers such as androgen receptor (AR) and prostate specific antigen 
(PSA) (Miki and Rhim, 2008). 
During this study, CD133-positive cells were not detected by flow cytometry in the PC3 
and DU145 cell lines.  This finding however, did not confirm the absence of a cancer stem 
cell population in these cell lines as this approach suffers from the fact that during 
processing, procedures such as trypsinization may cleave many of the surface markers 
thus, rendering them unavailable for antibody binding (Singh et al., 2012).  Moreover, 
CD133 is arguably an unreliable marker for prostate cancer stem cells since its expression 
may not be restricted to cancer stem cells and even CD133-negative cells have been shown 
to be tumourigenic (Shmelkov et al., 2008). 
Recently, a large study involving six prostate cancer cell lines, DU145, 22Rv1, LAPC-4, 
DuCaP, LNCaP, and PC-3, failed to identify a population of CD133-positive cells in all 
but DU145 cells (0.01%) by flow cytometry (Pfeiffer and Schalken, 2010).  Therefore, the 
inability to identify a population of CD133-positive cells in the PC3 cell line was 
consistent with the findings of this group.  Furthermore, their study also discredited CD133 
as a maker of CSCs in cell lines, based on the finding that the five CD133-negative cell 
lines demonstrated other properties of cancer stem cells (Pfeiffer and Schalken, 2010).  In 
addition to flow cytometry, which identified a population of CD133-positive cells in the 
DU145 cell line, Pfeiffer and Schalken (2010) also examined DU145 cells by 
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immunohistochemistry.  Interestingly, using this technique they failed to identify CD133-
expressing cells therefore, inconsistencies in the expression of the CD133 molecule were 
apparent within the same study.   
In an attempt to characterise the prostate cancer cell lines PC3, DU145 and P4E6 and 
determine whether they contained a population of putative PCSCs, this study also 
examined the expression of CD44, CD133 and several other markers by 
immunofluorescence.  Using this technique, the only marker found to be consistently 
expressed among the three cell lines was CD44.  This finding was in keeping with the 
results obtained for PC3 and DU145 using flow cytometry.  Although these three cell lines 
contained large populations of cells expressing the basal marker CD44, according to this 
study, they did not contain cells expressing the basal marker P63.  It is however, important 
to acknowledge that the P63 antibody used in this study was withdrawn from Abcam after 
this work was conducted, which may have been due to its inefficacy.  As such, this result 
was possibly unreliable.   
Immunofluorescence failed to identify the luminal markers AR, PSCA and CD24 in PC3 
and P4E6 cells, thereby confirming that these cell lines comprised cells with a basal 
phenotype.  The majority of DU145 cells however, appeared to be dual-positive for the 
expression of CD44 and CD24 thus, demonstrating a transit-amplifying/intermediate 
phenotype.   
As previously described (See Section 1.1.3.5), HLA-G is an immunomodulatory molecule 
that has been shown to be expressed by stem cells and putative cancer stem cells, among 
other cell types (Brown et al., 2012; Morandi et al., 2012).  It was important to investigate 
the expression of this molecule as the presence of HLA-G on putative prostate cancer stem 
cells would have serious implications when considering these cells as targets for 
immunotherapy.  Therefore, in an attempt to ascertain whether putative (CD133-positive) 
prostate cancer stem cells express this immunomodulatory molecule, PC3, DU145 and 
P4E6 cells were dual-stained with HLA-G and CD133 antibodies.  In this study, none of 
these cell lines were found to contain a population of cells expressing HLA-G.  
Furthermore, this technique also failed to identify cells expressing the CD133 molecule.  
Hence, as with flow cytometry, putative prostate cancer stem cells were not identified in 
any of the three prostate cancer cell lines examined using immunofluorescence.   
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As CD133-positive putative CSCs have been reported to comprise a very small population 
of cells (Collins et al., 2005; Wei et al., 2008), enrichment of these cells, prior to 
conducting flow cytometric/immunofluorescence analysis, was attempted using magnetic 
activated cell sorting (MACS).  However, this technique proved to be problematic for a 
number of reasons namely; too few cells were isolated to conduct flow cytometry, many 
cells died during the procedure and the majority of the isolated cells had to be sacrificed 
for immunofluorescence to confirm/disprove the success of the isolation procedure.  
Furthermore, this technique appeared to be unsuccessful as CD133-positive cells could not 
be identified from a cell line with a known, albeit small, population of CD133-expressing 
cells (P4E6), or primary cultures of epithelial cells derived from prostate cancer tissues. 
It is important to acknowledge that differences in culture conditions and the methods of 
harvesting and fixing cells may affect the expression of molecules such as CD133, hence, 
may account for the inconsistencies observed between the other groups and this study.  
Recently, using glioblastoma stem cells as a model, Sherman and colleagues (2011) 
revealed that the CD133 molecule is highly sensitive to fixation methods, which may 
provide an explanation as to why this molecule was not identified in any of the three cell 
lines or primary cell cultures during this study.  Throughout this study, cells were routinely 
fixed with 4% paraformaldehyde prior to conducting immunofluorescence.  Hence, this 
procedure may have damaged the CD133 molecule, thereby affecting antibody binding and 
resulting in false-negative results.  Furthermore, as too few cells were obtained for flow 
cytometric analysis following magnetic activated cell sorting (MACS), 
immunofluorescence was routinely exploited in attempt to confirm the success of the 
isolation procedure.  However, fixation of the cells following MACS may have led to 
false-negative results, implying that the procedure had failed or that the cell lines did not 
contain a population of CD133-positive cells.  Unfortunately, Sherman et al., (2011) 
released their paper more than two years after the experiments were conducted in this 
study, as such, time did not allow this issue to be addressed.  Furthermore, as a positive 
control for the expression of CD133 had not been identified for the purpose of this study 
(data not shown) it was not possible to verify that the antibodies and techniques used were 
suitable for the detection of this molecule.  Moreover, in addition to the CD133 molecule 
being extremely sensitive to culture, harvesting and fixing conditions, the availability of 
CD133 antibodies was largely limited to those which identified only glycosylated forms of 
CD133 (Osmond et al., 2010).   
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These facts emphasise the problems with exploiting CD133 as a marker to identify putative 
prostate cancer stem cells.  In addition to the aforementioned issues, long term in vitro 
passaging may also result in downregulation of the CD133 molecule, hence account for 
differences observed between cell lines, primary cells and tissue sections.  Therefore, the 
expression of CD133 is dynamic and easily influenced by environmental changes.  As 
such, when expressed, this molecule may well identify putative prostate cancer stem cells 
however, an absence of this molecule does not necessarily imply an absence of a putative 
PCSC population.  Consequently, the usefulness of this molecule as a marker of putative 
PCSCs is greatly limited by its sensitivity hence, there is a great need to identify more 
robust markers which may be exploited for the identification and isolation of putative 
prostate cancer stem cells. 
In light of the problems encountered during the study of putative CD133-expressing 
PCSCs, it was necessary to adopt an alternative approach to investigating cancer stem cells 
in prostate cancer.  In 2008, Mani and colleagues merged the field of cancer stem cells and 
epithelial to mesenchymal transition when they demonstrated that EMT generated cells 
with the properties of cancer stem cells in human breast cancer (Mani et al., 2008).  Since 
their discovery, this topic raised a great deal of attention and consequently, several others 
have provided further evidence for a link between EMT and CSCs in other cancers (Fazul 
et al., 2009; Santiseban et al., 2009; Kong et al., 2010).  Since cancer cells transitioning 
via EMT are easily identified using a panel of several markers, the investigation of this 
phenomenon and the acquisition stem-like attributes proved to be another approach for 
investigating the properties of prostate cancer stem cells.  Hence, further studies 
undertaken throughout the duration of this project sought to investigate the properties of 
EMT and ascertain whether or not this phenomenon generates cells with the properties of 
stem cells in human prostate cancer. 
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Chapter 4: 
Derivation of a Model for the Investigation of 
Epithelial to Mesenchymal Transition in 
Human Prostate Cancer 
 
4.1 Introduction 
In recent years, epithelial to mesenchymal transition has emerged as a key concept in 
cancer biology as it has been evidenced to play a critical role in cancer invasion and 
metastasis.  Although the cancer stem cell hypothesis and work in this field to date may 
provide evidence to address the cell of origin of a given tumour and provide explanations 
for tumour relapse following therapy, the causative role of migrating cancer stem cells in 
metastasis remains to be proven (Sampieri and Fodde, 2012).  However, cancer stem cells 
are often implicated in metastasis due to the consensus that they are unique in their ability 
to propagate tumours due to their inherent self-renewal capabilities.  Hence, the ability to 
form secondary metastases is believed by many to be restricted to cancer stem or cancer 
stem-like cells.  The discovery that epithelial to mesenchymal transition generates cells 
with the properties of stem cells provided a greater understanding of the processes 
underlying tumourigenesis.  Acquisition of mesenchymal traits by carcinoma cells via 
EMT facilitates invasion, via increased production of matrix-degrading MMPs, and 
metastasis, via decreased expression of adhesion molecules with a concomitant increase in 
the expression of molecules conferring motility, and the acquisition of stem cell traits 
confers self-renewal capabilities necessary for the formation of macrometastases (Mani et 
al., 2008; Bertram, 2012).  Previous work, conducted during this project, failed to identify 
CD133-positive putative PCSCs therefore, it was necessary to approach the topic of 
prostate CSCs from another angle.  Although the phenomenon of EMT and the generation 
of cancer stem-like cells has been largely studied in the context of breast cancer, further 
work in this area is required in the field of prostate cancer. 
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4.2 Results 
4.2.1 Identification and Selection of a Model Cell Line for the 
Investigation of Epithelial to Mesenchymal Transition 
In order to investigate the phenomenon of epithelial to mesenchymal transition in human 
prostate cancer, it was necessary to identify and select a model cell line, demonstrating 
evidence of this phenomenon, on which to conduct further studies.  To that end, five 
androgen-independent human prostate cancer cell lines, two from metastatic lesions and 
three derived from primary tissues, were selected and screened using immunofluorescence 
on a panel of several EMT and CSC-associated markers.  Phenotypic differences in cellular 
morphology between the cell lines were clearly observable microscopically (Figure 4.1), 
therefore, it was speculated that they would exhibit unique marker expression profiles.   
 
                                                                                                                                                     
 
 
 
 
 
 
 
                                                                                                                                                  
DU145 cells demonstrated a tight cobblestone morphology, characteristic of epithelial 
cells, whereas PC3 and OPCT-2 cells appeared to demonstrate mesenchymal-like 
phenotypes with loose cell-cell contact and spindle-like (fibroblastoid) morphologies.  
P4E6 cells appeared similar to DU145 cells.  The OPCT-1 cell line appeared to comprise a 
mixed population of both epithelial cells, forming colonies with tight cell-cell adhesion and 
mesenchymal cells, with spindle-like morphology present between the colonies.   
Figure 4.1:  Bright field images of human prostate cancer cell lines derived from metastatic lesions; 
DU145 and PC3, and primary tissues; P4E6, OPCT-1 and OPCT-2. Image magnification at x10. 
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Figures 4.2 to 4.11 demonstrate the results of the IF screening which identified the OPCT-
1 cell line as a model for the investigation of EMT in human prostate cancer.  In parallel to 
staining with test antibodies, appropriate isotype controls were used to gauge the level of 
background staining and confirm that any staining observed was as a result of specific 
antibody-antigen binding activity (See Appendix IV). 
Vimentin is a ubiquitous intermediate filament protein expressed by all primitive cells, 
however, upon differentiation most non-mesenchymal cell types replace vimentin with 
other intermediate filaments, such as cytokeratins.  As such, vimentin is perhaps the most 
common marker used to identify cells of mesenchymal origin (Korita et al., 2010).  
Therefore, throughout this study antibodies directed against vimentin were widely used to 
identify putative mesenchymal cells, which may have arisen as a result of EMT.  Figures 
4.2 to 4.5 confirm that vimentin was detected in all of the five cell lines, however the 
expression patterns varied markedly, hence, clear differences in the staining intensity, 
distribution and frequency of vimentin expression were observed among the cell lines.  The 
metastasis-derived cell lines, PC3 and DU145, and the primary cell line P4E6 
demonstrated focal vimentin expression in a high proportion of the cells.  Conversely, the 
primary cell lines, OPCT-1 and OPCT-2, demonstrated differential vimentin expression, 
with a sophisticated network of vimentin fibres throughout some cells, lower levels of 
vimentin appearing around the nucleus in other cells and a majority of cells which did not 
stain positive for this intermediate filament. 
E-Cadherin, one of several cell adhesion molecules (CAMs), is a key component in the 
formation of cell-cell adherens-type junctions in epithelial tissues.  As such, this protein is 
widely used to identify cells of epithelial origin. In normal epithelia one would observe E-
Cadherin expression at the cell surface, between cells (van Roy and Berx, 2008).  
However, E-Cadherin mediated cell-cell adhesion is lost during the development of most 
epithelial cancers and changes in E-Cadherin expression (from the membrane to the 
cytoplasm) have been strongly associated with aggressive, metastatic cancer (Christofori 
and Semb, 1999; Guziñska-Ustymowicz et al., 2004).  During this study, antibodies 
directed against E-Cadherin were used as a means to identify epithelial cells and 
distinguish them from mesenchymal cells within the prostate cancer cell lines. However, 
consistent with previous observations of epithelial cancers, E-Cadherin was atypically 
expressed in all five cell lines as, despite being expressed by the majority of cells, an 
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accumulation of this protein at the cell surface, between the cells was not evident in any of 
the cell lines examined (Figure 4.2). 
Cytokeratins are a family of intermediate filament proteins which are primarily expressed 
by differentiated epithelial cells.  In fact, they are generally considered to be the most 
fundamental markers of epithelial differentiation and the composition of cytokeratins is 
known to reflect both the cell type and differentiation status (Moll et al., 1982).  In the 
prostate, basal and luminal cells demonstrate differential expression of cytokeratins and 
these can be exploited to identify these cells from a mixed population.  As cytokeratins are 
produced in cell lineage dependent patterns and these patterns are reproduced with great 
fidelity, even in carcinomas, they are widely used in pathologic diagnosis and represent 
robust markers for cells of epithelial origin (Nagle, 1994).  For the purpose of this study, 
pan cytokeratin antibodies were exploited, in addition to E-Cadherin antibodies, as a means 
to identify and distinguish epithelial cells from mesenchymal cells in the prostate cancer 
cell lines.  As expected, cytokeratins were expressed by the majority of the cells in each of 
the cell lines tested (Figure 4.3). 
The use of epithelial markers, such as E-Cadherin and cytokeratins, in conjunction with 
vimentin enabled the identification of epithelial, mesenchymal and mixed populations 
within the cell lines. Indeed, the co-expression of epithelial and mesenchymal markers 
such as vimentin and cytokeratins is not uncommon and has been observed previously in 
both benign and malignant prostatic epithelia (Leong et al., 1988).  Despite marked 
differences in cell morphology, Figures 4.2 and 4.3 demonstrate that the metastasis-derived 
cell lines, DU145 and PC3, exhibited similar, mixed phenotypes with a high proportion of 
cells expressing both epithelial and mesenchymal markers. The same was only true of one 
of the primary-derived cell lines, P4E6, although the OPCT-2 cell line also contained a 
small population of dual-positive cells.  OPCT-1 was the only cell line to demonstrate 
distinct populations with regards to E-Cadherin/cytokeratins and vimentin expression 
(evidenced by single-positive staining which is indicated by the orange arrows in Figures 
4.2 and 4.3).  However, this cell line also contained a population of dual-positive cells.  
That is to say, the OPCT-1 cell line contained cells with properties of epithelial cells 
(single positive for E-Cadherin or cytokeratins), cells with properties of mesenchymal cells 
(single positive for vimentin) and cells with a mixed phenotype (dual positive for epithelial 
and mesenchymal markers).  Furthermore, the single vimentin-positive cells in this cell 
line grew in isolation and demonstrated fibroblastoid morphologies, consistent with cells of 
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mesenchymal origin, whereas the single E-Cadherin/cytokeratin-positive cells formed 
colonies of cells, consistent with cells of epithelial origin.  The dual-positive cells in this 
cell line may have represented cells which were transitioning between states. 
Beta-Catenin is a multifunctional protein which can be located in three cell compartments, 
namely the plasma membrane, where it associated with E-Cadherin, the cytoplasm and the 
nucleus (Orsulic et al., 1999).  Nuclear accumulation of β-Catenin has been associated with 
induction of EMT due to its downstream effects on several EMT-inducting transcription 
factors (Vincan and Barker, 2008; Polyak and Weinberg, 2009).  Therefore, the location of 
β-Catenin within a cell may reflect the cell status with regards to EMT.  Figure 4.4 
demonstrates that cytoplasmic β-Catenin staining was observed in all five cell lines 
however, membranous staining was only clearly observed in DU145 cells, as indicated by 
the white arrows.  The green arrows indicate nuclear staining which was most evident in 
the DU145 and OPCT-1 cells which also expressed vimentin.  The concomitant expression 
of nuclear β-Catenin and vimentin was consistent with the fact that accumulation of β-
Catenin in the nucleus is known to induce EMT.  However, it is important to acknowledge 
that the subcellular localisation of staining is not accurate when imaging samples with a 
fluorescence microscope and confocal microscopy would be required for this purpose.  
Cellular fibronectin is an extracellular matrix protein which is known to play a key role in 
cell proliferation, adhesion and migration.  This protein is primarily produced and secreted 
by mesenchymal cells and fibroblasts hence, has been widely utilised as a mesenchymal 
marker and  in studies of EMT (Mani et al., 2008; Phadnis et al., 2009; Araida et al., 
2010).  As this protein has been shown to be produced by other cell types, including 
epithelial cells, it was important to investigate the expression of cellular fibronectin in 
conjunction with vimentin (Kolachala et al., 2007).  The expression of fibronectin by 
vimentin-positive cells in a prostate cancer cell line provides compelling evidence of 
epithelial to mesenchymal transition as both proteins are characteristic of mesenchymal 
cells.  Furthermore, the expression of said proteins not only implies a phenotypic change in 
the transdifferentiated cells but also a functional modification.   Of the five prostate cancer 
cell lines examined, only OPCT-1 and OPCT-2 contained a population of cells expressing 
fibronectin (Figure 4.5).  The majority of cells which expressed fibronectin in the OPCT-1 
cell line co-expressed vimentin whereas, fibronectin expression was not confined to 
vimentin-positive cells in the OPCT-2 cell line.   
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Figure 4.2:  Dual immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
murine monoclonal antibody against the epithelial marker, E-Cadherin and a rabbit polyclonal antibody 
against the mesenchymal marker, vimentin.  E-Cadherin was labelled with an anti-mouse Alexa 
Fluor®568-conjugated secondary antibody and vimentin was labelled with an anti-rabbit Alexa 
Fluor®488-conjugated secondary antibody.  Nuclear staining was achieved using mounting media with 
DAPI. (n=3). Representative images.  Image magnification at x20.  Arrows demonstrate the epithelial 
and mesenchymal cell types present in the OPCT-1 cell line. 
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Figure 4.3:  Dual immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
murine pan polyclonal antibody against the epithelial marker, cytokeratin and a rabbit polyclonal 
antibody against the mesenchymal marker, vimentin.  Secondary antibody and nuclear staining were 
performed  as previously described in Figure 4.2. (n=3).  Representative images. Image magnification at 
x20.  Arrows demonstrate the epithelial and mesenchymal cell types present in the OPCT-1 cell line. 
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Figure 4.4:  Dual immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
murine monoclonal antibody against Beta-Catenin and a rabbit polyclonal antibody against the 
mesenchymal marker, vimentin.  Secondary antibody and nuclear staining were performed as previously 
described in Figure 4.2. (n=2).  Representative images.   Image magnification at x20.  The green arrows 
indicate nuclear Beta-Catenin staining.  The white arrow indicates membranous expression of Beta-
Catenin. 
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Figure 4.5:  Dual immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
murine monoclonal antibody against cellular fibronectin and a rabbit polyclonal antibody against the 
mesenchymal marker, vimentin.  Secondary antibody and nuclear staining were performed as previously 
described in Figure 4.2.  (n=2).   Representative images.  Image magnification at x20. 
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N-Cadherin, another member in the family of CAMs, is typically expressed by 
mesenchymal lineage cells (such as adipocytes, chondrocytes, osteoblasts and myoblasts), 
fibroblasts, endothelial cells and neurons (Wever and Mareel, 2003; Zeisberg and Neilson, 
2009).  Contrary to E-Cadherin, N-Cadherin has been shown to be upregulated in several 
carcinomas and has been implicated in invasion, migration and progression to castration 
resistance in prostate cancer (Derycke and Bracke, 2004; Tanaka et al., 2010).  As this 
molecule is expressed by a variety of healthy cell types, its expression on carcinoma cells 
is believed to facilitate perineural and muscular invasion as well as transendothelial 
migration by mediating adhesion to neural, muscular and endothelial cells (Maret et al., 
2010).  Furthermore, this molecule has been associated with epithelial to mesenchymal 
transition and the so-called “cadherin switch”, from E–Cadherin to N-Cadherin, is often 
used to monitor the EMT process in both embryonic development and cancer progression 
(Zeisberg and Neilson, 2009).  In light of this, the expression of N-Cadherin was examined 
in the five prostate cancer cell lines (Figure 4.6).  Interestingly, the expression of this 
molecule varied markedly among the cells as only PC3, P4E6 and OPCT-1 cells 
demonstrated  N-Cadherin expression.  Of particular interest was the observation that this 
protein appeared to be expressed at a higher level on the cells with fibroblastoid 
morphology in the OPCT-1 cell line.  Furthermore, the PC3 cell line, which exhibits 
fibroblastoid morphology, demonstrated the highest intensity of N-Cadherin staining 
overall.   
FSP1 is a cytoplasmic filament-binding S100 protein which has been reported to be 
uniquely expressed in fibroblasts (Strutz et al., 1995; Okada et al., 1998).  Furthermore, 
FSP1 has been shown be expressed during epithelial to mesenchymal transitions in vivo 
and  it has been employed to identify cells which have fully transitioned from epithelial 
cells to fibroblasts (Okada et al., 1997).  During this study, the five prostate cancer cell 
lines were screened for this marker in attempt to ascertain whether the 
vimentin/fibronectin-positive cells, identified in previous immunochemical tests, were 
fibroblasts which had arisen as a result of EMT.  However, Figure 4.7 demonstrates that 
FSP1 was not detected in any of the prostate cancer cell lines tested.  Therefore, the 
identity of the vimentin-positive cells remained elusive.   
In order to confirm that the absence of staining was not due to inefficacy of the antibody, 
the FSP1 antibody was tested on the murine fibroblast cell line, NIH 3T3  (Figure 4.12).  
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Figure 4.6:  Immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
murine monoclonal antibody against N-Cadherin.  Secondary antibody and nuclear staining 
were performed as previously described in Figure 4.2. (n=2)  Representative images.   Image 
magnification at x20. 
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Figure 4.7:  Immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
rabbit polyclonal antibody against fibroblast-specific protein 1 (FSP1).  Secondary antibody and 
nuclear staining were performed as previously described in Figure 4.2.  (n=2).  Representative 
images.  Image magnification at x20. 
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During this study, the five prostate cancer cell lines were examined for the expression of 
three zinc-finger transcription factors which have been widely reported to play pivotal 
roles in the induction of epithelial to mesenchymal transition.  
Snail and Slug (Snai2) are two of several transcription factors known to directly repress the 
expression of E-Cadherin hence, are potent inducers of EMT (Savagner et al., 1997; 
Haraguchi et al., 2009; Casas et al., 2011).  Ectopic expression of either of these 
transcription factors has been shown to be sufficient for EMT induction hence, several 
studies have artificially induced EMT in this manner (Mani et al., 2008; Bolos et al., 
2003).  In addition to inducing EMT, these transcription factors have been shown to 
repress the transcription of several factors involved in apoptosis and as such, have been 
implicated in the mediation of chemo- and radio-resistance observed in cells which have 
undergone EMT (Haraguchi, 2009; Kurrey et al., 2009).  During this study, the expression 
of Snail and Slug was investigated in the five prostate cancer cell lines in an attempt to 
identify cells undergoing EMT.  Figures 4.8 and 4.9 illustrate that only the DU145 and 
OPCT-1 cell lines contained populations of cells expressing Snail and Slug.  Please note, 
as the Slug staining of PC3 cells appeared ambiguous it was likely to have been non-
specific.  In contrast to OPCT-1, which contained very small populations of cells 
expressing Snail or Slug, a large proportion of DU145 cells appeared to express these 
transcription factors.   Interestingly, rather than being confined to the nucleus, positive 
staining was observed in the cytoplasm of DU145 and OPCT-1 cells.  This observation 
was consistent with other studies which have also reported the expression of Snail in the 
cytoplasm (Dominguez et al., 2003; Luo et al., 2012).  Furthermore, the “dotted staining” 
pattern reported by Dominguez et al., (2003) was also observed in these studies.   
Twist, another of the zinc-finger transcription factors known to repress E-Cadherin 
transcription and induce EMT, has been shown to play an essential role in tumour 
metastasis.  In contrast to Snail and Slug, Twist is an indirect repressor of E-Cadherin and 
has been shown to directly induce the expression of Slug in order to initiate EMT (Yang et 
al., 2004).  As with Snail and Slug, ectopic expression of Twist has been shown to induce 
EMT in vitro (Mani et al., 2008).  The expression of this key transcription factor was also 
investigated in the five prostate cancer cell lines however, Twist staining was not observed 
in any of the cells tested (Figure 4.10).  
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Figure 4.8:  Immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
goat polyclonal antibody against the transcription factor Snail.  Secondary antibody and nuclear 
staining were performed as previously described in Figure 4.2. (n=2)  Representative images.   
Image magnification at x20. 
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Figure 4.9:  Immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
goat polyclonal antibody against the transcription factor Slug.  Secondary antibody and nuclear 
staining were performed as previously described in Figure 4.2. (n=2).  Representative images.   
Image magnification at x20. 
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Figure 4.10:  Immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
rabbit polyclonal antibody against the transcription factor Twist.  Secondary antibody and 
nuclear staining were performed as previously described in Figure 4.2. (n=2).   Representative 
images.   Image magnification at x20. 
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In 2008, Mani et al., demonstrated that EMT of immortalised or transformed mammary 
epithelial cells generated cells with properties of stem cells and that the cells which had 
undergone this transition expressed high levels of CD44.  As CD44 is one of the markers 
of putative prostate cancer stem cells and a connection between EMT and the generation of 
CSCs has been shown in breast cancer cells, the expression of this molecule was also 
investigated in the five prostate cancer cell lines.  Figure 4.11 demonstrates that a high 
proportion of the cells in each of the prostate cancer cell lines examined expressed CD44.  
Two of the primary-derived cell lines, P4E6 and OPCT-2, appeared to exhibit the lowest 
staining intensities whereas the metastasis-derived cell lines, PC3 and DU145, and the 
primary-derived OPCT-1 cell line demonstrated the highest staining intensities. 
Figure 4.12 illustrates the immunofluorescent staining of the murine fibroblast cell line, 
NIH 3T3, which served as a positive control for the FSP1, Snail and Slug antibodies used 
throughout this study.  Although the efficacy of the FSP1 and Snail antibodies was 
confirmed using this cell line, very weak staining was observed with the Snail antibody.  
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Figure 4.11:  Immunofluorescent staining of DU145, PC3, P4E6, OPCT-1 and OPCT- 2 using a 
murine monoclonal antibody against CD44.  Secondary antibody and nuclear staining were 
performed as previously described in Figure 4.2. (n=3).  Representative images.   Image  
magnification at x20. 
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Figure 4.12:  Immunofluorescent staining of murine fibroblast NIH 3T3 cells as a positive 
control for the rabbit polyclonal antibody against FSP1 and goat polyclonal antibodies 
against Snail and Slug.  Appropriate isotype controls are also shown. Secondary antibody 
and nuclear staining were performed as previously described in Figure 4.2. (n=2)  
Representative images.  Image magnification at x20. 
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As anticipated, the five cell lines varied markedly with regards to the expression of several 
EMT-associated proteins.  Furthermore, differential expression of proteins conferring 
properties of epithelial and mesenchymal cells was evident, particularly in the OPCT-1 cell 
line. The results from the immunofluorescent screening of the five prostate cancer cell 
lines are recapitulated in Table 4.1.   
Table 4.1 Summarising the results of the IF screening of DU145, PC3, P4E6, OPCT-1 and 
OPCT-2 cells for the expression of several EMT-associated markers 
 
+ denotes 1 or more positive cells were observed  - denotes no positive cells were observed                                             
+ denotes that this cell line demonstrated expression of several EMT-associated markers 
 
The OPCT-1 cell line was the only cell line investigated in this study which expressed all 
of the EMT-associated markers, with the exception of Twist (Table 4.1).  Furthermore, this 
cell line was unique in its possession of morphologically distinct populations which could 
be observed by both light and fluorescence microscopy (Figure 4.13).  Although several of 
the EMT-associated markers were detected in all five of the cell lines examined, only the 
OPCT-1 cell line demonstrated a clear distinction between epithelial and mesenchymal 
populations. 
Therefore, immunofluorescent screening with a panel of EMT-associated antibodies 
identified the OPCT-1 cell line as model for further investigation of EMT in human 
prostate cancer.  Figure 4.14 summarises the positive staining patterns of OPCT-1 cells 
labelled with some of the most common marker combinations used for the investigation of 
EMT and provides justification for conducting further studies on this cell line. 
Protein 
Cells E-Cad CK B-cat Vim Fibro N-Cad Snail Slug Twist CD44 
           
DU145 + + + + - - + + - + 
PC3 + + + + - + - - - + 
P4E6 + + + + - + - - - + 
OPCT-1 + + + + + + + + - + 
OPCT-2 + + + + + - - - - + 
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Figure 4.13:  Bright field images and fluorescent micrographs of DU145, PC3, P4E6, OPCT-1 
and OPCT-2 cells stained with E-Cadherin and vimentin.  Secondary antibody and nuclear 
staining were performed as previously described in Figure 4.2.  Representative images.  Image 
magnification at x10 for BF images and x20 for fluorescent micrographs.  The red rectangle 
identifies the OPCT-1 cell line as a suitable model for the investigation of EMT. 
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Figure 4.14:  Summary composite of OPCT-1 stained with common markers used to investigate EMT; 
cytokeratin pan/vimentin, E-Cadherin/vimentin, fibronectin/vimentin.  Secondary antibody and 
nuclear staining were performed as previously described in Figure 4.2.   Representative images.  
Image magnification at x20. 
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4.2.2 Verification of the Observation of Epithelial to Mesenchymal 
Transition in OPCT-1 cells by Selective Cloning of the OPCT-1 Cell Line 
Information regarding the derivation and characterisation of the OPCT cell lines is scarce 
and is limited to three abstracts from AACR Meetings held in 2004, 2005 and 2007 and the 
profiles provided on the Asterand website, from where they can be purchased (please refer 
to links in Appendix IV).  Of concern was the notion that, rather than showing evidence of 
epithelial to mesenchymal transition, perhaps the OPCT-1 cell line was a mixed cell line 
comprised of immortalised stroma in addition to epithelial cells.  Figure 4.15 demonstrates 
that a cell line with a mixed population of epithelial and mesenchymal (stromal) cells may 
have resulted if the epithelial cells had not been separated from the stromal cells prior to 
transformation with the HPV16/18 genes E6 and E7. 
 
 
 
 
 
 
 
 
                                                                                                                                                  
 
In light of these concerns, it was necessary to establish whether the OPCT-1 cell line did 
contain a population of cells which were transitioning between epithelial and mesenchymal 
states.  In order to achieve this, the OPCT-1 cell line was cloned using the limiting dilution 
assay whereby less than one cell was seeded per well into the wells of six 96-well plates.  
Previous attempts to isolate individual E-Cadherin-positive OPCT-1 cells, using live cell 
Figure 4.15:  Illustrating concerns that the OPCT-1 cell line may be comprised of immortalised epithelial 
and stromal cells rather than demonstrating evidence of epithelial to mesenchymal transition.   
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laser capture microdissection failed however, cloning by limiting dilution yielded a total of 
74 clones, which were microscopically examined to confirm they were derived from single 
cells.  Figure 4.16 provides two examples of the individual colonies after 21 days of 
culture in the original 96 well plates in which they were cloned.  This figure demonstrates 
that the OPCT-1 clones arose from single colonies of cells, which were derived from single 
cells. 
 
 
 
 
Of the 74 clones, 51 were expanded, frozen down in liquid nitrogen at three passages 
(passage 1,2 and 3) and screened at the second passage (P2) for the expression of the 
epithelial marker E-Cadherin and the mesenchymal marker vimentin.  In addition to 
examining these markers, the 51 clones were screened at the same passage for CD44 and 
CD24 to address a possible correlation with the CSC phenotype.  Table 4.2 displays the 
results to the initial IF screening of the OPCT-1 clones. 
Figure 4.16:  Demonstrating individual colonies of cloned OPCT-1 cells after 21 days in culture. 
Representative images of A) edge of colony B) centre of colony.  x20 magnification. 
A: Clone P2E9 B: Clone P5E4 
151 
 
Table 4.2 The expression of E-Cadherin, vimentin, CD44 and CD24 by 51 OPCT-1 clones 
screened by immunofluorescence                                                                                                                                                                
 
Clone E-Cadherin Vimentin 
Dual 
positive? 
CD44 CD24 
Dual 
positive? 
 
P1C7 +++ +++ Yes +++ - n/a 
P1D2 +++ ++ Yes +++ ++ Yes 
P1D4 +++ ++ Yes +++ ++ Yes 
P1E6 +++ +++ Yes +++ - n/a 
P1G3 +++ ++ Yes +++ + No 
P2B9 +++ +++ Yes +++ + Yes 
P2D8 +++ ++ Yes +++ - n/a 
P2E7 +++ + Yes +++ - n/a 
P2E9 +++ + Yes +++ + Yes 
P2F3 +++ + Yes +++ + n/a 
P2G3 +++ + Yes +++ + Yes 
P3B11 +++ + Yes +++ - Yes 
P3D3 +++ + Yes +++ - n/a 
P3D10 +++ + No +++ - n/a 
P3D11 +++ ++ Yes +++ - n/a 
P3E5 +++ - n/a +++ + Yes 
P3G3 +++ ++ Yes +++ + Yes 
P3G10 +++ ++ Yes +++ - n/a 
P3H8 +++ +++ Yes +++ - n/a 
P4B6 +++ +++ Yes +++ - n/a 
P4C3 +++ + Yes +++ + Yes 
P4C7 +++ + Yes +++ - n/a 
P4E10 +++ + Yes +++ + Yes 
P4F2 +++ + Yes +++ - n/a 
P4F4 +++ +++ Yes +++ - n/a 
P4G6 +++ +++ Yes +++ + Yes 
P4G10 +++ ++ Yes +++ - n/a 
P5A5 +++ + Yes +++ + Yes 
P5A6 +++ + Yes +++ + Yes 
P5B3 +++ - n/a ++ ++ Yes 
P5B7 +++ +++ Yes +++ + Yes 
P5C3 +++ + Yes +++ - n/a 
P5D4 +++ +++ Yes +++ - n/a 
P5D6 +++ + No +++ + Yes 
P5E4 +++ + Yes +++ + Yes 
P5E8 
P5F8 
+++ 
+++ 
+ 
+++ 
Yes 
Yes 
+++ 
+++ 
+ 
- 
Yes 
n/a 
P5H8 +++ ++ Yes +++ + Yes 
P5H9 +++ ++ Yes +++ + Yes 
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Clone 
 
E-Cadherin 
 
Vimentin 
 
Dual 
positive? 
 
CD44 
 
CD24 
 
Dual 
positive? 
       
P5F2 +++ +++ Yes +++ + Yes 
P5F3 +++ ++ Yes +++ - n/a 
P6D4 +++ + Yes +++ + Yes 
P6E6 +++ +++ Yes +++ - n/a 
P6H5 +++ ++ Yes +++ + Yes 
P6C7 +++ ++ Yes +++ + Yes 
P6D1 +++ ++ Yes +++ + Yes 
P6D2 +++ +++ Yes +++ - n/a 
P6E10 +++ ++ Yes +++ + Yes 
P6F12 +++ + No +++ - n/a 
P5A2 +++ ++ Yes +++ + Yes 
P5G11 +++ + Yes +++ - n/a 
+++ expressed by ˜ 10-100% of cells   ++ expressed by ˜ 1-10% of cells    + expressed by ˜ <1% of cells   – no positive cells observed                                        
Yes = individual cells expressing both markers present   No = only single-positive cells observed 
 
Table 4.2 demonstrates that CD44 and E-Cadherin were both expressed by a high 
proportion of cells in each of the OPCT-1 clones.  Large variation in the number of 
vimentin-positive cells within each clone was evident and vimentin was detected in all but 
two of the 51 clones.  The expression of CD24 was minimal in the clones which expressed 
this protein.   
 
Not only did these data confirm that populations of cells derived from single OPCT-1 cells 
gave rise to epithelial and mesenchymal cell types, the variation in the level of vimentin 
expression across the clones also revealed that individual OPCT-1 cells differed in their 
ability and frequency to transdifferentiate.  Therefore, the OPCT-1 clones provided a range 
of phenotypes which could be exploited to investigate epithelial to mesenchymal transition 
in human prostate cancer.  As such, 12 clones with differing phenotypes were selected for 
further interrogation.  Please refer to Appendix IV for images of the 12 selected clones 
growing as single colonies in the 96-well plates in which they were cloned.  
 
In order to assess the stability of the phenotypes of the 12 clones of interest, ascertained 
from the original screening of the 51 OPCT-1 clones (Table 4.2), further screening of E-
Cadherin and vimentin expression was conducted by immunofluorescence.  To that end, 
the clones were passaged, cryopreserved, re-cultured and re-screened on two separate 
occasions.  Figures 4.17a and 4.17b display the results from these screens in addition to the 
results from the initial screening. 
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Figure 4.17a:  Dual immunofluorescent staining of 1-6 of 12 OPCT-1 clones of interest; P5B3, P3E5, 
P2E9, P4C7, P5E4, P6D4 using a murine monoclonal antibody against the epithelial marker, E-
Cadherin and a rabbit polyclonal antibody against the mesenchymal marker, vimentin.  Secondary 
antibody and nuclear staining were achieved as per Figure 4.2.   1
st
 screen represents the initial 
screening of the 51 clones, from which these clones were selected (P2),  2
nd
 screen represents the second 
screening conducted after defrosting and passaging the cells (P3) and 3
rd
 screen represents the third 
screening conducted after defrosting and passaging the clones for a second time (P4). (n=3).   
Representative images.   Image magnification at x20.  Yellow arrows indicate vimentin-positive cells and 
red arrows indicate that these two clones exhibited a change in phenotype. 
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Figure 4.17b:  Dual immunofluorescent staining of 6 of 12 OPCT-1 clones of interest;P4F2, P4G10, 
P5F3, P3H8, P2B9 and P4B6.  Stained as per the staining demonstrated in Figure 4.17a.  1
st
 screen 
represents the initial screening of the 51 clones, from which these clones were selected (P2), 2
nd
 screen 
represents the second screening conducted after defrosting and passaging the cells (P3) and 3
rd
 screen 
represents the third screening conducted after defrosting and passaging the clones for a second time 
(P4). (n=3).   Representative images.   Image magnification at x20. Red arrow indicates that clone 
P4G10 exhibited a change in phenotype. 
 
155 
 
The majority of the 12 clones maintained the original phenotype, observed in the first 
screening (Figures 4.17a and 4.17b).   However, during the third screening, vimentin-
positive cells were detected for the first time in clones P5B3 and P3E5 (indicated by 
yellow arrows).  Therefore, none of the clones were completely negative for the expression 
of vimentin.  Clone P4G10 also showed an increase in vimentin expression during the third 
screening. 
From the 12 clones of interest, five (presented in increasing order of vimentin expression) 
were selected for further studies; P5B3, P6D4, P5F3, P2B9, P4B6, in which they were 
interrogated and compared to parental OPCT-1 (Chapters 5 and 6).  To ensure maintenance 
of phenotype, these clones were assayed only at passages 2-5 and were screened by 
immunofluorescence in parallel to each assay throughout the duration of further studies.  
Figure 4.20 demonstrates the morphology of the five selected clones and parental OPCT-1 
observed using light microscopy. 
 
                                                                                                                                                         
Clear morphological differences between the clones are evident from Figure 4.18 where 
clone P5B3, the least vimentin-positive clone, exhibited cobblestone morphology and this 
morphology was gradually lost as the clones increased in vimentin positivity.  Clone P4B6, 
the most vimentin positive clone, possessed a high proportion of fibroblastoid cells which 
surrounded colonies of epithelial-looking cells.  
Figure 4.18:  Bright field images of five OPCT-1 clones selected for further study and parental OPCT-1.                 
Representative images.  Image magnification at x10. 
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Figure 4.19 demonstrates the distinct vimentin and E-Cadherin expression profiles of the 
five OPCT-1 clones selected for further studies.  These clones ranged from very low to 
high in terms of vimentin expression.  It is worth noting that although a single vimentin-
positive cell was detected in the 3
rd
 screening of clone P5B3, vimentin-positive cells were 
extremely rare and often not detected during immunofluorescent screening of this clone.   
These five clones provided a model which could be exploited to investigate the 
phenomenon of EMT in future in vitro and in vivo studies.   
 
 
Figure 4.19:  Dual immunofluorescent staining of  5 OPCT-1 clones of interest; P5B3, P6D4, P5F3, 
P2B9 and P4B6 arranged in increasing order of vimentin positivity. Stained as per the staining 
demonstrated in Figure 4.19a. (n=3).   Representative images.  Image magnification at x20. 
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4.3 Discussion 
Epithelial to mesenchymal transition is emerging as a vital process involved in the 
progression of early stage tumours towards malignancy.  Furthermore, this process has 
been implicated in the generation of cancer stem-like cells which are believed to contribute 
significantly towards therapeutic resistance and tumour relapse  (Mani et al., 2008; May et 
al., 2011).  This phenomenon has been most extensively studied using breast cancer as a 
model, therefore, there is a need to investigate the role and properties of EMT in other 
human malignancies, including prostate cancer.  The work documented in this chapter 
aimed to identify a suitable prostate cancer cell line from which clones could be derived 
for the investigation of epithelial to mesenchymal transition and the generation of cancer 
stem-like cells in human prostate cancer.   
The five prostate cancer cell lines selected for the investigation of EMT; PC3, DU145, 
P4E6, OPCT-1 and OPCT-2, demonstrated distinct morphologies, when examined 
microscopically, which did not necessarily reflect their EMT status, as determined by 
immunofluorescence.  However, despite morphological differences, a high proportion of 
the cells in each of the five cell lines expressed the putative cancer stem cell marker, 
CD44.   
Surprisingly, the metastasis-derived PC3 cell line, which exhibited a fibroblastoid, 
mesenchymal-like morphology, did not appear to express any of the investigated EMT-
associated transcription factors, Snail, Slug and Twist, or fibronectin, an extracellular 
matrix protein produced and secreted by mesenchymal cells.  Furthermore, PC3 cells 
expressed the epithelial markers E-Cadherin and cytokeratins, in addition to the 
mesenchymal markers N-Cadherin and vimentin.  Therefore, this cell line exhibited an 
intermediate phenotype which was neither epithelial nor mesenchymal.   
The metastasis-derived DU145 cell line however, which exhibited cobblestone 
morphology, typical of epithelial cells, demonstrated the highest staining intensities for 
Snail and Slug.  As with the PC3 cell line, DU145 cells demonstrated an intermediate 
phenotype, characterised by the co-expression of the epithelial markers, E-Cadherin and 
cytokeratins and the mesenchymal marker vimentin.  Unlike PC3 cells however, DU145 
cells did not express the mesenchymal cell adhesion molecule (CAM), N-Cadherin.  The 
DU145 cell line appeared to contain a population of vimentin-positive cells with nuclear 
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accumulation of β-Catenin, an EMT-associated  phenotype, however, this must be verified 
using confocal microscopy.  In keeping with the PC3 cell line, DU145 cells did not appear 
to express fibronectin or Twist.  Hence, despite marked differences in morphology, the 
metastasis-derived cell lines PC3 and DU145 both exhibited an intermediate phenotype 
with co-expression of epithelial and mesenchymal markers.   
Consistent with what was observed with the metastatic cell lines (DU145 and PC3) in this 
study, a large study conducted by Smith and colleagues (1979), on several cell lines 
derived from non-malignant tissues, primary carcinomas and metastatic carcinomas, 
demonstrated that cell lines derived from metastatic tumours displayed very little or no 
fibronectin expression.   
Despite being derived from a primary tumour, the EMT-associated marker profile of the 
P4E6 cell line was analogous to that of the PC3 cells.  Hence, this cell line also exhibited 
an overall intermediate phenotype with no clear distinction between epithelial and 
mesenchymal populations.  
Contrary to the PC3, DU145 and P4E6 cell lines, which comprised a majority of cells 
expressing vimentin, the OPCT-2 cell line possessed few vimentin-positive cells.  
However, the vimentin-positive OPCT-2 cells co-expressed epithelial markers hence, did 
not represent a pure mesenchymal population.  The production of fibronectin by this cell 
line may suggest the presence of mesenchymal-like cells.  However, this was not sufficient 
evidence as epithelial cells have also been shown to produce fibronectin (Smith et al., 
1979).  Furthermore, this cell line did not appear to express any of the three EMT-
associated transcription factors or the mesenchymal CAM, N-Cadherin.  Therefore, the 
OPCT-2 cell line may have contained a population of cells which had only partially 
transitioned via EMT.   
Microscopic examination of OPCT-1 cells revealed the presence of morphologically 
distinct populations, some of which resided in colonies with cobblestone morphology, 
while the other cell types demonstrated fibroblastoid/mesenchymal morphologies and were 
situated in between the colonies of epithelial-looking cells.  This observation was verified 
using immunofluorescence, which revealed that the OPCT-1 cell line was unique in its 
possession of distinct epithelial and mesenchymal populations as evidenced by single-
positive E-Cadherin and vimentin populations.  As anticipated, the colonies exhibiting 
cobblestone morphology showed high staining intensities for E-Cadherin and cytokeratins 
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whereas, the fibroblastoid cells frequently demonstrated single vimentin-positivity.  
However, co-expression of cytokeratins was also observed among some of the vimentin-
positive cells.  Dual-expression of vimentin and cytokeratins is not an uncommon finding 
in cancer cells and this observation supports the notion that the Type 3 EMT process, 
activated in cancer, may be incomplete (Leong et al., 1988; Hollier et al., 2009).  
Alternatively, these cells may have been in the process of transitioning via EMT.  
Interestingly, the vimentin-positive cells in this cell line exhibited sophisticated vimentin 
expression and the majority of these cells co-expressed fibronectin.  Nuclear accumulation 
of β-Catenin was also observed in OPCT-1 cells, however, as with the DU145 cell line, 
this finding must be verified using confocal microscopy.  The OPCT-1 and DU145 cell 
lines were unique in their expression of Snail and Slug.  However, while these transcription 
factors appeared to be expressed by the majority of cells in the DU145 cell line, fewer cells 
expressing Snail and Slug were observed in the OPCT-1 cell line. 
Immunofluorescent screening with a panel of several EMT-associated markers identified 
OPCT-1 as a model cell line for the investigation of EMT as, with the exception of Twist, 
this cell line expressed all of the EMT-associated markers examined.  Furthermore, unlike 
the other cell lines examined, a clear distinction between epithelial and mesenchymal 
populations was evident in the OPCT-1 cell line. 
Since carcinomas are cancers of epithelial cells, the presence of mesenchymal-like cells in 
the prostate carcinoma cell line OPCT-1 appeared to be indicative of EMT.  However, 
mesenchymal populations may also present in carcinoma cell lines as a result of stromal 
contamination, hence, the OPCT-1 cell line may have consisted of immortalised epithelial 
and stromal cells (Dollner et al., 2004).  In order to address this concern, and verify that 
the mesenchymal populations had arisen from epithelial cells, the OPCT-1 cell line was 
cloned by limiting dilution and 51 of the clones, derived using this technique, were 
screened by immunofluorescence for the expression of E-Cadherin and vimentin.  In 
addition, the 51 OPCT-1 clones were dual-stained with CD24 and CD44, to address the 
cancer stem cell phenotype (CD44
+
/CD24
-
)  reported for several human malignancies, 
including prostate cancer (Hurt et al., 2008).  However, since all of the clones expressed 
CD44, and the CD24 staining patterns were ambiguous, this screening did not provide 
convincing evidence for the presence of putative prostate cancer stem cells.   
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The results of the immunofluorescence screening of the 51 OPCT-1 clones revealed that 
they comprised mixed populations of E-Cadherin/vimentin-expressing cells.  Furthermore, 
distinct morphological differences were frequently observed between the single E-
Cadherin-positive and single vimentin-positive populations, within the clones.  Therefore, 
clonally derived OPCT-1 populations appeared to comprise a mixture of epithelial and 
mesenchymal cell types which had not arisen as a result of stromal contamination and 
rather, may have arisen via EMT.   
Interestingly, the clones varied considerably with respect to the abundance of vimentin-
positive cells.  In addition, some clones presented with single vimentin-positive, 
fibroblastoid populations whereas others presented with dual E-Cadherin/vimentin-positive 
cells that did not exhibit the fibroblastoid morphology typical of mesenchymal cells.  
Variation in vimentin-positivity among the OPCT-1 clones implied that these cells differed 
in their ability and frequency to execute the EMT programme.  Furthermore, since 
vimentin is the intermediate filament expressed by primitive cell types, the co-expression 
of E-Cadherin and vimentin by prostate cancer cells exhibiting epithelial morphology may 
have provided evidence for a population of primitive (i.e. stem-like) cells in the OPCT-1 
clones.   
This work demonstrated heterogeneity among clones derived from the same cell line.  
Therefore, these clones provided a model which could be exploited for the investigation  of 
EMT in human prostate cancer cells, without the need for artificial induction of this 
phenomenon via ectopic expression of EMT-inducing transcription factors or stimulation 
with growth factors such as TGF-β  (Mani et al., 2008; Kong et al., 2010; Li and Zhoul, 
2011; Moustakas and Heldin, 2012). 
In order to select appropriate clones for further investigation, 12 clones with differing 
proportions of vimentin-positive cells were selected and re-screened for the expression of 
E-Cadherin and vimentin by IF.  Repeated immunofluorescent screening, following 
freezing, thawing and passaging of the 12 clones in culture, revealed that most of the 
clones maintained a constant phenotype with respect to vimentin-positivity.  Interestingly, 
however, the two clones in which vimentin-positive cells had not previously been 
identified, demonstrated vimentin-positivity in a minute population of cells, which were 
only identified during the third IF screening.  Therefore, none of the 51 OPCT-1 clones 
proved to be vimentin-negative.   
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Following the three IF screenings of the 12 OPCT-1 clones of interest, five OPCT-1 
clones, which exhibited distinct and stable growth characteristics and  ranged from very 
low to very high in terms of vimentin-positivity, were selected for further interrogation 
(Chapters 5 and 6). 
In summary, the work reported in this study identified OPCT-1 as a suitable prostate 
cancer cell line for the investigation of epithelial to mesenchymal transition.  In addition, 
phenotypically distinct OPCT-1 clones were derived and selected for further investigation 
using in vitro and in vivo studies to address a possible correlation between EMT and a 
stem-like signature in human prostate cancer cells.   
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Chapter 5: 
Investigating the Expression of EMT and 
CSC-Associated Proteins by the OPCT-1 
Clones – is there a Link between the EMT and 
CSC Marker Profiles of Human Prostate 
Cancer Cells? 
 
5.1 Introduction 
Epithelial to mesenchymal transition has been studied extensively in the context of breast 
cancer however, although evidence is emerging, the significance of this phenomenon and 
its contribution to the generation of prostate cancer stem cells remains to be shown.  The 
derivation and selection of five OPCT-1 clones, which ranged from very low to high in 
terms of vimentin expression (Chapter 4), provided a model on which further studies on 
epithelial to mesenchymal transition in human prostate cancer cells could be conducted.   
Most recent studies, implicating EMT in the generation of cancer stem cells, interrogated 
cells in which EMT was artificially induced either via ectopic expression of transcription 
factors including Snail and Twist, stimulation with growth factors such as TGF-β and EGF, 
or overexpression of growth factors such as PDGF-D (Mani et al., 2008; Kong et al., 2010; 
Li and Zhoul, 2011; Moustakas and Heldin, 2012).  However, this study was conducted on 
a range of phenotypically distinct, clonally-derived cells, some of which transitioned 
spontaneously in culture. 
The initial interrogation of the five OPCT-1 clones, documented in this chapter, involved 
re-cloning the clones to confirm EMT, quantifying the percentage of vimentin-positive 
cells in each clone and screening the clones for a panel of EMT and CSC-associated 
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markers by immunofluorescence and Western blotting.  These studies were conducted in 
order to phenotype the clones with regards to their EMT and CSC status’, prior to 
conducting further in vitro and in vivo characterisation assays (Chapter 6). 
 
5.2 Results 
Throughout this study, parental OPCT-1 cells were assessed in parallel with the clones.  It 
is however, important to note that differences observed in the results obtained for parental 
OPCT-1 between tests and repeats were to be expected.  This is due to the fact that, unlike 
the clones, this cell line was not clonally derived and constituted a mixed population of 
cells with different properties, the proportions of which were subject to change during 
culture and, in turn, could influence the outcome of the assays.  In order to limit the 
variation between tests, throughout the duration of this study the clones and parental 
OPCT-1 were assayed within a range of four passages.  Furthermore, IF screening of the 
clones in parallel to each assay confirmed that they maintained the proportions of E-
Cadherin and vimentin-positive cells which were originally observed (data not shown).  
For ease of interpretation, unless otherwise stated, throughout the duration of this work the 
clones will be represented in order of increasing vimentin positivity; P5B3, P6D4, P5F3, 
P2B9, P4B6. 
5.2.1  Confirmation of EMT and Determination of Cloning Efficiency by 
Re-cloning  
Prior to conducting characterisation assays on the five OPCT-1 clones of interest, it was 
necessary to re-confirm that clonally derived populations of OPCT-1 cells did, in fact, 
consist of a mixture of epithelial and mesenchymal cells.  This was necessary as there was 
a chance that the procedures which followed the cloning by limiting dilution assay, 
namely; expansion, freezing and immunofluorescence screening of the clones, may have 
introduced contamination across different clones.  Hence, this could lead to false evidence 
of transitioning cells.  To address this possibility, each of the five OPCT-1 clones and 
parental OPCT-1 cells were seeded at single-cell density, 32 wells per clone, into 
fluorescence compatible 96-well plates using a MoFlo
TM
 XDP High-Speed Cell Sorter 
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(n=3).  After a period of growth, the wells were examined to confirm the presence of only 
one colony per well prior to counting, fixing and staining the colonies by 
immunofluorescence using antibodies directed against E-Cadherin and vimentin.  This 
assay ensured that minimal handling of the (re)cloned cells was necessary prior to 
conducting immunofluorescence directly in the wells in which they grew.  Therefore, it 
was fair to assume that any mixed populations occurred as a result of transitioning cells, 
rather than contamination with other clones. 
Figure 5.1 demonstrates that mixed populations of cells expressing both epithelial and 
mesenchymal markers arose in clonally derived populations of OPCT-1 cells.  In fact, all 
of the five OPCT-1 clones generated colonies with E-Cadherin and vimentin expression.  
Of a total of 96 wells seeded (across the three assays), clone P5B3, which contained a very 
small population of vimentin-positive cells, formed only one colony with vimentin-positive 
cells.  Interestingly, with the exception of clone P4B6, all clones and parental OPCT-1 
generated colonies of cells which were only positive for E-Cadherin.  Remarkably, clone 
P4B6 also generated loose fibroblastoid colonies which only expressed vimentin.  This was 
of particular interest as, until this observation, it remained to be shown in this study 
whether the vimentin-positive cells were capable of spawning more vimentin-positive 
cells.  Also of interest is the fact that some of the clones and parental OPCT-1 cells formed 
colonies with a number of cells exhibiting normal E-Cadherin expression – with 
accumulation of this protein in the junctions between cells (examples indicated by orange 
arrows). 
The localisation of the vimentin-positive cells, predominantly on the edge of the colonies, 
alluded to the fact that these had arisen as a result of epithelial cells transitioning via EMT.  
Furthermore, it was evident in some of the wells that the vimentin-positive cells were 
beginning to migrate away from the original colony (indicated by the white arrow).  
Therefore, this experiment provided an insight to the metastatic process. 
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Figure 5.1:  Dual immunofluorescent staining of re-cloned clones P5B3, P6D4, P5F3, P2B9, P4B6 and 
parental OPCT-1 in fluorescence-compatible 96 well plates using a murine monoclonal antibody against 
the epithelial marker, E-Cadherin and a rabbit polyclonal antibody against the mesenchymal marker, 
vimentin.  E-Cadherin was labelled with an anti-mouse Alexa Fluor®568-conjugated secondary 
antibody and vimentin was labelled with an anti-rabbit Alexa Fluor®488-conjugated secondary 
antibody.  Nuclear staining was achieved using mounting media with DAPI. (n=3). A-E represent 
separate wells from across the 3 assays.  Representative images.  Image magnification at x20.  Orange 
arrows indicate cells with membranous E-Cadherin expression.  White arrow identifies vimentin-positive 
cells which appeared to have migrated away from the original colony.  
 
 
 
 
 
A B C D E 
166 
 
Prior to conducting IF on the re-cloned clones, the colonies were counted in order to 
determine if statistically significant differences in the number of colonies formed by the 
clones and parental OPCT-1 were observed.  Figure 5.2 illustrates the number of colonies 
formed by each of the clones and parental OPCT-1 out of the 32 wells seeded (1 cell per 
well) in three separate assays.   
 
 
 
 
 
 
 
 
 
 
 
Overall, there was no statistical significance in the number of colonies formed by the 
clones per 32 wells.  On average, clones P6D4 and P4B6 formed the most colonies as more 
than  half of the cells seeded (>16) formed colonies in all three assays whereas clone P2B9 
formed the fewest colonies as less than half of the cells seeded formed colonies in all three 
assays. 
From this assay, the mean cloning efficiency of each of the clones and parental OPCT-1 
was calculated in order to explore a possible connection between an increase in vimentin 
positivity (i.e. EMT) and enhanced cloning efficiency.  Cloning efficiency relates to the 
percentage of (seeded) wells that grow a colony of cells from a single cell.  Hence, reflects 
the ability of a particular cell type to be cloned (i.e. form colonies from single cells).  
Figure 5.2:  Demonstrating the number of colonies formed by each of the clones and parental OPCT-1 
following cell sorting at single-cell density into 32 wells per cell line in three separate assays. (n=3) 
Data are represented as the mean number of colonies ± SEM.  
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The mean cloning efficiencies were calculated by dividing the average number of colonies 
which grew for each cell type by the number of wells seeded (32) and multiplying by 100.  
The results for each clone and parental OPCT-1 are displayed in Table 5.1. 
 
Table 5.1: Displaying the mean cloning efficiencies of parental OPCT-1 and five clones 
derived from this cell line 
 
 
 
 
 
 
 
 
 
 
Clones P6D4 and P4B6 showed the highest cloning efficiencies, even higher than that of 
the parental OPCT-1 cell line, whereas, clone P2B9 demonstrated the lowest cloning 
efficiency (Table 5.1).  These results confirmed that cloning efficiency did not increase 
concomitantly with vimentin positivity.  Therefore, in this experiment, EMT of prostate 
cancer cells did not confer enhanced cloning efficiency. 
 
 
 
 
Cells 
 
Mean Cloning 
efficiency 
 
 
Parental 
 
41% 
P5B3 42% 
P6D4 61% 
P5F3 58% 
P2B9 33% 
P4B6 61% 
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Figure 5.3:  Demonstrating sample flow cytometric data (A) from which the  percentage of vimentin-positive 
cells present in each of the clones and parental OPCT-1 was determined (p < 0.0019, Friedman statistic <19) 
(B). Sample data are shown for the least vimentin-positive clone; P5B3 and the most vimentin-positive clone; 
P4B6.  Flow cytometry was performed using a PE-conjugated isotype control to gate the cells and a PE-
conjugated anti-vimentin antibody to identify the population of cells expressing vimentin.  The positive 
populations were defined as cells present in gate B (vimentin-PE) and the percentage of positive cells present 
in each clone was calculated by subtracting the percentage of cells in gate A (iso-PE) from the percentage in 
gate B (vimentin-PE). Representative data. (n=4).   
 
 
 
5.2.2 Quantification of Vimentin-Positive Populations 
After having confirmed that the OPCT-1 clones were indeed showing evidence of EMT, 
flow cytometry was utilised to quantify the percentage of vimentin-positive cells within 
each clone.  This could serve as an indirect measure of the amount of EMT occurring in the 
clones, however it is important to consider that vimentin is also the intermediate filament 
expressed by naive epithelial cells hence, in theory, vimentin could also identify a cancer 
stem/progenitor cell population (Azumi et al., 1987; Korsching et al., 2005).   
Figure 5.3 demonstrates example flow cytometric data to exemplify how the percentage of 
vimentin-positive cells was determined and a graph to illustrate the variation in the 
percentage of vimentin-positive cells present among the clones.   
 
 
 
 
 
 
 
 
 
 
 
B 
A 
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The results depicted in Figure 5.3 (B) support the observations made by 
immunofluorescence and the rank order of the clones with regards to vimentin-positivity 
remained as; P5B3, P6D4, P5F3, P2B9, P4B6.  Furthermore, the differences in vimentin 
expression between the clones were statistically significant (p < 0.0019, Friedman statistic 
< 19). 
The mean percentages of vimentin-positive cells present in each clone and parental OPCT-
1 were calculated from the four independent flow cytometry experiments, conducted as 
described in Figure 5.3, and are presented in Table 5.2.  
 
Table 5.2: Displaying the average percentage of vimentin-positive cells present in parental 
OPCT-1 and five clones derived from this cell line 
 
 
 
 
 
 
 
 
 
 
Almost a third of P4B6 cells expressed vimentin (Table 5.2).  This clone was by far the 
most positive for the expression of vimentin, almost 100 times more positive than clone 
P5B3 and, with the exception of clone P2B9, more than 10 times more positive than the 
other clones and parental OPCT-1 cells.  Clone P2B9 was the second most vimentin-
positive clone with approximately five times fewer vimentin-positive cells than clone 
P4B6.  
Cells 
 
Mean % 
Vimentin
+
 cells 
 
 
Parental 
 
1.07% 
P5B3 0.33% 
P6D4 0.51% 
P5F3 1.29% 
P2B9 5.72% 
P4B6 29.86% 
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5.2.3 Investigating the Expression of EMT and CSC-Associated Markers 
by Immunofluorescence  
As with the five prostate cancer cell lines screened in Chapter 4, the OPCT-1 clones were 
screened by immunofluorescence for a panel of several EMT-associated markers.  In 
addition to these, they were also screened for the prostate cancer stem cell-associated 
markers; CD44 and integrin α2β1 and the three transcription factors critical for the 
maintenance of self-renewal and pluripotency in embryonic stem cells; Nanog, Oct4 and 
Sox2.   
Figures 5.4 to 5.12 demonstrate the results to the immunofluorescent screening of the 
clones, please refer to Appendix V for the appropriate positive and negative controls 
thereof. 
The clones were initially selected and subsequently re-screened based on their expression 
of the epithelial marker E-Cadherin and the mesenchymal marker vimentin.  In order to 
verify the existence of epithelial populations using an additional epithelial marker, they 
were screened for the expression of cytokeratins (CK) in conjunction with vimentin.  All 
five of the clones comprised cells which expressed cytokeratins (Figure 5.4).  Surprisingly, 
clone P5B3 appeared to be the least positive for cytokeratins as there were several CK-
negative cells present in this clone however, as they were also negative for the expression 
of vimentin, the identity of these dual-negative cells remained elusive.  All other clones 
comprised a mixture of cells, predominantly expressing only cytokeratins, but some co-
expressed cytokeratins and vimentin.  It is important to note that, although not represented 
in this figure, single vimentin-positive cells were observed in clones P2B9 and P4B6. 
As the expression of nuclear β-Catenin has been associated with induction of EMT, the 
expression of this protein was examined in the clones to investigate a possible correlation 
between an increase in vimentin positivity and β-Catenin accumulation in the nucleus.  
However, Figure 5.5 demonstrates that, although membranous and cytoplasmic β-Catenin 
expression was apparent in all five clones, without assessment by confocal microscopy it 
was difficult to ascertain whether nuclear staining was present in any of the cells.  
Interestingly, cells which were strongly positive for vimentin expression in clones P5F3, 
P2B9 and P4B6 appeared to express less β-Catenin than cells which did not express this 
intermediate filament. 
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Figure 5.4:  Dual immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
murine pan polyclonal antibody against the epithelial marker, cytokeratin and a rabbit polyclonal 
antibody against the mesenchymal marker, vimentin.  Secondary antibody labelling and nuclear staining 
were achieved as previously described in Figure 5.1. (n=3).  Representative images.  Image 
magnification at x20. 
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Figure 5.5:  Dual immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
murine monoclonal antibody against β-Catenin and a rabbit polyclonal antibody against the mesenchymal 
marker, vimentin.  Secondary antibody labelling and nuclear staining were achieved  as previously 
described in Figure 5.1. (n=3).  Representative images.  Image magnification at x20.   
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In order to ascertain whether the vimentin-positive cells in the clones were producing 
cellular fibronectin, another marker associated with mesenchymal cells, the clones were 
screened with fibronectin and vimentin antibodies (Figure 5.6).  As anticipated, the 
expression of fibronectin increased concomitantly with vimentin expression.  Interestingly, 
there was no fibronectin detected in clone P5B3 although a vimentin-positive cell was 
observed, based on the infrequency of vimentin-positive cells in this clone and the lack of 
fibronectin expression by these cells, the vimentin-expressing population in this clone may 
have represented primitive cells, rather than cells which had undergone EMT.  The same 
may be true of clone P6D4 which also contained a small population of vimentin-positive 
cells which did not express fibronectin.  Hence, not all of the vimentin-positive cells 
produced fibronectin.  Furthermore, clone P6D4 demonstrated the expression of 
fibronectin by a vimentin-negative cell (indicated by blue arrows).  Therefore, although 
fibronectin expression increased concurrently with vimentin expression overall, the 
expression of this protein was not exclusive to vimentin-positive cells.  This finding is 
consistent with studies which have demonstrated the production and secretion of 
fibronectin by cultured epithelial cells (Smith et al., 1979). 
N-Cadherin is another marker associated with mesenchymal cells and has been shown to 
be upregulated and replace E-Cadherin in the so-called “cadherin switch” during EMT of 
prostate cancer cells (Gravda et al., 2007).  As such, the expression of this protein was 
expected to be highest in the clones with the largest populations of vimentin-positive cells.  
Figure 5.7 demonstrates that N-Cadherin expression was observed in all of the clones with 
the exception of clone P5B3.  As anticipated, the highest levels of this protein were 
observed in the clones with the highest percentage of vimentin-positive cells; clones P2B9 
and P4B6.  Clone P4B6 exhibited intense staining in the cells with fibroblastoid 
morphology however the staining appeared to be more intense in the colonies of cells in 
clone P2B9.  Please note that the apparent staining in clone P5B3 was due to non-specific 
staining of dividing cells.   
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Figure 5.6:  Dual immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
murine monoclonal antibody against cellular fibronectin and a rabbit polyclonal antibody against the 
mesenchymal marker, vimentin.  Secondary antibody labelling and nuclear staining were achieved  as 
previously described in Figure 5.1.  (n=3).  Representative images.  Image magnification at x20.  Blue 
arrows indicate fibronectin expression by vimentin-negative cells. 
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Figure 5.7:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
murine monoclonal antibody against N-Cadherin.  Secondary antibody labelling was achieved 
using an Alexa Fluor®588-conjugated anti-mouse antibody.  Nuclear staining was achieved as 
previously described in Figure 5.1.  (n=3).  Representative images.  Image magnification at x20.  
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Snail, Slug and Twist are three of several zinc finger transcription factors which are known 
to suppress E-Cadherin expression and induce EMT.  The expression of these transcription 
factors was investigated in the OPCT-1 clones in an effort to provide further evidence to 
support the hypothesis that the vimentin-high clones were undergoing EMT.   
As can be observed in Figure 5.8, Snail was detected in all of the clones.  The staining of 
the clones with the Snail antibody achieved similar patterns to those previously observed in 
parental OPCT-1 and DU145, in that Snail was localised in the cytoplasm with a dotty 
appearance.  Clones P5F3 and P4B6 demonstrated the highest staining intensities and 
clones P5B3 and P2B9 demonstrated the lowest staining intensities for Snail.  The 
comparatively low levels of Snail in clone P2B9 were surprising as this clone comprised 
the second largest population of vimentin-positive cells.  However, the low levels of this 
transcription factor in clones P5B3 and P6D4 was consistent with the fact that these clones 
expressed low levels of vimentin. 
Analogous to the staining patterns observed with the Snail antibody, all five clones showed 
evidence of Slug expression with clones P5B3 and P2B9 exhibiting very low levels and 
clones P5F3 and P4B6 demonstrating higher staining intensities (Figure 5.9).  However, 
clone P6D4 appeared to express higher levels of Slug than Snail.  Positive staining of clone 
P4B6 was predominantly observed in cells with a mesenchymal/fibroblastoid morphology.   
Figure 5.10 demonstrates that none of the OPCT-1 clones stained positive for the 
expression of the transcription factor Twist.  This was consistent with the lack of staining 
observed in previous studies with parental OPCT-1 however; it was hypothesised that 
perhaps with an enriched population of cells undergoing EMT, Twist would be observed.  
It is important to note that this antibody failed to detect Twist in a positive control cell line 
(data not shown) therefore, the efficacy of this antibody, using the IF method followed 
throughout this study, was questionable.  However,  as this antibody was capable of 
detecting Twist in whole cell lysates of the OPCT-1 clones and parental OPCT-1 by 
Western blotting (Figure 5.14), it is likely that it was unsuitable for IF and that some of the 
clones did express this transcription factor. 
Overall, these results did not demonstrate a direct correlation between vimentin-positivity 
and the expression of EMT-inducing transcription factors as clone P2B9 demonstrated 
lower levels of Snail and Slug staining than clones P5F3 and P6D4.  However, verification 
by dual staining with vimentin would be necessary to confirm this.                                                 
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Figure 5.8:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
goat polyclonal antibody against Snail.  Secondary antibody labelling was achieved using an 
anti-goat Alexa Fluor®568-conjugated secondary antibody and nuclear staining was performed  
as previously described in Figure 5.1.  (n=3).  Representative images.  Image magnification at 
x20. 
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Figure 5.9:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
goat polyclonal antibody against Slug.  Secondary antibody labelling was achieved using an anti-
goat Alexa Fluor®568-conjugated secondary antibody and nuclear staining was performed  as 
previously described in Figure 5.1.  (n=3).  Representative images.  Image magnification at x20.  
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Figure 5.10:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
rabbit polyclonal antibody against Twist.  Secondary antibody labelling was achieved using an 
anti-rabbit AlexaFluor®488-conjugated secondary antibody and nuclear staining was performed  
as previously described in Figure 5.1.  (n=3).  Representative images.  Image magnification at 
x20. 
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Recently there has been a surge of interest surrounding the topic of EMT and its 
involvement in the generation of CSCs.  Immunofluorescence using a panel of several 
EMT-associated markers revealed that the OPCT-1 clones provided a model for the 
investigation EMT of prostate cancer cells.  As such, these clones enabled the examination 
of a possible link between EMT and the generation of prostate CSCs.  In 2005, Collins et 
al., identified putative prostate cancer stem cells using a panel of markers which had been 
previously exploited to identify normal prostate stem cells (Collins et al., 2005).  
Therefore, as the markers for EMT and prostate cancer stem cells were well established, it 
was possible to exploit some of these to investigate a potential correlation between EMT 
and PCSCs using the OPCT-1 clones.  To that end, the OPCT-1 clones were screened for 
two of the cell-surface proteins shown to be highly expressed by PCSCs; CD44 and 
integrin α2β1, in addition to three transcription factors known to play a key role in the 
maintenance of self-renewal and pluripotency; Nanog, Oct4 and Sox2. 
Figure 5.11 illustrates that all of the OPCT-1 clones stained positive for the expression of 
CD44, a family of proteins shown to regulate growth, survival, differentiation and 
migration of cancer cells (Orian-Rousseau, 2010).  Clones P5F3 and P4B6 appeared to 
express the highest levels of CD44 and clones P5B3 and P2B9 contained the largest 
number of CD44-low/negative cells among the clones (indicated by yellow arrows).  
Therefore, CD44 positivity did not directly correspond with vimentin positivity as the 
clone with the second largest population of vimentin-positive cells (P2B9) presented with 
several CD44-low/negative cells and did not demonstrate the second highest staining 
intensity overall.   
Integrin α2β1 is a transmembrane receptor for extracellular matrix proteins such as 
collagen and laminin, adhesion molecules such as E-Cadherin and several other ligands 
including matrix metalloproteinase-1 (MMP-1).  Among other functions, it is known to 
play a role in the generation and organisation extracellular matrix proteins and mediate 
interactions between adhesion molecules on adjacent cells (Zutter and Edelson, 2007).  
Figure 5.12 demonstrates variable expression of this molecule among the clones with clone 
P5B3 expressing the highest levels and clone P6D4 expressing the lowest levels.  Clone 
P4B6 presented with two distinct populations with regards to the expression of this 
molecule, where the colonies of cells expressed integrin α2β1 and the loose, mesenchymal-
like cells (indicated by yellow arrows) did not.  This is of particular interest as prostate 
cancer stem cells were shown by Collins and colleagues to express high levels of this 
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receptor protein however it appears that the mesenchymal-like (EMT derived) cells were 
negative for the expression of this protein.  Therefore, this provides evidence to support the 
notion that prostate cancer stem cells and EMT-derived cells are mutually exclusive.  
Although dual vimentin/integrin α2β1 staining was not conducted on clone P4B6, it was 
conducted on parental OPCT-1.  Figure 5.13 demonstrates that vimentin and integrin α2β1 
were differentially expressed in parental OPCT-1 cells (indicated by arrows) therefore, this 
figure provides evidence to suggest that EMT of prostate cancer cells does not generate the 
same prostate cancer stem cells as those identified by Collins et al., 2005.  
 
As tumour development has long been compared with abnormal embryogenesis, it is 
hardly surprising that several studies have reported the expression of three key 
transcription factors involved in the maintenance of self-renewal and pluripotency of 
embryonic stem cells (Nanog, Oct4 and Sox2) in putative cancer stem cells (Kim et al., 
2008; Gong et al., 2012; Kumar et al., 2012; Shan et al., 2012).  To address whether these 
transcription factors were more highly expressed in clones which contained populations of 
cells undergoing EMT, hence draw parallels between the CSC and EMT phenotype, the 
OPCT-1 clones were examined by immunofluorescence for the presence of Nanog, Oct 
and Sox2.  Using this technique, none of these transcription factors were detected in any of 
the OPCT-1 clones (See Appendix V).  Additional immunofluorescent staining of the 
pluripotent embryonic carcinoma cell line, NTERA2/D1, confirmed that the antibodies 
used were suitable for the detection of these transcription factors by IF (See Appendix V).  
However, as with the Twist antibody, these antibodies were capable of detecting the 
corresponding proteins in whole cell lysates of the OPCT-1 clones and parental OPCT-1.  
The inconsistencies in the results obtained from the two techniques may be due to 
differences in the experimental conditions employed and will be discussed in more detail 
in Section 5.3. 
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Figure 5.11:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
mouse monoclonal antibody against CD44.  Secondary antibody labelling was achieved using an 
anti-mouse AlexaFluor®568-conjugated secondary antibody and nuclear staining was performed  
as previously described in Figure 5.1. (n=3).  Representative images.  Image magnification at 
x20.  Yellow arrows indicate areas of low CD44 expression.  
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Figure 5.12:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9 and P4B6 using a 
mouse monoclonal antibody against integrin α2β1.  Secondary antibody labelling was achieved 
using an anti-mouse AlexaFluor®568-conjugated secondary antibody and nuclear staining was 
performed as previously described in Figure 5.1.  (n=3) Representative images.  Image 
magnification at x20.  Yellow arrows demonstrate integrin α2β1-negative cells in the P4B6 clone. 
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Figure 5.13 demonstrates that the EMT-derived, vimentin-positive cells present in the 
OPCT-1 cell line did not express integrin α2β1.  This result confirmed that the EMT-
derived cells must have been distinct from the putative prostate cancer stem cells 
(CD44
+
/CD133
+
/integrin α2β1hi) described by Collins et al., 2005 therefore, integrin α2β1 
expression potentially distinguishes between the original tumour-initiating prostate cancer 
stem cells and the cancer stem-like cells generated by EMT.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: Dual immunofluorescent staining of parental OPCT-1 using a mouse monoclonal antibody 
against integrin α2β1 and a rabbit polyclonal antibody against vimentin.  Secondary antibody labelling and 
nuclear staining was performed as previously described in Figure 5.1. (n=3). Red arrows indicate integrin 
α2β1-positive cells, yellow arrows indicate vimentin-positive cells.  Representative images.  Image 
magnification at x20.  
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5.2.4 Investigating the Expression of EMT and CSC-Associated Markers 
by Western blotting  
In order to validate and confirm the results of the IF screening, where possible, Western 
blotting was performed on the same markers using whole cell lysates prepared from the 
clones and parental OPCT-1.   
Figure 5.14 reveals the protein banding patterns achieved by Western blot analysis of 
seven EMT-associated markers.  
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                          
Western blot analysis revealed that P4B6 expressed the lowest levels of the epithelial 
marker E-Cadherin but the highest levels of the mesenchymal markers vimentin, N-
Cadherin and EMT transcription factor Twist.  Using this technique, vimentin was only 
detected in clones P5F3, P2B9 and P4B6, with expected increasing levels.  As anticipated, 
clone P5B3 consistently expressed the lowest levels of vimentin, N-Cadherin and Twist.  
Figure 5.14:  Western blot analysis of EMT-associated marker expression by clones P5B3, 
P6D4, P5F3, P2B9, P4B6 and parental OPCT-1.  Proteins were stained overnight using  
antibodies which were previously optimised using a mixed cell lysate.  (n=5) Representative 
images.   
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Overall, these results were consistent with the staining patterns achieved by IF however, 
Snail and Slug were not detected in any of the clones using this method.   
Figure 5.15 demonstrates the protein banding patterns achieved by Western blot analysis of 
four CSC-associated markers. 
 
 
 
 
 
                                                                                                    
 
 
 
These results illustrate that clone P4B6, the most vimentin-positive clone, expressed the 
highest levels of CD44 and Oct4 but the lowest levels of Nanog.  Consistent with IF, clone 
P5B3, the least vimentin-positive clone, expressed the lowest levels of CD44.  
Interestingly, clone P6D4 expressed the highest levels of Nanog but not the highest levels 
of Oct4.  Using this method, Sox2 expression was only detected in parental OPCT-1, 
which also expressed the highest levels of Oct4.  The two bands detected for Oct4 may 
represent the two isoforms of this transcription factor; Oct4 A and Oct4 B. 
It is important to note that, while the clones with the highest and lowest protein expression 
remained consistent across the five repeats, the intermediate banding patterns varied.  
Hence, it was not possible to rank the clones in order of expression of each of the proteins 
and measurement by densitometry was unsuitable.   
Figure 5.15:  Western blot analysis of CSC-associated marker expression by clones 
P5B3, P6D4, P5F3, P2B9, P4B6 and parental OPCT-1.  Proteins were stained 
overnight using  antibodies which were previously optimised using a mixed cell lysate.  
(n=5) Representative images.   
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Copper staining of the nitrocellulose membrane prior to immunoprobing (not shown) and 
β-actin staining confirmed that equal amounts of protein were loaded into the SDS-PAGE 
gels. 
In order to confirm the efficacy of the antibodies used to detect the CSC associated 
transcription factors, lysates from NTERA2/D1 cells were prepared and analysed by 
Western blotting.  Lysates from the murine embryonic fibroblast cell line, NIH 3T3, were 
also used as a positive control for the expression of the EMT-associated transcription 
factors Snail and Slug.   
Figure 5.16 demonstrates the protein banding patterns obtained from the positive control 
cell lines.  
 
 
 
 
 
 
The Nanog, Oct4, Sox2, Snail and Slug antibodies used in this study were suitable for the 
detection of protein by Western blotting (Figure 5.16).    
5.2.5 Summary of Immunofluorescence and Western Blot Analysis       
Tables 5.3 and 5.4 summarise and compare the results obtained from the 
immunofluorescence (IF) screening and Western Blot analyses (WB) of the EMT and CSC 
associated marker expression of the OPCT-1 clones, respectively.  Please note that the 
following summary tables do not distinguish between low and high protein expression, 
only absence or presence.  Please refer to Figures 5.4 to 5.15 to observe differences in the 
staining intensities between the clones. 
A B 
Figure 5.16:  Western blot analysis of CSC-associated transcription factor expression by 
NTERA2/D1 (A) and EMT-associated transcription factors by NIH 3T3 (B).  Proteins were 
stained overnight using antibodies which were used in accordance with the manufacturer’s 
instructions.  (n=2) Representative images.   
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 Table 5.3 Summarising the results of the IF and WB screening of the OPCT-1 clones with the 
EMT-associated markers 
Note:  - (+) denotes that vimentin positive cells were very rarely observed in clone P5B3 
                                                                                                                                                         
E-Cadherin, vimentin, fibronectin and N-Cadherin staining patterns among the clones were 
mostly consistent between IF and WB.   However, the results obtained for Snail, Slug and 
Twist were inconsistent between the two methods.                                                                                                                                           
                                                                                                                                                                          
Table 5.4 Summarising the results of the IF and WB screening of the OPCT-1 clones with the CSC-
associated markers 
 
 
 
 
 
 
                                                                                                                                                    
The CD44 and Sox2 staining patterns observed among the clones were mostly consistent 
between IF and WB.  However, CD44 was not detected in clone P5B3 by Western blotting 
but the immunofluorescence screening demonstrated clear expression of this protein by 
this clone.  The results obtained for the transcription factors Nanog and Oct4 were 
inconsistent between the two methods in that neither of these proteins were detected in the 
clones by IF however both were detected in the clones by WB.   
 
Protein 
E-cad CK B-cat Vim Fibro N-cad Snail Slug Twist 
Cells IF WB IF WB IF WB IF WB IF WB IF WB IF WB IF WB IF WB 
P5B3 + + + n/a + n/a - (+) - - + - + + - + - - + 
P6D4 + + + n/a + n/a + - + + + + + - + - - + 
P5F3 + + + n/a + n/a + + + + + + + - + - - + 
P2B9 + + + n/a + n/a + + + + + + + - + - - + 
P4B6 + + + n/a + n/a + + + + + + + - + - - + 
 
Protein 
CD44 Intα2β1 Nanog Oct4 Sox2 
Cells IF WB IF WB IF WB IF WB IF WB 
P5B3 + - + n/a - + - + - - 
P6D4 + + - n/a - + - + - - 
P5F3 + + + n/a - + - + - - 
P2B9 + + + n/a - + - + - - 
P4B6 + + + n/a - + - + - - 
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5.3 Discussion 
This work aimed to verify that clonally derived populations of OPCT-1 cells were capable 
of generating mesenchymal-like cells via EMT, quantify the percentage of vimentin-
positive cells in each of the five OPCT-1 clones and profile the clones with respect to the 
expression of selected EMT and CSC-associated markers. 
The re-cloning of the five OPCT-1 clones into fluorescence-compatible 96 well plates, 
followed by IF staining with E-Cadherin and vimentin antibodies, confirmed that clonally 
derived populations gave rise to mixed cell types, as evidenced by the expression of 
epithelial (E-Cadherin) and mesenchymal (vimentin) markers.  In fact, this assay revealed 
that all five of the OPCT-1 clones were capable of generating mixed populations, with 
regards to E-Cadherin and vimentin expression, from the single cell level.  The location of 
the vimentin-positive cells, predominantly on the edge of the colonies, indicated that these 
cells had activated the EMT programme.  Furthermore, the observation of isolated 
vimentin-positive cells, identified in colonies derived from the P4B6 clone, which 
appeared to have migrated away from the original colony, provided an insight into the 
phenomena observed in patients with metastatic disease, whereby cells at the tumour-host 
interface (invasive front) begin to break away, invade and migrate to distant sites (Thiery 
et al., 2009).   
With the exception of clone P4B6, the re-cloned OPCT-1 clones also formed colonies 
which exclusively expressed E-Cadherin.  Previous studies have demonstrated that clonally 
derived populations, isolated from melanoma and breast cancer cell lines differed 
significantly with regards to their metastatic capabilities in vivo and this may be due to 
differences in the EMT-status of the cells (Kozlowski et al., 1984; Uruid et al., 2002).  The 
re-cloning experiment conducted in this study was particularly interesting, as it indicated 
that even within a clonally derived population, cells differed in their ability to activate the 
EMT programme.  This variation was likely to be governed by the epigenetic nature of the 
changes which activate EMT in many cases (Brabletz, 2012).   
Remarkably, clone P4B6 formed clonal populations which were 100% vimentin-positive/                  
E-Cadherin-negative and, unlike the E-Cadherin-expressing colonies, these colonies 
consisted of loose clusters of fibroblastoid cells.  Furthermore, these colonies comprised 
fewer cells than those with E-Cadherin expression.  This observation revealed that the 
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cloned, EMT-derived, mesenchymal-like carcinoma cells were capable of proliferating.  
However, the comparatively smaller cell numbers present in the single vimentin-positive 
colonies provided evidence in support of the hypothesis that epithelial carcinoma cells are 
more proliferative than their EMT-derived, mesenchymal-like counterparts.  Hence, 
following migration and extravasation, metastatic (mesenchymal-like) cancer cells are 
believed to re-differentiate into epithelial cells via mesenchymal to epithelial transition 
(MET), in order to form macrometastases (Kalluri and Weinberg, 2009; Foroni et al., 
2012). 
In order to investigate the MET programme, a clonally derived population of vimentin-
positive/E-Cadherin-negative cells was established from clone P4B6.  Preliminary 
observations revealed that this clone appeared to proliferate at a slower rate than the other 
OPCT-1 clones in culture (data not shown) however, further in vitro and in vivo studies 
will be conducted to address whether or not these cells are capable of differentiating into 
epithelial cells.  This work will be of great interest because, although activation of MET by 
mesenchymal-like carcinoma cells has been hypothesised to be necessary for 
macrometastasis formation, the role of MET in cancer progression remains to be 
conclusively demonstrated (Brabletz, 2012). 
The re-cloning assays revealed that clones P6D4, the second least vimentin-positive clone,  
and P4B6, the most vimentin-positive clone, possessed the joint-highest cloning 
efficiencies and clone P2B9, the second most vimentin-positive clone, demonstrated the 
lowest cloning efficiency.  However, due to large variation in the number of colonies 
formed by clone P5F3 across the three repeats, these results were not statistically 
significant overall.  Nonetheless, the data obtained demonstrated that cloning efficiency 
did not correlate with vimentin-positivity. 
Using flow cytometry, this study determined that the order of vimentin-positivity among 
the clones was in keeping with what was previously observed by IF.  Furthermore, the 
variation in vimentin-positivity across the clones was shown to be statistically significant.   
The results obtained from the IF and WB analyses were mostly as expected in that clone 
P5B3, the least vimentin-positive clone, had  an epithelial signature with low expression of 
the mesenchymal markers (vimentin), fibronectin and N-Cadherin and high expression of 
the epithelial markers E-Cadherin and cytokeratins and clone P4B6, the most vimentin-
positive clone, not only demonstrated the highest levels of the mesenchymal markers, 
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(vimentin) and N-Cadherin, but also had the lowest expression of the epithelial marker, E-
Cadherin.  However, clone P4B6 also expressed high levels of epithelial cytokeratins, thus, 
this clone exhibited a mixed signature with the highest proportion of mesenchymal-like 
cells of the clones.   
With regards to clone P4B6, the IF and WB screenings appeared to demonstrate that cells 
with an EMT signature also demonstrated a CSC signature.  This is because, as well as 
exhibiting high mesenchymal-marker expression, this clone also expressed the highest 
levels of the CSC-associated proteins CD44 and Oct4.  Oct4 expression in cancer cells is 
frequently implied to mark putative cancer stem cells (Jeter et al., 2009).  Furthermore, 
Oct4 has also been demonstrated to be an important mediator of migration and invasion 
(Chang et al., 2008).  However, the expression of Oct4 by P4B6 was not enough to 
confirm that this clone possessed stem-like attributes and this hypothesis required 
verification in future sphere-forming, clonogenic, proliferation, tumourigenesis and 
invasion assays (Chapter 6).  Interestingly, clone P4B6 demonstrated low levels of the 
stem cell-associated transcription factors Nanog and Sox2, which was inconsistent with 
findings by others that have demonstrated the co-expression of Nanog, Oct4 and Sox2 in 
glioma cancer stem cells (Guo et al., 2011).  
Surprisingly, clone P6D4 expressed the highest levels of Nanog, but not the highest levels 
of Oct4 and Sox2 (detected by Western blotting).  Furthermore, the prostate cancer stem 
cell marker, integrin α2β1 was not detected in this clone by IF.  Recently, Jeter et al., 2011, 
revealed that Nanog promoted cancer stem cell characteristics, therapeutic resistance, 
CD133 and ALDH upregulation and prostate cancer resistance to androgen deprivation.   
Therefore, despite comprising very few vimentin-positive cells and failing to express one 
of the putative prostate cancer stem cell markers, this clone may be enriched for cancer 
stem cells hence, may be expected exhibit an aggressive stem-like phenotype.  This 
concept is re-visited in more detail in Chapter 6 where the potential stem-like properties of 
the OPCT-1 clones are thoroughly investigated. 
The second most vimentin-positive clone, P2B9, did not demonstrate the same staining 
intensities as clone P4B6 in that it expressed higher levels of E-Cadherin and fibronectin 
and lower levels of CD44 and Oct4.  Therefore, despite expressing the second highest 
levels of vimentin, this clone did not appear to exhibit a stem-like signature.   
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As anticipated, clone P5F3 represented an intermediate phenotype with neither the highest 
nor lowest expression of any of the proteins examined. 
Several inconsistencies were observed between the IF and WB results.  The CD44 and 
Sox2 staining patterns observed among the clones were mostly consistent between IF and 
WB, however, CD44 expression was not detected in clone P5B3 by Western blotting 
although the IF screening demonstrated clear expression of the CD44 protein by this clone.  
In addition, the results obtained for the transcription factors Nanog, Oct4 and Twist were 
inconsistent between the two methods in that none of these proteins were detected in the 
clones by IF however, all three were detected in the clones by WB.  Conversely, Snail and 
Slug expression were detected by IF but not Western blotting.  
The inconsistencies observed between the IF and WB results were likely to have occurred 
due to differences in the procedures.  Immunofluorescence detects proteins in their native 
form, whereas Western blotting involves a denaturation step which may interfere with 
antibody binding by damaging the epitopes, thereby rendering the antibody unable to bind 
to the protein during Western blotting.  Conversely, protein denaturation may assist with 
antibody binding by exposing epitopes which may otherwise be concealed, accounting for 
positive WB results but negative IF results.  In addition, the transcription factors examined 
in this study are known to be transiently expressed in only a small population of cells 
hence, Western blotting may not be sufficiently sensitive for the detection of these 
proteins.  The inability to detect Snail by WB may be accounted for by the fact that this 
protein is extremely unstable, with a half-life of only 20-30 minutes in most cancer cell 
lines (Garcia de Herreros and Baulida, 2012).   
Interestingly, Maitland et al., 2011, reported that they had observed high levels of vimentin 
in their primary cultures of high-grade prostate cancer cells.  However, the present study 
provided evidence to support the notion that the prostate cancer stem cells reported by 
Collins et al., 2005, and EMT-derived cancer stem-like cells are distinct.  This is because 
the EMT-derived vimentin-positive, fibroblastoid cells in the parental OPCT-1 cell line did 
not express the putative PCSC marker integrin α2β1.  Therefore, perhaps integrin α2β1-
negativity could prove useful for the identification of EMT-derived mesenchymal cells in 
clinical specimens.  However, one previous study contradicted this finding as it 
demonstrated that an increase in integrin α2β1 coincided with collagen/FGF-1 induced 
EMT (Valles et al., 1996).  Therefore, an extensive investigation into the expression of 
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integrin α2β1 in EMT-derived populations would prove to be an interesting avenue of 
research. 
In summary, the five OPCT-1 clones of interest proved to be capable of generating 
epithelial and mesenchymal populations from a single cell, thus, showed evidence of EMT.  
Moreover, flow cytometric analysis, which determined the percentage of vimentin-positive 
cells present in each clone, corresponded with previous observations by 
immunofluorescence.  The five OPCT-1 clones demonstrated distinct phenotypes with 
regards to the expression of several EMT and CSC-associated proteins.  Therefore, these 
clones provided a suitable model for investigating the properties of cells with and without 
an EMT signature.  The present work revealed that an EMT-signature did not always 
correspond with a stem-like profile (clone P2B9) and conversely, vimentin-low cells may 
demonstrate expression of stem cell-associated markers (clone P6D4).  However, these 
findings must be supported with in vitro and in vivo cancer stem-cell characterisation and 
tumourigenesis assays.   Therefore, further interrogation of the five OPCT-1 clones is 
required in order to conclusively ascertain or disprove a link between epithelial to 
mesenchymal transition and cancer stem-like cells in human prostate cancer.   
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Chapter 6: 
Functional Assessment of the OPCT-1 Clones 
– is there a Link between Epithelial to 
Mesenchymal Transition and an Aggressive 
Cancer Stem Cell Phenotype in Human Prostate 
Cancer? 
 
6.1 Introduction 
Having profiled the OPCT-1 clones with regards to the expression of several EMT and 
CSC-associated markers (Chapter 5), it was then necessary to examine their biological 
characteristics and determine whether the expression of EMT-associated markers 
corresponded with properties attributed to an aggressive, migratory, cancer stem cell-like 
phenotype. 
As previously described (Section 1.56), in order to satisfy the conditions of a cancer stem 
cell, several criteria must be tested, exploiting the specific growth characteristics unique to 
cancer stem cells.  Therefore, to investigate a possible correlation between epithelial to 
mesenchymal transition and the acquisition of stem cell traits, the five OPCT-1 clones 
were subjected to several stem cell assays.  Furthermore, since cancer stem cells and EMT-
derived cells have both been implicated in metastasis, the invasive and migratory capacity 
of the five clones was also investigated.  In addition, to ascertain a possible relationship 
between EMT and drug resistance, the drug sensitivity of the clones was examined.  The 
quintessential property of cancer stem cells is their tumour-initiating capacity.  Therefore, 
to address whether cells with an EMT-signature possess enhanced tumourigenic 
capabilities, in vivo tumourigenesis assays were also conducted. 
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6.2 Results 
6.2.1 Proliferation Assays 
Among other properties, cancer stem cells have been shown to possess a marked capacity 
for proliferation (Clevers, 2011).  In order to ascertain a possible link between an EMT 
phenotype and proliferation, the proliferation of the OPCT-1 clones compared with 
parental OPCT-1 was investigated using three independent proliferation assays, the 
ViaLight
®
Plus assay, the Thymidine incorporation assay and the MTT assay (Figure 6.1). 
  
 
 
 
 
 
 
                                                                                                                                             
The OPCT-1 clones and parental OPCT-1 exhibited significant differences in proliferation 
as evidenced by three separate assays, statistically analysed using a non-parametric, 
Friedman ANOVA (p < 0.0001 for all assays).  Despite variation in the methods of 
measuring proliferation, the data obtained from the ViaLight® Plus (A) and Thymidine (B) 
assays were similar. These two assays clearly demonstrated that clone P4B6 was the most 
proliferative and clones P2B9 and P5B3 were the least proliferative.  Furthermore, the 
results obtained from The ViaLight® Plus (A) and Thymidine (B) assays corresponded 
with the degree of confluency microscopically observed during cell culture, in that clone 
P4B6 was consistently the first clone to reach full confluence and clones P5B3 and P2B9 
were consistently the last to reach full confluence.   
The results obtained using the MTT assay (C) were the least consistent with what was 
observed microscopically during cell culture as this assay showed little variation between 
the cells with the exception of clone P4B6.  As such, this assay was not utilised in further 
Figure 6.1:  ViaLight® Plus (p < 0.0001, Friedman statistic < 38.27) (A), Thymidine (p < 0.0001, Friedman 
statistic < 51)  (B) and MTT Proliferation (p < 0.0001, Friedman statistic < 47.62) (C) assays conducted on 
clones P5B3, P6D4, P5F3, P2B9, P4B6 and parental OPCT-1 cells. (n=3)  
 
A B C 
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studies. Although the results to this assay were highly significant when analysed using a 
non-parametric, Friedman ANOVA, this analysis was likely to have been influenced by the 
large number of technical replicates as well as the large difference between clone P4B6 
and the rest of the cells.   
6.2.2 Investigation of Drug Resistance 
Drug resistance is a property attributed to cancer stem cells and recent studies have shown 
that mesenchymal-like cancer cells, generated via EMT, can demonstrate resistance to 
chemotherapeutic agents (Huang et al., 2006; Singh and Settleman, 2010; Wang et al., 
2010).  Therefore, the chemotherapeutic sensitivity of the five OPCT-1 clones was 
investigated.   
Docetaxel therapy is the “standard of care” for patients with metastatic, castrate-resistant 
prostate cancer (Bracarda et al., 2011).  Therefore, this drug was selected for studies with 
the OPCT-1 clones.  Prior to conducting drug assays on the clones, it was necessary to 
determine a suitable drug dose to apply.  This was achieved by incubating parental OPCT-
1 cells with a wide range of docetaxel concentrations in order to determine a suitable 
range, followed by dose-response ViaLight® Plus and Thymidine proliferation assays 
which generated a curve from which the IC50 of parental OPCT-1 could be determined for 
each assay.  The IC50 is the half maximal inhibitory concentration of a substance and is a 
quantitative measure of how much of a substance is required to inhibit a biological process 
(in this case proliferation) by 50% (Cheng and Prusoff, 1973). 
The docetaxel IC50 doses of parental OPCT-1 were successfully calculated using two 
independent assays (Figure 6.2).  Using the ViaLight® Plus assay the IC50 of docetaxel on 
parental OPCT-1 was calculated as 11.15 nM.  The docetaxel IC50 value of  parental 
OPCT-1 determined using the Thymidine assay was approximately half the dose of the  
IC50 determined using ViaLight® Plus assay; 5.617 nM.  
Due to the unsatisfactory dose response curve obtained using the ViaLight
®
 Plus 
proliferation assay (Figure 6.2B), the Thymidine assay was selected for further drug 
assays.   
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Figure 6.2:  Dose response curve and IC50 determination of docetaxel on parental OPCT-1 using the 
ViaLight® Plus (A) and Thymidine (B) proliferation assays.  IC50 values were calculated using 
GraphPad Prism software. (n=3)  
A 
B 
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After determining the docetaxel IC50 doses for parental OPCT-1, drug assays on the five 
OPCT-1 clones were conducted.  The OPCT-1 clones and parental OPCT-1 were subjected 
to treatment with the determined IC50 dose (5.5 nM), double the IC50 dose (11 nM) and 
media alone, prior to assessing proliferation using the Thymidine assay (Figure 6.3). 
Significant differences in the proliferation rates of the clones, in response to different 
docetaxel treatments, were observed (p < 0.014715, F < 2.318) (Figure 6.3).  Statistical 
analysis was performed by means of a Factorial ANOVA using STATISTICA software.  
The mean inhibitory effect of each drug dose on proliferation was calculated as a 
percentage and is presented in Table 6.1.   
This assay revealed that clone P6D4 was the most resistant, only 10% inhibition with the 
IC50 dose and 14% inhibition with double the IC50 dose, and clone P5B3 was the most 
sensitive to treatment with docetaxel, 41% inhibition with the IC50 dose and 60% 
inhibition with double the IC50 dose.  Clones P6D4, P5F3 and P4B6 were more resistant 
to docetaxel treatment than parental OPCT-1 and clones P5B3 and P2B9 were more 
sensitive to this drug than parental OPCT-1.   
Therefore, according to the results obtained, drug resistance did not necessarily correspond 
with vimentin-positivity. 
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Table 6.1 Displaying the mean percentages of docetaxel inhibition on the proliferation of the 
five OPCT-1 clones and parental OPCT-1. 
Figure 6.3: Demonstrating the proliferation of the OPCT-1 clones and parental OPCT-1 treated with 
control media, the docetaxel IC50 dose (5.5 nM) and double the docetaxel IC50 dose (11 nM) of 
parental OPCT-1. Assessed using the Thymidine proliferation assay. Data were analysed by means of a 
Factorial ANOVA using STATSTICA software (p < 0.014715, F < 2.318). (n=5) 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
  
 
 
 
 
 
 
 
 
 Percentage Inhibition of Proliferation 
Cells 5.5 nM 11 nM 
 
Parental 
 
37% 
 
55% 
P5B3 41% 60% 
P6D4 10% 14% 
P5F3 9% 40% 
P2B9 35% 58% 
P4B6 27% 31% 
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6.2.3 Assessment of Clonogenicity, Sphere-formation and Self-renewal 
6.2.3.1 Clonogenic Assay 
Cancer stem cells demonstrate increased clonogenic capacity compared with other cancer 
cells.  Therefore, clonogenic assays have been used to identify populations of cancer cells 
with stem-like characteristics (Kong et al., 2010).  During this study, the clonogenicity of 
the five OPCT-1 clones and parental OPCT-1 cells was determined using an assay 
whereby cells were seeded at low (clonal) density and allowed to grow prior to counting 
the number of colonies.  The cells which formed the largest number of colonies were 
deemed the most clonogenic.   
 
 
 
 
 
 
 
 
  
Highly significant differences were observed in the clonogenic abilities of the clones, 
statistically analysed using a non-parametric, Friedman ANOVA (p < 0.0003, Friedman 
statistic < 23.66) (Figure 6.4).  Clone P4B6 and clone P5B3 possessed the highest and 
lowest clonogenicities, respectively.  This assay confirmed that the two most vimentin-
positive clones, clone P4B6 and clone P2B9, were also the most clonogenic.  Hence, this 
assay appeared to associate EMT with increased clonogenicity.  However, the colonies 
formed by these clones were very distinct as clone P2B9 formed small colonies with few 
cells and clone P4B6 formed large, diverse colonies of many cells.  Overall, clonogenicity 
did not increase with vimentin positivity, in a stepwise manner. 
Figure 6.4:  Demonstrating the results of the Clonogenic Assay performed on clones P5B3, P6D4, 
P5F3, P2B9, P4B6 and parental OPCT-1 and example images of the colonies which grew in the 6 
well plates. Cells were plated at clonal density, cultured for a period of 10 days, fixed with ethanol 
and stained with crystal violet prior to enumerating the colonies (p < 0.0003, Friedman statistic < 
23.66). (n=3) 
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6.2.3.2 Sphere-forming Assay 
Sphere-forming, or anchorage independent growth, assays have been exploited in several 
studies as a means to identify cancer cells with stem-like properties (Collins et al., 2005; 
Mani et al., 2008; Kong et al., 2010; Clevers, 2011; Pastrana et al., 2011).  These assays 
are believed to assess stemness as anchorage-independent growth and formation of spheres 
is a quality which is attributed only to stem and progenitor cells, the latter of which may be 
excluded from the counts based on size (Pastrana et al., 2011).  In the present study, the 
ability of the clones and parental OPCT-1 to form spheres in non-adherent conditions was 
assessed in order to ascertain whether there was an association between sphere-forming 
ability and EMT.  
 
This assay revealed that all five of the OPCT-1 clones were capable of anchorage 
independent growth (Figure 6.5).  Furthermore, the differences observed in the sphere-
forming abilities of the clones were highly statistically significant, statistically analysed 
using a non-parametric, Friedman ANOVA (p < 0.0001, Friedman statistic < 41.57).  
Clone P4B6 and clone P2B9 were the most and least sphere-forming, respectively.  
Therefore, although the most sphere-forming clone was the most vimentin-positive (P4B6), 
the second most vimentin-positive clone was the least capable of sphere-formation in non-
adherent conditions (P2B9).  Moreover, clones P5B3 and P6D4 formed more spheres than 
the more vimentin-positive clones P5F3 and P2B9. Therefore, EMT did not necessarily 
bestow enhanced sphere-forming ability.  Parental OPCT-1 formed a surprisingly low 
number of spheres considering that this cell line comprises a mixed population of cells.   
Clones P2B9 and P5F3 were less capable of forming spheres than parental OPCT-1 hence, 
these clones appeared to possess a smaller cancer stem/progenitor cell population than the 
parental cell line from which they were derived.  Clones P5B3, P6D4 and P4B6 however, 
formed more spheres than parental OPCT-1 therefore, were likely to be more enriched with 
CSC/progenitor cells.   
In order to investigate the expression of E-Cadherin and vimentin in the spheres formed by 
the OPCT-1 clones and parental OPCT-1, the spheres were stained by immunofluorescence 
(Figure 6.6).  Vimentin expression in the spheres was not only of interest with regards to 
the occurrence of EMT but also because vimentin is known to be expressed by primitive 
(i.e. stem/progenitor) cells (Langa et al., 2000) hence in this case, vimentin expression may 
have also identified CSCs. 
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Figure 6.5:  Demonstrating the results of the Sphere-forming Assay performed on clones P5B3, P6D4, 
P5F3, P2B9, P4B6 and parental OPCT-1 and example images of the spheres.  Cells were plated at clonal 
density in normal media, in ultra-low adherent 24-wel plates and cultured over a period of 12 days prior 
to enumerating the spheres.(p < 0.0001, Friedman statistic < 41.57).  (n=3).  Representative images.  
Image magnification at x10 and x20. 
 
x20 x40 x10 x20 
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Figure 6.6 A:  Demonstrating the expression of E-Cadherin and vimentin in spheres formed by clones 
P5B3, P6D4, P5F3,P2B9, P4B6 and parental OPCT-1.   Cells were plated at clonal density in normal 
media, in ultra-low adherent 24-well plates and cultured over a period of 12 days prior to conducting 
immunofluorescence with a murine monoclonal anti-E-Cadherin and a rabbit polyclonal anti-vimentin 
antibody.  Secondary antibody and nuclear staining were achieved as previously described in Figure 
5.1. (n=2) Representative images.  Image magnification at x40. 
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Vimentin-positive cells were observed in the spheres generated by every cell type (Figure 
6.6 A).  Furthermore, the distribution of the vimentin-positive cells was non-uniform as 
they were present in both the centre and on the surface of the spheres for all of the cell 
types.  It should be noted that the representative images do not necessarily depict the 
diversity of the localisation of vimentin-positive cells for each cell type.   
Surprisingly, clone P5B3 formed spheres with a relatively high number of vimentin-
positive cells.  This was unexpected as this clone possessed the smallest population of 
vimentin-positive cells in previous assays.  However, the predominantly central location of 
the vimentin-positive cells present in the spheres of clone P5B3 may imply that rather than 
cells which had undergone EMT, these vimentin-positive cells may have represented 
primitive cells.  This is supported by previous IF studies with the clones in 2D culture 
which demonstrated that EMT occurred primarily on the periphery of the colonies (See 
Chapter 5 Figure 5.1).  However, further experiments would undoubtedly be required in 
order to support this hypothesis. 
Consistent with what was observed in 2D culture, clone P4B6 formed spheres with the 
largest population of vimentin-positive cells.  Spheres formed by clone P6D4 demonstrated 
the highest levels of E-Cadherin and the lowest levels of vimentin.  Interestingly, E-
Cadherin expression was low on the perimeter of most of the spheres. 
Figure 6.6 B illustrates that minimal background staining was observed with the isotype 
control antibodies and that such staining was distinct from the staining observed with the 
test antibodies. 
 
Figure 6.6 B:  Isotype control staining of spheres formed by parental OPCT-1.   Cells were plated as 
described in Figure 5.28 A and stained with rabbit and murine isotype control antibodies.  Secondary 
antibody and nuclear staining were achieved as previously described in Figure 5.1. (n=2) 
Representative images.  Image magnification at x40. 
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6.2.3.3 Self-renewal Assay 
The self-renewal assay is an extension of the sphere forming assay which assesses self-
renewal based on the ability of cells from disaggregated spheres to re-form spheres 
following re-seeding at clonal density in non-adherent conditions.  Since a property of stem 
cells (and cancer stem cells) is their ability to self-renew infinitely, the spheres formed by 
stem cells and CSCs should be capable of re-forming following countless passages in vitro.  
This assay is believed to distinguish between spheres formed by progenitor cells and 
spheres formed by stem cells because progenitor cells lack self-renewal capacity, a 
property unique to stem cells (Pastrana et al., 2011).  
This assay was conducted on the OPCT-1 clones and parental OPCT-1 in order to ascertain 
whether any of these cells contained a population of self-renewing cells and whether self-
renewal corresponded with vimentin-positivity i.e. EMT.   
Highly statistically significant differences in primary (p < 0.0001, Kruskal-Wallis statistic 
< 54.60) and secondary (p < 0.0001, Kruskal-Wallis statistic < 37.74) sphere-formation 
were observed across the clones.  As can be observed, the patterns of primary and 
secondary sphere-formation were distinct (Figure 6.7).  Surprisingly, clone P4B6, which 
formed the most primary spheres, did not form the largest number of secondary spheres.  
Furthermore, on average, clone P5B3 formed the most secondary spheres of the clones, 
however, was not the most capable of primary sphere-formation.  Interestingly, although 
not the most proficient at primary sphere-formation, Parental OPCT-1 was, on average, the 
most capable of forming secondary spheres.  The clone with the most consistent sphere-
forming abilities across the assays was clone P2B9, which formed the least primary 
spheres and appeared incapable of secondary sphere-formation, hence, self-renewal. 
The results of this assay implied that self-renewal ability did not correlate with vimentin 
positivity; on the contrary, with the exception of clone P4B6, secondary sphere-forming 
ability (self-renewal) of the clones was almost inversely proportional to vimentin-
positivity.  The cells most capable of self-renewal were parental OPCT-1 and clone P5B3, 
suggesting that clone P5B3 potentially contains the largest population of cancer stem cells.  
However, this hypothesis requires further confirmation.   
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Figure 6.7:  Demonstrating the results to the Self-renewal Assay performed on clones P5B3, P6D4, 
P5F3, P2B9, P4B6 and parental OPCT-1 and example images of primary and secondary spheres.  Cells 
were plated at clonal density in normal media, in ultra-low adherent 24-wel plates and cultured over a 
period of 12 days prior to enumeration, disaggregation and re-plating at clonal density for 12 days 
prior to counting secondary spheres. The red cross demonstrates that clone P2B9 was incapable of 
secondary sphere-formation. (n=3) Representative images. Image magnification at x10.  Primary 
sphere-formation (p < 0.0001, Kruskal-Wallis statistic < 54.60).  Secondary sphere-formation (p < 
0.0001, Kruskal-Wallis statistic < 37.74). 
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6.2.4 Evaluation of Aldehyde Dehydrogenase 1 Activity 
 
Aldehyde dehydrogenase 1 (ALDH1) is an enzyme involved in stem cell survival and early 
differentiation and as such, has been exploited to identify adult tissue stem cells.  Recently, 
ALDH1 activity has also been utilised to identify cancer stem cells and several studies 
have associated ALDH1
hi 
populations with increased migration, drug resistance and 
tumourigenicity (Chute et al., 2006; Ginestier et al., 2007; Charafe-Jauffret et al., 2009; 
Douville et al., 2009; Jiang et al., 2009; Tanei et al., 2009).  In order to investigate a 
possible relationship between cancer stem cells and EMT, the ALDH1 activity of the 
clones and parental OPCT-1 was assessed using a commercially available, flow cytometry-
based assay.                                                                                                                                                           
The results of the Aldefluor
TM
 assay with example flow cytometric data of the clone with 
the smallest ALDH1
hi
 population, P5B3, and the clone with the largest ALDH1
hi
 
population, P6D4, are shown in Figure 6.8.  The observed differences in the percentage of 
ALDH1
hi 
cells among the clones were statistically significant, as determined using a non-
parametric, Kruskal-Wallis ANOVA (p < 0.0244, Kruskal-Wallis statistic < 12.89) (Figure 
6.8).  The flow cytometric data shown, illustrate that ALDH1
hi
 cells presented as a shift in 
the population rather than a distinct population of cells.  This shift is typical of cells from 
solid malignancies and is consistent with the results observed with the recommended 
control cell line, SK-BR-3 (data not shown).  This assay elucidated that ALDH1
hi
 cells 
were present in all of the clones and parental OPCT-1 cells. 
The mean percentages of ALDH1
hi 
cells present in each cell line are shown in Table 6.2.  
Almost half of the cells present in clone P6D4, the second least vimentin-positive clone, 
expressed high levels of the enzyme aldehyde dehydrogenase 1.  Clone P4B6, the most 
vimentin-positive clone, possessed the second highest population of ALDH1
hi 
cells 
however, clone P2B9, the second most vimentin-positive clone, had the second lowest 
population of ALDH1
hi
 cells.  Clone P5B3, which expressed the lowest levels of vimentin, 
also had the smallest population of ALDH1
hi
 cells.   
Overall, this assay failed to demonstrate a direct correlation between vimentin-positivity 
and ALDH1 activity.  Once again, these results reveal the importance of examining a range 
of EMT phenotypes when investigating a relationship between epithelial to mesenchymal 
transition and cancer stem cells.   
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Table 6.2  Displaying the average percentage of ALDH1
hi
 cells present in parental OPCT-1 and 
five clones derived from this cell line. 
 
 
 
 
 
 
 
Cells 
Mean % 
ALDH1
hi
 cells 
 
Parental 
 
37.31% 
P5B3 13.65% 
P6D4 45.73% 
P5F3 35.54% 
P2B9 34.18% 
P4B6 40.38% 
Figure 6.8:  Demonstrating the results of the Aldefluor
TM
 Assay with sample flow cytometric data from 
which the percentage of ALDH1
hi
 cells present in each of the clones and parental OPCT-1 was determined.  
Flow cytometry was performed using control cells treated with DEAB prior to addition of the Aldefluor
TM
 
reagent, to gate the cells, and test cells were treated with Aldefluor
TM
 reagent alone.  Sample data are  
shown for the clones with the smallest; P5B3 and largest; P6D4 population of ALDH1
hi
 cells. (n=4). (p < 
0.0244, Kruskal-Wallis statistic < 12.89).
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6.2.5 Investigation of Invasive and Migratory Potential 
6.2.5.1  Matrigel
TM
 Invasion Assay 
Nowadays, it is widely accepted that cancer cells induce the latent EMT programme in 
order to break away from the primary tumour, invade surrounding tissues and metastasise 
to distant sites (Acloque et al., 2009; Kalluri and Weinberg, 2009; Polyak and Weinberg, 
2009; Thiery et al., 2009; Scheel and Weinberg, 2012).  Therefore, EMT is largely 
implicated in metastasis.  However, it is also accepted that cells must possess necessary 
self-renewal capabilities in order to colonise at distant sites.  As such, cancer stem cells are 
also implicated in metastasis (Sarkar et al., 2009; Sapieri and Fodde, 2012; Scheel and 
Weinberg, 2012).  In order to confirm a link between EMT and invasiveness, Matrigel
TM 
invasion assays were conducted on the OPCT-1 clones and parental OPCT-1 and the 
percentage invasion was calculated for each (Figure 6.9; Table 6.3).   
The OPCT-1 clones and parental OPCT-1 exhibited significant differences in invasiveness 
according to the Matrigel
TM 
 invasion assay, statistically analysed using a non-parametric 
Friedman ANOVA (p < 0.0024, Friedman statistic < 18.49). 
As anticipated, the most vimentin-positive clone (P4B6) was clearly the most invasive, 
with a median percentage invasion of 17.5.  (Figure 6.9; Table 6.3).  However, the second 
most vimentin-positive clone (P2B9) appeared to be the least invasive clone, with a median 
of 4.5%  invasion.  Therefore, there was no direct correlation between vimentin-positivity 
and invasiveness.   
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Figure 6.9:  Demonstrating the results of the Matrigel
TM 
Invasion Assay.  Cells were plated into BD 
Biocoat
TM
 control or Matrigel
TM
 inserts and incubated overnight prior to removing non-invading 
cells, fixing invading cells, PI staining and enumerating the invading cells using a C.T.L ELISPOT 
plate reader.  Percentage invasion  was determined by dividing the number of cells on the 
Matrigel
TM 
inserts by the number on the control inserts and multiplying by 100. Data are 
represented as median ± quartile range.  (p < 0.0024, Friedman statistic < 18.49). (n=3). 
 
 
 
 
 
 
 
 
 
Table 6.3  The average percentage invasion of parental OPCT-1 and five clones derived from this 
cell line. 
 
 
 
 
 
 
 
 
 
Cells 
 
Median % 
Invasion 
 
 
Parental 
 
3.5% 
P5B3 6% 
P6D4 6.5% 
P5F3 5% 
P2B9 4.5% 
P4B6 17.5% 
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6.2.5.2  In vitro Scratch Assay 
The in vitro scratch assay is a simple method that is widely used to measure cell migration 
(Liang et al., 2007).  The method usually involves creating a “scratch” in a cell monolayer, 
capturing images of the closure of the scratch and quantifying the migration rate of the 
cells.  However, in this study the nature of the cells which migrated into the scratch was of 
more interest than the rate at which they migrated.  Therefore, this assay was modified in 
order to immunofluorescently stain the cells prior to complete closure of the scratch.  To 
that end, the assay was conducted in fluorescence compatible 96 well-plates in which IF 
could be performed immediately after the assay (12 hours after the scratch was introduced) 
with antibodies directed against vimentin and E-Cadherin. 
Figure 6.10 clearly demonstrates that the vimentin-positive cells in clones P2B9 and P4B6 
migrated into the scratch.  Furthermore, the vimentin-negative cells on the edge of the 
scratch of clone P4B6 were also negative for E-Cadherin.  Downregulation of E-Cadherin 
is an early event in EMT therefore, the vimentin-negative cells in clone P4B6 may have 
been activating the EMT programme.  This is supported by the presence of vimentin-low 
cells which were presumably in the process of transitioning (indicated by orange arrows).  
Vimentin positive cells were not observed in or along the scratches of clones P5B3, P6D4, 
P5F3 and parental OPCT-1 therefore, it appeared that only the EMT-derived cells in clones 
P2B9 and P4B6 possessed enhanced migratory capacity. 
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Figure 6.10:  Demonstrating the results of the modified in vitro Scratch Assay with dual 
immunofluorescent staining of clones  P5B3, P6D4, P5F3, P2B9, P4B6 and parental OPCT-1 stained 
with E-Cadherin (red) and vimentin (green), conducted  in  fluorescence-compatible 96 well plates as 
described in Figure 5.1. (n=3).  Representative images.  Image magnification at x20. Orange arrows 
demonstrate P4B6 cells with low vimentin-expression which may have been in the process of 
transitioning via EMT. 
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6.2.6 In vivo Assays  
6.2.6.1  Evaluation of in vivo Tumourigenesis 
Cancer stem cells are believed to be solely responsible for tumourigenesis, tumour 
differentiation, tumour maintenance and tumour progression (Moltzahn et al., 2008).  
Several groups have identified, isolated and injected CSCs into immunocompromised mice 
in order to assess their tumourigenicity and differentiation potential compared with CSC-
depleted populations (Ailles and Weissman, 2007; Clevers, 2011).  In 2008, Mani et al., 
demonstrated that the induction of an EMT in breast cancer cells generated cells with the 
properties of stem cells (Mani et al., 2008).  In order to assess the correlation between 
EMT and enhanced tumourigenesis in a prostate cancer model, four OPCT-1 clones; P5B3, 
P6D4, P2B9 and P4B6 and parental OPCT-1 were injected with Matrigel
TM
, 
subcutaneously into the right flank of male, athymic nude mice and monitored over a 
period of 52 days.  On completion of the experiment (day 52) the mice were euthanised 
and the tumours were excised, snap-frozen in OCT, cryostat-sectioned and stained by 
immunofluorescence. 
Clear differences were observed in the tumourigenicities of the clones (Figure 6.11).  
Clone P4B6, the most vimentin-positive clone, formed tumours in every mouse which 
were significantly larger than those formed by parental OPCT-1 and this was the only 
clone to form tumours in all of the mice injected.  Furthermore, the tumours formed by 
clone P4B6 were at least twice the size of those formed by the other cells.  Clone P2B9, the 
second most vimentin-positive clone, however, only formed a tumour in one of five mice.  
Clone P5B3, the least vimentin-positive clone, did not form tumours in any of the six mice 
injected.  However, clone P6D4, the second least vimentin-positive clone, was the second 
most tumourigenic of the clones and formed tumours in three out of five mice.  Although 
only the most vimentin-positive clone (P4B6) was more tumourigenic than parental OPCT-
1, taken together, these results failed to directly demonstrate a correlation between EMT 
and tumourigenesis as the rank order of tumourigenicity did not increase with vimentin-
positivity (Figure 6.12).  Once again, this study demonstrated the importance of using a 
range of cells to investigate an association between EMT and aggressivity as clones P5B3 
and P4B6 supported the notion that EMT confers an aggressive phenotype however clones 
P6D4 and P2B9 contradicted this.   
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Figure 6.11:  Demonstrating the results of the in vivo Tumourigenesis Assay with images of 
excised tumours.  Clones P5B3, P6D4, P2B9, P4B6 and parental OPCT-1 were injected 
subcutaneously into the right flanks of male athymic nude mice, six mice per cell line.  Tumour 
growth was monitored using calliper measurements and mice were euthanised once one of the 
tumours reached 1cm in diameter.  Data are represented as the mean tumour area ± STDEV.  
A student T-test was used to determine statistical significance in the difference between clone 
P4B6 and parental OPCT-1, for the last three measurements.   (n=1).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                                                                                                                                               
  P5B3         P2B9        P6D4       Parental         P4B6  
   (0/6)          (1/5)          (3/5)           (5/6)             (4/4) 
 
 
 
Increase in tumourigenicity 
Figure 6.12:  Demonstrating the rank order of four OPCT-1 clones and parental OPCT-1 
with regards to tumourigenicity in male athymic nude mice.  
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6.2.6.2  Investigating the in vivo Phenotype 
In order to evaluate whether the clones had maintained the same proportions of vimentin-
positive cells in vivo and examine the distribution of the vimentin-positive cells within the 
tumours, the tumours were sectioned and stained by immunofluorescence.  However, due 
to the fact that vimentin is highly conserved and the antibody used also recognises murine 
vimentin, it was necessary to ensure that murine cells were not present in the tumours.  To 
that end, sections were dual-stained with anti-vimentin and anti-H2Kb (an antibody which 
recognises murine MHC class I) (Figure 6.13) prior to staining subsequent sections with 
vimentin and E-Cadherin (Figures 6.14 and 6.15).  Murine cells were not detected in any of 
the tumour-sections (Figure 6.13).  Therefore, it was possible to proceed with dual-staining 
the tumour sections with E-Cadherin and vimentin antibodies (Figures 6.14 and 6.15). 
Figure 6.14 demonstrates low-magnification images which provide an overview of the 
tumour sections stained with E-Cadherin and vimentin and isotype control antibodies.  
With regards to isotype staining, the level of background staining achieved with the isotype 
control antibodies was acceptable and distinct from the staining patterns achieved with the 
test antibodies.  This experiment revealed that the cells did not all maintain their 
phenotypes, with regards to E-Cadherin and vimentin positivity, in vivo.  This is because 
there were no vimentin-positive cells observed in the tumour section from clone P2B9, the 
population of vimentin-positive cells for clone P6D4 was far greater in vivo than in vitro 
and there were fewer vimentin-positive cells observed in clone P4B6 in vivo.  This figure 
reveals that clone P6D4 appeared to form glandular structures – some of which were 
surrounded by a layer of vimentin-positive cells.  The organised structure of these tumours 
was possibly indicative of a population of stem-like cells, capable of differentiating into 
distinct cell types.  The vimentin-positive cells present in the P4B6 tumours were 
predominantly localised close to the periphery of the tumour, as would be expected of cells 
activating EMT as a means to escape and metastasise.  The vimentin-positive cells in the 
tumours of parental OPCT-1 were also predominantly situated towards the periphery 
however there were also several scattered throughout.  
A closer view of the stained tissue sections is provided in Figure 6.15.  From this figure, it 
is evident that clone P6D4 formed gland-like structures with areas of high E-Cadherin 
positivity (red) as well as structures surrounded by vimentin-positive cells (green).  Even at 
high magnification, no vimentin-positive cells were observed in the tumour formed by 
216 
 
clone P2B9.  It is important to note that the “vacuoles” observed in the P2B9 tumour are 
likely to have been artefacts created during sectioning as this tumour was the smallest and 
most difficult to section.   Clone P4B6 and parental OPCT-1 formed tumours with tight 
cell-cell contact and fewer glandular structures than clone P6D4 although structures were 
also observed in these tumours.  Please refer to Appendix VI for isotype control images at 
x10, x20 and x40 magnification. 
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Figure 6.13:  Demonstrating the immunofluorescent staining of tumour sections derived 
from clones P5B3, P6D4, P2B9, P4B6 and parental OPCT-1 and murine kidney as a 
positive control for H2Kb expression.  Sections were labelled with murine monoclonal anti-
H2Kb and rabbit polyclonal anti-vimentin.  Secondary antibody staining was achieved 
using anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 568 antibodies. Nuclear 
staining was achieved as described in Figure 5.1. (n=2). Representative images. x20 
magnification. 
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Figure 6.14:  Demonstrating the immunofluorescent staining of tumour sections derived from clones 
P5B3, P6D4, P2B9, P4B6 and parental OPCT-1.  Sections were stained with anti-E-Cadherin (red) 
and anti-vimentin (green) (left) and murine and rabbit isotype control antibodies (right).  Secondary 
antibody and nuclear staining were achieved as described in Figure 5.1. (n=2). Representative 
images. x4 magnification. 
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Figure 6.15:  Demonstrating the immunofluorescent staining of tumour sections derived from clones P5B3, 
P6D4, P2B9, P4B6 and parental OPCT-1.  Sections were stained with anti-E-Cadherin (red) and anti-
vimentin (green). Secondary antibody and nuclear staining were achieved as described in Figure 5.1. 
(n=2). Representative images. x10, x20 and  x40 magnification. 
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6.2.7 Summary of Findings 
The findings from this study are summarised in Table 6.4.  The most vimentin positive 
clone (P4B6) exhibited the most aggressive phenotype overall as, with the exception of 
docetaxel resistance and self-renewal ability, this clone ranked highest in all assays.  The 
second most vimentin-positive clone (P2B9) however, demonstrated the least aggressive 
phenotype overall.  Clone P5B3, which was the least vimentin-positive, also demonstrated 
an overall non-aggressive phenotype.  The second least vimentin-positive clone (P6D4) 
however, was the second most aggressive overall and demonstrated higher docetaxel 
resistance than clone P4B6.  Clone P5F3 represented an intermediate phenotype, which 
was neither the least, nor the most positive in any of the assays conducted.     
 
Table 6.4 Summarising the results to the characterisation assays conducted on the   OPCT-1 clones 
 
Clone 
 
Proliferation 
Docetaxel 
Resistance 
Colony 
Formation 
Sphere  
Formation 
Self-
Renewal 
ALDH1 
Activity 
Matrigel
TM
 
Invasion 
Tumouri-
genesis 
P5B3 + + + ++ +++ + + - 
P6D4 ++ ++++ ++ ++ ++ ++++ + +++ 
P5F3 +++ +++ ++ + + +++ + n/a 
P2B9 + + +++ -/+ - +++ + + 
P4B6 ++++ +++ ++++ ++++ +++ ++++ ++++ ++++ 
 
Key: Negative V.low Low Moderate  High  V.high 
 - -/+ + ++ +++ ++++ 
 
 
Overall these results demonstrate the importance of using a range of phenotypes to 
investigate a relationship between EMT and an aggressive CSC phenotype as, when all of 
the clones are considered, it is evident that there is not always a direct relationship between 
the two phenomena.   
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6.3 Discussion 
Previous work led to the derivation of five OPCT-1 clones which were subsequently 
phenotyped according to their expression of EMT and CSC-associated markers (Chapters 4 
and 5).  The expression of vimentin differed significantly among these clones, therefore, as 
vimentin-positivity has been shown to correspond with EMT in carcinoma cells, the five 
OPCT-1 clones provided a model to investigate the properties of epithelial to mesenchymal 
transition in human prostate cancer cells.  Using a range of different assays, this study 
aimed to thoroughly interrogate these clones in order to establish whether or not EMT of 
prostate cancer cells generates cells with the properties of stem cells. 
In order to investigate a possible link between EMT and enhanced proliferative capacity, a 
property attributed to prostate cancer stem cells (Collins et al., 2005; Jeter et al., 2011), 
three distinct proliferation assays were conducted on the five OPCT-1 clones.  Despite 
differences in the methods of assessing proliferation, the ViaLight
®
 Plus assay and the 
Thymidine assay generated analogous results.  Furthermore, these results were consistent 
with microscopic observation of the clones, with regards to the speed at which they 
reached confluency.  The MTT assay however, generated results that were inconsistent 
with microscopic observations hence, this assay was not exploited for further experiments.   
The ViaLight
®
 Plus and Thymidine proliferation assays revealed that the most vimentin-
positive clone, P4B6, was also the most proliferative.  However, these assays also revealed 
that the second most vimentin-positive clone, P2B9, was one of the least proliferative, 
along with the least vimentin-positive clone, P5B3.  If one were to examine the 
proliferation of the least vimentin positive clone, clone P5B3, and compare it with the 
proliferation of the most vimentin positive clone, clone P4B6, one would assume that the 
EMT process confers an increase in proliferation.  However, the fact that the two most 
vimentin-positive clones, P2B9 and P4B6, demonstrated vast differences in their abilities 
to proliferate confirms that this is not necessarily the case.  Therefore, since proliferative 
capacity did not increase corresponding to vimentin-positivity overall, there did not appear 
to be a direct relationship between EMT and enhanced proliferation of prostate cancer 
cells.  This finding emphasises the importance of investigating a number of clones with a 
range of EMT phenotypes as opposed to simply comparing an EMT-negative population 
222 
 
with an artificially-induced population of EMT-derived mesenchymal cells – as several 
studies have done (Mani et al., 2008; Kong et al., 2010; Li and Zhoul, 2011; Moustakas 
and Heldin, 2012). 
Paradoxically, cancer stem cells are widely believed to possess enhanced proliferative 
capacity (although they may also undergo periods of quiescence) however, induction of 
EMT has been shown to be associated with reduced proliferation and a state of growth 
arrest (Postigo, 2003; Vega et al., 2004; Brabletz, 2012).  Since clone P4B6 was the most 
vimentin (EMT)-positive and the most proliferative, these data corresponded with the 
notion that EMT confers enhanced proliferative capacity, perhaps by bestowing stem-like 
properties.  Conversely, since P2B9, the second most vimentin-positive clone, was the least 
proliferative, this finding corresponded with the studies which showed that EMT confers 
reduced proliferation and growth arrest.  Therefore, there appeared to be more than one cell 
type generated via EMT across the clones.   
Cancer stem cells and EMT-derived mesenchymal-like cells are believed to have serious 
implications for cancer therapy (See Section 1.6.3.8).  Through a variety of different 
mechanisms, including expression of ABC transporters, active DNA repair, increased 
expression of anti-apoptotic proteins and high ALDH1 activity, both populations have been 
shown to be highly resistant to chemotherapeutic agents (Conticello et al., 2004; Hollier et 
al., 2009; Alison et al., 2012; Tiwari et al., 2012).  As such, these populations present a 
serious problem for cancer biologists and oncologists hence, further characterisation of 
CSCs and EMT-derived cells to determine viable therapeutic targets is of utmost 
importance.  During this study, the sensitivity of the five OPCT-1 clones to the first line 
advanced prostate cancer chemotherapeutic agent, docetaxel, was assessed in attempt to 
ascertain a possible correlation between vimentin-positivity and chemotherapeutic 
resistance.   
Using parental OPCT-1 as a model to ascertain the IC50 dose for use in further studies, the 
Thymidine proliferation assay was found to be most suitable for assessing the 
chemotherapeutic sensitivity of the OPCT-1 clones.  Using docetaxel, the Thymidine assay 
revealed that statistically significant variation in chemotherapeutic resistance was evident 
among the clones, however, resistance did not correspond with vimentin-positivity.  On the 
contrary, the most drug resistant clone, P6D4, expressed the second lowest levels of 
vimentin whereas the second most vimentin-positive clone, P2B9, was the second most 
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sensitive to docetaxel treatment.  Surprisingly, the most vimentin-positive clone, P4B6, 
proved to be more than twice as sensitive to docetaxel treatment as the most resistant 
clone, P6D4.  Overall, the least vimentin-positive clone, P5B3, proved to be the most 
sensitive to docetaxel treatment however, when taking all other results into consideration, 
this result was not considered to be due to low vimentin-positivity. 
Previous work revealed that clone P6D4 expressed the highest levels of the transcription 
factor Nanog (Chapter 5).  Recently, CD133
+
/CD44
+
/integrin α2β1+ putative prostate 
cancer stem cells, isolated from the PC3 cell line, were shown to exhibit increased 
expression of Nanog (Gong, et al., 2012).  Furthermore, Nanog has been shown to promote 
cancer stem cell characteristics, such as enhanced clonal growth and tumour regenerative 
capacity, and drug resistance via upregulation of ALDH1 (Jeter et al., 2011).  Therefore, 
since clone P6D4 was the most Nanog-positive and drug resistant clone, but one of the 
least vimentin-positive clones, it is plausible that this clone may be enriched for prostate 
cancer stem cells, which are distinct from the stem-like cells generated via EMT.   
Interestingly, although docetaxel is an anti-mitotic chemotherapy medication (Tannok et 
al., 2004), therapeutic sensitivity did not correspond with high proliferative capability and 
vice versa, evidenced by the fact that the most proliferative clone was not the most 
sensitive to docetaxel treatment (P4B6) and the second most sensitive clone was the least 
proliferative (P2B9). 
Since therapeutic resistance was not shown to correlate with vimentin-positivity, these 
results suggested that EMT of prostate cancer cells did not greatly enhance therapeutic 
resistance.  Hence, this study did not provide evidence to support the consensus that EMT 
confers acquired drug resistance (Hollier et al., 2009; Tiwari et al., 2012).  However, since 
clone P4B6 and P2B9 comprise a mixed population of epithelial cells, cells undergoing 
EMT and EMT-derived-mesenchymal cells, the drug sensitivity may have only been 
attributed to the epithelial fraction, which makes up the majority of the clones.  As such, in 
order to accurately ascertain a link between EMT and drug sensitivity, perhaps it would be 
necessary to conduct drug assays on a pure population of cells which have undergone 
EMT.  That said however, if EMT were to confer drug resistance, one would expect a 
clone with such a high proportion of EMT-derived cells  (P4B6) to demonstrate higher 
resistance than a clone with a low number of these cells, derived from the same cell line 
(P6D4).  However, this was not the case.  In order to address the chemotherapeutic 
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sensitivity of a pure EMT-derived population, the drug sensitivity of the 100% vimentin-
positive/E-Cadherin negative OPCT-1 clone (discussed in Chapter 5) will be assessed in 
comparison to the five OPCT-1 clones with mixed vimentin/E-Cadherin expression, in 
future studies. 
Akin to normal stem cells, cancer stem cells have been shown to possess enhanced 
clonogenic capacity (colony forming ability).  Therefore, in order to address a possible 
correlation between EMT and stemness, the clonogenicity of the five OPCT-1 clones was 
investigated.  According to this assay, the OPCT-1 clones differed very significantly with 
regards to clonogenicity.  Interestingly, clonogenicity corresponded with vimentin-
positivity hence, EMT, as the two most vimentin-positive clones, P4B6 and P2B9, were 
also the most clonogenic and the least vimentin-positive clone, P5B3, was the least 
clonogenic.  However, the colonies formed by the two most vimentin-positive/clonogenic 
clones differed notably in that clone P4B6 formed the largest colonies of all the clones 
whereas clone P2B9 formed the smallest colonies.  The results obtained in this study were 
consistent with another study on prostate cancer cell lines which also demonstrated that 
cells with an EMT phenotype possessed enhanced clonogenic capacity (Kong et al., 2010). 
Based on the reported capacity to evaluate self-renewal and differentiation at the single-
cell level in vitro, the sphere-forming assay is one of the most widely used assays for the 
identification and enrichment stem cells and cancer stem cells (Dontu et al., 2003; Mani et 
al., 2008).  Therefore, the stemness of the five OPCT-1 clones was assessed with regards 
to their sphere-forming potential.  This assay revealed that all five clones were capable of 
sphere-formation in non-adherent conditions and highly significant differences in the 
ability of the clones to form spheres were observed.  However, although the most 
vimentin-positive clone, P4B6, was by far the most capable of anchorage independent 
growth (sphere-formation), the second most vimentin-positive clone was by far the least 
capable hence, vimentin-positivity did not correlate with sphere-forming ability.  
Therefore, EMT did not appear to bestow enhanced sphere-forming abilities upon these 
prostate cancer cells.  As with the proliferation assays, this experiment highlighted vast 
behavioural differences between the two most vimentin-positive clones, thereby indicating 
that EMT may give rise to distinct cell types in different settings.  Interestingly, clone 
P6D4, formed the second highest number of spheres across the three assay repeats.  This 
finding provided additional evidence that the P6D4 clone was enriched for cancer stem 
cells.  
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Overall, the data obtained from the sphere-forming assay conflicted with other studies 
which demonstrated enhanced sphere-formation by cells with an EMT phenotype (Mani et 
al., 2008; Kong et al., 2010). 
Following the sphere-forming assays, the spheres were immunofluorescently stained with 
E-Cadherin and vimentin antibodies to assess the distribution of these proteins among the 
spheres and ascertain whether or not the spheres were enriched for vimentin-positive cells.  
As previously stated, vimentin is also expressed by primitive cell types prior to 
differentiation (Langa et al., 2000) therefore, in addition to EMT-derived cells, it is 
possible that vimentin may also identify cancer stem cells.  Immunofluorescence revealed 
that all of the clones formed spheres containing vimentin-positive cells, with clone P4B6 
containing the most and clone P6D4 containing the least.  Interestingly, with the exception 
of the spheres formed by clones P6D4 and P2B9, (which approximately maintained the 
same proportion of vimentin-positive cells) compared to 2D culture, all spheres were 
enriched for vimentin-positive cells.  Unexpectedly, the majority of the spheres showed 
low expression of E-Cadherin towards the periphery.  However, since E-Cadherin loss is a 
hallmark of EMT (Zeisberg and Neilson, 2009), perhaps the downregulation of this protein 
on the periphery of the spheres was indicative of EMT in some cases. 
Of particular interest was the fact that the least vimentin-positive clone in 2D culture 
(P5B3) formed spheres with multiple vimentin-positive clones, located towards the centre 
of the spheres.  Since EMT is believed to occur predominantly at the periphery of tumours 
(Thiery et al., 2009), perhaps the cells located towards the centre of the spheres 
represented a cancer stem cell component in clone P5B3.  However, thus far, all assays 
failed to reveal that clone P5B3 exhibited a cancer-stem cell signature, therefore, this 
hypothesis undoubtedly requires further evidence.  Investigating the expression of other 
EMT-associated markers such as fibronectin and N-Cadherin may confirm that the 
vimentin-positive cells in clone P5B3 spheres were not EMT-derived therefore may 
provide further evidence to suggest that they represented a CSC population.  However, 
since clone P6D4, which previously demonstrated cancer stem cell attributes, contained a 
low population of vimentin-positive cells within the spheres, perhaps CSCs do not 
necessarily express this intermediate filament.  Therefore, it would be interesting to 
ascertain whether putative prostate cancer stem cells, with the cell surface phenotype 
identified by Collins et al., 2005 (CD133
+
/CD44
+
/integrin α2β1hi), express vimentin. 
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Self-renewal ability is believed to be a property unique to stem cells and cancer stem cells 
(Zhao et al., 2008).  As such, the ability of the OPCT-1 clones to self-renew following 
sphere-culture was investigated in an attempt to explore a correlation between stemness 
and EMT.  Surprisingly, the least vimentin-positive clone, P5B3, formed the most 
secondary spheres, thus, was the most capable of self-renewing and the second most 
vimentin-positive clone, clone P2B9, was incapable of forming secondary spheres in two 
out of three assays.  Therefore, vimentin-positivity certainly did not correspond with self-
renewal abilities and, with the exception of clone P4B6 which formed the second largest 
number of secondary spheres,  self-renewal was almost inversely proportional to vimentin-
positivity.   
Aldehyde dehydrogenase (ALDH1) activity has been shown to be increased in stem cells 
and cancer stem cells hence, this enzyme provides a marker for cancer stem cells from 
several malignancies (Chute et al., 2006; Ginestier et al., 2007; Charafe-Jauffret et al., 
2009; Douville et al., 2009; Jiang et al., 2009; Tanei et al., 2009; Jeter et al., 2011).  This 
study revealed that all five of the OPCT-1 clones contained a population of ALDH1
hi
 cells, 
the percentage of which differed significantly among the clones.  Although the most 
vimentin-negative clone also expressed the lowest levels of ALDH1, there was no direct 
correlation between ALDH1 activity and vimentin-positivity.  In keeping with the pervious 
assays, which revealed that clones P6D4 and P4B6 presented with stem-like properties, 
these clones were shown to express the highest ALDH1 activities.  Interestingly, the levels 
of this enzyme corresponded with drug resistance, in that the clone with the lowest 
ALDH1 activity, P5B3, was also the most sensitive to docetaxel treatment and the clone 
with the highest ALDH1 activity, P6D4, was the most resistant to docetaxel treatment.  
This finding is in keeping with the fact that ALDH1 is known to play a role in drug 
detoxification (Dockham et al., 1997) hence, high levels would be expected to confer drug 
resistance.  The validity of this assay in assessing stemness however, is questionable.  This 
is because it was expressed by more than 10% of the population in every clone and up to 
almost 50% of the cells in clone P6D4 but CSCs are generally reported to represent a small 
population.  Furthermore, the high percentage of ALDH1
hi
 cells in the P2B9 clone was not 
in keeping with the fact that this clone had  not demonstrated an overall stem-like signature 
according to other assays.  It is worth noting that the doubts regarding the validity of 
ALDH1 as a bona fide CSC marker are shared with other groups, which have 
demonstrated that ALDH1 activity failed to select for aggressive cells in malignant 
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melanoma (Prasmickaite et al., 2010) and failed to identify cancer stem cells in prostate 
cancer (Yu et al., 2011). 
Both cancer stem cells and EMT have been implicated in invasion and metastasis and 
several studies have utilised Matrigel
TM 
invasion assays to assess the invasive capacity of 
cell populations in vitro.  The expression of matrix-degrading MMPs and vimentin by 
EMT-derived cells, are believed to confer invasive and migratory capacity, respectively 
(Kalluri and Weinberg, 2009) and cancer stem cells have also been shown to present with a 
mesenchymal phenotype which may assist with migration (Mani et al., 2008).  In order to 
investigate a relationship between EMT and invasion, the five OPCT-1 clones were 
assessed using  the Matrigel
TM 
invasion assay.   This assay revealed that the most vimentin-
positive clone, P4B6, was by far the most invasive.  However, clone P2B9, the second 
most vimentin-positive, was the least invasive.  Therefore, these clones failed to 
demonstrate a correlation between vimentin-positivity and invasiveness.   
In order to ascertain which cells were most capable of migrating into an artificial “scratch” 
in a confluent cell monolayer, the in vitro scratch assay (Liang et al., 2007) was modified 
so that it could be executed in fluorescence-compatible 96-well plates, in which IF could 
be conducted following completion of the assay.  This study convincingly revealed that the 
vimentin-positive cells in clones P4B6 and P2B9 were capable of migrating into the 
“scratch”.  Therefore, in keeping with the literature (Ivaska et al., 2007), the vimentin-
expressing cells were shown to possess enhanced migratory capacity.  This assay could not 
identify whether the vimentin-positive cells migrated into the “scratch” from a distance or 
whether the cells on the edge of the “scratch” underwent EMT and migrated into the 
scratch.  However, evidence of the latter was provided as the cells on the edge of the P4B6 
“scratches” did not demonstrate E-Cadherin expression and in addition, low-levels of 
vimentin expression were also detected in cells along the edge of these scratches. 
Cancer stem cells are largely implicated in tumourigenesis and have been shown to initiate 
tumours in a murine model with as few as 100 cells (Al-Hajj et al., 2003).  Furthermore, 
depletion of putative cancer stem cells from the bulk of the tumour often leads to a 
decrease in in vivo tumourigenicity (Al-Hajj et al., 2003).  Therefore, since EMT has been 
shown to generate cells with the properties of stem cells (Mani et al., 2008) tumourigenesis 
may be expected to increase with vimentin-positivity.  In order to address this hypothesis, 
four of the OPCT-1 clones were injected into male athymic nude mice to assess their 
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tumourigenic capacity in vivo.  This assay revealed that the most vimentin-positive clone, 
P4B6, was the most tumourigenic and that the least vimentin-positive clone, P5B3, was the 
least tumourigenic.  However, as the second most vimentin-positive clone, P2B9 was the 
second least capable of forming tumours in mice, tumourigenesis was not shown to 
correlate with vimentin-positivity.  Consistent with the other assays, which revealed that 
clone P6D4 possessed properties attributed to CSCs, this (vimentin-low) clone was the 
second most tumourigenic.  However, only clone P4B6 was shown to be more 
tumourigenic than parental OPCT-1 and the tumours that formed from this clone were 
significantly larger than those formed by the parental cell line from which they were 
derived.  Therefore, as demonstrated in several of the other assays, the behaviour of clones 
P4B6 and P2B9 varied markedly, despite expressing the highest numbers of vimentin-
positive cells.  
Following completion of the tumourigenesis assay, the tumours were excised, cryostat-
sectioned and immunofluorescently stained for the expression of E-Cadherin and vimentin.  
This assay revealed that the clones did not maintain the same proportions of vimentin-
positive cells in vivo and that the distribution of vimentin-positive cells varied according to 
the clone.  Interestingly, clone P2B9, which expressed the second highest levels of 
vimentin in vitro, failed to express this protein in vivo.  Also, clone P4B6, in which 
approximately 30% of the cells were shown to express vimentin in 2D culture in vitro 
(Chapter 5), demonstrated lower vimentin-positivity in vivo.  Therefore, the injected 
vimentin-positive cells either died in vivo or differentiated via MET into epithelial cells.  
On the contrary, clone P6D4 formed tumours with a higher abundance of vimentin-positive 
cells than had been observed in vitro. 
In keeping with the literature, which generally reports that cells at the tumour-host 
interface (i.e. the periphery) activate EMT in order to break-away from the primary tumour 
and metastasise (Kalluri and Weinberg, 2009), the vimentin-positive cells in the P4B6 and 
parental tumours were predominantly located towards the periphery of the tumours.  
Intriguingly, clone P6D4 formed tumours with E-Cadherin-high gland-like structures and 
structures which were surrounded by vimentin-positive cells.  Therefore, the organised 
nature of the tumours formed by this clone implied that there may have been a stem-cell 
component present.  This finding was in keeping with other assays, which revealed that 
this clone demonstrated cancer stem cell attributes. 
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Throughout the duration of this study, the two most vimentin-positive clones often 
generated contrasting data, with clone P4B6, the most vimentin-positive, demonstrating a 
highly aggressive phenotype overall and clone P2B9, the second most vimentin-positive, 
predominantly showing a non-aggressive phenotype.  Type 1 and 3 EMTs generate 
mesenchymal cells whereas, Type 2 EMT gives rise to fibroblasts (See Section 1.6.3) 
(Kalluri and Weinberg, 2009).  Therefore, it is plausible that there may also be distinct 
EMT events that give rise to different cell products in cancer.  As such, in some cases 
EMT may confer stem-like properties, whereas in others, it may generate non-stem-like 
progeny such as fibroblasts.   
In 2010, Battula and colleagues revealed that EMT-derived cells exhibit multi-lineage 
differentiation potential and a gene signature similar to mesenchymal stem cells (Battula et 
al., 2010).  Therefore, EMT of cancer cells may also generate mesenchymal stem-like 
cells.  As such, the stem-like attributes of clone P4B6 may be bestowed by a population of 
mesenchymal stem-like cells.  This hypothesis requires verification by flow cytometry 
using a panel of mesenchymal stem cell markers, which are currently under optimisation, 
and by demonstrating multilineage differentiation into the progeny of mesenchymal stem 
cells; osteoblasts, chondrocytes and adipocytes.   
In summary, although the most vimentin-positive clone, P4B6, demonstrated several 
attributes of cancer stem cells and the most aggressive phenotype overall, conflicting data 
generated from the second most vimentin-positive clone, P2B9, failed to support the 
hypothesis that EMT generates cells with stem-like properties.  Furthermore, one of the 
least vimentin-positive clones, P6D4, demonstrated more stem-like properties than clone 
P2B9.  As such, this study failed to establish a definitive link between EMT and stemness 
in every case.  However, it is evident that in some settings, EMT of prostate cancer cells 
does generate cells with the properties of stem cells, i.e. clone P4B6, whereas in others, 
such as clone P2B9, it does not.  Therefore, future studies will aim to identify the cell types 
generated via EMT in different OPCT-1 clones and primary cultures of prostate cancer 
cells, in order to ascertain whether EMT of prostate cancer cells is capable of generating 
more than cell type and determine how these cells may be targeted, taking into 
consideration the need to circumvent any inherent resistance mechanisms.  In addition to 
revealing potential evidence of distinct EMT events in human prostate cancer, this study 
demonstrated CSC-like attributes from a vimentin-low clone, thereby providing evidence 
that multiple populations of cancer stem-like cells may exist within a given tumour.  
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Therefore, in order to achieve permanent tumour eradication, it is essential to identify and 
target the underlying mechanisms governing the aggressive cancer stem cell phenotype.  
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Chapter 7: 
Preliminary Studies on Human Prostate 
Cancer Patient Tissue 
 
7.1 Introduction 
Human prostate carcinoma cells are notoriously difficult to culture in vitro.  Consequently, 
very few prostate cancer cell lines are available for research and most of these are derived 
from metastases.  The most commonly used cell culture models of prostate cancer are the 
spontaneously established, metastasis-derived, cell lines PC3, DU145 and LN-CaP 
(Bosland et al., 1996).  However, these do not represent the whole range of prostate cancer 
phenotypes and also fail to represent primary adenocarcinomas (Peehl, 2005). Since 
prostate carcinoma cells may have a finite lifespan, senescing after approximately 30 
population doublings (Miki and Rhim, 2008), artificial immortalisation with viral 
oncogenes has also been employed to derive immortal cell lines, an example of which is 
the OPCT-1 cell line.  However, despite the use of viral constructs, the proportion of 
patient samples that give rise to immortalised cultures remains disappointingly low (Miki 
and Rhim, 2008).  Furthermore, artificial immortalisation and long-term culture are 
believed to alter the biological properties of cell lines hence, their usefulness as a model of 
prostate cancer is often debated (Peehl, 2005).  As such, primary cells are widely regarded 
as superior culture models of prostate cancer (Peehl, 2005; Oldridge et al., 2011).  
Despite compelling evidence for the role of EMT in human cancer progression, this 
hypothesis is not accepted by all (Garber, 2008).  Controversy regarding the role of EMT 
in carcinogenesis has been largely due to a lack of sufficient evidence in patient tumour 
samples (Tarin, 2005).   
Therefore, this work endeavoured to investigate the occurrence of EMT in primary cultures 
of high-grade human prostate carcinoma cells and sectioned prostate cancer tissue in 
attempt to provide further evidence of EMT in human prostate cancer.  
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Figure 7.1:  Illustrating the procedures followed for the separation and investigation of epithelial and 
stromal populations from fresh prostate cancer and benign hyperplastic prostate samples.  Tissues were 
collected, cut into small pieces and digested overnight in collagenase solution.  The stromal cells were 
separated from the epithelial cells in a series of centrifugation steps and cultured in simple media with FCS.  
The epithelial fraction was then treated with trypsin and versine prior to culturing on collagen-coated flasks 
in defined serum-free media.  Once confluent, cells were plated and examined by IF. 
 
7.2 Results 
Previous studies demonstrated the occurrence of epithelial to mesenchymal transition in 
the transformed prostate cancer line OPCT-1 (Chapters 4-6).  In order to confirm that this 
phenomenon had not merely occurred as a result of artificial immortalisation (with HPV 
genes E6 and E7) and long term cell culture of the OPCT-1 cell line, it was necessary to 
demonstrate evidence of EMT in non-immortalised cultured primary prostate cancer cells 
and sectioned high-grade prostate cancer and benign hyperplastic prostate (BPH) tissues 
obtained from Trans Urethral Resectioning of the Prostate (TURP) procedures. 
7.2.1 Examination of Primary Stromal and Epithelial Cultures  
In order to investigate EMT in primary cultures of prostate cells, fresh patient material, 
either high-grade PCa tissue (Gleason 8-10) or BPH tissue, was collected from TURP 
procedures and processed immediately following the method optimised by Professor 
Norman Maitland’s research group at The University of York (Collins et al., 2005), but 
without integrin α2β1 selection and addition of feeder cells to the epithelial fraction.  
Figure 7.1 summarises the work flow for the separation, culture and examination of 
cultured primary prostate stromal and epithelial cells. 
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7.2.1.1  Microscopic Examination of Primary Stromal and Epithelial Cultures                                                                                                
Primary cultures from two benign and 13 malignant prostate tissues were derived as 
previously described (Figure 7.1). After approximately 1-2 weeks in culture, microscopic 
examination of the cultured epithelial and stromal fractions revealed distinct morphological 
differences between the two populations and confirmed that they had been successfully 
separated (Figures 7.2 to 7.5).  Occasionally, a few stromal cells were observed in some of 
the benign epithelial cultures (indicated by red arrows in Figure 7.4) however, the serum-
free conditions and cholera toxin, which provided an inhospitable environment for primary 
stromal cells, ensured that these cells were infrequent and did not outgrow the epithelia.  
Despite the omission of irradiated murine fibroblast feeder cells, the epithelial cells 
isolated from malignant tissue grew well, albeit slowly, in culture (Figure 7.2).  They 
formed predominantly dense colonies which exhibited the cobblestone morphology 
characteristic of epithelial cells.  As demonstrated in Figure 7.2, slight variation in the cell 
size and density of the colonies was observed however, the cells were certainly 
morphologically distinct from the stromal cells isolated from malignant tissue (Figure 7.3).  
As anticipated, the epithelial cells isolated from BPH samples (Figure 7.4) did not grow as 
well as those derived from high-grade PCa tissue.  They grew in looser colonies with a 
stressed appearance as indicated by the presence of intracytoplasmic vacuolation (indicated 
by black arrows) (Henics and Wheatley, 1999).  Furthermore, cultures of BPH-derived 
epithelial cells often senesced prior to reaching confluence.  In fact, both benign and 
malignant epithelial populations were difficult to culture as they were strongly adherent, 
hence resisted trypsinisation, many clumped and died during passaging and even the 
prostate cancer derived epithelial cells senesced after 3-4 passages.  However, senescence 
is not atypical of primary prostate epithelial cultures as normal human prostate epithelial 
cells and even primary prostate cancer cells have a finite lifespan and typically undergo 30 
population doublings prior to becoming senescent (Peehl, 2005; Mikki and Rhim, 2008).                   
As evidenced in Figure 7.3, the stromal population isolated from high-grade prostate 
cancer tissues consisted of multiple cell types which may have included pericytes, 
fibroblasts, myofibroblasts and smooth muscle cells.  Contrary to the epithelial cells, these 
cells appeared to proliferate extremely rapidly in culture and were cultured beyond six 
passages without immortalisation.  This was in contrast to the stromal fraction isolated 
from BPH tissues which also contained a mixture of cell types (Figure 7.5) but appeared to 
proliferate at a slower rate in culture and senesced after approximately 3-4 passages.  
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Figure 7.2: Representative images of cultured epithelial cells isolated from high-grade prostate 
cancer tissues and cultured on collagen-coated flasks in complex, defined serum-free media 
optimised for the promotion of self-renewal and inhibition of differentiation of primary epithelial 
cells.  Image magnification at x10.  A-H represent individual cultures of epithelial cells derived from 
prostate cancer patients. 
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Figure 7.3: Representative images of cultured stromal cells isolated from high-grade prostate cancer 
tissues and cultured on polystyrene flasks in simple media with 10% serum.  Image magnification at 
x10. A-H represent individual cultures of stromal cells derived from prostate cancer patients. 
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Figure 7.5: Representative images of cultured stromal cells isolated from BPH tissues and cultured 
on polystyrene flasks in simple media with 10% serum.  Image magnification at x10. A-D represent 
individual stromal cultures derived from BPH patients.   
 
Figure 7.4: Representative images of cultured epithelial cells isolated from BPH tissues and cultured 
on collagen-coated flasks in complex, defined serum-free media optimised for the promotion of self- 
renewal and inhibition of differentiation of primary epithelial cells.  Image magnification at x10.         
A-D represent individual epithelial cultures derived from BPH patients. Black arrows indicate 
cytoplasmic vacuolation.  Red arrows indicate stromal contamination.  
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7.2.1.2 Examination of Primary Stromal  and Epithelial Cells by Immunofluorescence                                                                                            
The aforementioned problems encountered during the culture of primary epithelial cells 
limited the investigation of these populations as it was not possible to conduct long-term 
studies and assays such as sphere formation, proliferation, migration and drug resistance. 
Therefore, the epithelial cells were only preliminarily examined by immunofluorescence. 
In order to confirm that the epithelial and stromal cells had been successfully separated, 
dual immunofluorescence was conducted on the two populations using a pan cytokeratin 
antibody to identify cells of epithelial origin and a vimentin antibody to identify cells of 
mesenchymal origin (example images shown in Figure 7.6).  The stromal cells were free 
from epithelial contamination, as evidenced by the lack of cytokeratin staining.  However, 
the results for the epithelial fraction were complicated by two factors A) it was not possible 
to determine whether vimentin-positive cells with fibroblastoid morphology present in 
epithelial cultures were contaminants or if they had arisen as a result of EMT and B) the 
media used to maintain the epithelial cultures was optimised for the maintenance of 
primitive cells hence, enriched for stem and transit-amplifying (progenitor) cells which 
may also express vimentin (Korsching et al., 2005).  Therefore, using these two markers it 
was not possible to distinguish between contaminating stromal cells, cells which had 
undergone EMT and putative prostate cancer stem/progenitor cells.  As such, it is 
important to stress that the data provided in this chapter are preliminary and therefore, 
open to interpretation.  It is however, apparent that the majority of vimentin-positive cells 
in the epithelial cultures were morphologically distinct from the cells in the stromal 
cultures, which were all single vimentin-positive and exhibited spindle-like morphology.  
In addition, several vimentin-low cells were observed in the epithelial cultures (indicated 
by white arrows) and these may have been in the process of upregulating vimentin, hence, 
transitioning via EMT.   
In an attempt to address the identity of the vimentin-positive cells in the epithelial and 
stromal cultures, dual staining with vimentin and fibronectin antibodies was conducted on 
cultures from different donors (Figure 7.7).  This figure demonstrates that there was more 
than one type of vimentin-expressing cell present in the epithelial cultures, those which 
were large and co-expressed fibronectin (indicated by red arrows), and those which were 
small and did not express this extracellular matrix protein (indicated by yellow arrows).  
Although it is not possible to ascertain whether the dual vimentin/fibronectin-positive cells 
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arose as a result of stromal contamination or EMT of the epithelial cells, it is evident that 
the vimentin-positive/fibronectin-negative cells were smaller and morphologically distinct 
from the dual positive cells hence, may have represented the transit amplifying/stem cell 
component as opposed to mesenchymal cells.  Immunofluorescent screening of stromal 
populations demonstrated that all cells co-expressed vimentin and fibronectin. 
As differentiated epithelial cells replace vimentin with cytokeratin upon differentiation, the 
presence of vimentin in cancerous epithelial cells could denote primitive cancer cells (i.e. 
cancer stem cells) or cells which are transitioning from an epithelial to a mesenchymal 
state (EMT).  The demonstration of vimentin/cytokeratin co-expression by cultured 
prostate cancer epithelia was not sufficient proof of EMT.  Nonetheless, the frequent 
observation of multinucleate, vimentin-positive cells in two distinct primary cultures of 
prostate cancer-derived epithelia provided exciting evidence of either EMT or putative 
cancer(ous) stem/progenitor cells which merited further investigation (Figure 7.8, 
multinucleate cells identified by arrows).   
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Figure 7.6: Dual staining of cultured epithelial and stromal cells isolated from high grade prostate 
cancer tissues stained with a pan cytokeratin antibody to identify epithelial cells and a vimentin antibody 
to identify stromal cells/primitive epithelial cells.  Image magnification at x20. Representative images.  
White arrows indicate cells with low vimentin expression which may be in the process of upregulating 
this protein via activation of the EMT programme 
 
 
 
 
 
 
 
Figure 7.7: Dual staining of cultured epithelial and stromal cells isolated from high grade prostate 
cancer tissues stained with a fibronectin and vimentin antibodies to identify stromal cells.  Image 
magnification at x20. Representative images.  Red arrows indicate large dual vimentin/fibronectin-
positive cells and yellow arrows indicate small, single vimentin-positive cells thus, revealing that distinct 
vimentin-positive populations were present in the epithelial fraction. 
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Figure 7.8: Demonstrating evidence of putative cancer stem/progenitor cells or EMT-derived cells in 
primary cultures of epithelia from two patients.  Cells were stained with A) E-Cadherin/vimentin B) and C) 
Pan cytokeratin/Vimentin D) CD44/vimentin .  Image magnification at x20. Representative images.  Arrows 
indicate multinucleate cells co-expressing vimentin and epithelial markers (A, B, C) and vimentin and the 
prostate basal/intermediate/stem cell marker CD44.  
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7.2.1.3  Karyotyping of Stromal Cells  
The observation that cultured stromal cells derived from prostate cancer specimens grew 
faster than those derived from BPH tissues and did not senesce after more than six 
passages, led to the hypothesis that the stromal fractions isolated from high grade prostate 
cancer tissue may have contained a population of malignant EMT-derived cells which may 
have been tumourigenic.  Due to ethical constraints, this could not be tested by 
investigation of tumourigenesis in vivo.  Therefore, in order to address this hypothesis and 
ascertain whether cancer cells were present in the stromal cultures, stromal cells isolated 
from one high-grade PCa tissue and one BPH tissue, as a control, were sent for preliminary 
karyotyping by Dr Karen Sisley at The University of Sheffield. 
The karyotyping revealed that some random numerical changes and tetraploidy were 
observed in both samples, however, no identifiable structural alterations or specific 
abnormalities were noted (data not shown).  Therefore, the stromal cells isolated from 
benign and malignant TURP tissue appeared normal (i.e. non-cancerous) overall but both 
had developed random alterations associated with a loss of cell cycle regulation.  However, 
without repeating the analysis and examining a larger number of cells, it was not possible 
to completely rule out the changes observed.  Furthermore, as the sample size was very 
small, these results were only preliminary hence, could not provide conclusive evidence for 
or against the hypothesis.  Therefore, it would be necessary to expand this study and 
examine the karyotypes of several benign and malignant stromal populations to better 
address the hypothesis presented.  Furthermore, amendments to the ethics regarding the use 
of the patient material would enable in vivo studies with the stromal cells which may 
provide additional evidence of in vivo tumour development to address the notion that 
EMT-derived cancer cells are present in stromal populations of patients with high grade 
prostate cancer. 
In addition to karyotyping the stromal cultures, the epithelial cultures should also be 
karyotyped in order to confirm their benign or malignant cell origins. 
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7.2.1.4 Investigating Evidence of EMT in High Grade Prostate Cancer and BPH 
Tissue Sections by Immunofluorescence                                                                          
In order to investigate evidence of EMT in an in vivo setting, frozen sections of PCa and 
BPH tissues were dual-stained with antibodies directed against E-Cadherin and vimentin.  
Although vimentin expression identifies stromal cells, co-expression of vimentin and E-
Cadherin could be restricted to either primitive epithelial cells or epithelial cells 
undergoing EMT.  Stem and transit-amplifying cells are known to represent a small 
population of cells in both healthy and malignant tissue (Richardson et al., 2004; Collins et 
al., 2005; Charruyer et al., 2009).  Therefore, the observation of multiple dual-positive 
cells in prostate cancer tissue sections was likely to be indicative of EMT.   
This study provided potential evidence of EMT in prostate cancer tissue, as evidenced by 
the presence of multiple dual vimentin/E-Cadherin-positive cells in malignant patient 
tissue sections (Figures 7.9 and 7.10 Malignant 1-5).  As anticipated, the benign sample 
consisted of predominantly single-positive cells, with a clear distinction between epithelial 
and mesenchymal populations (Figures 7.9 and 7.10 Benign).  On the contrary, separation 
of the colours (Figure 7.10) clearly illustrated that in patients 4 and 5, all of the E-
Cadherin-positive (epithelial) cells co-expressed vimentin, perhaps suggesting that the 
epithelial cells in these samples were undergoing EMT.   
Interestingly, despite the highly disorganised appearance and lack of distinct glandular 
structures (characteristic of high-grade prostate cancer) present in malignant patient 1, this 
sample appeared to present with few dual-positive cells.  However, evidence of EMT was 
observed for some of the cells in this sample, as indicated by yellow staining, which 
denotes dual-positivity, predominantly observed on the edges of the colonies of E-
Cadherin-positive cells (highlighted by black arrows in Figure 7.9 and circles in Figure 
7.10). 
Downregulation of E-Cadherin is one of the key steps involved in the EMT programme 
(Zeisberg and Neilson, 2009).  Therefore, the observation of cytoplasmic, as opposed to 
cell-surface, E-Cadherin staining in the dual-positive cells present in sections from 
malignant patients 2 and 3, supported the notion that these cells were undergoing EMT 
(indicated by circles in Figures 7.9 and 7.10).   
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Figure 7.9: Dual immunofluorescent staining of frozen tissue sections from five high-grade prostate cancer 
patients and one BPH patient stained with E-Cadherin (red) and vimentin (green) antibodies.  Image 
magnification at x10, x20 and x40. Representative images. Benign and Malignant-1-5 represent separate 
patients.  Circles highlight regions of dual vimentin/E-Cadherin-positive cells.  
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Figure 7.10: Dual immunofluorescent staining of frozen tissue sections from five high-grade prostate 
cancer patients and one BPH patient stained with E-Cadherin (red) and vimentin (green) antibodies with 
separation of colours to assist identification of dual or single-positive cells.  Image magnification at x20. 
Representative images. Benign and Malignant-1-5 represent separate patients.  Circles highlight regions of 
low/cytoplasmic E-Cadherin expression by vimentin-positive cells.  
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7.2.2  Parallel Observations between Primary Cultures & OPCT-1 Cells 
Throughout the duration of the study, similarities between the primary cultures and the 
clonally derived OPCT-1 populations were frequently observed.   
Mixed primary cultures of epithelial and stromal cells appeared to grow with similar 
patterns to the vimentin-high OPCT-1 clone, P4B6 (Figure 7.11).  Although not identical, 
the similarities observed in the organisation of the cell types, with the 
stromal/mesenchymal populations (yellow arrows) surrounding the epithelial cells (red 
arrows), were apparent (cell types are distinguished based on morphological differences).   
Furthermore, cultured stromal cells, isolated from high grade prostate cancer tissues, 
frequently formed the circular patterns observed in Figure 7.12 which was mirrored by the 
mesenchymal cells that circled the epithelial cells in clone P4B6.  This observation was 
also confirmed by IF, where vimentin-positive mesenchymal cells circled the 
cytokeratin/E-Cadherin-positive epithelial cells (Figure 7.13 A and B).  As can be observed 
in Figure 7.13 C and D, non-fibroblastoid cells co-expressing epithelial and mesenchymal 
markers were observed in both primary prostate cancer epithelial cultures and clonally 
derived OPCT-1 cells, thus inferring that these populations may have represented cells 
undergoing EMT.  This is further evidenced by the increased expression of vimentin by 
cells on the edge of the colonies in E and F which appear more fibroblastoid than the 
vimentin-positive cells in the centre of the colonies and are reminiscent of metastatic 
disease whereby cancer cells are believed to activate EMT in order to break away from the 
primary tumour and migrate to distant sites.  In addition to these parallel observations, 
large cytokeratin-positive cells with nuclear vimentin expression were observed in both the 
primary cultures and the OPCT-1 clones (G and H). 
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Primary cells Clone P4B6 
Figure 7.11:  Bright field images of cultured primary prostate cancer-derived cells and OPCT-1 clone P4B6 
demonstrating similarities in the organisation of the stromal/mesenchymal cells (indicated by yellow arrows) 
which surrounded the epithelial cells (indicated by red arrows).  Image magnification at x10. Representative 
images.   
 
Figure 7.12:  Bright field images of cultured primary prostate cancer-derived stromal cells and clone P4B6 
demonstrating similarities in the organisation of the stromal/mesenchymal cells.  Image magnification at x10. 
Representative images. Circled regions demonstrate the circular arrangement patterns of 
mesenchymal/stromal cells which frequently formed in the primary stromal cultures, despite the absence of 
epithelia, and perhaps reflected what was observed in clone P4B6 where the mesenchymal cells frequently 
surrounded the circular colonies of epithelial cells.   
 
Primary cells Clone P4B6 
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Figure 7.13: Demonstrating parallel observations made between primary prostate cancer cells 
and OPCT-1 clones by dual immunofluorescent staining with E-Cadherin/cytokeratin and vimentin 
antibodies. Image magnification at x20. Representative images.   A, C, E and G provide evidence 
of EMT in primary prostate cancer epithelial cultures.  B, D, F and G show parallel observations 
made in the P4B6 cell line which was previously shown to undergo EMT.  
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Figure 7.13: Demonstrating parallel observations made between primary prostate cancer cells 
and OPCT-1 clones by dual immunofluorescent staining with E-Cadherin/cytokeratin and vimentin 
antibodies. Image magnification at x20. Representative images.   A, C, E and G provide evidence 
of EMT in primary prostate cancer epithelial cultures.  B, D, F and G show parallel observations 
made in the P4B6 cell line which was previously shown to undergo EMT.  
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The OPCT-1 clones were derived and examined as a model to investigate EMT.  As 
parallel observations were made between these clones and the primary cultures, it could be 
argued, and indeed suggested, that EMT was observed in primary cultures of prostate 
cancer epithelia.  However, it is important to acknowledge that these results are 
preliminary, on a limited sample set, and that further work on clonally derived populations 
would be required in order to conclusively provide evidence of EMT in primary cultures of 
prostate cancer cells. 
 
7.3 Discussion 
Epithelial to mesenchymal transition is a complex biological process which is reported to 
be critical for the acquisition of an invasive and metastatic phenotype by carcinoma cells.  
Previous work provided evidence of this phenomenon in the human prostate cancer cell 
line OPCT-1 (Chapter 4).  In addition, model clones, representing a range of phenotypes 
with respect to EMT, were derived and thoroughly interrogated in order to investigate a 
possible correlation between EMT and the acquisition of stem-like traits (Chapters 4, 5 and 
6).   
Since artificial immortalisation, employed to generate the OPCT-1 cell line, and long-term 
in vitro cell culture are known to impact on the biological properties of cancer cells, the 
usefulness of cell lines for the investigation of cancer stem cells has been questioned 
hence, primary cultures are believed to be superior as they are thought to better reflect the 
characteristics of the original tissues (Peehl, 2005; Miki and Rhim, 2008).   
Earlier work attempted to identify and isolate putative prostate cancer stem cells with the 
marker profile CD133
+
/CD44
+
/integrin α2β1hi (determined by Collins et al., 2005) from 
primary prostate cancer cell cultures, however, this was to no avail (Chapter 3).  
Consequently, the focus of this study shifted to investigating epithelial to mesenchymal 
transition in human prostate cancer.  Having established methods to identify EMT-derived 
cells in prostate cancer cell lines, the primary cultures were re-visited in a preliminary 
attempt to reveal evidence of EMT in primary prostate cancer cells.  In addition, tissue 
sections derived from benign and malignant patient samples were examined for potential 
evidence of EMT.  Intriguingly, interrogation of primary cultures revealed similarities 
between these populations and the EMT-positive OPCT-1 clone P4B6. 
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Prior to investigating EMT in primary cells, it was necessary to establish individual 
cultures of epithelial and stromal cells and confirm that these were free from contamination 
with the undesired cell types.  Epithelial cells are known to express cytokeratin 
intermediate filaments, hence, demonstration of cytokeratins in primary cultures is positive 
confirmation of epithelial origin and is easily accomplished using immunochemical 
methods such as immunohistochemisty and immunofluorescence (Peehl, 2002).  
Conversely, mesenchymal cells and fibroblasts are known to express vimentin intermediate 
filaments hence, vimentin-positivity may be used to identify stromal populations, which 
are predominantly comprised of fibroblasts and smooth-muscle cells (Peehl and Sellers, 
1997).  However, whilst mesenchymal cells do not express cytokeratins, identification of 
pure epithelial cultures is complicated by the fact that epithelial cells from different tissues 
of both benign and malignant origin have frequently been shown to co-express cytokeratins 
and vimentin (Leong et al., 1988; Viale et al., 1988; Raymond and Leong, 1989; 
Lauweryns et al., 1993; Ghoubay-Benallaoua et al., 2011).  Co-expression of both 
cytokeratin and vimentin intermediate filaments may occur as a result of epithelial to 
mesenchymal transition and dual-positive circulating tumour cells have even been 
identified, the existence of which supports the role of EMT in cancer progression (Barriere 
et al., 2012; Kasimir-Bauer et al., 2012).  Alternatively, there is evidence to suggest that 
vimentin is expressed by primitive epithelial cell types including stem and 
progenitor/transit amplifying cells (aka intermediate cells) (Lauweryns et al., 1993; 
Korsching et al., 2005; Ghoubay-Benallaoua et al., 2011), therefore, vimentin expression 
in cultured prostate cancer-derived epithelia may indicate the presence of prostate cancer 
stem/progenitor cells.  Further complications are apparent since there are no markers to 
distinguish between EMT-derived mesenchymal cells and cells of the prostate stroma, 
hence, it is very difficult to ascertain whether or not primary epithelial cultures present 
with stromal contamination, as a result of inadequate separation procedures, or evidence of 
EMT.  However, co-expression of cytokeratins and vimentin on fibroblastoid cells may be 
indicative of EMT since non-EMT-derived stromal cells would not express cytokeratins.  
Nonetheless, in order to identify the vimentin-positive cells that may present in epithelial 
cultures, additional mesenchymal markers must be employed. 
Morphological differences between cultured epithelial and stromal populations are clearly 
identifiable microscopically.  Epithelial cultures generally present with colonies of small 
cuboidal cells exhibiting cobblestone morphology whereas stromal cells demonstrate 
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spindle-like, fibroblastoid morphology (See Figure 1.13) (Peehl, 2002).  During this study, 
microscopic examination suggested that separate epithelial and stromal cultures had been 
successfully derived from prostate cancer and BPH patient material and in order to confirm 
this, immunofluorescence was conducted using epithelial (cytokeratins) and mesenchymal 
(vimentin) markers.   
Immunochemical testing confirmed that the stromal cultures were single vimentin-positive 
hence, free from epithelial contamination however, dual vimentin/cytokeratin-positive cells 
were observed in the epithelial cultures.  The co-expression of cytokeratins by several of 
the vimentin-positive cells in the epithelial cultures ruled out the possibility that these cells 
were contaminating stromal cells.  However, due to the aforementioned problems, using 
these two markers it was not possible to conclusively confirm whether the dual-positive 
cells represented primitive cell types or EMT-derived populations.   
In a preliminary attempt to distinguish between primitive cells, contaminating stroma and 
EMT-derived mesenchymal cells, the stromal and epithelial cultures were co-stained with 
vimentin and fibronectin.  This staining revealed that all cells within the stromal cultures 
co-expressed these markers, hence, it would be fair to assume that any stromal 
contaminants present in epithelial cultures would co-express vimentin and fibronectin.   
However, several studies, including the present study, have revealed that EMT-derived 
cells may also co-express vimentin and fibronectin.  Furthermore, cells which have fully 
transitioned via EMT have been shown to replace cytokeratins with vimentin, hence would 
be indistinguishable from stromal/mesenchymal cells using vimentin/cytokeratin staining 
(Savagner, 2010).  In addition, to date, there are no markers which successfully distinguish 
between normal stromal cells and populations which have fully transitioned via EMT.  
Therefore, although co-expression of epithelial and mesenchymal markers may identify 
transitioning cells, cells which have fully transitioned via EMT may be confused with 
stromal contaminants (Thompson and Newgreen, 2005).   
Furthermore, epithelial cells have also been shown to express fibronectin (Kolachala et al., 
2007).  However, since distinct morphological differences are apparent between epithelial 
and mesenchymal populations, a combination of marker profile and observation of cellular 
morphology may be used to distinguish between primitive epithelia and mesenchymal cell 
types although it is not currently possible to ascertain the source of the 
mesenchymal/stromal cells.   
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Interestingly, co-staining with vimentin/fibronectin revealed that there were at least two 
distinct vimentin-positive populations within the primary malignant epithelial cultures; 
those which were large, exhibited fibroblastoid morphology and co-expressed fibronectin, 
and those which were small, non-fibroblastoid and single vimentin-positive.  The large, 
dual-positive, fibroblastoid cells may have been stromal contaminants or cells which had 
fully transitioned via EMT.  Whereas, the lack of the mesenchymal marker, fibronectin, 
coupled with the small size and epithelial morphology of the other vimentin-positive 
population, suggested that these cells may have represented primitive cell types such as 
transit-amplifying/stem cells or epithelial cells which were in the early stages of EMT 
(Korsching et al., 2005).  
It is evident that several markers would be required in order to conclusively identify the 
distinct vimentin-positive populations within epithelial cell cultures, employing stem cell-
associated markers in addition to EMT-associated markers to distinguish between primitive 
and transitioning cells.  Unfortunately, however, immunofluorescence is limited with 
regards to the number of markers that can be examined.  Therefore, while this technique 
may have provided preliminary evidence of EMT or primitive populations in primary 
cultures of prostate cancer epithelia in the present study, these data must be supported with 
further experimental evidence.  However, several problems, encountered during the culture 
of primary prostate epithelia, restricted the interrogation of these populations using other 
techniques.  Such issues included senescence prior to reaching confluence, strong cell-
substratum adhesion, which rendered these cells extremely difficult to harvest, and, 
consequently, sensitivity of these cells to harvesting, which generally resulted in cell 
clumping and a substantial loss of cell viability.  As a consequence, techniques requiring a 
large number cells, such as flow cytometry, which enables examination of multiple 
markers, thus, would have proven ideal for the identification of distinct cell types, could 
not be performed and cells were only examined using immunofluorescence.  Moreover, 
since several cell-surface markers, including the epithelial marker E-Cadherin, are 
sensitive to harvesting methods, flow cytometric analysis may have generated false 
profiles.  Therefore, a combination of assays would have been required in order to provide 
substantial evidence of EMT in prostate cancer tissue-derived epithelial cultures. 
However, in order to conclusively demonstrate EMT in primary prostate cancer epithelial 
cells, it would be necessary to work on clonally derived cultures and confirm that single 
epithelial cells give rise to mixed populations of epithelial and mesenchymal cells.  Indeed, 
252 
 
it has long been known that even clonally-derived cultures of primary mammalian epithelia 
may present with apparent fibroblast overgrowth, as a result of EMT (Zeisberg and 
Neilson, 2009).  As such, single-cell laser-capture-microdissection (LCM) was attempted 
on single E-Cadherin-positive (epithelial) cells.  In addition, cloning of the epithelial 
cultures by limiting dilution was attempted.  Despite several attempts however, it was not 
possible to clone the primary epithelial cells using either of these techniques.  Therefore, 
studies on primary cells were restricted to mixed (non-clonally-derived) populations that, 
subsequently, resulted in ambiguous results.   
Consequently, it is important to acknowledge that the data presented in this chapter are 
preliminary and on a limited sample set.  Thus, future work, on a larger number of prostate 
cancer tissue-derived epithelial cultures, using varied techniques, with an extended panel 
of EMT and CSC-associated markers, is required in order to provide compelling evidence 
of EMT in primary cultures of prostate cancer epithelia.  Furthermore, since the expression 
of vimentin in human carcinomas has been shown to correlate with invasiveness and 
metastasis (Takemura, 1994; Singh, 2003; Zeisberg and Neilson, 2009), in vitro and in vivo 
invasion and metastasis assays should be conducted on the vimentin-positive primary 
epithelial cultures in attempt to correlate the EMT-phenotype with characteristics 
associated with tumour progression.  
During this study, cells co-expressing epithelial and mesenchymal markers in prostate 
cancer epithelial cultures could not be conclusively identified as carcinoma cells 
transitioning via EMT or cancer stem/progenitor populations.  Nonetheless, the observation 
of multinucleate (i.e. cancer) cells co-expressing epithelial markers (E-
Cadherin/cytokeratins) and vimentin in epithelial cultures, arguably provided evidence for 
either of these phenomena which undoubtedly justified the investigation of cancer stem 
cells and epithelial to mesenchymal transition in human prostate cancer. 
In recent years, the critical involvement of the stromal microenvironment in 
tumourigenesis has received much attention and tumour associated fibroblasts (aka 
activated-fibroblasts/myofibroblasts) have been shown to contribute significantly towards 
cancer growth and progression (Kalluri and Zeisberg, 2006; Pietras and Ostman, 2010; Li 
et al., 2012; Tripathi et al., 2012).  Although the role of EMT in the generation of tumour-
associated stroma remains controversial and unproven, carcinoma cells have been shown to 
be capable of activating EMT in vitro and stromal cells adjacent to primary epithelial 
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tumour nodules have been shown to share some genetic mutations with tumour cells, 
indicating a contribution of neoplastic cells to stroma formation via EMT (Wernet et al., 
2001).  Considering these factors, it is not unfeasible that tumours may contribute to their 
own stromal microenvironment via EMT.   
During this study, prostate cancer-derived stromal cultures appeared to proliferate at a high 
rate and were cultured beyond six passages without senescing whereas, the BPH-derived 
stromal cultures appeared to grow much slower, often failed to reach confluence and 
senesced prior to being passaged four times.  In light of these observations, it was 
hypothesised that the stromal cells derived from prostate cancer tissues may contain a 
population of self-renewing, cancer cells, derived from EMT of the carcinoma cells.  
Therefore, these cultures were hypothesised to comprise mesenchymal-like cancer cells, 
hence, possess tumourigenic capabilities.  Since ethical constraints prohibited in vivo 
studies using patient material, to test this hypothesis, a preliminary karyotyping was 
conducted on one BPH and one PCa-derived stromal population by Dr Karen Sisley at The 
University of Sheffield.  This proof-of-principle analysis was inconclusive, however, it did 
reveal that changes could be observed therefore, in future a larger sample set, comprising 
multiple benign and malignant primary cultures, may provide a suitable model to test this 
hypothesis.  The ultimate proof of this concept would be provided by demonstrating in vivo 
tumour-formation by tumour-derived stromal cells however, until ethical approval is 
granted, this experiment cannot be conducted.   
Although a large body of in vitro evidence, supporting the role of EMT in cancer 
progression, has been reported using cultured cells from several malignancies, an apparent 
lack of evidence in clinical specimens has rendered the role of EMT in cancer progression 
a controversial and disputed topic (Tarin, 2005; Garber, 2008).  However, as outlined in 
Section 1.6.3.6, several explanations may account for the apparent inability to observe 
EMT in clinical specimens namely; the transient nature of EMT, which may result in it 
being overlooked, the lack of markers that can distinguish between EMT-derived 
mesenchymal cells and normal stroma, the possible infrequency of EMT events in vivo and 
the potential of metastasising EMT cells to revert via MET to an epithelial form, thereby 
eliminating evidence of the EMT process (Foroni et al., 2012).  However, though direct 
proof of cancer-derived mesenchymal populations in clinical specimens has been difficult 
to obtain, several studies have correlated the presence of EMT-associated 
markers/phenotypes, including EMT-inducing transcription factors and Cadherin switching 
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(from E to N), in clinical specimens with disease progression, relapse and poor survival, 
thereby, associating the EMT phenotype with tumourigenesis (Hirohashi, 1998; Wang et 
al., 2004; Kwock et al., 2005; Gravdal et al., 2007).   
In an attempt to provide evidence of EMT in clinical specimens, this study examined the 
presence of E-Cadherin and vimentin in sectioned PCa and BPH tissues.  Although 
vimentin is largely expressed by normal stromal cells, and cells which had fully 
transitioned via EMT would have been indistinguishable from the normal stromal cells, the 
co-expression of E-Cadherin and vimentin may have identified cancer cells transitioning 
via EMT.  As previously discussed, co-expression of epithelial markers and vimentin may 
also identify primitive cells however, since these cells have been reported to constitute rare 
populations, in both benign and malignant prostate tissues (Collins et al., 2005), an 
abundance of dual-positive cells would, arguably, be more likely to represent cells 
activating the EMT programme.   
This study revealed potential evidence of EMT in multiple clinical specimens of high-
grade prostate cancer, as evidenced by the presence of several cells co-expressing E-
Cadherin and vimentin in the cancer specimens but not in sectioned BPH tissues.  
Furthermore, samples differed in the abundance of co-positive populations, with some 
samples demonstrating few dual positive cells compared to others in which all E-Cadherin-
positive cells co-expressed vimentin.  An abundance of EMT-derived populations in high 
grade prostate cancer tissue specimens would account for the aggressivity associated with 
this disease pathology as EMTs have been shown to possess enhanced migratory and 
invasive capacity, hormone resistance and resistance to chemotherapy, all of which are 
features of advanced castration-resistant hormone-refractory prostate cancer (Kasper and 
Cookson, 2006; Arumugam et al., 2009; Voulgari and Pintzas, 2009).   
Although two markers are not sufficient to conclusively demonstrate EMT, these 
preliminary data provide evidence of EMT in an in vivo setting which may be verified in 
future studies using a larger panel of EMT-associated antibodies.  One study revealed that 
the levels of the EMT-inducing transcription factor Twist positively correlated with 
Gleason Grade and metastasis (Kwok et al., 2005).  Therefore, examination of EMT-
inducing transcription factors in combination with a larger panel of epithelial/mesenchymal 
markers in serial sections of prostate cancer tissue may provide more compelling evidence 
of EMT in vivo.  
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Previous work identified the OPCT-1 clone, P4B6, as being positive for epithelial to 
mesenchymal transition (Chapters 4 and 5).  Throughout this study, similarities observed 
between primary cultures of prostate cancer-derived cells and the EMT-positive OPCT-1 
clone, P4B6, provided further evidence of EMT in patient material.  Not only were 
morphological similarities observed, in the arrangement of stromal and epithelial cells in 
primary cultures and in clone P4B6, microscopically, the analogous patterns of 
mesenchymal cells surrounding epithelial colonies were confirmed by 
immunofluorescence.  Furthermore, primary prostate cancer-derived stromal cultures 
appeared to reflect the organisation of the mesenchymal cells in the P4B6 clone.   
Collectively, these data supported the notion that tumours contribute to their own stromal 
microenvironment via EMT, as a clonally derived population of prostate cancer cells 
(clone P4B6) not only generated mesenchymal cells, but also organised these cells in such 
a way as to enable them to perform the functions they would perform in vivo (paracrine 
feeding of the parenchymal epithelial cells).  Furthermore, this finding validates the use of 
cell lines to investigate the phenomenon of EMT because, despite artificial transformation 
with HPV genes and several passages in vitro, the clonally derived P4B6 cells were able to 
organise themselves in the same manner as the primary cells.   
In addition to these findings, several other comparable observations were made between 
clone P4B6 and primary epithelial cultures by immunofluorescence using EMT-associated 
markers.  Perhaps the most noteworthy of which was the observation that cells on the edge 
of the colonies of the primary prostate cancer-derived epithelia were shown to express 
vimentin and appeared more spindle-like than those in the centre of the colony.  This 
finding closely resembled the staining of the P4B6 cells following cloning into 
fluorescence-compatible 96 well plates (See Figure 5.1).  Furthermore, this staining pattern 
provided evidence for the hypothesis that cancer cells on the periphery of the tumour 
activate the EMT programme, invade and metastasise to distant sites. 
In summary, the work embodied in this Chapter provided preliminary evidence of 
epithelial to mesenchymal transition events in both primary cultures derived from prostate 
cancer tissue and sectioned prostate cancer tissues.  In addition, preliminary evidence to 
support the hypothesis that tumours contribute towards their own stromal 
microenvironment via EMT, was also provided.  Although this work was preliminary, 
hence, open to interpretation and scrutiny, these initial findings provide justification for 
further, extensive studies on patient material.  Furthermore, analogous observations 
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between primary epithelial cultures and the EMT-positive P4B6 clone not only provided 
evidence of EMT in primary cultures, but also validated the use of prostate cancer cell 
lines to investigate this phenomenon in human prostate cancer.  
Future studies using primary prostate cultures should focus on deriving clones, which 
should be karyotyped to confirm the benign or malignant cell of origin and exploited as a 
model to investigate evidence of EMT and the reverse phenomenon MET in non-
immortalised primary prostate cultures.  
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Chapter 8: 
Discussion 
 
8.1 Introduction 
Prostate cancer  represents a major health  concern worldwide since, being the third most 
common  cancer in men, it is a significant cause of morbidity and mortality, particularly 
among men  in the developed world (Groenberg, 2003; Drewa et al., 2008).  Malignancies 
of the prostate gland account for a quarter of all new cancer cases diagnosed in men in the 
UK, hence, prostate cancer  is the most common  male malignancy in the UK (Cancer 
Research UK, 2012).  Although in the case of localised prostate cancer surgery and 
radiation therapy can prove to be curative, this is not true of the majority of cases, which 
present with locally advanced or widespread disease. In the case of advanced disease, 
androgen ablation hormone therapy is the standard first line of palliative treatment. 
However, despite hormone therapy achieving castrate-levels of testosterone, cancer 
progression to biochemical or metastatic hormone refractory disease often leads to death 
since metastatic hormone-refractory prostate cancer (HRPC) currently remains an 
incurable disease  (Hadaschik and Gleave, 2007; Stavridi et al., 2010). 
In recent years, the cancer stem cell (CSC) hypothesis has emerged as a model to describe 
cancer development.  Unlike previous models, which proposed that cells within a tumour 
are equally malignant, the CSC hypothesis postulates that tumours are organised in a 
hierarchical manner, with only a rare subpopulation of cancer cells (i.e. the CSCs) 
possessing the unique biological properties required to initiate tumourigenesis (Lawson 
and Witte, 2007).  While there is evidence to suggest that CSCs arise from the malignant 
transformation of normal tissue stem cells in some cancers (Collins et al., 2005; Merlos-
Suárez et al., 2011), the origin of CSCs remains a controversial topic, with several 
alternative theories having been proposed.  Indeed, there may be more than one population 
of so-called cancer stem cells present within a given tumour, all of which may play a 
significant role in tumourigenesis (May et al., 2011). 
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Not only are CSCs believed to be the origin of a given malignancy, hence, the site of 
malignant transformation and subsequent tumour-initiation, they are also hypothesised to 
contribute to tumour maintenance, metastasis and resistance to therapy.  Moreover, these 
cells are held accountable for tumour relapse, as it is believed that, akin to normal stem 
cells, CSCs possess multiple resistance mechanisms and are capable of undergoing long 
periods of quiescence, which enable them to resist and reside following therapy, while 
awaiting appropriate microenvironmental signals for the re-initiation of tumour growth, 
sometimes several years later (Moore and Lyle, 2011).  As such, it is believed that current 
cancer therapies fail to target the resistant CSCs and in order to achieve complete tumour 
eradication, it is necessary to develop CSC-specific therapies that may be used in 
combination with conventional therapies to successfully target the bulk of the tumour as 
well as the CSCs maintaining its growth (Neuzil et al., 2007; Dunning et al., 2011).   
Recent advances in stem cell technologies have enabled the identification, isolation and 
characterisation of putative cancer stem cells from haematological and solid human 
malignancies including AML, CML,  breast,  ovarian , pancreatic, colon, brain,  head and 
neck, lung, liver, skin and prostate cancers (Bonnet and Dick, 1997; Singh et al., 2003; 
Fang et al., 2005; Collins et al., 2005; Szotek et al., 2006; Li et al; 2007; Ricci-Vitiani et 
al., 2007; Zhao et al., 2008; Visvader and Lindeman, 2008).  
In 2005, Collins et al., provided evidence for the stem cell origin of prostate cancer when 
they isolated putative prostate cancer stem cells using the marker profile they had 
previously established for normal prostate stem cells (Collins et al., 2005).  However, it is 
important to acknowledge that the origin of prostate cancer still remains an elusive and 
much debated topic (Maitland et al., 2011).   
By exploiting the putative prostate cancer stem cell (PCSC) marker profile and the 
methods established by Collins and colleagues (2005), this project originally sought to 
identify, isolate and characterise putative human PCSCs from cell lines and fresh tissue 
samples, with a view to examining their immunological status, identifying potential 
expression of cancer-associated antigens and ascertaining whether or not these cells could 
represent viable targets for immunotherapy.  However, perhaps due to the sensitivity of the 
CD133 molecule, a cell-surface molecule shown to be key for the identification of putative 
PCSCs, and the limited availability of appropriate antibodies for the recognition of this 
antigen (problems acknowledged by Maitland et al., 2011), putative prostate cancer stem 
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cells, with the marker profile CD133
+
/CD44
+
/integrin α2β1hi, were neither identified nor 
isolated using various immunological techniques during this study.  Consequently, it was 
necessary to approach the topic of prostate cancer stem cells from an alternative angle. 
Epithelial to mesenchymal transition (EMT) is a vital process which is activated during 
embryogenesis and throughout life during organ remodelling and tissue repair in response 
to injury.  Recently, EMT has been implicated in the conversion of early stage tumours 
into invasive, metastatic malignancies.  Furthermore, this process is believed to generate 
cells with the properties of stem cells, thereby bestowing multiple mechanisms of 
therapeutic resistance including periods of quiescence which may be accountable for 
tumour recurrence (Mani et al., 2008; Hollier et al., 2009).  Since metastasis is accountable 
for more than 90% of cancer-associated mortalities, the convergence of the EMT and CSC 
fields was an exciting progression in cancer research as the proposed acquisition of the 
invasive and migratory mesenchymal traits coupled with the stem-like self-renewal 
capabilities, bestowed by EMT events, are believed to account for the successful 
completion of the invasion-metastasis cascade by metastatic cancer cells (Brabletz, 2012).  
However, as the EMT and CSC fields remain in their infancy, it is apparent that 
discrepancies are prevalent within the literature (Kong et al., 2011).  For example, 
although it is evident that the cancer stem-like cells generated via EMT of carcinoma cells 
(i.e. EMT-derived CSCs) must be distinct from the original tumour-initiating CSCs, while 
some groups acknowledge that there appear to be more than one type of so-called “cancer 
stem cell” (May et al., 2011; Chaffer et al., 2011), others reject the original, hierarchal 
cancer stem cell hypothesis in favour of EMT (Satisteban et al., 2009).  Furthermore, it 
remains to be shown whether EMT events always confer stem-like properties (Brabletz, 
2012), and whether or not the ability to activate EMT is restricted to certain populations 
within a tumour. 
To date, much of the research into EMT has been conducted using breast cancer as a 
model, although evidence pertaining to the significance of this phenomenon in prostate 
cancer progression is also emerging and the prostate cancer gene fusion TMPRSS2/ERG 
has even been implicated in the promotion of EMT (Kong et al., 2010; Nauseef et al., 
2011; Leshem et al., 2011).   
This study aimed to identify a model prostate cancer cell line, showing evidence of 
spontaneous EMT-events, which could be cloned in order to investigate whether cancer 
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cells derived from the same tumour exhibit equal potential to activate the EMT 
programme.  Furthermore, this study sought to determine whether or not EMT events 
always generate cells with the properties of stem cells in a prostate cancer model.  
Moreover, using these clones, this project aspired to resolve some of the discrepancies in 
the literature by demonstrating that epithelial to mesenchymal transition and cancer(ous) 
stem cells are distinct but related phenomena.  By creating a model to investigate EMT in 
human prostate cancer, this project hoped to enable future work on the EMT-derived 
populations, with a view to determining whether distinct EMT events may give rise to 
different cell types, such as mesenchymal stem cells and fibroblasts, and whether these 
cells can be targeted using immunotherapeutic strategies.  In addition to cell line studies, 
this project aimed to provide preliminary evidence of EMT in primary prostate cancer-
derived cultures and clinical specimens. 
8.2 OPCT-1 is a Model Cell Line for the Investigation of 
EMT in Human Prostate Cancer 
Investigation of epithelial to mesenchymal transitions in vitro has previously been 
achieved in many studies via artificial induction of EMT using one of several methods 
including stimulation with growth factors such as TGF-β and EGF, forced overexpression 
of growth factors such as PDGF-D and ectopic expression of EMT-inducing transcription 
factors such as Snail and Twist (Mani et al., 2008; Kong et al., 2010; Li and Zhoul, 2011; 
Moustakas and Heldin, 2012).  This study however, sought to identify a cell line in which 
spontaneous EMT-events were occurring. 
To that end, five prostate cancer cell lines, two derived from metastatic lesions and three 
from primary tumours, were examined for the expression of several EMT-associated 
markers (Mani et al., 2008; Zeisberg and Neilson, 2009; Kong et al., 2010).  Interestingly, 
all five cell lines demonstrated expression of mesenchymal proteins however, only the 
OPCT-1 cell line appeared to present with distinct epithelial and mesenchymal 
populations.  Therefore, the OPCT-1 cell line was selected as a potential model to 
investigate EMT in human prostate cancer.  However, unlike the well characterised PC3 
and DU145 cell lines, which have been previously exploited in studies investigating 
epithelial to mesenchymal transition (Kong et al., 2008; Kong et al., 2009; Kong et al., 
2010; Viticchiè et al., 2011), OPCT-1 remains poorly characterised, with very few 
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publications reporting studies on this cell line (Li et al., 2011).  Consequently, prior to 
conducting further assays, it was necessary to ascertain that the mesenchymal populations 
had not arisen as a result of stromal contamination (prior to the cell line being 
immortalised with the HPV16/HPV18 E6 and E7 genes) and rather, that the mesenchymal-
like cells represented cells that had transitioned via EMT.  Cloning by limiting dilution 
assays revealed that single OPCT-1 cells gave rise to mixed populations of epithelial and 
mesenchymal cells, thereby suggesting that the OPCT-1 cell line comprised cells capable 
of activating the EMT programme.  Subsequently, 12 phenotypically distinct OPCT-1 
clones, with regards to vimentin expression, were selected and re-screened in order to 
investigate the stability of their E-Cadherin/vimentin marker-profiles.  Interestingly, the 
majority of the OPCT-1 clones maintained the same proportions of vimentin-positive cells, 
with some clones expressing very low and others expressing high levels of vimentin.  
Therefore, these clones  provided a suitable model for the characterisation and comparison 
of vimentin-high and vimentin-low populations, derived from the same prostate cancer cell 
line.   
8.3 Clones Derived from the OPCT-1 Cell Line Exhibit 
Distinct EMT-associated Marker Profiles 
Prior to conducting characterisation assays, five of the phenotypically stable OPCT-1 
clones (ranging from very low to high in terms of vimentin expression) were selected, 
seeded at the single cell level into fluorescence-compatible 96 well plates, and examined 
after a period of growth by immunofluorescence in order to re-confirm that single OPCT-1 
cells were capable of generating mixed progeny.  Since vimentin expression by carcinomas 
is widely used as an indicator of Type 3 EMT (Kalluri and Weinberg, 2009), the 
expression of vimentin, predominantly by cells on the periphery of the colonies, was 
indicative of EMT in some of the OPCT-1 clones.  However, as cancer cells are genetically 
unstable, aberrant expression of vimentin is not necessarily indicative of EMT.  
Furthermore, primitive epithelial cell types are also known to express vimentin (Langa et 
al., 2000) and cancer cells may also de-differentiate, thereby reverting to a more primitive 
form (Chaffer et al., 2011).  Consequently, prior to conducting further characterisation 
assays, it was necessary to examine the five OPCT-1 clones for the expression of several 
mesenchymal-associated markers and EMT-inducing transcription factors to conclusively 
demonstrate evidence of EMT in the vimentin-high clones. 
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As anticipated, high vimentin expression, determined by flow cytometry in addition to 
immunofluorescence, correlated with the expression of other EMT-associated markers, 
examined by IF and Western blotting.  Hence, the OPCT-1 clones expressing the highest 
levels of vimentin appeared to contain the largest populations of mesenchymal cells, as 
identified by the expression of mesenchymal markers such as N-Cadherin and fibronectin.  
In contrast, the least vimentin-positive clone demonstrated very low/no levels of all EMT-
associated markers, thus, appeared to represent an epithelial-only (EMT-negative) clone.   
In summary, the five OPCT-1 clones, selected for further interrogation, were shown to 
exhibit a range of EMT phenotypes hence, this study revealed that carcinoma cells derived 
from the same cell line varied considerably in their ability to activate the EMT programme.  
Therefore, the derivation of clones with a range of EMT phenotypes provided a suitable 
model for the investigation of epithelial-mesenchymal transition in human prostate cancer.  
8.4 EMT Does Not Always Generate Cells with the 
Properties of Stem Cells 
The recent convergence of the emerging EMT and CSC fields by Mani and colleagues, in 
2008 provided an explanation for several of the previously unexplained phenomena in 
cancer biology (Mani et al., 2008).  In addition to bestowing apoptotic resistance 
(Conticello et al., 2004; Liu et al., 2006; Qi et al., 2012) and immune evasion strategies 
(Wu et al., 2007; Brown et al., 2012; Morandi et al., 2012), the acquisition of stem cell 
traits by invasive carcinoma cells is believed to account for the enhanced proliferation and 
self-renewal abilities required for the formation of macroscopic metastases (Brabletz, 
2012).  Since the discovery by Mani et al., (2008), several other groups have verified a 
connection between EMT and stemness, particularly in models of breast cancer (Morel et 
al., 2008; Santisteban et al., 2009; Asiedu et al., 2011; Kasimir-Bauer et al., 2012; Yoon et 
al., 2012).  However, there have also been studies linking epithelial to mesenchymal 
transition with stem cell signatures in other malignancies including prostate, liver, 
colorectal and pancreatic cancers (Kong et al., 2010; Dang et al., 2011; Fan et al., 2012; 
Rhim et al., 2012).          
In 2010, Kong et al., artificially induced EMT in the prostate cancer cell line PC3, by 
forced expression of PDGF-D, and compared the gene signatures of the EMT-induced cells 
with the original PC3 cell line.  Microarray analysis revealed that the expression of the 
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stem cell-associated transcription factors, Sox2, Nanog and Oct4 was significantly 
increased in the EMT-induced cells, compared with the original cell line, and this was 
further validated by RT-PCR and Western blot analysis.  In addition, the EMT-induced 
cells demonstrated stem cell attributes such as increased clonogenic capacity and self-
renewal ability (Kong et al., 2010).  In an attempt to validate these findings, using a 
spontaneous model of EMT to investigate a possible correlation between EMT and the 
generation of stem-like cells by prostate carcinoma cells, this study investigated the protein 
expression of the prostate cancer stem cell associated markers, integrin α2β1 and CD44, 
and the stem-cell associated transcription factors, Sox2, Nanog and Oct4, by the five 
OPCT-1 clones and parental OPCT-1.  In addition, several assays, assessing stemness, 
drug resistance, invasive/migratory capacity and in vivo tumourigenicity were conducted in 
attempt to ascertain whether or not OPCT-1 clones with increased vimentin-positivity (i.e. 
EMT) presented with a more aggressive, cancer stem-like phenotype.   
Western blot analyses revealed that the most vimentin positive clone (P4B6) expressed the 
highest levels of the PCSC marker, CD44, in addition to the highest levels of the stem-cell-
associated transcription factor, Oct4.  However, this clone was not shown to express the 
highest levels of the additional pluripotency transcription factors, Nanog and Sox2, a 
finding which was inconsistent with that of Kong et al (2010), who demonstrated that 
EMT-derived cells expressed significantly higher levels of Nanog and Sox2 than the 
parental cell line from which they were derived.  Interestingly, one of the least vimentin-
positive clones (P6D4) was shown to express the highest levels of Nanog.  Therefore, the 
expression of stemness genes was not restricted to clones with a high proportion of EMT-
derived cells thus, overall, Western blot analysis failed to demonstrate a direct link 
between EMT and increased expression of stem-cell associated proteins. 
Several assays, conducted throughout the duration of this study, revealed that the most 
vimentin-positive clone (P4B6) exhibited an aggressive, migratory, cancer-stem-like 
phenotype.  Consistent with this finding, the least vimentin-positive clone (P5B3) 
demonstrated a non-aggressive phenotype, with limited evidence of stem-like attributes.  
Taken alone, these two clones conformed to the hypothesis that epithelial to mesenchymal 
transitions of human prostate cancer cells generate cells with properties of stem cells, 
however, when all five OPCT-1 clones were taken into consideration, aggressivity and 
stem-like attributes did not correspond concomitantly with an increase in the percentage of 
EMT-derived cells.   
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Paradoxically, in contrast to the most vimentin-positive clone (P4B6), the second most 
vimentin-positive clone (P2B9) exhibited one of the least aggressive phenotypes overall, 
with little evidence of stem-like characteristics.  As such, it is plausible that the 
mesenchymal-like cells derived from the EMT events in this clone were distinct from the 
EMT-derived cells from the most vimentin-positive clone.  Therefore, this study provided 
evidence to suggest that EMT of prostate cancer cells may give rise to distinct progeny 
hence, epithelial to mesenchymal transitions of human carcinomas may not always 
generate cells with the properties of stem cells.  
The possibility of heterogeneous EMT events may have been overlooked in previous 
studies, which artificially induced EMT to demonstrate a link between this reprogramming 
event and the generation of cancer stem cells (Mani et al., 2008; Morel et al., 2008; 
Santisteban  et al., 2009; Kong et al., 2010; Asiedu et al., 2011; Dang et al., 2011; Fan et 
al., 2012; Kasimir-Bauer et al., 2012; Rhim et al., 2012; Yoon et al., 2012) as, unlike this 
study, the EMT-positive carcinomas investigated in the aforementioned studies did not 
comprise mixed populations of epithelia which spontaneously generated  mesenchymal-
like cells and rather, represented pure populations of (artificially induced) EMT-derived 
mesenchymal-like cells.  Hence, whereas artificial induction of EMT, via ectopic 
expression of transcription factors, stimulation with growth factors or forced expression of 
growth factors, may generate cells with the properties of stem cells, naturally occurring 
EMTs may give rise to distinct cell types in different contextual settings in cancer.  Since 
Type 1 and Type 2 EMT events have been shown to generate mesenchymal cells and 
fibroblasts, respectively (Kalluri and Weinberg, 2009), it is plausible that cancer cells may 
also generate distinct cell types via EMT and the results presented in Chapter 6 certainly 
provide evidence for this hypothesis. 
8.5 The OPCT-1 Clones Provide Evidence for the 
Existence of More Than One Type of Cancer Stem Cell 
in Human Prostate Cancer                                                                                                              
Interrogation of the five OPCT-1 clones (Chapter 6) revealed that clones P4B6 and P6D4 
both demonstrated aggressive CSC-associated characteristics.  Interestingly, although the 
clone with the most CSC-like attributes was the most vimentin-positive (P4B6), the second 
most aggressive/stem-like clone (P6D4) expressed the second lowest levels of the 
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intermediate filament protein, vimentin.  Therefore, as previously stated, vimentin 
positivity did not always correlate with stemness and aggressivity.  
Consistent with previous studies (Mani et al., 2008; Morel et al., 2008; Santisteban  et al., 
2009; Kong et al., 2010; Asiedu et al., 2011; Dang et al., 2011; Fan et al., 2012; Kasimir-
Bauer et al., 2012; Rhim et al., 2012; Yoon et al., 2012), the most vimentin-positive clone 
(P4B6) also exhibited heightened migratory/invasive capacity and stem-like 
characteristics, such as enhanced proliferative capacity, superior colony and sphere-
forming ability, and elevated ALDH1 activity.  Moreover, this clone was the most 
tumourigenic in vivo, as shown by the formation of tumours that were significantly larger 
than those formed by the parental cell line from which this clone was derived.  Since the 
cancer stem cell hypothesis postulates that only CSCs possess the unique properties 
required for tumour initiation (Lawson and Witte, 2007), tumourigenicity is the 
quintessential feature of cancer stem cells.   Therefore, taking all assays into consideration, 
this clone undoubtedly demonstrated cancer-stem-like attributes hence, was likely to be 
enriched for a population of (EMT-derived) cancer stem cells. 
Intriguingly however, clone P6D4, the second least vimentin-positive clone, also appeared 
to be enriched for cancer stem cells.  This was evidenced by the fact that this clone was by 
far the most drug resistant of the OPCT-1 clones, a characteristic largely attributed to 
cancer stem cells (Dean et al., 2005; Zhou et al., 2009; Frank et al., 2010; Borst, 2012), in 
addition to expressing the highest levels of Nanog and ALDH1, both of which are widely 
regarded as stem cell and CSC markers (Ginestier et al., 2007; Douville et al., 2009; Jeter 
et al., 2009; Jiang et al., 2009; Tanei et al., 2009; Jeter et al., 2011).  Furthermore, this 
clone was the second most tumourigenic of the OPCT-1 clones and the histology of the 
tumours derived from this clone, which appeared to demonstrate the formation of glandular 
structures, indicated that a stem cell component, capable of differentiating into distinct cell 
types, may have been present.  
Therefore, while the most vimentin-positive OPCT-1 clone and the second least vimentin-
positive clone were clearly distinct with regards to EMT-status, they both demonstrated 
aggressive phenotypes with cancer stem-like attributes.  This finding provided evidence for 
the hypothesis that tumours comprise more than one type of so-called “cancer stem cell”, 
all of which may contribute significantly towards tumourigenesis.  For example, the EMT-
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derived CSCs are likely to play a critical role in metastasis whereas other CSCs may be 
more accountable for therapeutic resistance and subsequent tumour relapse. 
Perhaps the most compelling evidence, provided in this study, for the existence of multiple 
cancer stem cell populations was the discovery that the vimentin-positive (EMT-derived) 
cells in the OPCT-1 cell line did not express the extracellular matrix receptor integrin 
α2β1, one of the markers Collins et al., (2005) showed to be highly expressed by putative 
prostate cancer stem cells.  Furthermore, clone P6D4, which seemed to be enriched for 
cancer stem cells, did not express integrin α2β1.   
Therefore, this study provided indirect evidence for the existence of at least three distinct 
putative prostate cancer stem cell populations; those derived via EMT, the putative CSCs 
represented in clone P6D4 and the cancer(ous) stem cells reported by Collins and 
colleagues in 2005. 
8.6 Primary Cultures and Clinical Specimens Showed 
Preliminary Evidence of EMT 
Due to the fact that primary cultures are widely regarded as superior models for prostate 
cancer (Peehl, 2005; Miki and Rhim, 2008), this study aimed to provide evidence of 
epithelial to mesenchymal transitions in primary prostate cancer-derived epithelial cultures.  
Furthermore, since there is currently a lack of substantial evidence of EMT in clinical 
specimens (Foroni et al., 2012), this study sought to identify proof of this phenomenon in 
frozen prostate cancer tissue sections. 
Although it was not necessarily possible to distinguish between cancer stem/progenitor 
cells, dedifferentiated cancer cells, stromal contamination and EMT-derived cells in some 
cases, primary cultures of prostate cancer epithelia demonstrating staining patterns 
analogous to those of the EMT-positive OPCT-1 clone P4B6, provided preliminary 
evidence of EMT in prostate cancer cells.  However, in order to conclusively demonstrate 
evidence of EMT in primary cultures, the cells must be cloned and examined using a panel 
of EMT-associated markers, in the same manner by which the OPCT-1 study was 
conducted.   
The demonstration of cells co-expressing epithelial and mesenchymal markers in several 
clinical specimens of high-grade prostate cancer provided preliminary evidence of EMT 
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however, sections of BPH tissue failed to demonstrate proof of multiple dual-positive cells.  
An abundance of dual-positive, potentially EMT-derived, populations in high-grade 
prostate cancer tissue specimens compared with BPH tissues could arguably account for 
the aggressivity associated with this disease pathology.  This is because EMT-derived cells 
have been shown to possess enhanced migratory and invasive capacity, hormone resistance 
and resistance to chemotherapy, all of which are features of advanced castration-resistant 
hormone-refractory prostate cancer (Kasper and Cookson, 2006; Arumugam et al., 2009; 
Voulgari and Pintzas, 2009).  However, since dedifferentiated cancer cells may also 
express vimentin, it is important to further characterise the dual vimentin/E-Cadherin-
positive cells in the prostate cancer specimens by staining serial sections with a panel of 
mesenchymal markers and EMT-associated transcription factors.   
In summary, difficulties encountered during the culture of primary prostate epithelial cells 
limited the investigation of these populations, which, consequently, were only examined 
using immunofluorescence.  Using this method, preliminary evidence of EMT was 
observed in primary prostate cancer cells and tissue sections however, these studies must 
be expanded using a larger panel of EMT-associated markers in order to conclusively 
demonstrate evidence of EMT in non-immortalised prostate cancer cells.  
8.7 Tumours Contribute to Their Own Micro-
environment via EMT 
In recent years, the tumour microenvironment has been increasingly recognised as an 
integral component in tumour initiation, growth and progression (Kalluri and Zeisberg, 
2006; Pietras and Ostman, 2010; Li et al., 2012; Tripathi et al., 2012).  In fact, 
transformation of carcinoma cells from a stationary, epithelial cell type to an invasive and 
migratory mesenchymal cell type via the EMT programme is believed to be activated in 
vivo through secretion of growth factors, such as TGF-β, by the tumour-associated stroma 
(Polyak and Weinberg, 2009).  Although there is some evidence in the literature to suggest 
that tumours may contribute to their own microenvironment via EMT (Wernert et al., 
2000), the general consensus is that tumour cells recruit stromal cells and stimulate local 
fibroblasts to differentiate into myofibroblasts (aka cancer-associated fibroblasts) to supply 
them with growth factors and nutrients to support tumourigenesis (Schedin et al., 2004; de 
Miranda et al., 2011; Kidd et al., 2012). 
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In vivo, the growth and survival of parenchymal epithelial cells is supported by the stromal 
compartment, which surrounds the parenchyma and secretes growth factors and 
extracellular matrix proteins to maintain the epithelial cells (Grossfeld et al., 1998).  
Incredibly, this relationship was observable in clonally-derived populations of cells from 
the OPCT-1 prostate cancer cell line, which were shown to activate the EMT-programme 
to generate mesenchymal cells that surrounded the epithelial colonies in the same manner 
observed in mixed stromal/epithelial primary cultures.  This observation provided 
compelling evidence to suggest that tumours may be capable of contributing to their own 
stromal microenvironment hence, tumour-associated stroma may well contain malignant, 
EMT-derived cells.  This hypothesis is supported by the study by Wernert et al., (2000) 
who demonstrated frequent genetic alterations in non-hereditary, invasive human colon 
and breast tumour cells and adjacent fibroblastic tumour stroma and revealed that both 
components can share clonal features. 
In addition to observations in clonally-derived populations from the OPCT-1 cell line, 
evidence for this hypothesis was provided in primary cultures of stromal cells derived from 
high grade prostate cancer tissue which, not only appeared to proliferate much faster than 
the stromal cells derived from benign tissues, but were also passaged more than six times 
without reaching a senescent state.  In order to test this hypothesis, preliminary 
karyotyping was performed on one benign and one cancer-tissue derived population.  
However, this experiment was inconclusive hence, must be repeated. 
In summary, this study provided evidence to suggest that, in addition to activating local 
stroma and recruiting distant stromal cells to the site of the tumour, tumour cells may be 
capable of contributing to their own stromal microenvironment via EMT.  Intriguingly, a 
similar concept, differentiation of cancer cells to endothelial cells, has also been shown to 
contribute to the generation of blood vessel walls during the process of angiogenesis 
(Ricci-Vitiani et al., 2010).  Collectively these data reveal that tumours may represent self-
sustaining entities, capable of modelling their own microenvironment to ensure their 
growth, survival and subsequent dissemination.   
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8.8  Conclusions  
This study created a model for the investigation of epithelial to mesenchymal transition in 
human prostate cancer and revealed heterogeneity in EMT-events among clonally derived 
populations of prostate cancer cells, some of which generated cells with the properties of 
cancer stem cells and others generated cells with a non-aggressive phenotype.  Using this 
model, the present study also provided evidence for the existence of distinct cancer stem 
cell populations in human prostate cancer, which may play both separate and overlapping 
roles in prostate cancer tumourigenesis.  In addition, this work provided preliminary 
evidence of EMT in primary cultures and clinical specimens.  Finally, based on 
observations made from both primary stromal cultures and one of the model EMT-positive 
clones, this study revealed that tumour cells may contribute to their own stromal 
microenvironment via epithelial to mesenchymal transition. 
8.9  Future Work 
This study has paved the way for future projects to further characterise epithelial to 
mesenchymal transition in human prostate cancer and determine the molecular 
mechanisms which govern the EMT-events that generate cancer stem cells compared to 
those which generate less aggressive progeny.  Furthermore, this project has enabled the 
investigation of EMT-derived cells with a view to identifying which specific cell types 
they represent and determining whether these cells can be targeted using 
immunotherapeutic strategies.  In future studies, the OPCT-1 clones may be used as a 
model to investigate metastatic disease and mesenchymal to epithelial transition (MET) 
events.  In addition, future work should aim to provide further evidence of EMT in clinical 
specimens and primary epithelial cultures of human prostate cancer. 
8.9.1  Molecular Characterisation of the OPCT-1 Clones 
Molecular biology currently represents an important area in cancer research and by 
providing a detailed overview of the molecular changes involved in tumour progression, 
molecular techniques may consequently lead to a better understanding of the 
carcinogenesis process and enable the development of new prognostic markers and novel 
therapeutic targets (Nannini et al., 2009).  By simultaneously mapping the expression of 
thousands of genes in a single tumour sample, gene expression profiling analysis with 
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microarray technology shows great potential in cancer research (Nannini et al., 2009), 
enabling the identification of up and down regulated genes which may contribute 
significantly to tumourigenesis. 
Previous studies identified and characterised clones with unique EMT profiles however, 
the underlying genetic and epigenetic mechanisms which govern the EMT events in these 
clones remain to be determined.  To address the genetic mechanisms underlying the 
differences between the OPCT-1 clones, four of the previously characterised OPCT-1 
clones of interest, the two most and the two least aggressive, and a mesenchymal-only 
clone, derived from one of these clones, will be analysed using microarray technology.  A 
whole-genome approach, comparing the gene expression profiles of these clones, may 
identify previously unexplored pathways which may contribute to tumour aggressivity and 
the cancer-stem cell phenotype and consequently, may represent viable targets for cancer 
therapies. 
8.9.2  Investigating the Identity of the EMT-derived Cells 
In 2010, Battula et al., demonstrated that EMT-derived cells exhibited multilineage 
differentiation potential similar to mesenchymal stem cells (Battula et al., 2010).  In 
addition, this study also demonstrated the ability of EMT-derived cells to home to wounds 
in vivo, in the same manner as mesenchymal stem cells have been shown to do so.  The 
generation of mesenchymal stem-like cells by EMT of tumour cells could account for 
several of the phenomena observed in human cancer.  Not only are mesenchymal stem 
cells inherently capable of resisting apoptosis via a number of different mechanisms 
(Szegezdi et al., 2009; Roodhart et al., 2011; Houthuijzen et al., 2012), these cells also 
possess multiple immunosuppressive functions, including the expression of growth factors  
such as TGF-β and the expression and secretion of HLA-G (Nasef et al., 2007; Qi et al., 
2012).  Furthermore, mesenchymal stem cells possess homing abilities, a feature which 
may account for why cancer cells often metastasise to the bone (Chapel et al., 2003; Erices 
et al., 2003; Msaouel, et al., 2008; van der Pluijim, 2011).  It is also plausible that the 
cancerous mesenchymal stem-like cells may generate the (cancerous) progeny of these 
cells, which may include osteoblasts, chondrocytes and adipocytes.  Evidence for this 
hypothesis is prevalent in the literature as abnormal ECM production is one of the defining 
features of cancer stroma (Hanahan and Weinberg, 2000) and studies have even shown the 
production of chondrocyte proteins in the mammary gland (Bauer et al., 2010).  
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Furthermore, microcalcifications can be the early and only presenting signs of breast 
cancer (Nalawade, 2009) and these may potentially be caused by the aberrant 
differentiation of EMT-derived mesenchymal stem cell progeny (osteoblasts). 
In order to provide evidence for this hypothesis in human prostate cancer cells, future work 
could  involve flow cytometric analysis using a panel of mesenchymal stem cell markers to 
confirm the presence of putative cancerous mesenchymal stem-like cells in the EMT-
positive OPCT-1 clones.  Furthermore, the multilineage differentiation potential of the 
EMT-derived cells, into osteoblasts, chondrocytes and adipocytes, could be investigated 
using a commercially available kit.  
8.9.3  Investigating the Immunological Status of EMT-derived Cells 
In order to ascertain whether or not EMT-derived cancer stem cells represent viable targets 
for immunotherapy, it would be necessary to investigate the immunoglogical status of 
these cells.  Future work could therefore examine the expression of classical HLA class I 
molecules by EMT-derived cells, in addition to investigating the expression of the non-
classical, immunosuppressive molecules such as HLA-G, which has been previously 
shown to be expressed by mesenchymal stem cells (Nasef et al., 2007), cancer stem cells 
(Brown et al., 2012) and metastatic bone-marrow infiltrating cells from different tissues 
(Morandi et al., 2012). 
In addition, susceptibility to NK and T-cell mediated cytotoxicity and relative lysis of 
epithelial versus mesenchymal cancer cells should be investigated and considered when 
developing a strategy for immunotherapy.    
8.9.4  Metastasis Assays with GFP-tagged EMT-derived Cells 
In order to prove the theory that, like mesenchymal stem cells, EMT-derived mesenchymal 
stem-like cells are capable of homing to the bone, an in vivo metastasis assay, using EMT-
derived cells transfected with a vimentin-GFP reporter construct, could be conducted in 
immunocompromised mice.  This study would require the successful generation of EMTs 
stably transfected with the vimentin-GFP reporter construct, followed by injection of the 
cells into the tail vein of a suitable immunocompromised mouse model.  The migration of 
these cells could potentially be monitored using live-animal imaging technology and 
following completion of the assay, the bone marrow cells could be harvested and examined 
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for the presence of GFP-positive cells using fluorescence microscopy. This assay may 
provide an explanation for the frequent occurrence of bone metastases in breast and 
prostate carcinomas (van der Pluijim, 2011). 
8.9.5  Investigation of Mesenchymal to Epithelial Transition (MET) 
Plasticity of tumour cells is one of the traits currently believed to be critical in cancer 
metastasis.  So-called “plasticity type I metastasis” is believed to be characterised by 
transient EMT-MET processes, whereas “genetic type II metastasis” is characterised by a 
permanent switch from an epithelial to a mesenchymal state (Brabletz, 2012).  Though 
there is much evidence to support the critical role of epithelial to mesenchymal transitions 
in tumourigenesis, there is less evidence of the reverse process, mesenchymal to epithelial 
transition (MET).  In an attempt to address this and provide potential evidence of MET 
events by prostate cancer cells, clone P4B6 B, a mesenchymal-only clone, clonally derived 
from the EMT-high clone P4B6, could be cloned at single-cell density into fluorescence-
compatible 96-well plates using a high-speed cell sorter, and stained for epithelial and 
mesenchymal markers after a period of growth.  The presence of cells expressing epithelial 
markers would provide in vitro evidence for the occurrence of MET.  In addition, evidence 
of MET events could be investigated in vivo by injecting the mesenchymal-only clone into 
immunocompromised mice and subsequently excising, sectioning and staining the tumours 
for the expression of epithelial and mesenchymal markers.    
8.9.6  Further Work on Patient Tissue 
Work conducted in this study provided only preliminary evidence of EMT in prostate 
cancer patient samples.  Consequently, it is necessary to expand the number of tissues 
examined and repeat the aforementioned procedures, this time using a larger panel of 
EMT-associated antibodies.  In addition, clonally-derived populations must be established 
from single primary prostate cancer cells in order to rule out the possibility of stromal 
contamination affecting the interpretation of the results.   
Due to the difficulties encountered with the culture of the primary prostate cancer epithelia, 
it may be necessary to immortalise these cells using a three plasmid hTERT system.  
Indeed, permission for the use of this construct to generate “in house” cell lines from the 
cultured prostate cancer epithelia was sought and approved at Nottingham Trent 
University.  However, since immortalisation would undoubtedly affect the biological 
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properties of these cells, this procedure would only be necessary if the problems with 
culturing primary prostate cancer epithelia could not be overcome. 
In addition to studies with the tissue sections and epithelial cultures, the stromal cultures 
derived from prostate cancer tissue should also be karyotyped, along with benign controls.  
Furthermore, the tumourigenic potential of these cells should also be investigated in an in 
vivo murine model.  These experiments would provide conclusive evidence for the 
hypothesis that tumours contribute to their own stromal microenvironment. 
 
8.10  Final remarks 
In summary, this study generated a model that has enabled investigation into the properties 
of epithelial to mesenchymal transition and cancer stem cells in human prostate cancer 
cells.  In addition, this project established primary cell culture techniques and provided 
preliminary evidence of epithelial to mesenchymal transition in primary cultures of 
prostate cancer epithelia and clinical specimens.  The foundations laid by the completion of 
this project have provided considerable scope for future studies which  may  identify the 
cell types generated by distinct EMT events, examine the immunological status and 
metastatic capability of EMT-derived cells, investigate evidence of mesenchymal to 
epithelial transition and determine the underlying mechanisms governing distinct EMT 
events.  Taken together, these data provide exciting insights into the fundamental 
mechanisms involved in prostate cancer progression.  
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Appendix I 
 
Information pertaining to the derivation and characterisation of the OPCT cell lines 
used in this study.  
Derivation and initial characterization of three new prostate cancer cell lines and three new 
immortalized normal prostate epithelial cell lines 
http://aacrmeetingabstracts.org/cgi/content/abstract/2004/1/183-a 
Characterization of three pairs of prostate cells lines derived from tumor and adjacent 
normal tissues 
http://aacrmeetingabstracts.org/cgi/content/abstract/2005/1/462 
Comparison of gene expression profiles in cell line pairs derived from tumor and adjacent 
normal prostate tissues 
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2007/1_Annual_Meetin
g/1186?maxtoshow=&hits=10&RESULTFORMAT=&searchid=1&FIRSTINDEX=0&mi
nscore=5000&resourcetype=HWCIT 
OPCT Cell line information 
OPCT-1 
http://www.asterand.com/Asterand/human_tissues/OPCT1.htm 
OPCT-2 
http://www.asterand.com/Asterand/human_tissues/OPCT2.htm 
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Appendix II 
 
The full list of equipment used throughout the duration of this study. 
 
 
Equipment       Supplier 
-80°C Freezer       Thermo Scientific 
-20°C Freezer       Standinova 
37°C Incubator      Sanyo 
2100 Bioanalyzer      Agilent Technologies 
Biofuge Pico 4
o
C Micro-Centrifuge    Heraeus 
CCD Camera       Fuji Systems 
Class II Safety Cabinet     Walker/ Envair 
Confocal Microscope      Leica 
Coulter Counter      Beckman Coulter 
Cryostat       Leica 
Cryo 200 Liquid Nitrogen Freezer    Forma Scientific 
Drying Cabinet      SLS 
Electrophoresis Gel Tanks     Geneflow 
Combined 4
o
C Fridge/-20
o
C Freezer    Premier 
Filtermate Harvester      Perkin Elmer 
Flow Cytometer       BD Biosciences 
Gallios Flow Cytometer     Beckman Coulter 
iCycler I Q Multicolour RT PCR Machine   Qiagen 
PALM Laser-capture microdissector (LCM)   Carl Zeiss 
Microcentrifuge       MSE 
Micropipettes (2 µl,10 µl, 20 µl, 100 µl, 200 µl, 1000 µl) Genex/ Beta/ Gilson/ Sealpette 
Microplate Luminometer Berthold Detection Systems 
Microwave       Matsui 
Midi MACS magnet      Miltenyi 
Mikro 22R Centrifuge Hettich zentrifugen, Germany 
Mini MACS magnet      Miltenyi  
Mini-orbital shaker      Stuart 
MoFlo
TM
 XDP High-Speed Cell Sorter   Beckman Coulter 
Nanodrop ND-800 spectrophotometer   Thermo Scientific 
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Nanopure Diamond water reservoir    Barnstead 
Nikon Eclipse Ts100 Light Microscope   Olympus  
NXT Top-Count Microplate Scintillation Counter  Perkin Elmer 
Octo MACS magnet      Miltenyi 
Olympus BX51 Fluorescence Microscope   Olympus 
Orbital Incubator      Stuart 
pH meter       Mettler Toledo 
Plate reader       Biorad and Tecan 
Plate rocker       VWR 
96-well plate harvester     Packard 
PCR workstation cabinet     Grant-Bio 
Power packs       Biorad 
Real-time qPCR thermal cycler    Qiagen 
Refrigerated Centrifuge     Mistral 1000, MSE 
Refrigerated Centrifuge 5702 R (4°C)   Eppendorf 
Refrigerator Lec refrigeration PLC, 
England 
Refrigerator        BOROLABS, UK 
Rocking platform      VWR 
Sonicator       VWR 
Sealing tape (Nescofilm)     Bando Chemicals 
Tecan Ultra Microtiter Plate Reader    Tecan 
Transfer apparatus      Geneflow 
37
o
C/5%CO2 incubators     Forma Scientific 
Top count scintillation counter    Packard 
UNO-thermoblock      Biometra 
Vortex mixer       Scientific Industries 
Water Bath       Grant Instruments 
Weighing scale      Fisherbrand 
Whirlimixer       Scientific Industries 
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Figure A3.3:  Dual immunofluorescent isotype control staining of P4E6 cells.  Secondary antibody and 
nuclear staining were achieved as described in Figure 3.1a.  (n=3).  Representative images.  Image 
magnification at x20. 
Figure A3.2:  Dual immunofluorescent isotype control staining of DU145 cells.  Secondary antibody and 
nuclear staining were achieved as described in Figure 3.1a.  (n=3).  Representative images.  Image 
magnification at x20.  
Figure A3.1:  Dual immunofluorescent isotype control staining of PC3 cells.  Secondary antibody and 
nuclear staining were achieved as described in Figure 3.1a.  (n=3).  Representative images.  Image 
magnification at x20. 
Appendix III 
 
Isotype control staining of PC3, DU145 and P4E6 cells 
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Appendix IV 
 
Demonstrating the 12 OPCT-1 clones of interest growing as single-colonies after 21 days 
in culture following cloning by limiting dilution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                   
 
Figure A4.1:  Demonstrating representative images of the individual colonies formed by the 12 OPCT-
1 clones of interest after 21 days in culture. x10 and x20 magnification.   
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Dual-isotype control staining of 5 prostate cancer cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4.2:  Murine and rabbit isotype control staining of DU145, PC3, P4E6, OPCT-1 and OPCT-
2 cells.  Secondary antibody and nuclear staining were performed as previously described in Figure 
4.2. (n=3).   Representative images.  Image magnification at x20. 
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Figure A4.3:  Goat isotype control staining of DU145, PC3, P4E6, OPCT-1 and OPCT-2 cells.  
Secondary antibody and nuclear staining were performed as previously described in Figure 4.2.   
(n=2) Representative images.  Image magnification at x20. 
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Appendix V 
Negative staining of five OPCT-1 clones stained with 3 stem cell associated transcription 
factors. 
Nanog, a homeodomain-containing transcription factor, is essential for the maintenance of 
pluripotency and self-renewal in embryonic stem cells (Kim et al., 2008).  Furthermore, 
the expression of this protein has been detected  in putative cancer stem cells  from cancers 
including prostate cancer (Gong et al., 2012; Shan et al., 2012).  Figure A5.1 demonstrates 
that, using this technique, Nanog was not detected in any of the OPCT-1 clones. 
The transcription factor Oct4 is another key regulator of pluripotency and has been shown 
to be expressed by CSC-like cells in different cancers (Kim et al., 2008; Kumar et al., 
2012).  Figure A5.2 illustrates that this protein was not detected by immunofluorescence 
on any of the OPCT-1 clones. 
Along with Nanog and Oct4, Sox2 is an essential regulator of pluripotency and as such, is 
associated with uncommitted dividing stem and precursor cells (Avilion et al., 2003).  As 
with Nanog and Oct4, Sox2 was not detected in any of the OPCT-1 clones by 
immunofluorescence (Figure A5.3).   
Positive control staining of NTERA2/D1 
NTERA2/D1 is a pluripotent embryonal carcinoma cell line which does not require feeder-
cells to maintain its undifferentiated potential (Simões and Ramos, 2007).  As such, it was 
utilised in this study as a positive control for the pluripotency markers Nanog, Oct4 and 
Sox2.  Figure A5.4 demonstrates that the Nanog, Oct4 and Sox2 antibodies used in this 
study were suitable for the detection of these transcription factors by immunofluorescence. 
Isotype control staining of five OPCT-1 clones 
Figures A5.5 and A5.6 demonstrate that minimal background staining was observed with 
isotype control antibodies and that such background staining was distinct from the staining 
patterns achieved using the test antibodies. 
 
 
 
282 
 
Figure A5.1:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9, and P4B6 using 
a rabbit monoclonal antibody against Nanog.  Secondary antibody labelling was achieved using 
an anti-rabbit AlexaFluor®488-conjugated secondary antibody and nuclear staining was 
performed  as previously described in Figure 5.1.  (n=3).  Representative images.  Image 
magnification at x20. 
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Figure A5.2:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9, and P4B6 using 
a rabbit polyclonal antibody against Oct4.  Secondary antibody labelling was achieved using an 
anti-rabbit AlexaFluor®488-conjugated secondary antibody and nuclear staining was performed  
as previously described in Figure 5.1. (n=3).  Representative images.  Image magnification at 
x20.  
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Figure A5.3:  Immunofluorescent staining of clones P5B3, P6D4, P5F3, P2B9, and P4B6 using 
a rabbit  monoclonal antibody against Sox2.  Secondary antibody labelling was achieved using 
an anti-rabbit AlexaFluor®488-conjugated secondary antibody and nuclear staining was 
performed  as previously described in Figure 5.1.  (n=3).  Representative images.  Image 
magnification at x20. 
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Figure A5.4:  Immunofluorescent staining of the pluripotent embryonal carcinoma cell line 
NTERA2/D1 as a positive control for the expression of  Nanog, Oct4 and Sox2.  Secondary 
antibody labelling was achieved using an anti-rabbit AlexaFluor®488-conjugated secondary 
antibody and nuclear staining was performed as previously described in Figure 5.1. (n=2).  
Representative images.  Image magnification at x20. 
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Figure  A5.5:  Murine and rabbit isotype control immunofluorescent  staining of clones P5B3, P6D4, P5F3, 
P2B9 and P4B6.  Secondary antibody and nuclear staining were performed as previously described in 
Figure 5.1. (n=3).   Representative images.  Image magnification at x20. 
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Figure A5.6:  Goat isotype control immunofluorescent staining of clones P5B3, P6D4, P5F3, 
P2B9 and P4B6.  Secondary antibody labelling was achieved using an anti-goat Alexa Fluor®568-
conjugated secondary antibody and nuclear staining was performed as previously described in 
Figure 5.1.  (n=3).  Representative images.  Image magnification at x20. 
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Figure A6.1:  Mouse and rabbit isotype control immunofluorescent staining of tumour sections 
derived from clone P6D4, P2B9, P4B6 and parental OPCT-1.  Secondary antibody labelling was 
achieved using an anti-mouse Alexa Fluor®568-conjugated secondary antibody and an anti-rabbit 
Alexa Fluor(R)488-conjugated secondary antibody. Nuclear staining was achieved using mounting 
media with DAPI.  (n=2).  Representative images.  Image magnification at x10, x20, x40. 
 
Appendix VI 
Isotype control staining of tumours derived from four OPCT-1 clones and parental   
OPCT-1.  
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Abstract Cancer stem cells have been implicated in a
number of solid malignancies including prostate cancer. In
the case of localised prostate cancer, patients are often
treated with surgery (radical prostatectomy) and/or radio-
therapy. However, disease recurrence is an issue in about
30% of patients, who will then go on to receive hormone
ablation therapy. Hormone ablation therapy is often palli-
ative in a vast proportion of individuals, and for hormone-
refractory patients, there are several immunotherapies tar-
geting a number of prostate tumour antigens which are
currently in development. However, clinical responses in
this setting are inconsistent, and it is believed that the
failure to achieve full and permanent tumour eradication is
due to a small, resistant population of cells known as
‘cancer stem cells’ (CSCs). The stochastic and clonal
evolution models are among several models used to
describe cancer development. The general consensus is that
cancer may arise in any cell as a result of genetic mutations
in oncogenes and tumour suppressor genes, which conse-
quently result in uncontrolled cell growth. The cancer stem
cell theory, however, challenges previous opinion and
proposes that like normal tissues, tumours are hierarchical
and only the rare subpopulation of cells at the top of the
hierarchy possess the biological properties required to
initiate tumourigenesis. Furthermore, where most cancer
models infer that every cell within a tumour is equally
malignant, i.e. equally capable of reconstituting new
tumours, the cancer stem cell theory suggests that only the
rare cancer stem cell component possess tumour-initiating
capabilities. Hence, according to this model, cancer stem
cells are implicated in both tumour initiation and pro-
gression. In recent years, the role of epithelial–mesenchy-
mal transition (EMT) in the advancement of prostate
cancer has become apparent. Therefore, CSCs and EMT
are both likely to play critical roles in prostate cancer
tumourigenesis. This review summarises the current
immunotherapeutic strategies targeting prostate tumour
antigens taking into account the need to consider treat-
ments that target cancer stem cells and cells involved in
epithelial–mesenchymal transition.
Keywords Cancer stem cells  Prostate cancer  Prostate
tumour antigens  Immunotherapy  EMT  PIVAC 10
Prostate cancer, tumour antigens and their role
in immunotherapy
Prostate cancer constitutes a major health problem world-
wide since it is a significant cause of morbidity and mor-
tality in men, particularly in the developed world [1]. It is
the third most common cancer in men worldwide and is
most prevalent in European and North American men [2].
Prostate cancer accounts for a quarter of all new cancer
cases diagnosed in men in the UK; hence, it is the most
common male malignancy in the UK. Although in the case
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of localised prostate cancer, surgery and radiation therapy
can prove to be curative, this is not true of the majority of
cases which present with locally advanced or widespread
disease. In the case of advanced disease, androgen ablation
hormone therapy is the standard first-line palliative treat-
ment. However, despite hormone therapy achieving
castrate levels of testosterone, cancer progression to bio-
chemical or metastatic hormone-refractory disease often
leads to death since metastatic hormone-refractory prostate
cancer (HRPC) currently remains an incurable disease
[3, 4]. There is an ongoing need to develop new, more
accurate screening tests for prostate cancer so that the
disease can be identified early on where the treatment
options are much more effective. For those hormone-
refractory patients, new treatment options are required to
help eradicate and/or manage their disease, and to this end,
immunotherapy is one line of attack for advanced disease.
In the last two decades, advances in tumour immunol-
ogy have led to the discovery of many peptides from
tumour antigens that are recognised by cytotoxic T lym-
phocytes [5, 6]. There are two main adoptive immuno-
therapeutic approaches: undefined antigen-based (whole
tumour immunome) therapies and the specific antigen
-based therapies [7]. The first approach does not allow
monitoring the anticancer immune response to therapy
because of the lack of information on the recognised
antigen(s), whereas the activity of antigen-specific T cells
(CD8?/CD4?) can be assessed when using specific anti-
gen-based immunotherapies [8]. The criteria for a tumour
antigen to be a quintessential target for immunotherapy
include its specificity to cancer cells, its high expression in
cancer cells, its key role in cancer progression, its high
frequency in patients, its location on the cell surface or its
ability to be efficiently presented on major histocompati-
bility complex (MHC) molecules and its ability to induce a
specific, potent and lasting immune response.
In order to combat the phenomenon of tumour immu-
noediting, vaccines should include inhibitors of the activity
of regulatory cells (Treg) [9, 10], adjuvants such as toll-like
receptor (TLR) agonists (e.g. CpG oligodeoxynucleotides
that bind to TLR9) to activate the immune cells [11] and T
cells with receptors that have been genetically engineered
to be specific to the antigen(s) of interest [12, 13]. Also,
antibody-based therapy, radiotherapy, hormonal ablation
therapy, chemotherapy or anti-angiogenic therapy should
be used in conjunction with the vaccine to increase the
death or at least enhance the antigen-presenting capability
of cancer cells as well as removing suppressor cells
[14–16]. Finally, chemotherapeutic agents can help to
increase cytotoxic T-cell entry into the site of the tumour
by disrupting the tumour stromal cells [17]. Treating
patients with immunotherapy as an adjuvant therapy at
earlier disease stages will improve clinical benefits when
compared with the vaccination of patients already bearing
high-grade tumours [18–20].
Prostate cancer is a promising tumour for targeted
treatment using vaccine approaches due to the expression
of unique prostate-associated antigens [21]. Tumour anti-
gens were first identified in the early 1970s by Abelev et al.
(alpha-fetoprotein) [22] and Gold and Freedman (carcino-
embryonic antigen) [23]. Over the last 20 years, the family
of tumour antigens identified has vastly increased to
include antigen categories such as tumour-associated anti-
gens [24, 25], splice-variant antigens [26], antigens enco-
ded by mutated genes [27], cancer-related autoantigens
[28], fusion proteins [29] and, the most promising category
of all, cancer testis antigens [30]. Table 1 outlines some of
the more promising prostate tumour antigens that have
been taken forward into clinical trials in prostate cancer.
Dendritic cells are known to play an essential role in the
establishment of both innate and adaptive antitumour
immune responses. Dendritic cell-based vaccines have
already shown promising results by producing significant
immune responses against prostate tumour antigens such as
PAP [31, 32], PSMA [33–35] and PSA [36] as well as
being essentially free of side effects [37]. For example, a
dendritic cell-based multi-epitope vaccine using prostate
stem cell antigen (PSCA14–22), prostatic acid phosphatase
(PAP299–307), prostate-specific membrane antigen
(PSMA4–12) and prostate-specific antigen (PSA154–163)
has elicited significant cytotoxic T-cell responses and the
generation of memory T cells [38]. Of particular signifi-
cance, and an important landmark for the treatment of
asymptomatic or minimally symptomatic, metastatic
HRPC, was the formulation of the first adoptive cell
transfer regimen, called sipuleucel-T (PROVENGE),
which was approved by the United States Food and Drug
Administration in April 2010 [16]. Sipuleucel-T is com-
posed of autologous dendritic cells which are harvested by
leukapheresis and processed in vitro in order to express
recombinant PAP (PA2024) linked to GM-CSF. The anti-
gen-presenting cells are then intravenously injected to the
patient within 2 days and the regimen is given 3 times in
total, once every 2 weeks [16]. Patients participating in
late-stage randomised trials had a statistically significant
extension of their life of at least 4 months, with an overall
survival of about 20 months (P = 0.01) [39]. The treat-
ment was deemed safe and the most common side effects
were fever, tremor, rigours and hypersensitivity to cold.
Antibody and T cell-specific activities to PA2024 were
observed in the treated patient population. A large phase III
study was then conducted with 512 patients, and the data
confirmed the preliminary findings and also showed that
treating this patient population with sipuleucel-T signifi-
cantly reduced the risk of death by 22% when compared
with placebo (P = 0.032) [21]. However, PROVENGE is a
1182 Cancer Immunol Immunother (2011) 60:1181–1193
123
good example of the current limitations of cancer vaccines
as it is very complex and expensive to produce and only
reduces the rate of disease progression rather than curing
the cancer [39]. It could be argued that earlier intervention
with such forms of immunotherapy would provide longer-
lasting clinical benefits.
There are also other prostate antigens that are still in
early development and have only been tested in mouse
models of prostate cancer. These include six-transmem-
brane epithelial antigen of the prostate (STEAP), which
demonstrated the inhibition of prostate cancer progression
when TRAMP-C1 mice were immunised with recombinant
DNA and Ankara vectors delivering PSCA and STEAP
antigens [40]. Monoclonal antibodies against STEAP-1
significantly inhibited tumour growth in mouse models
using patient-derived LAPC-9 prostate cancer xenografts
[41]. Prostate secretory protein of 94 amino acids (PSP-94)
has also demonstrated efficacy in mouse models; syngeneic
models of rat prostate cancer were given either subcuta-
neous or intracardiac injections of MatLyLu-PTHrP cells,
and administration of PSP-94 resulted in tumour growth
inhibition and prevention of skeletal metastases [42, 43].
Some of the identified prostate tumour antigens have also
been investigated as potential disease biomarkers. Alpha-
methyl acyl-CoA racemase (AMACR) is routinely used in
combination with p63 on ambiguous clinical prostate can-
cer biopsies, and trace amounts of autoantibodies against
AMACR have been detected in the circulation of prostate
cancer patients [44, 45]. Other prostate-related proteins
have been included in urine-based diagnostic tests, and
these include differential display code antigen 3 [46] and
glutathione s-transferase P1 (GSTP1) [47]. In addition,
several prognostic and diagnostic markers have been iden-
tified, and these include EZH2, a biomarker for post-
prostatectomy relapse [48, 49], human kallikrein 2 [50] and
early prostate cancer antigen which has been incorporated
into an ELISA measuring serum levels for prostate cancer
diagnosis [51]. Of particular interest to our group is the
prostate-associated tumour antigen termed T21 [52]. T21
was originally identified via the serological screening of a
testis cDNA library with sera from prostate cancer patients.
The technique of identification alone strongly demonstrates
that the immune system of patients with prostate cancer is
able to illicit an immune response against T21. Further work
on T21 has demonstrated its low-level expression in normal
tissues at both the mRNA level and protein level. In prostate
cancer, we found T21 mRNA to be significantly over-
expressed in malignant glands compared with benign glands
and stroma. At the protein level, T21 expression was higher
in patients with a high Gleason score, and it was signifi-
cantly over-expressed in patients with stage pT4 disease.
These findings suggest that T21 is a promising marker for
late-stage disease and may also prove to be a valuable target
for prostate cancer immunotherapy.
Table 1 Clinically relevant studies utilising prostate-associated antigens
Antigen Function Clinical studies
Prostate-specific
antigen (PSA)
A 34-kDa kallikrein protein with serine protease activity
[53]. Routinely used to assess disease progression in
prostate cancer patients. Also expressed by cells in the
salivary gland, small intestine, smooth muscle and renal
microtubules [54]
PROSTVAC—a recombinant vaccinia-PSA [55].
Dendritophage-rPSA—autologous DCs pulsed with
recombinant human PSA protein [56]. PSA-TRICORM—
a recombinant pox virus vector containing PSA and 3
human T-cell co-stimulatory molecules [57, 58]. DCs
loaded with PSA peptides [38, 59] or transfected with PSA
mRNA [36]. Co-delivery of PSA and PSMA DNA
vaccines using electroporation [60]
Prostate-specific
membrane
antigen (PSMA)
A 110-kDa membrane-bound glycoprotein expressed on the
surface of prostatic epithelial cells. Its expression has been
shown to increase after androgen deprivation therapy [61,
62], and higher levels are correlated with disease stage and
Gleason score [61, 63]
Prost30—PSMA directed monoclonal antibody [64, 65].
DCvax—autologous cells exposed to 2 PSMA peptides
[34]. DCs loaded with PSMA peptides [33, 54, 66, 67]
Prostatic acid
phosphatise
(PAP)
A 386-amino acid protein that is secreted by the prostate
[68]. Increased levels of PAP have been detected in the
circulation of patients with advanced stage disease [69].
Decreases in PAP levels have been correlated with
response to therapy [70]
PROVENGE—a DNA vaccine consisting of a combination
of PAP and GM-CSF introduced ex vivo into autologous
DC before reinjection into the patient [31]
Prostate stem cell
antigen (PSCA)
A GPI-anchored cell surface antigen related to the LY-6/Th-
1 superfamily with 30 % homology to stem cell antigen 2
[71]. PSCA is localised to the basal cell epithelium in
normal prostates and in prostate cancer it is highly
expressed on the secretory epithelium. The acquisition of
androgen independence and metastatic disease leads to
elevated expression [72–74]
DCs loaded with PSCA peptides administered to hormone
and chemo-resistant patients [75]. DCs loaded with a
combination of PAP, PSMA and PSA peptides
administered to hormone-resistant patients [38]
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Cell types of the prostate
The three most abundant epithelial cell types within the
normal, adult prostate are the secretory luminal, basal and
neuroendocrine cells, respectively. The androgen-depen-
dent secretory luminal cells are terminally differentiated
and secrete prostate-specific antigen (PSA) and prostatic
acid phosphatase (PAP) into the glandular lumina in
response to androgens. Basal cells, which are not dependent
on androgens for their survival and are less differentiated
than luminal cells, surround the luminal cells and rest on the
basement membrane. The neuroendocrine cells, which are
relatively rare in comparison with the other cell types, are
terminally differentiated and androgen-insensitive. These
cells are involved in the production of neuropeptides which
include serotonin and calcitonin. All three cell types are
thought to derive from prostate epithelial stem cells which
reside in the basal cell compartment [53, 54].
Of late, there has been much evidence implicating epi-
thelial prostate stem cells as targets for transformation in
prostate cancer, and this has been the topic of several well-
written reviews and research articles [53–59]. Indeed, the
role of the so-called cancer stem cells in prostate cancer
initiation and progression has sparked huge interest, and, as
such, prostate cancer stem cells are the subject of intense
investigation.
Cancer stem cells
Cancer stem cells and their potential role in tumourigenesis
have been the topic of much debate in recent years as they
may help to elucidate some of the unexplained phenomena,
including cancer relapse and metastasis. Recent advances
in stem cell biology have led to the identification of adult
tissue stem cells in various organs which, in turn, has
enabled research into such populations as potential candi-
dates for malignant transformation. To date, putative can-
cer stem cells have been identified and isolated from solid
and haematological malignancies including prostate, pan-
creatic, brain, colon, head and neck, gastric, lung, liver,
acute myeloid leukaemia, multiple myeloma, melanoma
and ovarian cancers [60–73] (Table 2).
The cancer stem cell is hypothesised to be the original
cell of a tumour which is held solely responsible for tumo-
urigenesis, tumour differentiation, tumour maintenance,
Table 2 Properties and
reported markers of cancer stem
cells
Properties
Asymmetrical and symmetrical division
Highly resistant to drugs and toxins
Resistant to apoptosis
Highly proliferative
Marked capacity for differentiation
Responsible for tumour initiation
Reported markers Cancer types References
CD133? Hepatic, brain, colon, lung, prostate, pancreas [64, 65, 68, 72, 74–78]
CD44? Breast, prostate, ovarian, pancreatic,
head and neck squamous cell carcinoma, colon
[76, 79–84]
CD24-/low Breast [79, 83]
CD24? Pancreatic [81]
CD34? Acute myeloid leukaemia [85–87]
CD38- Acute myeloid leukaemia [85–87]
CD123? Acute myeloid leukaemia [85–87]
CD117? Ovarian [84]
CD90? Liver [88]
Nanog? Ovarian, oral, prostate [84]
Oct-3/4? Ovarian, breast, oral, lung, prostate [84]
ALDH1? Breast [89]
EpCAMhigh Colon [80]
ESA? Pancreatic [81]
ABCB5? Melanoma [66]
Integrina2b1high Prostate [76]
1184 Cancer Immunol Immunother (2011) 60:1181–1193
123
tumour spread (metastasis) and tumour relapse following
therapy [74]. Cancer stem cells have been shown to dem-
onstrate a marked capacity for proliferation, self-renewal
and differentiation and are generally believed to constitute a
very rare population of cells among a majority of tumour
cells with a more differentiated phenotype. Aside from their
self-renewal and differentiation capabilities, cancer stem
cells have been shown to share many other properties with
adult stem cells. For example, akin to normal stem cells,
cancer stem cells are reported to be highly resistant to drugs
and toxins, through the expression of drug efflux pumps and
are to resist to apoptosis, through a variety of mechanisms
including active DNA repair [75–83].
Considering these facts, the proposed properties of
cancer stem cells may explain why disease relapses occur
in many cancers since it is believed that current cancer
therapies only eliminate the bulk of the tumour, leaving the
(resistant) cancer stem cells behind to reinitiate tumour
growth [84]. Cancer stem cells have been reported to
express many genes known to be important in somatic
(normal) stem cell maintenance such as BMI-1 and Oct3/4
[85]. Furthermore, many of the markers known to identify
putative CSCs in several tumour types are common to the
normal adult stem cells from the healthy tissue [60, 86–88].
Such findings support the notion that cancer stem cells are
in fact transformed adult stem cells. However, although the
cancer stem cell theory draws parallels between normal
tissue stem cells and tumour-initiating cells, thus far, not all
studies have addressed whether or not cancer arises from
the transformation of normal stem cells and have rather
suggested that cancers consist of a heterogeneous popula-
tion of cells which may be organised in a hierarchical
manner much like normal tissues [89]. Hence, tumours are
thought to contain a stem-like component which drives
proliferation although the source of such a component is
controversial, with more than one theory for the origin of
cancer stem cells having been proposed.
Figure 1 demonstrates that CSCs could potentially arise
from mutated adult tissue stem cells, mutated progenitor
cell/transit amplifying cells or differentiated cells which
acquire mutations conferring de novo self-renewal and
differentiation capabilities. Although the origin of the
cancer stem cell has not yet been elucidated for every
tumour type, there is evidence to support all three mech-
anisms and perhaps CSCs can arise by any one, or even all,
of the three proposed pathways.
There is a large body of evidence to suggest that cancer
stem cells are derived from transformed adult tissue stem
cells [58, 90–94]. It has been suggested that normal stem
cells may be the only cells which live long enough to
acquire sufficient genetic mutations to become cancer stem
cells [95]. Alternatively, there is also much evidence to
suggest that CSCs derive from a more committed
progenitor/transit amplifying cell [90, 92, 94] but there is
less data to support the notion that cancer stem cells arise
from transformed differentiated cells which acquire stem-
like properties. However, since it has been proven that
differentiated cells can be reprogrammed to induce pluri-
potency [96, 97], it is plausible that activating mutations in
otherwise silenced stem cell genes such as Oct3/4, Sox2,
and c-Myc may confer stem-like properties in differenti-
ated cells.
Stem cells in prostate cancer and EMT
The stem cell model for prostate epithelia was established
by Isaacs and Coffey (1989) following a series of androgen
cycling experiments in a rodent model. In demonstrating
that the prostate, an androgen-dependent organ, could
completely regenerate following castration once androgen
levels were restored, they proposed that androgen-inde-
pendent stem cells yield a population of androgen-
responsive cells which in turn give rise to the more dif-
ferentiated androgen-dependent secretory luminal cells.
This model for the hierarchy of the prostate gland is now
widely accepted and prostate stem cells have since been
isolated and investigated [87] Fig. 2.
In 2005, Collins et al. isolated ‘tumourigenic prostate
cancer stem cells’ using the same markers they had pre-
viously established for normal prostate tissue stem cells
[58, 87]. The marker profile identified for prostate cancer
stem cells was integrina2b1
high/CD44?/CD133?. Inte-
grina2b1 (also referred to as VLA-2) is a transmembrane
receptor for extracellular matrix proteins such as laminin,
collagen and fibronectin and adhesion molecules such as
E-cadherin. Among other functions, it is known to play a
role in the generation and organisation of extracellular
matrix proteins and mediate interactions between adhesion
molecules on adjacent cells. CD44, a cell surface glyco-
protein involved in cell–cell interactions, cell adhesion,
migration and lymphocyte activation, has been implicated
as a cancer stem cell marker for several other cancers
including breast, head and neck and colorectal [98–100].
CD133 has also been implicated as a marker for putative
cancer stem cells in other cancers including brain, pan-
creatic and lung [72, 101, 102]. To date, the function of this
molecule remains to be elucidated.
Collins et al. [58] demonstrated that cells which were
positive for all three markers possessed significant capacity
for self-renewal, differentiation and invasiveness in vitro,
all properties which have been attributed to cancer stem
cells. Such cells may be responsible for both the initiation
and progression of prostate cancer, i.e. relapse and meta-
static spread despite androgen ablation or other methods.
However, this may not necessarily be the case.
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Recently, there has been much interest in the phenome-
non referred to as epithelial to mesenchymal transition
(EMT) and its role in cancer progression and metastasis.
Epithelial to mesenchymal transition is a crucial transdif-
ferentiation programme which is known to occur during
embryogenesis and in adult tissues following wound repair
and organ remodelling in response to injury [103]. During
the EMT process, epithelial cells undergo multiple bio-
chemical changes involving the down-regulation of epithe-
lial markers, which confer cell–cell and cell–extracellular
matrix (ECM) adhesion, and the up-regulation of mesen-
chymal markers, conferring increased production of ECM
components, enhanced migratory capacity, invasiveness and
increased resistance to apoptosis [104, 105]. The hallmarks
of an EMT are also characteristic of metastatic cancer cells,
as such EMT has recently been implicated in cancer
metastasis as the enhanced migratory capacity and inva-
siveness of mesenchymal cells is believed to facilitate the
dissemination of cancer [106]. Furthermore, since EMT has
been shown to confer increased resistance to apoptotic
Fig. 1 The cancer stem cell
hypothesis (adapted from [99]).
Summary of the cancer stem
cell hypothesis and some of the
proposed origins of the cancer
stem cell
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agents commonly used in chemotherapy, this phenomenon
is thought to be a critical step in tumour metastasis
[107–109]. In order to establish new tumours at the meta-
static sites, it is believed that the cells which transition from
an epithelial to a mesenchymal state and migrate must
undergo the reverse procedure, mesenchymal to epithelial
transition (MET) [110]. Therefore, metastasis is considered
to be a dynamic and complex process involving cellular
plasticity.
One study conducted in 2005 demonstrated that the
expression levels of Twist, a key transcription factor in
EMT, were positively correlated with Gleason grading and
metastasis [111]. Furthermore, Twist has been shown to
inhibit apoptosis in cancer cells and it is thought to play a
central role in the resistance to microtubule-disrupting
agents [112]. Indeed, the potential of Twist as a target in
advanced and/or metastatic prostate cancer has been dis-
cussed [105]. In addition, other studies have correlated the
presence of critical EMT drivers with disease relapse and
poor survival [113, 114]. A recent study, conducted by
Tanaka and colleagues, demonstrated a clear link between
the expression of N-cadherin, a mesenchymal cadherin
associated with EMT, and invasive, metastatic, castration-
resistant prostate cancer (CRPC). In this study, N-cadherin-
specific antibodies were shown to delay the progression to
castration resistance, inhibit the invasion of surrounding
tissues, suppress tumour growth and reduce metastasis in
castrated mice. Hence, this work provides further support
for the critical role of EMT in prostate cancer progression
and the potential of immunotherapy as a strategy to combat
this disease [115].
In 2008, Mani et al. [116] established a link between
EMT and epithelial stem cells in that the products of an
EMT, artificially induced in immortalised mammary epi-
thelial cells, demonstrated stem cell properties and that
stem-like cells (CD44hiCD24lo) isolated from mouse/
human mammary glands or carcinomas expressed EMT
markers [116]. These findings indicate that epithelial to
mesenchymal transitions of differentiated cancer cells may
give rise to cancer stem/stem-like cells in breast cancer.
However, this study does not address the cell of origin of
breast cancer, and in this human cancer at least, the original
tumour-initiating cell may be distinct from the cancer stem/
stem-like cells involved in tumour progression and
metastasis. One study, conducted on circulating tumour
cells (CTCs) of metastatic breast cancer patients, demon-
strated that a major proportion of these cells were positive
for both stem cell and EMT markers, thus providing further
evidence for a link between cancer stem cells and epithelial
to mesenchymal transition [117].
The cancer stem cell theory holds the cancer stem cell
solely responsible for tumour initiation, progression and
metastasis. There is much evidence to support the role of
EMT in prostate cancer metastasis [115, 118, 119], yet the
putative cancer stem cell markers identified by Collins
et al. [58] are not entirely consistent with the EMT phe-
notype therefore, perhaps both have a role to play in
prostate cancer. As such, it is plausible that the progeny of
transformed stem cells are also tumourigenic and that such
progeny may undergo EMT which then confers the ability
to invade and metastasise. Therefore, whereas the stem cell
may be the initial site of malignant transformation, their
transdifferentiating progeny, rather than the cancer(ous)
stem cells themselves, may be accountable for invasion and
metastasis. As such, the term ‘cancer stem cell’ may be
considered to refer to a number of different cell populations
including transformed SCs and EMTs, rather than one
‘super-malignant’ cell population, all of which have a role
to play in tumourigenesis. Conversely, EMT may be
restricted to the cancer stem cell component of a tumour;
however, this remains to be demonstrated in prostate can-
cer. Consequently, in order to achieve full and permanent
eradication of the tumour, cancer therapies should aim to
target the tumour-initiating cancer stem cells as well as
their more differentiated progeny and potentially the pop-
ulations undergoing EMT.
Therapies to target prostate cancer stem cells
Chemotherapy can increase patient survival by a few
months, but the quality of life is often reduced by
uncomfortable side effects [120, 121], and patients with
metastatic disease often fail to respond to treatment. Fur-
thermore, drug-resistant proteins (e.g. MDR1 and ABC
transporters) are more likely to be expressed by cancer
stem cells than the more differentiated cancer cells and
render the CSCs more resistant to chemotherapeutic drugs
Fig. 2 Demonstrating the process of an epithelial to mesenchymal
transition whereby epithelial markers are down-regulated and mes-
enchymal markers are up-regulated, conferring the loss of cell–cell
adhesion and cell polarity and the acquisition of migratory and
invasive properties
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[122]. Therefore, although the tumour mass may decrease
following therapy, the few surviving cancer stem cells are
thought to eventually regenerate the bulk of the tumour,
hence the disease will inevitably progress.
There is a need to develop treatment modalities for
metastatic prostate cancer which destroys the cancer stem
cells, but not normal tissue stem cells [122]. Normal stem
cells and cancer stem cells will share many signalling
pathways (e.g. pluripotency programmes); however, it is
likely that these pathways will be more active/required in
the cancer stem cells due to cell-intrinsic (e.g. mitotic
activity) and cell-extrinsic (e.g. regenerative activity in the
tissue) factors [122]. As the prostate epithelium is removed
in patients undergoing radical prostatectomy, an acceptable
side effect of therapy targeting the prostate cancer stem
cells would be the loss of prostate epithelial stem cells but
not other essential stem cells [122]. Chemotherapeutic
drugs have already proven to be selective in killing cancer
stem cells in testicular germ cell cancers (e.g. cisplatin) and
leukaemia (idarubicin with a proteasome inhibitor) [123,
124].
In order to target the cancer stem cell component of a
tumour by immunotherapy, it is essential to establish
whether these cells express functional MHC molecules.
There is very little literature addressing the MHC status of
cancer stem cells; however, normal stem cells, including
embryonic stem cells (ESCs) and mesenchymal stem cells
(MSCs), have been shown to express MHC class I [125,
126]. Drukker et al. demonstrated that embryonic stem
cells expressed low levels of MHC class I which was
dramatically up-regulated following treatment with inter-
feron gamma. They did not observe the expression of MHC
class II or HLA-G, a non-classical HLA class I molecule
involved in immunomodulation. Conversely, Selmani et al
[127] identified the expression and secretion of HLA-G by
human adult bone marrow-derived MSCs. This study
demonstrated the modulation of both adaptive and innate
immunity by HLA-G through the suppression of allogenic
T-cell proliferation, the expansion of CD4-CD25high-
FOXP3 regulatory T cells, the inhibition of natural killer
(NK) cell-mediated cytolysis and the inhibition of inter-
feron gamma secretion. The expression of HLA-G by
cancer stem cells would prove problematic when consid-
ering these cells as targets for immunotherapy. Therefore,
it is prudent to investigate the immune status of cancer
stem cells, with regard to the expression of non-classical
molecules as well as classical HLA molecules, in order to
develop strategies to target this population using immu-
notherapy. One study, investigating the immunogenicity of
putative astrocytoma and glioblastoma cancer stem cells
(CD133? cells), revealed that the majority of CD133-
expressing cells did not express detectable MHC class I or
NK cell-activating ligands. Therefore, not only would such
cells prove resistant to adaptive and innate immune sur-
veillance, they would appear to be unsuitable targets for
immunotherapy. However, up-regulation of MHC class I
and NK cell ligands was successfully achieved following
treatment with interferon gamma, hence the immunoge-
nicity of the cells was restored [128]. Despite low levels of
MHC class I being reported in both embryonic stem cells
and putative astrocytoma and glioblastoma cancer stem
cells, expression of this molecule was dramatically
increased in both studies following treatment with inter-
feron gamma. As such, the implementation of interferon
gamma in an immunotherapy regimen targeting cancer
stem cells may render these cells more susceptible to
immune attack.
The MHC status of cancer cells undergoing EMT and
the reverse process MET is also of importance when con-
sidering these cells as targets for immunotherapy. Fur-
thermore, it is critical to identify unique markers expressed
by these cancerous transdifferentiating cells which could
be exploited for immunotherapy. Although transcription
factors involved in EMT, such as Twist and Snail, may
appear attractive targets for cancer therapy, they may not
prove to be ideal targets for immunotherapy as EMT is an
essential programme required for tissue repair and organ
remodelling throughout life. Hence, targeting critical EMT
factors may prove detrimental to the patient. It is therefore
necessary to identify unique antigens, mutated forms of
essential transcription factors/key EMT drivers, or antigens
which are only up-regulated in cancer cells undergoing
EMT. Epithelial to mesenchymal transition has been
reported to play a critical role in cancer progression and
metastasis. Providing that cancer cells undergoing these
transdifferentiation programmes retain malignant charac-
teristics which distinguish them from healthy cells in both
states (epithelial and mesenchymal), these cells may prove
to be ideal targets for immunotherapy.
Comparison of gene-expression profiles of normal tis-
sues/stem cells versus cancer cells/cancer stem cells can
identify novel target antigens for therapy which are pref-
erentially expressed in cancer stem cells [122]. Patients
who present a macroscopic tumour could be given immu-
notherapy against the antigens found on the more differ-
entiated cells in order to remove the bulk of the tumour, as
a first-line treatment, while patients who present residual
disease following a regimen of therapies could be given
immunotherapy tailored against the cancer stem cell-spe-
cific antigens [129]. Yawata and colleagues have recently
demonstrated the transcriptional activation of the cancer
testis antigen (CTA) gene locus in glioma stem cells which
showed frequent and high expression of CTA genes [130].
Most of the researchers working on the subject of
prostate cancer stem cells agree that studies must be carried
out on primary cancer cells rather than cancer cell lines,
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whenever possible. Changes in the environment are inev-
itable in in vitro cell culture and in vivo animal models/
xenografts, and these could be inducing a deregulation of
the expression of cancer stem cell markers leading to
inaccurate measurements of their activity. It is therefore
essential to precisely recreate the tumour stroma/microen-
vironment to allow observation and report of true phe-
nomena in order to develop effective therapeutics [131,
132].
Concluding remarks
Although the clinical responses observed with the current
immunotherapies are encouraging, they are not entirely
satisfactory [133, 134]. For instance, an important drop in
the level of PSA is indicative of a good response to any
therapeutic intervention in HRPC; however, no such phe-
nomenon was observed following the administration of
existing immunotherapies [135, 136]. These treatment
failures could be explained by the unsuccessful targeting
and elimination of the cells responsible for metastasis and
recurrence. Since cancer stem cells and EMT have both
been implicated in tumourigenesis, it is critical to examine
both populations and determine their immune statuses in
order to develop strategies to target these populations using
immunotherapy. Novel immunological targets are required
and should comprise the specific antigens expressed by
differentiated cancer cells, EMTs and CSCs.
It is critical to fully characterise the nature and rela-
tionships between these populations in order to develop
specific vaccines which will provide the efficient and long-
term eradication of all cancer cells, thus a cure and not just
another palliative treatment. The target cells must not only
express high levels of the prostate tumour antigens of
interest but also high levels of MHC class I molecules must
be expressed or inducible. Research should also focus on
developing tailored treatments by identifying patients who
are likely to respond to a specific therapeutic regimen.
Molecular and biochemical technologies including whole-
genome microarrays and mass spectrometry, respectively,
could indicate the presence or absence of tumour antigens,
thus allowing an informed decision to be made prior to
immunotherapy [137, 138].
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